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Table 4.2 Pearson's Correlation Coefficients for Total APP/Goa
mRNA Data
(Control, Age-Related Change, AD, AD + Parkinson's Disease and
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Abstract
Alzheimer's disease (AD) is the commonest cause of dementia. Its aetiology remains
largely unknown and it is, as yet, untreatable. The prevalence of AD increases with
age, afflicting 10.8% of 80 to 89 year olds (Rocca et al., 1991). Moreover, a more
than 100% increase in the U.K. population over 85 years is predicted to occur by the
year 2022. AD represents a personal and societal tragedy the economic costs of
which are enormous.
In this thesis, four independent studies of messenger RNA (mRNA), in tissue from
normal and diseased post-mortem human brains, are presented. The following
paragraphs summarise the findings in each of these four separate studies.
Gs and Go are members of the heterotrimeric G protein family whose members are
crucial to cellular responsiveness. Gs stimulates the catalytic subunit of adenyl
cyclase and a marked increase in the mRNA encoding the a subunit of Gs (Gsa) has
been demonstrated in the hippocampus of AD sufferers in comparison to controls
(Harrison et al., 1991 c). Four splice variants of Gsa mRNA are known to exist
generated by the inclusion or exclusion of a span of 45 nucleotides encoded on exon
3 and by the use of a variable splice junction at the end of intron 3 (Kozasa et al.,
1988). However, it proved impossible to identify the splice variant(s) responsible for
the increase identified in Gsa mRNA using the chosen technique of quantitative
reverse transcription coupled with the polymerase chain reaction (RT-PCR).
Go is believed to regulate phospholipase C dependent phosphoinositide hydrolysis
(Moriarty et al., 1990) and to control neuronal calcium and potassium channels
(Ewald el al., 1988; Hescheler et al., 1987; Kleuss et al., 1991; VanDongen et al.,
1988). Nishimoto and colleagues (1993) postulate that Go is constitutively activated
by amyloid precursor protein (APP) in AD. APP is a glycosylated transmembrane
protein (Kang et al., 1987) from which (3-amyloid, the major protein constituent of
the plaque and meningovascular amyloid deposits which characterise AD, is cleaved
(Glenner and Wong, 1984; Masters et al., 1985a). APP and Goa mRNA levels were
found to be reduced in the dentate gyrus of AD sufferers in comparison to controls
and were positively correlated in this region irrespective of diagnosis.
The APP gene is encoded on chromosome 21 and APP mRNA levels are increased in
Down's syndrome in keeping with the 50% increase in gene dosage associated with
trisomy 21 (Tanzi et al., 1987). Increased APP mRNA levels are postulated to be
responsible for the early appearance of the pathological stigmata of AD in
individuals with this condition. However, a comprehensive analysis of APP mRNA
levels in the hippocampus and visual cortex of diseased and control brains concluded
that increased APP mRNA levels are not a feature of AD. An increase in the ratio of
potentially amyloidogenic KPI-encoding, relative to KPI-lacking, APP mRNA
transcripts was documented with age in the visual cortex of diseased and control
brains. Further, the major determinant of this ratio differed between the visual cortex
and the hippocampus.
iv
Ubiquitin is a highly conserved member of the heat shock protein family essential to
ATP-dependent non-lysosomal proteolysis. Ubiquitin mRNA, when expressed as a
proportion of polyadenylated mRNA, was increased in the visual cortex of
individuals diagnosed as suffering from borderline AD in comparison to the other
diagnostic groups studied.
In conclusion, the challenges inherent in the application of biomedical research
techniques to the study of a uniquely human disease like AD, using human
post-mortem brain tissue, are briefly discussed.
V
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1.1 The Clinical Diagnosis of Alzheimer's Disease
Alzheimer's disease (AD) is the commonest cause of dementia. Its aetiology remains
largely unknown and it is, as yet, untreatable. In 1906 Alois Alzheimer (1864-1915),
the Bavarian psychiatrist and neuropathologist (Thomas and Isaac, 1987), presented
the case of a 51 year old woman whose illness he believed merited the status of a
new syndrome. Using the silver stain developed by Bielschowsky in 1902,
Alzheimer demonstrated the senile plaques and neurofibrillary tangles now regarded
as the pathological stigmata of AD. Alzheimer published his preliminary findings
the same year, followed in 1907 by his paper Uber eine eigenurtige Erkrankung der
Himrinde, (About a peculiar disease of the cerebral cortex) in the Allgemeine
Zeitschriftfur Psychiatrie und Psychisch-Gerichtliche Medizin.
Dementia is a global impairment of cognitive function, accompanied by a
deterioration in personality and behaviour, which occurs in clear consciousness
(World Health Organisation, 1992). Dementing illnesses are aetiologically,
clinically and neuropathologically heterogeneous and primarily afflict the elderly,
but may occur in individuals as young as 18 years (Will et al., 1996). Particularly at
risk are those individuals who suffer from Down's syndrome (trisomy 21), who
invariably develop symptoms of dementia characterised neuropathologically as AD,
if they survive beyond the age of 40 years (Mann, 1988). Examination of the brains
of Down's syndrome individuals allows the earliest manifestations of AD to be
studied in a population destined ultimately to develop the disease. Thus, the
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developmental sequence of the neuropathology of AD may be discerned (Mann et
al., 1989).
Jorm (1987), in his meta-analysis of prevalence studies for dementia published
world-wide between 1945 and 1985, found the rate doubled every 5.1 years up to the
age of 95 years. Prevalence rates for the over 65 years age group vary from 3.6 to
10.5%, while for populations over 85 years, prevalence rates reach 23.9 to 29.8%
(Ebly et al., 1994). Approximately 1-2% of the population aged 65 years and over
develop dementia each year (Brayne, 1993).
There are at least 60 disorders which can give rise to dementia (Tien et al., 1993)
and since there is no definitive, non-invasive test for AD it is a diagnosis of
exclusion. Prevalence rates for AD are, therefore, affected by how assiduously other
causes of dementia are excluded. In North America and Europe, AD accounts for
approximately 50% of all cases of dementia (Breitner and Folstein, 1984). The
proportion of dementia cases attributable to AD increases with age up to the age of
85 years. A Canadian study of the very old attributed 75.3% of cases of dementia in
the 85 years and over group to AD (Ebly et al., 1994). Rocca and colleagues (1991),
in an analysis of 1980 to 1990 European prevalence studies of AD, arrived at an
overall European prevalence rate of 0.3% population for the age group 60 to 69 years
and 10.8% population for the age group 80 to 89 years. Though there is no sex
difference in the prevalence of dementia overall, prevalence rates for AD in women
are significantly higher than those for men of the same age (Jorm et al., 1987; Rocca
et al., 1991). In contrast to the presumed significant international differences in risk
factors for AD, incidence and prevalence rates for the disease show little
geographical variability (Rocca el al., 1991).
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A substantial surge is predicted in the number of people living to be very old due to
the increased life expectancy of those born in the decade following the second world
war, the so called 'baby boomers'. Over the next 23 years the number of people in
the UK over the age of 65 years is predicted to increase from 9 to 14.5 million. The
UK population over the age of 85 years, meanwhile, is set to increase from 1 to 2.2
million by the year 2022; a more than 100% increase (Department of Health, 1997).
Since age is a major risk factor for AD, the prevalence of AD is set to increase
accordingly. AD represents an enormous personal, social (Selkoe, 1991) and
financial cost. Minimum losses to the US economy for the year 1991, as a result of
AD, have been estimated at 536 billion (annual direct) and 1.75 trillion (total cost)
dollars (Ernst and Hay, 1994). Gray and Fenn (1993), in a more cautious analysis
which excluded the costs of informal care, estimated the total annual cost of
providing health and social services, to individuals over the age of 65 years suffering
from AD in England, to be £1,039 million at 1990/1991 prices.
The clinical manifestations of AD present themselves insidiously. Memory
impairment is the most prominent and usually the first symptom (Weiner et al.,
1991a) and at presentation is universal (Price et al., 1993). Over a two to three year
period, abnormalities in other cognitive domains follow, though the pattern of
cognitive deficits is highly variable (Kurz et al., 1992) and no orderly progression of
cognitive involvement in AD can be discerned (Ritchie and Touchon, 1992).
Nevertheless, focal abnormalities or prominent behavioural difficulties at
presentation are rare in AD that develops in middle to late adulthood (Price et al.,
1993). Deterioration is steady and relentless: neither fluctuations nor remissions are
characteristic of the disease (Lishman, 1987). AD sufferers lose the ability to deal
with abstract concepts and complete complex tasks, and their grasp of language
dwindles. The language deficit in AD is almost always that of a fluent aphasia (Price
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et al., 1993). Sufferers become disorientated and display impaired social judgement.
They develop apraxias and agnosias.
Depressive symptoms, such as feelings of sadness or despair, are a common
accompaniment to AD (Burns et al., 1990a; Weiner et al., 1991b), but the incidence
and prevalence of major depression is low (Burns et al., 1990a; Weiner et al., 1994).
Ballard and colleagues (1997) have demonstrated that depressive illnesses identified
in dementia sufferers are of similar severity and duration regardless of whether the
Diagnostic and Statistical Manual of Disease, 3rd Edition Revised (DSM-III-R), the
Research Diagnostic Criteria (RDC) or the Cornell Depression Scale (CDS), a scale
developed specifically for the assessment of depression occurring in the setting of
dementia, is employed. Weiner and colleagues (1991b) conclude that depression is
relatively mild or absent in those with organic brain disease and that it is a rare cause
of excess morbidity in AD.
Half or more of individuals with dementing illnesses suffer agitation or psychotic
symptoms, or both, during the course of their illness (Tariot, 1996). A significant
proportion of AD sufferers exhibit behavioural disturbances such as aggression,
wandering and incontinence (Burns et al., 1990b) and it is often these behaviours
which precipitate admission to institutional care (Hope and Keene, 1996).
Behavioural disturbances become more common as dementia severity increases
(Burns et al., 1990b).
In the final stage of AD, bladder and bowel control is lost and bodily wasting is
prominent. In advanced disease, primitive reflexes, myoclonus and dyskinesias
appear (Benesch et al., 1993) and the gait becomes stooped and shuffling. Save for
these neurological signs, there are no clinically observable physical stigmata of the
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disease (Weiner et al., 1991a). Death supervenes approximately 4 to 10 years from
diagnosis, usually as a result of sepsis to which the enfeebled, bed-ridden elderly are
particularly susceptible (Weiner et al., 1991a).
The clinical diagnosis of AD necessitates a detailed history from the patient, and an
informant, and a thorough physical examination. The clinical guidelines of
McKhann and colleagues (1984), developed by a National Institute of Neurological
and Communicative Disorders and Stroke-Alzheimer's Disease and Related
Disorders Association (NINCDS-ADRDA) work group, under the auspices of the
Department of Health and Human Services Task Force on Alzheimer's Disease in the
USA, remain the gold standard for the clinical diagnosis of AD.
No specific laboratory test exists to support the diagnosis of AD, though ancillary
investigations may help exclude other diagnoses. Computerised tomography has
proved useful as an adjunct to clinical examination, particularly for the exclusion of
intracranial mass lesions, though it has, thus far, proved disappointing as a means of
distinguishing the normal aged elderly from those suffering from AD (Burns, 1990).
Functional neuroimageing techniques, such as positron emission tomography (PET)
and single photon emission tomography (SPECT), yield characteristic abnormalities
in AD and have been reported to be of great use in the diagnosis of the disease (Tien
et al., 1993). SPECT studies have demonstrated bilaterally decreased cerebral blood
flow in the parietal and temporal lobes, with involvement of the frontal lobes in
advanced disease (Geaney and Abou-Saleh, 1990), and are consistent with the
regional decreases in metabolism and cerebral blood flow identified by PET (Foster
et al., 1984). Perfusion abnormalities on SPECT imageing with 99nvpc_bjcjsate
have been shown to correlate significantly with severity of cognitive impairment
(Waldemar et al., 1994). However, Powers and co-workers (1992) found the
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sensitivity of PET to be too low to be of routine clinical use. Similarly, Van Gool
and colleagues (1995) concluded from a study of ^^mTc-HMPAO SPECT that
routine scans performed in the mildly demented elderly did not substantially
contribute to diagnostic accuracy.
A definitive diagnosis of AD is only possible on histological examination of brain
tissue obtained either at biopsy or autopsy (Powers et al., 1992). The
neuropathological criteria for AD, established at a National Institute of Mental
Health and American Association of Retired Persons workshop on AD
(Khachaturian, 1985), are widely, though not universally (Mirra et al., 1991), applied
to the neuropathological diagnosis of AD. These criteria, however, were developed
as guidelines to aid in uniform assessment of neuropathological specimens, rather
than as quantitative thresholds, and have not yet been empirically validated
(Silverman and Wisniewski, 1993).
Martin and co-workers (1987) assessed the accuracy of a clinical diagnosis of
'probable AD' made according to the NINCDS-ADRDA criteria of McKhann and
colleagues (1984). The diagnosis of AD in this small (n=l 1), highly selected group
with clinically typical AD was 100% accurate. The utility of these criteria was
affirmed in another study (Galasko et al., 1994), which reported a 90% accuracy of
the diagnoses of'probable' or 'possible' AD according to NINCDS-ADRDA criteria.
Unsurprisingly, the diagnosis of'possible' AD and non-AD dementias is less accurate
than that of'probable' AD resulting in calls for more specific clinical guidelines for
the diagnosis of non-AD dementias and the sub-division of the 'possible' AD group to
improve accuracy (Galasko et al., 1994). Joachim and colleagues (1988a) studied
the histological findings in an unselected group of 150 patients who came to autopsy
from multiple sources in several different US states, with a clinical diagnosis of AD
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made by many different physicians. In their study, 87% of those diagnosed clinically
as suffering from AD were found to have a pathological diagnosis of AD with or
without additional pathology. In two of their clinically demented subjects no
histological correlate for dementia could be found. They concluded that the wide
range of physicians involved in their study were highly accurate in their diagnosis of
clinical AD.
1.2 The Neuropathology of Alzheimer's Disease
1.2.1 Introduction
The first description of the clinicopathological condition that Alzheimer was to
establish as a distinct syndrome, appeared in 1865 in Wilhelm Griesinger's textbook
entitled Die Pathologie und Therapie der Psychischen Krankheiten (Thomas and
Isaac, 1987). He described a presenile dementing process, distinct from that due to
neurosyphilis or arterial disease, in which brain atrophy was a constant feature. The
gross atrophy, particularly of the temporal and frontal lobes which characterises AD,
is the result of extensive neuronal degeneration (Lishman, 1987). Mann (1996)
concludes, that the neocortical neurons lost in AD are primarily large pyramidal
cells; the same cells most affected by neurofibrillary tangle formation. Younger AD
afflicted subjects exhibit a more profound loss of these large pyramidal cells than
those individuals who develop the disease in old age. However, loss of large nerve
cells is a feature of normal ageing, thus total cell loss is the same in both groups of
patients (Mann, 1996). Astrocytosis is a feature of normal ageing, but the
proliferation of astrocytes is accentuated in degenerative diseases of the central
nervous system, including AD (Frederickson, 1992). In addition, subtle, but definite,
abnormalities in the blood brain barrier have been identified in AD (Stewart et al,
1992).
8
The neuropathological stigmata of AD are found throughout the cerebral cortex,
though there is relative sparing of the primary sensory and motor areas (Terry, 1993).
The most extensive neuropathological change within the cortex is seen in the medial
temporal lobe, including the parahippocampal gyrus, the entorhinal cortex, the
amygdala and the hippocampus, particularly CA1 (Pearson and Powell, 1989). AD
neuropathological change has been demonstrated to progress in a predictable fashion
(Pearson and Powell, 1989) from the most severely affected medial temporal lobe to
areas of association cortex in the parietotemporal and frontal lobes. Degeneration is
also seen in the projection neurons of the nucleus basalis of Meynert, locus ceruleus,
dorsal raphe and ventral tegmental area. The lower brainstem and spinal cord, in
contrast, are unaffected by the disease process and the cerebellum shows only
minimal involvement (Terry, 1993).
Microscopically, the major hallmarks of AD are the senile plaques and
neurofibrillary tangles first described by Alzheimer (1907). Both structures contain
amyloid, a generic term for a family of pathological, extracellular filaments, derived
from a variety of proteins, which share certain physical and optical properties
(Wisniewski, 1993). All amyloids are associated with two extracellular matrix
components, heparan sulfate proteoglycan and amyloid P component (Perlmutter et
al., 1994). In addition to these features, degeneration with Hirano body formation
and granulovacuolar degeneration, especially of the hippocampal pyramidal cells,
are also seen in AD (Wisniewski and Wegiel, 1992).
1.2.2 Plaques in Alzheimer's Disease
Plaques are active structures and exist in a number of forms thought to represent
stages in the development of the plaque from nascence to maturity (Mann at al.,
1989). The major proteinaceous component of AD plaques is P-amyloid, a 40 to 43
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amino acid cleavage product of amyloid precursor protein (APP) (Masters et al.,
1985a). Abundant cortical P-amyloid containing plaques are a feature not only of
Alzheimer's disease (McKee et al., 1991), but also of normal ageing (McKee et al.,
1991), Down's syndrome (Mann et al., 1986) and dementia pugilistica (Gentleman et
al., 1993).
Plaques are classified as diffuse or neuritic. Neuritic plaques may be either primitive
or mature: mature neuritic plaques are also referred to as senile plaques. Diffuse
plaques are amorphous collections of non-aggregated P-amyloid identifiable in
normal aged, AD and Down's syndrome brains (Frucht et al., 1992) and in the brains
of individuals with dementia pugilistica (Gentleman et a/., 1993). They are thought
to represent an early stage in plaque formation (Giaccone el al., 1989). Diffuse
plaques do not stain with classical silver staining techniques, nor do they exhibit
green birefringence on exposure to polarised light when stained with Congo red
(Yamaguchi et al., 1988). They fail to generate a neuritic reaction in the surrounding
neuropil and are not surrounded by reactive astrocytes or activated microglia.
Diffuse plaques are identifiable using antiserum to synthetic P-amyloid peptide
(Yamaguchi et al., 1988) or by the application of modified silver staining methods,
such as the Campbell-Switzer modification of the Hicks silver method (Campbell et
al., 1987) or Hedreen and colleagues (1994) modification of Bielschowsky-type
silver staining.
Primitive neuritic plaques are thought to represent an intermediate stage of plaque
development. Such plaques are surrounded by neuritic pathology and contain
irregularly aggregated fibrillary P-amyloid, but lack a central compacted core
(Wisniewski, 1993). Senile, or mature neuritic plaques, consist of a compacted,
spherical core of P-amyloid surrounded by a halo of activated microglia, reactive
astrocytes and distended, dystrophic axons, dendrites and synaptic processes (Wegiel
and Wisniewski, 1990). The activated microglia cover 80% or more of the surface
area of the amyloid core (Wegiel and Wisniewski, 1990). The core consists of
aggregated 7 to 10 qm fibrils of (3-amyloid (Wisniewski and Wegiel, 1992). Such
plaques are argyrophilic with classical silver stains and exhibit green birefringence
on exposure to polarised light following staining with Congo red, suggesting that the
(3-amyloid has adopted a (3-pleated sheet conformation (Wisniewski and Wegiel,
1992). Other components of senile plaque cores include aluminosilicates (Candy et
al., 1986), heparin sulfate proteoglycans, amyloid P component, nucleoside
diphosphatase, a-l-antichymotrypsin and cathepsins D and B (Frank and Greenberg,
1994).
1.2.3 Neurofibrillary Tangles and Dystrophic Neurites
Neurofibrillary tangles (NFT) are intracellular bundles of fragmented and twisted
fibres that occupy the perikarya of cells in a number of neurodegenerative diseases,
including AD. These fibre bundles are composed of paired helical filaments (PHF),
straight 10 qm filaments and combinations of both paired and straight filaments
(Markesbery et al., 1993). PHF consist of pairs of fibrils of 10-13 qm in diameter
wound around each other to form either a right handed or left handed helix.
Dystrophic neurites, also known as curly fibers or neuropil threads, are
ultrastructurally similar to NFT, but are located in dendritic and axonal processes
(Kowall and McKee, 1993). It is hypothesised that the disruption of fine neuronal
processes, consequent upon the formation of dystrophic neurites, results in NFT
formation and ultimately in cell death. While dystrophic neurites are associated with
senile plaques in AD (Iqbal et al., 1987), the majority are found in the neuropil
independent of senile plaques (Markesbery et al., 1993).
In 1985, Masters and colleagues concluded that the NFT was composed of the same
4 kDa peptide from which AD amyloid plaque cores and the cerebrovascular
deposits of amyloid in AD were formed (Masters et al., 1985b). Perry and
colleagues (1992) extended these observations, demonstrating that P-amyloid
immunoreactivity could be enhanced by pre-treatment with formic acid such that
previously unreactive extracellular NFT became immunoreactive. However,
Joachim and co-workers (1988b), in their protein chemical and immunochemical
study of cerebrovascular amyloid, provided data suggesting that NFT were not
composed of P-amyloid. In 1994 Zelman and colleagues attempted to clarify these
conflicting results by electrophoretically purifying PHF. They found PHF to be
largely composed of a 66 kDa peptide that was immunoreactive to antibodies raised
against the P-amyloid region of the carboxyl terminus of APP. Their data prompted
them to reject the hypotheses that PHF was contaminated by P-amyloid, or that the
two peptides shared homologous sequences, and conclude that conformational
homologies between P-amyloid and PHF were responsible for the cross-reactivity
observed between PHF and P-amyloid detecting antibodies.
The main protein constituent of PHF is believed to be abnormally
hyperphosphorylated tau, a major microtubule associated protein (Khatoon et al.,
1994) which forms part of the neuronal cytoskeleton. It is unclear whether
differences in amino acid sequence identified between PHF and tau are due to
contamination, alternative post-translational modification, or differing amino acid
composition, or indeed whether PHF contain other substances in addition to tau
(Iqbal et al., 1987). Soluble, abnormally hyperphosphorylated lau is also found in
the cytosol in AD. The phosphorylation state of tau in vitro has been demonstrated
to influence the speed and extent of microtubule assembly (Lindwall and Cole,
1984), and immunochemical studies in AD suggest that microtubule stability is lost
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in AD (Kowall and McKee, 1993). Like primitive and mature neuritic plaques,
NFTs are argyrophilic and congophilic due to their P-pleated sheet conformation.
Ultimately, the cell membrane may disintegrate releasing the NFT. Such 'ghost' or
'tombstone' NFTs are usually found in the entorhinal cortex and are unusual in
neocortex (Terry, 1993).
NFTs are not restricted to AD. They are also found in Guam Parkinsonism dementia
complex, dementia pugilistica, post-encephalitic Parkinsonism and Down's syndrome
(Iqbal et al., 1987). Thus, they can be found in neurodegenerative disorders of
traumatic, viral, toxic and metabolic origin. However, NFTs and dystrophic neurites
in the neocortex are constant neuropathological features in those individuals with
AD whose cognitive impairment is functionally significant (McKee et al., 1991).
The projection cells of the pre-a layer of the transentorhinal/entorhinal cortex are
among the first neurons in the brain to exhibit neurofibrillary change (Braak et al.,
1994). Further, Braak and colleagues (1994) have demonstrated that the formation
of dystrophic neurites and NFTs in this region is preceded by the appearance of
immunochemically detectable, abnormally hyperphosphorylated tau throughout the
entire nerve cell.
1.2.4 Meningovascular Amyloid
Cerebrovascular amyloidosis, the deposition of P-amyloid in the meningeal and/or
cortical vessels, is a virtually invariable accompaniment to AD, though its severity
varies widely (Joachim et al., 1988a). Initially, P-amyloid is found deposited
between the smooth muscle cells of the tunica media or in the cytoplasm of these
cells, but later is found in all layers of the walls of affected vessels (Frackowiak et
al., 1994). Mandybur (1975) found cerebrovascular amyloid to be variously absent,
minimal or severe in AD, and was unable to establish a clear relationship between
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the presence or degree of cerebrovascular amyloid and the age of the patient,
duration of their illness or the degree of cortical atrophy present. Glenner and Wong
first isolated, purified and sequenced cerebrovascular P-amyloid in 1984. The
following year Masters and colleagues purified and characterised the amyloid of
plaque cores in AD establishing the common origin of these proteins (Masters et al.,
1985a). The P-amyloid deposited in the cerebrovasculature in AD, however, is
subtly different from the P-amyloid found in AD plaques. The amino termini of
plaque P-amyloid are variable, possibly because they undergo processing in situ
(Masters et al., 1985a), whereas minimal heterogeneity is encountered in the amino
termini of vascular p-amyloid. Further, meningovascular P-amyloid has three
residues missing from the carboxyl end of the peptide such that it is generally 39
amino acids in length. In p-amyloid derived from AD and Down's syndrome plaque
cores, and from Down's syndrome meningovasculature, a glutamic acid residue is
found at position 11 (Masters et uL, 1985a). In contrast, in p-amyloid derived from
AD meningovasculature the glutamic acid residue is replaced by glutamate. These
findings were confirmed by Prelli and colleagues (1988) who hypothesised that P
-amyloid is processed in a tissue specific manner.
1.2.5 The Relationship between Senile Plaques and Neurofibrillary
Tangles in Alzheimer's Disease
In a study of mentally retarded adults without a history of Down's syndrome,
hydrocephalus or metabolic disorders, Silverman and co-workers (1993) found no
regional association between senile plaques and NFTs. They concluded that the
production of senile plaques and NFTs proceeds independently. In AD, the
relationship between senile plaques and NTTs remains elusive (Kowall and McKee,
1993) and controversial. However, since neuropathologically cases with numerous
senile plaques in the presence of minimal numbers of NFTs are seen and vice versa,
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the two lesions would appear to be independent of one another in the disease (Iqbal
et al., 1987).
Beta-amyloid load increases with age, but is not an invariable feature of aged brain
(McKee et al., 1991) and widespread and numerous senile plaques are found in
cognitively well-preserved elderly persons (Tomlinson 1970, 1968; McKee et al.,
1991). Kowall and McKee (1993) believe that P-amyloid deposition precedes
neurofibrillary pathology. In a study of brain tissue from Down's syndrome patients
of varying ages, whose morphological features are presumed to reveal an age-related
sequence of events in the development of the neuropathology of AD, Mann and
colleagues (1989) established that p-amyloid deposition occurred prior to the
development of dystrophic neurites or NFTs. Conversely, Braak and Braak (1991)
demonstrated that cortical neurofibrillary change occurred in a number of the AD
cases they examined histologically that had no evidence of P-amyloid deposition and
concluded that P-amyloid deposition is not a necessary prerequisite for
neurofibrillary change. Braak and Braak (1991) introduced the concept of
neuropathological stageing in AD, based on qualitative evaluation of the distribution
patterns of NFTs and dystrophic neurites. They point out that the development of
neuropathological change in AD is a seamless process, such that the differentiation
of AD from non-AD dementia is artificial (Braak and Braak, 1991).
1.3 Neurotransmitter Abnormalities in Alzheimer's Disease
The identification, in post-mortem human brain, of AD-specific neurotransmitter
dysfunction is complicated by the effects of agonal state, the instability of proteins
post-mortem and the variable length of post-mortem delay, and the fact that most
tissue examined post-mortem represents the end-stage of the disease. Numerous
abnormalities have been identified in neurotransmitter and neuromodulator levels in
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AD, in the concentrations of the enzymes that synthesise them and in the
morphology of the neurotransmitter and neuromodulator producing neurons
themselves (Selkoe, 1991). Projection neurons synthesising acetylcholine,
noradrenaline, serotonin and dopamine and cortical neurons producing gamma
butyric acid (GABA), glutamate, somatostatin, neuropeptide Y, cortocotrophin
releasing factor, substance P and other neuromodulators have been shown to be
affected in AD (Selkoe, 1991).
The cholinergic system was the first neurotransmitter system to be identified as
abnormal in AD and led to the cholinergic hypothesis of the disease. In 1976,
Bowen and colleagues demonstrated a reduction in choline acetyltransferase activity
in post-mortem AD brain; a finding replicated in numerous subsequent studies
(Palmer, 1996). Ante-mortem studies ofbiopsy tissue from AD sufferers has
confirmed that there is presynaptic cholinergic dysfunction in the disease and that
this is an early event in the pathogenesis of the disease (Palmer, 1996). Empirical
support for the cholinergic hypothesis comes from the demonstration of cognitive
deficits similar to those seen in individuals suffering from mild, but not moderate or
severe, AD in young and elderly persons treated with the cholinergic blocking drug
scopolamine (Christensen et al., 1992).
The reactive astrocytes found in association with senile plaques in AD have been
demonstrated in vitro to bear muscarinic acetylcholine receptors, suggesting that
astrocytes in this location may be responsive to acetylcholine and, therefore,
potentially to cholinergic drugs (Messamore et al., 1994). Further, Nitsch and
colleagues (1992) have demonstrated that the release of soluble APP derivatives
from a human embryonal kidney cell line transfected with the genes for human brain
muscarinic acetylcholine receptors, could be increased by stimulation of the ml and
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m3 muscarinic acetylcholine receptor subtypes. Thus, APP processing appears to be
under neurotransmitter control (Nitsch, 1996).
Palmer and colleagues (1987) demonstrated a presynaptic deficit in noradrenergic
transmission in a study of tissue from AD temporal cortex obtained ante-mortem.
Similar findings were obtained on examination of patients who had been
symptomatic for less than two years, suggesting that noradrenergic disturbance is an
early feature of AD. Post-mortem data suggestive of serotonergic dysfunction in AD
has been confirmed by ante-mortem work that has established serotonergic
denervation as an early feature of the disease (Palmer et al., 1987; Palmer, 1996).
Cortical dopaminergic function is preserved in AD (Palmer et al., 1987), though
neostriatal dopaminergic function may not be (Palmer, 1996). Abnormalities
observed in the GABA and somatostatin neurotransmitter systems in post-mortem
AD brain have not been confirmed in ante-mortem studies and likely represent either
the end-stage of the disease process or a post-mortem artefact (Palmer, 1996; Yates
etal., 1990).
1.4 Clinicopathological Correlations
Elucidation of the pathological correlates of cognitive decline in AD has been
fraught with difficulties. Initial studies suggested that the severity of dementia in AD
was related to the numbers of senile plaques, but later work has undermined this
conclusion (See Kowall and McKee, 1993 for review). McKee and co-workers
(1991) found that the number of NFTs and dystrophic neurites were correlated with
the clinical severity of dementia. Further, in their study, the presence of dystrophic
neurites in the neocortical neuropil successfully differentiated the AD subjects from
the control subjects. However, the authors specifically excluded those individuals
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with early or atypical features of AD and acknowledge that the presence of
dystrophic neurites might be a feature of individuals with AD who exhibit
functionally significant cognitive impairment rather than a marker of those with AD
per se. Other workers have found inverse correlations between the clinical severity
of dementia and the degree of cholinergic dysfunction (Perry et al, 1978; Palmer et
al, 1987; Palmer, 1996), loss of neurons (Neary et al, 1986; Procter, 1996; Mann,
1996; Palmer, 1996) and loss of synapses (Sambrook et al., 1989). Mann (1996)
points out that the strong correlations found between the degree of cognitive
impairment and the numbers of surviving pyramidal cells or synapses is not
unexpected, given that the latter two represent both damage accumulated over the
whole time course of the disease and the integrative capacity of the neocortex.
1.5 Factors Predisposing to the Development of Alzheimer's
Disease
1.5.1 The Genetics of Alzheimer's Disease
1.5.7.1 Introduction
Dissection of the heterogeneous and complex genetic underpinnings of AD (St
George-Hyslop et al., 1990) has proved both attractive to investigators and fruitful
(Schellenberg, 1995). The painstaking collection of family pedigrees and the
rigorous attention to accurate diagnosis of AD can proceed successfully even when,
as now, the aetiology and pathogenesis of AD remains largely obscure. Schellenberg
(1995) has likened the biochemical analysis of post-mortem human AD brain tissue
to molecular archaeology, yet genetic analysis is not without its difficulties. The
accurate diagnosis of AD, especially in older age groups where the diagnosis is
complicated by inter-current physical and psychological diseases and when other
causes of dementia, some of them superficially similar to AD, are common, is
fraught with difficulties. Further, AD is a common disorder, particularly among the
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old, so that family clustering need not necessarily indicate a common genetic basis
for the disease; it may represent, for example, a chance occurrence, or the presence
of more than one aetiologically distinct form of AD (Schellenberg, 1995). Finally,
the collection of large family pedigrees in which to examine the inheritance of AD is
problematic in a disease the prevalence of which increases with age, since some
individuals may succumb to other diseases before they could be expected to develop
the stigmata of AD (Schellenberg, 1995).
Approximately 15 to 20% of all cases of AD arise before the age of 65 years: a
subgroup referred to as suffering from early onset AD or pre-senile dementia. Of all
cases of AD developing before the age of 60 years, between 10 and 50% exhibit a
pattern of autosomal dominant inheritance with apparently complete penetrance, and
these family pedigrees are often referred to as suffering from Familial AD (FAD)
(Sandbrink et a/., 1996). In this discussion, the abbreviation 'FAD' will be used
solely to denote those cases of AD that exhibit this pattern of autosomal dominant
inheritance with apparently complete penetrance: cases which generally also present
at an early age. The unabbreviated term 'familial' will be retained to describe those
cases of AD for whom at least one first degree relative can be identified who also
suffers from the disease. Sporadic AD refers to those cases for whom no other
family members can be identified as suffering from the disease, though this by no
means implies that the disease is non-genetic in origin (Schellenberg, 1995).
Significantly, no consistent, recognisable clinical pattern can be discerned that would
allow differentiation of sporadic AD from FAD cases (Sandbrink et a/., 1996).
7.5.1.2 Amyloid Precursor Protein
The majority, if not all, of the FAD forms of AD have now been identified
(Sandbrink et al., 1996). Though they represent a minority of all cases of AD,
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elucidation of their genetic basis and exploration of the mechanism by which these
genetic abnormalities result in disease may point to fruitful avenues of research into
the more common sporadic form of AD. The association between Down's syndrome
and AD, and the localisation to the APP gene to chromosome 21, made the APP gene
an obvious target for study (Schellenberg, 1995). The first mutation in the APP gene
to be associated with neurological disease was a point mutation in codon 693 of exon
17 that results in the substitution of glutamic acid with glutamine. This mutation is
associated with Hereditary Cerebral Haemorrhage with amyloidosis of Dutch type, a
rare disorder with an autosomal dominant inheritance that results in extensive
amyloid deposition in the meningeal and cerebral microvessels. The disease is
characterised by recurrent cerebral haemorrhages from the age of 25 years with death
occurring prematurely in the sixth decade (Levy et al., 1990). The identification of
other mutations in the APP gene associated with FAD followed. John Hardy's group
at St. Mary's Hospital Medical School (Goate et al., 1991) identified a point mutation
in codon 717 of exon 17 which results in an amino acid substitution. In these
families, the amino acid three residues beyond amino acid 43 of p-amyloid, is
converted from valine to isoleucine. Two other point mutations in codon 717 of
exon 17 were identified in two other FAD kindreds which result in the substitution of
valine with glycine (Chartier-Harlin et al., 1991) and valine with phenylalanine
(Murrell et al., 1991). In 1992 a double mutation in exon 16 of the APP gene was
identified that co-segregated with the AD phenotype in two Swedish families with
early onset disease (Mullan et al., 1992). These two base pair changes result in the
substitution of two amino acids immediately preceding the P-amyloid sequence. The
Swedish double mutation results in the conversion of codon 670 from lysine to
asparagine and the conversion of codon 671 from methionine to leucine. A further
mutation has been identified within the P-amyloid sequence of APP that
co-segregates with a clinical presentation of cerebral haemorrhage and early onset
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dementia in a family of Dutch origin. This mutation at codon 692 results in the
replacement of alanine with glycine (Hendriks et al., 1992).
1.5.1.3 Apolipoprotein E and Alzheimer's Disease
The apolipoprotein E gene appears to act as a susceptibility gene for the
development of late onset sporadic AD (Saunder et al., 1993), sporadic AD (Rebeck
et al., 1993) and late onset AD in families in which at least one other member can be
identified who has the disease (Strittmatter et al., 1993). Apolipoprotein E is a
protein constituent of plasma lipoproteins that exhibits high affinity binding to the
low density lipoprotein (LDL) receptor, leading to cellular uptake and degradation of
cholesterol and other lipids. Two other receptors bind apolipoprotein E containing
complexes: the LDL receptor-related protein (LRP), also known as the
a2-macroglobulin receptor (Rebeck et al., 1993), and a postulated hepatic receptor
known as the 'chylomicron remnant receptor' (Mahley, 1988). While plasma
lipoproteins are crucial to lipid transport and cholesterol homeostasis (Pitas et al.,
1987), the precise function of brain apolipoprotein E is unknown, though it is
postulated to play a role in lipid transport, tissue repair, immunoregulation and the
modulation of cell growth and differentiation (Mahley, 1988). Since, unlike plasma,
there is no apolipoprotein B in cerebrospinal fluid (CSF), apolipoprotein E is a major
lipoprotein in the CSF.
Apolipoprotein E is secreted by astrocytes, including specialised astrocytic cells, but
not by neurons or other glia (Boyles et al., 1985). The CNS is second only to liver as
a source of apolipoprotein E. Rat astrocytes in primary culture possess LDL
receptors capable of binding and internalising apolipoprotein E containing
lipoproteins (Pitas et al., 1987). Furthermore, Pitas and co-workers (1987) have
demonstrated that LDL receptors are down-regulated by the internalisation of
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lipoprotein cholesterol. Thus, appropriate lipid metabolism in brain requires
co-ordination of both apolipoprotein synthesis and LDL receptor expression.
Three major apolipoprotein E alleles, s2, s3 and s4, exist at a single gene locus on
chromosome 19 (Das et al., 1985). The apolipoprotein E isoform s3 is regarded as
the parent form of the protein, with the s2 and s4 forms existing as variants (Mahley,
1988). Apolipoprotein E e2 differs from the parent form by a single amino acid: the
arginine at position 158 is replaced by a cysteine residue. Apolipoprotein E s4
differs from apolipoprotein E s3 at amino acid position 112 by substitution of the
cysteine for an arginine. Post-translational glycosylation results in a secondary form
of polymorphism of apolipoprotein E.
The different apolipoprotein E alleles appear to affect the rate of expression of AD
(Corder et al., 1993). Corder and co-workers (1993) studied individuals aged 60
years and above, both affected and unaffected by AD, who had a family history of
late onset AD. They observed that the proportion of AD afflicted individuals
increased with the number of s4 apolipoprotein E alleles, such that the rate of
development of AD was 20% of individuals bearing the genotype s2/s3 or s3/s3,
47% of individuals with the genotype s2/s4 or s3/s4 and 91% of subjects bearing the
s4/s4 genotype. The age of onset of the disease was also decreased in proportion to
the number of s4 alleles. The authors concluded that a double dose of the s4 allele
was virtually sufficient to cause AD by the age of 80 years. The apolipoprotein s4
allele is not, however, either necessary nor sufficient to cause AD, since between 50
and 60% of all AD patients do not possess such an allele (Schellenberg, 1995), and
not all s4/s4 individuals develop the disease (Sandbrink et al., 1996).
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Zubenko and co-workers (1994), in a series of autopsy-confirmed cases, confirmed
the association between apolipoprotein E s4 genotype and AD, though not the
association between the dosage of the e4 allele and the age of onset of the disease.
Kawamata and colleagues (1994), in their study of Japanese patients, found a
significantly increased frequency of the e4 apolipoprotein E allele in patients with
late onset sporadic AD, but not in those with early onset sporadic AD or in vascular
dementia compared with controls. However, Frisoni and co-workers (1994) found an
association between the apolipoprotein E s4 allele and not only AD, but vascular
dementia and dementia of the frontal type, in a Caucasian population.
The contention, that the association between apolipoprotein E s4 genotype and AD is
the result of a genetic linkage disequilibrium, is rejected by Tsuda and colleagues
(1994) who studied the allelic frequency of polymorphisms in the apolipoprotein E
and apolipoprotein CII genes in late onset AD and control subjects of Ashkenazi
Jewish origin. The authors found that the apolipoprotein E s4 genotype was
associated with late onset AD, but that apolipoprotein CII, which lies within 50 kb of
apolipoprotein E gene, was not. Thus, the authors demonstrated in this single ethnic
group that the two genes do not necessarily co-segregate. While they point out that
this does not exclude a genetic linkage disequilibrium, it makes it less likely.
Further, the association of apolipoprotein E genotype with late onset AD in diverse
ethnic groups argues against a spurious association between the two.
In vitro studies regarding the binding of apolipoprotein E isoforms to p-amyloid
have yielded conflicting results. Strittmatter and colleagues (1993) observed that the
P-amyloid peptide bound more avidly to the s4 than to the s3 form of apolipoprotein
E while, in contrast, LaDu and co-workers (1994) found a higher degree of binding
of P-amyloid to the s3 than to the s4 isoform. In addition, the
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microtubule-associated protein tau has been demonstrated to bind avidly, in vitro, to
the apolipoprotein E s3 isoform, but not to the s4 isoform (Strittmatter et al., 1994).
Strittmatter and colleagues (1994) demonstrated that it is the LDL receptor-binding
domain of apolipoprotein E s3 that interacts with tau. Tau adheres to apolipoprotein
E s3 through its microtubule-binding domain, the region believed to cause the
self-assembly of tau into paired helical filaments. The authors suggest that
interactions between tau and specific isoforms of apolipoprotein E may regulate the
metabolism of tau and influence the rate of formation of paired helical filaments and
NFTs. Wisniewski and his colleagues (1993) suggest, from their work on the
binding of apolipoprotein E to synthetic P-amyloid bound to affinity membranes,
that apolipoprotein E is capable of binding to soluble P-amyloid, a normally
occurring peptide in the CSF and other biological fluids.
In AD, apolipoprotein E immunoreactivity is present on NFTs and neuropil threads,
and on the amyloid of senile plaques and the congophilic angiopathy of cerebral
vessels (Namba et al., 1991). Wisniewski and Frangione (1992) suggest that
apolipoprotein E acts as a pathological chaperone that reduces the solubility, and
promotes the aggregation, of P-amyloid and other amyloidogenic proteins. Han and
colleagues (1994a), predictably, found immunochemical evidence of apolipoprotein
E in non-neuronal cells and tangle bearing neurons in AD. However, they also
identified apolipoprotein E in neurons free of neurofibrillary pathology in AD and in
the hippocampal neurons of aged, non-demented controls. They concluded that
apolipoprotein E is a feature of apparently normal hippocampal neurons in AD,
Parkinson's diseased and normal aged brain. Thus, since apolipoprotein E is
intraneuronal, it may be capable of influencing the development of neuronal
pathology in AD from its earliest stage (Han et al., 1994)
1.5.1.4 Presenilin 1 and Presenilin 2
It became clear that mutations in APP could not be responsible for most of the cases
of either FAD or late onset AD, since no linkage to chromosome 21 could be found
in studies involving large numbers of such families, and recombinants between the
APP gene and the FAD gene were found in a large numbers of FAD kindreds
(Schellenberg, 1995). Evidence of linkage of FAD to a locus on chromosome 14
was first made by Schellenberg and colleagues in 1992. In 1995, Sherrington and
co-workers identified five different missense mutations in a novel gene on
chromosome 14 referred to as SI82 and later renamed presenilin 1. In total thirty-
one FAD associated mutations have now been identified in this gene (Sandbrink and
Beyreuther, 1996), which is believed to encode an integral membrane protein that
spans the membrane between six and nine times (Sandbrink et al., 1996).
Sherrington and colleagues (1995) hypothesise that it functions as a receptor,
channel protein or structural membrane protein. Mutations in presenilin 1 are
believed to account for approximately 70% of all cases of FAD (Sandbrink et al.,
1996).
However, genetic linkage to chromosomes 21, 19 or 14 could not be established for a
smaller group of FAD families referred to as the 'Volga Germans', implicating a
further gene responsible for FAD. The Volga Germans emigrated from the Hesse
region of Germany to the Volga valley in Russia in the 1760's where they remained
culturally distinct from the local population. At the end of the nineteenth century a
further migration of this kinship to the USA occurred. Missense mutations amongst
these subjects have been identified by two research groups. Levy-Lahad and
co-workers (1995) discovered a point mutation in a gene on chromosome 1, later to
be denoted presenilin 2, that was highly homologous to the presenilin 1 gene on
chromosome 14 already discovered. The base substitution they uncovered in
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codon 141 resulted in the conversion of asparagine to isoleucine. The same
substitution was identified simultaneously by another group (Rogaev et al., 1995),
who documented a further point mutation at codon 239 resulting in the replacement
of methionine with valine in a family of Italian origin with pathologically confirmed
FAD.
Significantly, all of the FAD mutations examined thus far are associated with an
increase in the levels of extracellular P-amyloid(l-42), with or without increased
levels of extracellular P-amyloid(l-40) (Sandbrink and Beyreuther, 1996). However,
as Sandbrink and Beyreuther (1996) observe, only 10% of sporadic AD subjects
exhibit increased plasma P-amyloid(l-42) levels. Nevertheless, such a marker may
be of diagnostic importance in the future if it allows targeting of effective preventive
strategies if, and when, these become available.
1.5.2 Head Injury and Alzheimer's Disease
Severe head injury resulting in concussion is the environmental factor most
consistently associated with AD (Gentleman et al., 1993). Rarely, classical AD has
been documented to occur after a single severe head injury (Rudelli et al. 1982).
Dementia pugilistica afflicts approximately 17% of professional boxers as a result of
repeated head trauma (Roberts et al., 1990a) and the condition has also been
documented in a victim of repeated domestic violence (Roberts et al., 1990b). These
individuals exhibit cortical NFTs that are immunochemically and morphologically
indistinguishable from the NFTs of AD, and P-amyloid deposition in the form of
diffuse plaques. In addition, abnormalities of the septum pellucidum, cerebellar
scarring and loss of pigmented neurons in the substantia nigra (Roberts et al. 1990)
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are also seen. The link between trauma and AD is unclear, but Gentleman and
co-workers (1993) hypothesise that head trauma precipitates the deposition of
(3-amyloid in the brains of vulnerable individuals and that, further, the induction of
APP expression in brain is a neuronal response to stress.
1.5.3 Other Factors Relating to the Development of Alzheimer's Disease
1.5.3.1 Inflammation and Immune System Dysfunction
Several lines of evidence point to the involvement of immune and inflammatory
mechanisms in the pathophysiology of AD. The central amyloid cores of senile
plaques in AD are surrounded by a halo of activated microglia for which [3-amyloid
may be the chemotactic stimulus (Davis et a/., 1992). Glial-derived proteins, such as
al-antichymotrypsin, heparan sulphate proteoglycan, apolipoproteins E and J,
interleukin-1, interleukin-6 and other acute-phase proteins, are found in abundance
in AD plaque amyloid (Saitoh et al., 1997). Microglia, when activated, proliferate
and undergo phenotypic and morphological changes (McRae et al., 1997). They are
known to possess antigens of the major histocompatibility complex (MHC) whose
expression alters with the state of activation of the microglial cell (McRae et al.,
1997). Reactive microglia strongly expressing MHC surface glycoproteins are found
in the plaques and NFTs of AD (Palmer, 1996). Cytokines, particularly
interleukin-1, interleukin-6 and tumour necrosis factor, are the primary mediators of
the acute phase response (Aisen and Davis, 1994). Microglia are the primary source
of interleukin-1 in brain (Rothwell and Relton, 1993) and are likely to be pivotal to
the acute phase response in brain (Aisen and Davis, 1994). Resting microglia are
immunoreactive for (3-2 integrins, some of which are receptors for complement
proteins, and these molecules are up-regulated in reactive microglia (Akiyama and
McGreer, 1990). It is thus conceivable, that the co-localisation of senile plaques and
reactive microglia in AD is complement-mediated (Lue and Rogers, 1992).
Senile plaque amyloid and extracellular ghost tangles in AD are heavily decorated by
complement proteins of the classical complement cascade (Itagaki et al., 1994). The
classical cascade, however, is usually activated by immune complexes. Though
immunoglobulin deposition has been demonstrated immunochemically in AD brain,
such immunoreactivity does not co-localise with senile plaques (Eikelenboom and
Stam, 1982) and, indeed, may be artefactual, since extravascular leakage and uptake
of serum proteins into neurons, especially damaged neurons, has been demonstrated
in aged control and AD brains (Mori et al., 1991). P-amyloid has been
demonstrated, in vitro, to bind and activate Clq of the complement cytolytic
pathway, which leads to activation of the classical complement cascade, in the
absence of immunoglobulin (Rogers et al, 1992). Thus, P-amyloid may exert
neurotoxic effects through complement activation in an antibody independent
fashion (Aisen and Davis, 1994). Activation of the classical cascade of complement
leads to the formation of a macromolecule known as C5b-9 or the 'membrane attack
complex of complement' (MAC). This complex inserts itself into the lipid bilayer of
cell membranes forming transmembrane channels that are implicated in cell lysis
(Itagaki et al., 1994). Using immunochemical techniques, Itagaki and colleagues
(1994) demonstrated the presence of MAC-like deposits in association with
dystrophic neurites and tangle bearing neurons in AD, suggesting that these
structures are the targets of complement-mediated injury in the disease. The authors
postulate that complement activation occurs at sites of amyloid deposition and that
the resulting MAC inserts into neuronal membranes nearby. In a study of cerebellar
plaques, MAC immunoreactivity could only be identified in senile and not diffuse
plaques (Lue and Rogers, 1992). APP has itself been considered an acute phase
reactant since interleukin-1 and interleukin-6 dramatically influence its expression
(Aisen and Davis, 1994).
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Individuals taking anti-inflammatory drugs long term, such as those suffering from
rheumatoid arthritis, are believed to be less likely to develop AD (Palmer, 1996;
Wilcock, 1996), and Breitner and colleagues (1995) report that sustained use of
non-steroidal anti-inflammatory drugs is associated with a reduced risk, and delayed
onset, ofAD in sibships with a high risk of the disease. Rogers and colleagues
(1993) in a small, double-blind, placebo-controlled trial, found that 100 to 150 mg
per day of the non-steroidal anti-inflammatory drug indomethacin had a significant
protective effect in mild to moderate AD.
However, the usually encountered stigmata of inflammatory disease are not apparent
on physical examination of the AD patient (Aisen and Davis, 1994), and plasma
concentrations of acute phase reactants in AD sufferers are similar to those of
age-matched normal aged controls (Kalaria et al., 1996a), suggesting that any
inflammatory response is confined to the brain. Further, there is no direct evidence
that inflammatory or immune mechanisms result in the stigmata of AD, and the slow
progression of the disease is not in keeping with a disorder of inflammatory
aetiology (Aisen and Davis, 1994).
Nevertheless, in 1994 Aisen and Davis concluded that sufficient evidence had
accrued to warrant clinical trials of anti-inflammatory and immunosuppressive drugs
in AD and results of the drug studies performed to date, suggest that these drugs are
of some benefit in the disease (Wilcock, 1996; Kalaria et al, 1996a).
1.5.3.2 Educational Status
The prevalence of dementia, particularly AD, has been found to be inversely related
to educational status (Ott et al., 1995). This finding is reviewed by Katzman (1993),
who proposes that education mediates its protective effect by stimulating an increase
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in synaptic density in neocortical association areas. The consequent delay in the
emergence of the symptoms of AD results in a reduction in the prevalence of
dementia.
/. 5.3.3 Gender and Oestrogen Deficiency
Age-specific prevalence rates of AD are higher for women than for men, and some
studies suggest that the incidence rate of AD in women is higher also (Rocca et al,
1991). Some authors have proposed that oestrogen loss, associated with the
menopause, might contribute to the increased risk of AD for women (Paganini-Hill
and Henderson, 1994; Brenner et al., 1994). Henderson and colleagues (1994), in a
case-control retrospective analysis of oestrogen replacement therapy, found a
significantly lower rate of oral oestrogen use among AD subjects compared with
non-demented control subjects. AD subjects using oestrogen preparations at the time
of the study did not differ from non-oestrogen users suffering from AD in terms of
age, education or symptom duration, yet their mini-mental state examination scores
were significantly better. The authors concluded that post-menopausal oestrogen
replacement therapy may decrease the risk of AD and improve the cognitive
performance of women with the disease. In contrast, Brenner and colleagues (1994),
in a case-control study in which exposure to oestrogen was ascertained from
computerised pharmacy records, found no evidence that oestrogen exposure had any
impact on the risk of developing AD among women. In the light of the above
studies, Tang and co-workers (1996) interviewed 1124 elderly women, initially free
of AD, Parkinson's disease or stroke, about their use of oestrogen, and found that a
history of oestrogen use during the post-menopausal period significantly delayed the
onset, and lowered the risk, of AD.
1.6 Clinical Management of Alzheimer's Disease
Old age psychiatrists specialise in the care of people over the age of 65 years
suffering from mental illnesses including dementia. They clinically examine,
investigate and diagnose cases of dementia, and manage co-existing psychological
and behavioural disturbances. They also support carers, place elderly people in
appropriate care, gate-keep expensive investigations, advise on legal matters, such as
power of attorney, act as advocates for their patients and occasionally act as the
moral guardians of the elderly people in their care. They co-ordinate nursing,
home-help and social services, advise and support general practitioners and other
physicians, and liaise with voluntary bodies serving the elderly.
There are no drugs available, as yet, that are proven to be capable of preventing AD
or delaying its onset (Schneider, 1996). Amongst the most promising agents are the
cholinesterase inhibitors. Tacrine or l,2,3,4-tetrahydro-9-aminoacridine (THA) was
the first agent to be approved in the United States by the Food and Drug
Administration for the treatment of AD and is a reversible, non-selective inhibitor of
both acetylcholinesterase and butyrlcholinesterase. A statistically significant, though
clinically modest, improvement in cognitive function has been demonstrated with
THA (Rabins, 1996), though its use is complicated by an elevation in hepatic
transaminase in a substantial number of patients taking the drug (Schneider, 1996).
Donepezil hydrochloride (E2020) is a second generation acetylcholinesterase
inhibitor that was cleared for marketing for the treatment of AD by the Food and
Drug Administration in the USA in November 1996 and became the first UK
licensed treatment for AD, amid a blaze of publicity (Mcintosh, 1997), in April
1997. Donepezil hydrochloride, trade name Aricept, is a reversible selective
inhibitor of acetylcholinesterase that has little effect on peripheral
butyrylcholinesterase (Rogers et at., 1991). Improvements in quality of life and
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cognitive function have been demonstrated for donepezil hydrochloride in sufferers
of mild to moderate AD (Rogers et al., 1996). A month's supply of the 5 mg per day
starting dose of the new drug costs £68 while a month's supply of the 10 mg per day
dose costs £95. The approximate cost of donepezil hydrochloride per patient, per
year, is one thousand pounds, yet since this amount is only sufficient to pay for three
to four weeks of nursing home care, even slight clinical improvements as a result of
the drug may make it a financially defensible option (McKeith, 1997).
The availability of a drug in the UK licensed specifically for the treatment of AD has
profound implications for existing psychiatric and geriatric services. It is likely that,
aside from the expense of the drug itself, demands on resources will rise as referrals
for accurate diagnosis of dementia increase and existing services are forced to
monitor systematically the physical, cognitive, psychological and behavioural effects
of the drug on those individuals for whom it is prescribed. No doubt considerable
energy will also be expended counselling those for whom the drug is deemed to be
unsuitable. Further, autopsy confirmation of AD may become more attractive given
the hope of treatment in promptly recognised AD in surviving family members.
The interpretation of a double-blind, placebo-controlled, multi-centre trial of
selegiline and alpha-tocopherol in the treatment of moderately severe AD is
complicated by differences in mini-mental state scores at base-line between the
placebo and treatment groups (Sano et al., 1997). When the authors adjusted for
these differences in their analysis, both agents could be shown to significantly delay
functional deterioration in those with the disease. No effect on cognitive function
was observed. As Sano and colleagues (1997) point out, this finding requires
replication and extension to groups of patients with less advanced disease. Other
therapeutic approaches in AD include the use of muscarinic and nicotinic agonists,
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modifiers of acetylcholine release, monoamine oxidase inhibitors and growth factors
(See Schneider, 1996 for review).
1.7 Experimental Considerations
1.7.1 The Rationale for Using Human Post-mortem Tissue
The lack of a completely satisfactory animal model of AD is regarded by some as a
major obstacle to AD research (Games et ai, 1995). Animal studies allow the living
conditions, food and opportunities for socialisation of the animals, for example, to be
controlled. The animals can be killed, not only swiftly, but in a uniform manner and
dissection and freezing of the brain tissue can be rapid. The most promising animal
model of AD is a transgenic mouse expressing all three major isoforms of a mutant
human APP. These mice exhibit Alzheimer-like pathology in the form of numerous
extracellular fibrillar deposits of P-amyloid, neuritic plaques, synaptic loss,
astrocytosis and microgliosis. They do not, however, display NFTs: a major
neuropathological hallmark of AD (Games et a/., 1995).
The use of human tissue for molecular biological research certainly poses a number
of problems not encountered in animal work, yet these are not insurmountable, and
certain benefits accrue from the use of such tissue. Wisniewski (1993) has described
the brain as a 'multi-organ organ' with respect to the number of distinct, but
inter-related, functional groups of cells within it and, indeed, no less than a third of
the genome is committed to brain mRNA (Harrison and Pearson, 1989). No doubt
there are important species-specific aspects of brain function, such that no model of
a uniquely human neuropsychiatric disease like AD can be complete in all its
respects. Identifying and grappling with the difficulties posed by the use of human
tissue in experimental work allows us to work with the real disease: a crucial
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complement to animal and tissue culture work in arriving at a balanced
understanding of AD.
Consent for the use of tissue for research purposes can be faced squarely with human
subjects, though requesting permission for autopsy is not without its difficulties
(Turner and Raphael, 1997). Further, the confirmation of AD already requires
removal of tissue at autopsy or biopsy for neuropathological examination (Powers et
al., 1992). It is also conceivable that identifying the problems inherent in the use of
human tissue for research, and adapting to accommodate them, may expand the
number of applications for which human tissue is suitable. It is likely that demand
for accurate post-mortem diagnosis of AD will increase in the future, in order to
refine diagnosis of the disease during life now that drugs specifically aimed at AD
are available. It is conceivable that the availability of tissue for research purposes
will increase also.
Tissue from brain biopsy is rarely available in the UK, most tissue being obtained at
post-mortem. The processing of post-mortem brain can be time-consuming. The
brain must be manipulated from the cranium, weighed, examined for evidence of
gross pathology and dissected, before tissue can be taken for freezing. Scrutiny of all
aspects of the handling of post-mortem human tissue is necessary if it is to be
optimally preserved.
It is possible to extract approximately 600 pg/g of total RNA from post-mortem
human tissue, and no significant differences in yield of either total RNA or mRNA
per gram of tissue have been demonstrated between normal and diseased human
post-mortem brains (Leonard et al., 1993). However, the yield, intactness and
activity of RNA may vary several fold between individual human brains (Barton et
al., 1993; Harrison et al., 1995). Ross and colleagues (1992) found that the
difference in mRNA levels between sample groups was dwarfed by inter-individual
differences in mRNA. This study is instructive since, though differences in the
interval between post-mortem and freezing of the tissue between the sample groups
was addressed, pre-mortem factors such as pyrexia, drug use, hypoxia and mode of
death, were not. Such heterogeneity in routine clinical samples may necessitate the
use of large numbers of subjects to ensure statistically meaningful results (Leonard et
al, 1993) and render minor differences in RNA between sample groups invisible
(Barton et al., 1993). Similarly, AD subjects must be appropriately and carefully
matched to a control group of subjects free of neurological disease. In addition,
positive controls, such as individuals suffering from non-AD neurodegenerative
conditions like Picks disease, multi-infarct dementia and Parkinson's disease, are
useful in controlling for non-specific factors associated with chronic
neurodegenerative brain disease (Harrison et al., 1991a). Three other factors are of
importance in the use of post-mortem human tissue for the study of mRNA: the
interval between death and freezing of the tissue, known as the post-mortem interval
or PMI, the pre-mortem course of the patient's illness, also known as the agonal state,
and storage of the tissue prior to use.
1.7.2 The Effect of Agonal State on RNA levels in Post-mortem Human
Brain
No effect of agonal state has been demonstrated on overall levels or activity of RNA
in post-mortem human brain (Barton et al., 1993). However, there is evidence that
some mRNAs are vulnerable to the effects of agonal state (Barton et al., 1993),
while others are not (Harrison et al., 1993). Harrison and colleagues (1991a), in a
study of temporal cortex from individuals with AD and other neurodegenerative
conditions, found no association between total polyadenylated mRNA levels and
duration of coma. However, glutamate decarboxylase (GAD) activity and Ml
muscarinic receptor mRNA levels both significantly declined in association with
increasing duration of coma. Other mRNA species, such as hsx70 a member of the
70 kDa heat shock protein family, appear to be uninfluenced by agonal state factors
such as pyrexia and coma (Harrison et al., 1993). The basis of this selective
vulnerability of mRNA species to the effects of agonal state is unknown (Barton et
al., 1993).
In 1976, Bowen and colleagues demonstrated that GAD activity in post-mortem
human brain was affected by agonal state and hypothesised that terminal cerebral
hypoxia was responsible for its depletion. Tissue pH is also related to the severity of
agonal state (Harrison et al., 1995; Yates et al., 1990) and has been found to be a
useful measure of pre-mortem acidosis and hypoxia (Barton et al., 1993). Yates and
co-workers (1990) found GAD activity to be correlated with tissue pH and lactate in
human post-mortem brain and concluded that acidosis, consequent upon terminal
hypoxia, has a detrimental effect on GAD activity. Harrison and colleagues (1995)
concluded that the pH of homogenised brain tissue was superior to clinical
assessment of pre-mortem course in predicting the preservation of mRNA. A linear
relationship exists between brain and CSF pH and, moreover, brain pH is stable after
death and during freezer storage (Harrison et al., 1995). Harrison and co-workers
(1991b) found no relationship between pH and poly(A+) mRNA levels in human
post-mortem brain, and though they demonstrated that some mRNA species were
vulnerable to pH, others were not. The study of enzyme activity in post-mortem
human brain has similarly revealed that the activity of some enzymes is influenced
by pH while others are resistant to the effects of acidosis (Yates et al., 1990).
Kingsbury and co-workers (1995) studied a large series of normal and neurologically
diseased subjects and found that tissue pH was strongly correlated with the
preservation of four specific mRNA species: aldolase C, an enzyme, (3-tubulin, a
structural protein, and preproenkephalin and preprotachykinin, both neurotransmitter
peptides. Acidotic samples were associated with low or absent ISHH signal over all
three brain regions studied, and electrophoresis and Northern blotting of these
samples demonstrated little intact ribosomal RNA. Age of the subjects at death did
not appear to influence the vulnerability of mRNA to degradation. Most of the
diseased brains employed in this study were obtained from individuals who had
suffered from Parkinson's disease and no association was identified between brain
disease and brain tissue pH. Further, mRNA preservation was similar in control and
diseased brains of similar pH. While Kingsbury and colleagues (1995) found no
difference in the relationship of pH to mRNA across the three brain areas studied,
Harrison and colleagues (1995) suspect that there may be regional differences in the
response of mRNA to pH.
1.7.3 The Effect of Post-mortem Interval on RNA Levels in Post-mortem
Human Tissue
The effect of PMI has been extensively studied in relation to post-mortem human
tissue (See Barton et al., 1993 for review). Ross and co-workers (1992) found RNA
degradation correlated poorly with PMI, and Leonard and colleagues (1993), in their
examination of the suitability of brain bank tissue for RNA work, concluded that
PMI was unlikely to be a significant factor in the degradation of RNA. Robinson
and co-workers (1994) found no relationship between RNA degradation and a PMI
of up to 24 hours. Barton and colleagues (1993), in a review of the subject,
concluded that abundant and biologically active RNA exists in human tissue frozen
36 or more hours after death, and that as such routine autopsy tissue is suitable for
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RNA studies. Harrison and co-workers (1995) have confirmed, in the rat, the
robustness of RNA to the effects of increasing PMI, demonstrating no effect of a
PMI of up to 48 hours. Data from rat studies also confirm that no changes in mRNA
occur in the first few hours after death, a time period inaccessible to investigators
using post-mortem human tissue (Harrison et al., 1995), and this concurs with the
findings in biopsied human tissue (Barton et al., 1993). Kingsbury and colleagues
(1995) found no correlation between PMI and mRNA preservation among either
their control or neuropathologically diseased subjects, suggesting that the presence of
disease does not make mRNA degradation with increasing duration of PMI more
likely.
Unsurprisingly, no correlation has been demonstrated between poly(A+) mRNA
levels and PMI (Barton et al., 1993). The conclusion, however, that all mRNA
species are equally impervious to PMI may be erroneous (Leonard et al., 1993;
Barton et al., 1993), since as Barton and co-workers (1993) caution, the effect of
PMI on peptides is selective and, while disease state, age and region of brain (Ross et
al., 1992) have not been demonstrated to influence the sensitivity of mRNA to PMI,
it cannot be concluded that this is invariably the case (Barton et al., 1993). Robinson
and colleagues (1994), in a study of post-mortem human neocortex, found that
sensitivity to degradation differed between mRNA transcripts, and Burke and
co-workers (1991) found the three major isoforms of APP mRNA to be differentially
affected by pre-mortem and post-mortem variables.
Johnston and co-workers (1996a) employed solution hybridisation-RNase protection
assay to examine the effects of PMI on APP mRNA levels in AD brain and in the
brains of non-demented controls and those with other neurological diseases. This
technique can be performed on fragmented mRNA and is sensitive; it can detect 1 pg
of target mRNA and so does not require target amplification using the polymerase
chain reaction. Johnston and colleagues (1996a) found a significant correlation
between increased duration of PMI and reduced APP, APLP2 and KPI-containing
isoforms of APP mRNA in the superior frontal, but not mid-temporal cortex, in AD.
No correlation between PMI and mRNA reduction was observed for the control
groups, even though the longest PMI in the AD group was only 280 minutes while
the PMI in the control groups were generally longer than this. Johnston and
colleagues (1996a) speculate that a region-specific loss of APP and APLP2 mRNA
may be occurring in AD tissue in the hours immediately following death that are
masked by using longer PMI. In contrast, Harrison and colleagues (1994) found no
effect of PMI on APP mRNA levels in the frontal cortex in AD in a series of rapid
autopsy brains using ISHH. The longest PMI of the brains used was 210 minutes. It
is conceivable that solution hybridisation-RNase protection assay is more sensitive to
the amounts of specific mRNA species than ISHH. In conclusion, while it appears
that PMI is not a barrier to the use of human post-mortem tissue for RNA research,
specific mRNA species in specific brain areas may be adversely affected by PMI.
Therefore, scrupulous attention to matching pre-mortem and post-mortem variables
between diseased and control subjects is advised (Burke et al., 1991).
1.7.4 Freezer Storage of Post-mortem Human Tissue
Leonard and co-workers (1993) concluded that less than five years freezer storage of
post-mortem human tissue does not significantly diminish the yield of mRNA, but
that storage of tissue for more than five years might be detrimental to specific
mRNA species. Harrison and co-workers (1995) found no loss of any of the eight
species of mRNA they studied in post-mortem human brain with freezer storage of
up to 33 months at -70°C. There is widespread agreement, however, that repeated
thaw-freeze cycles are deleterious to mRNA (Ross et al., 1992; Harrison et al..
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1995). The true limit of freezer storage of post-mortem human tissue is unknown
(Harrison et al., 1995).
1.8 Aims and Objectives
Gene expression encompasses all of the events from the transcription of
deoxyribonucleic acid (DNA), the genetic basis for heredity, into messenger
ribonucleic acid (mRNA), to the delivery of a functionally competent protein to the
correct location. Messenger RNA is, thus, a key intermediary in gene expression
(Harrison et al., 1991) and accounts for between 3% and 5% of total cellular RNA.
Messenger RNA levels are dynamic and accessible to study using techniques such as
RNA extraction, purification of mRNA from total RNA, Northern blotting, reverse
transcription, the polymerase chain reaction, in vitro translation and in situ
hybridisation histochemistry. The presence of a specific mRNA indicates that the
region or cells examined are actively transcribing the corresponding genes and are
synthesising the encoded protein. Further, in general, the abundance of a given
mRNA reflects the rate of synthesis of the encoded protein (Harrison el al., 1991b).
As is usual in RNA research (Barton et al., 1993), this study concentrated on the
examination of a number of specific species of mRNA, although in some cerebral
regions measurements of total mRNA were also made. The techniques of RNA
extraction, Northern blotting, reverse transcription, amplification of reverse
transcribed mRNA by the polymerase chain reaction and in situ hybridisation
histochemistry were employed in this study to explore mRNA levels in an attempt to
elucidate further the molecular underpinnings of AD.
The brain in AD is characterised by abnormal peptide aggregations in the form of
P-amyloid containing plaques and NFTs, and by the persistence of usually
short-lived peptides such as ubiquitin, a member of the evolutionarily conserved heat
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shock protein family. It is unclear whether increased gene expression, unusual
stability of the peptide produced, failure of the degradative pathways or a
combination of these factors, results in the abnormal accumulation of these peptide
forms.
The expression, in AD, of two specific mRNA species, Goa, a member of the
heterotrimeric G protein family involved in signal transduction, and ubiquitin, a
peptide that tags abnormal and short-lived proteins in an energy dependent process in
preparation for their proteolysis, was addressed in this thesis. The rationale for the
selection of these particular species of mRNA in relation to AD is discussed fully in
the appropriate chapters. However, the main body of work contained in this thesis
addresses the expression of APP mRNA in AD. The deposition of P-amyloid
appears to play a fundamental role in the pathophysiology of AD (Wilcock, 1996)
and simple overexpression of APP, as is proposed to be the case in Down's
syndrome, might be one mechanism by which the aggregation of P-amyloid is
triggered (Harrison et al, 1996). However, although the question as to whether APP
mRNA expression in the brain is indeed altered in AD is a pivotal one, it has been
exceedingly difficult to answer unequivocally (Harrison et al, 1996). The basis upon
which an attempt was made to answer this question definitively was as follows.
Brain tissue was carefully selected from a large number of human post-mortems. In
some cases this tissue was characterised by the availability of pre-mortem and
post-mortem information unparalleled in its detail. Control and diseased brains were
assiduously matched for known confounding variables and accepted methods of
handling the raw data generated were critically appraised. Following the exacting
prosecution of this work, the advice of a biomedical statistician was sought to ensure
that the complex statistics performed on the raw data were exemplary and the





In situ hybridisation histochemistry (ISHH), the main technique employed in this
thesis, has been described as an elegant synthesis of molecular biology and histology
(Palmert et al, 1988). This method is particularly apposite to the study of complex
heterogeneous populations of cells such as exists in the central nervous system, since
in allows scrutiny of gene expression within both discrete anatomical regions and
single cells.
ISHH allows the detection, localisation and relative quantitation of mRNA species
by the use of specifically designed and tagged probes. The tendency for the basic
side chains of single stranded nucleic acids to form stable bonds in a highly specific
way is the principle upon which ISHH is based. The nucleic acids DNA and RNA
are linear polymers composed of nucleotides. Each nucleotide is composed of a
pentose, a phosphate group and a basic side-chain. The basic side-chains, the
purines guanine (G) and adenine (A), and the pyrimidines, cytosine (C), thymine (T)
and uracil (U), form base pairs according to the following rules: G forms three bonds
with C, and A forms two bonds with T, in DNA, or U, in RNA. Where the
nucleotide sequence of a target mRNA is known, a strand complementary to it, and
in the reverse orientation, can be synthesised. Under predetermined conditions this
'probe' is allowed to hybridise to the mRNA of the tissue specimen under
investigation. Appropriate tagging of the probe allows the hybrids to be detected by
either autoradiographic or histochemical means. Accompanying controls are
designed to minimise the risk of the probe hybridising to a similar, but unrelated,
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mRNA and to quantify the extent of non-specific binding of the probe to the tissue or
glass slide.
Messenger RNA is transcribed from nuclear DNA by RNA polymerase II. Within
the nucleus, the introns of the primary transcript are spliced out and a cap of
7-methylguanosine attached to the 5' end. A sequence of adenylate residues attached
to the 3' end of the mRNA, the poly(A)+ tail, is also added to most mRNAs before
they are transported, fully matured, to the cytoplasm. The presence of a particular
mRNA in the cytoplasm of a cell is suggestive that the cell is actively synthesising
the encoded peptide, and in an amount proportional to the abundance of the mRNA.
Of course, ISHH cannot guarantee the integrity of the detected mRNA or establish
that it is being translated normally, nor can it provide assurance that any protein
produced will reach its correct destination and be functionally active on its arrival.
ISHH in this study was performed on cryostat cut frozen tissue sections mounted on
glass slides. It therefore allowed the examination of specific mRNAs without
disruption of the surrounding tissue, permitting not only regional, but cellular,
localisation of the mRNA under study. Clearly, ISHH, which can allow examination
of a specific region or cellular type, has important advantages over techniques that
involve the homogenisation of a mixed population of cells.
The probes employed in this thesis were 30 to 45 base oligodeoxynucleotide probes,
commercially synthesised to order, and 3' end labelled with radioactive p^sjdATP.
Radioactive labels have the advantage of superior sensitivity over non-radioactive
methods and the particles emitted by this isotope are of relatively low energy (167
keV) permitting single cell resolution of ISHH signal. While excellent accuracy is
also achievable with the low energy particles (18.5 keV) emitted by [^H], the
12.35 year half life, and therefore long exposure times required by this isotope,
preclude its convenient use. In this respect [-^S] with its 87.5 day half life and thus
relatively short exposure times compares favourably. While the half life of P^P] is
only 14.2 days, the high energy (3 particles emitted by this isotope (1.6 MeV) result
in relatively poor spatial resolution of ISHH signal and necessitate the use of
appreciable protective shielding.
2.2 Preparation for ISHH
Endogenous and exogenous ribonucleases, capable of degrading the desired target
mRNA, are ubiquitous. Precautions were taken to eliminate, as far as possible,
contamination by ribonucleases. Deionised purified water, incubated with
diethylpyrocarbonate (DEPC) and subsequently autoclaved, was used for all
solutions. Prepared solutions, glassware and plasticware were autoclaved before use.
Disposable, sterile gloves were used throughout the procedure.
2.3 Collection of Post-mortem Human Brain Tissue
Four series of brains were used in the course of this work, the details of which are
presented in appendix II. Series I and II comprised brains collected mainly from
Oxford (courtesy of Drs. B. McDonald and M. Esiri, Radcliffe Infirmary) but also
from the North Middlesex Hospital, London (courtesy of Dr. W.J. Harrison).
Donated control brains, in these series, were accepted from individuals clinically free
of neuropsychiatric disease. Series III was obtained from the Oxford Study to
Investigate Memory in Ageing (OPTIMA) project (courtesy of Drs. P.J. Harrison, Z.
Nagy, B. McDonald, M. Esiri, C. Joachim, J. Morris, L. Barnetson and A.D. Smith).
The use of brains from Series III afforded the opportunity to study tissue obtained
from individuals, both dementia sufferers and age matched controls, who were
extensively investigated during life. Series IV comprised selected cases from Series
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II and Series III, supplemented by cases studied by two other independent
investigators working in Professor Pearson's laboratory, Dr. A.J. Barton and Dr. M.
Griffith.
The brains were dissected by Drs. P.J. Harrison, B. McDonald and Prof. M. Esiri
(Department of Neuropathology, University of Oxford) or Prof. P. Lantos (Medical
Research Council Brain Bank, Department of Neuropathology, Institute of
Psychiatry, London). All AD cases were diagnosed clinically and satisfied standard
histopathological criteria for the disease (Khachaturian, 1985).
At post-mortem, tissue blocks of approximately 1 cnC were taken from visual cortex
(Brodmann area 17), middle temporal gyrus (Brodmann area 21) and
mid-hippocampus. Tissue blocks from Series I and II were embedded in OCT
embedding compound on a dry ice and alcohol slurry and stored at -70°C in
individual plastic bags. Series III tissue blocks were mounted on cork discs with
OCT embedding compound and stored at -70°C in individual plastic bags. Ten pm
(Series I and II) or eighteen pm (Series III), fresh frozen sections were cut on a
Bright cryostat at -20°C with the assistance of Mr M.W. Sanders and Miss J.M.
Heffernan, and thaw mounted on subbed slides (see appendix I). Thereafter, the
sections were stored at -20°C for less than two weeks until pre-treated. The sections
were labelled with individual codes that gave no indication as to diagnosis; thus
sections were processed blind to case details.
2.4 Pre-treatment of Cryostat Cut Frozen Tissue
Pre-treatment of the mounted, cryostat cut, frozen sections prior to ISHH had three
objectives: to preserve tissue RNA, protect the cytoarchitecture of the tissue and
minimise non-specific binding of the radio-labelled oligodeoxynucleotide probes
(Heath et al, 1996). In addition, the fixative chosen had to permit adequate
penetration of the probe.
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The sections were allowed to thaw at room temperature and then transferred to
autoclaved racks. Where possible, solutions and equipment were autoclaved before
use. All solutions used were at room temperature and the procedure was carried out
in a fume hood. The following solutions were used:
4% paraformaldehyde/phosphate buffered saline 5 minutes
Phosphate buffered saline Brief rinse
Triethanolamine hydrochloride/acetic anhydride 10 minutes
Phosphate buffered saline Brief rinse
70% ethanol 2 minutes
80% ethanol 2 minutes
95% ethanol 2 minutes
100% ethanol 2 minutes
Chloroform 10 minutes
100% ethanol 1 minute
95% ethanol 1 minute
Paraformaldehyde (PFA) was freshly prepared before use, because of its tendency to
polymerise on standing, and particular care was taken to time this step accurately.
PFA, an aldehyde fixative, acts by promoting cross-linking of tissue proteins and
combines superior mRNA retention and good tissue morphology with adequate
probe penetration. An approximate physiological solution with buffering capacity,
phosphate buffered saline, was used to rinse the tissue.
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The acetic anhydride acetylates basic proteins and neutralises negative charges on
the glass slides, preventing electrostatic binding of the radio-labelled
oligodeoxynucleotide probe to the specimen and surrounding slide. It cannot be
autoclaved and was added to the triethanolamine immediately prior to use.
Following dehydration of the tissue by immersion in increasing concentrations of
alcohol, delipidation of the sections was achieved by a ten minute incubation in
chloroform. Lipids are present in high concentration in nervous tissue and promote
troublesome non-specific binding of oligodeoxynucleotide probes. The sections
were air dried, returned to their boxes and stored at -20°C until needed.
Pre-treatment solutions were discarded after treatment of approximately 200
sections. For details of all solutions see appendix I.
2.5 Oligodeoxynucleotide Probe Selection
DNA probes are inherently more robust than RNA probes. The shorter the
nucleotide sequence chosen as the probe, the higher the chance of this same
sequence existing in another unrelated mRNA. In practice probe sequences of 30 to
45 bases can be highly target specific. Full length probes show poorer tissue
penetration than oligodeoxynucleotide probes, require higher hybridisation
temperatures, with the risk of tissue damage, and are obviously unsuitable for
investigation of alternatively spliced variants of a single gene. The incorporation of
radioactively labelled bases into full length probes can improve sensitivity of signal
when investigating a very low copy gene or when using less suitable tissue. In this
study, however, 3' end labelling, in which approximately 10 labelled bases are added
to each oligodeoxynucleotide probe, provided perfectly satisfactory sensitivity in
relation to the mRNA species examined.
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HPLC purified oligodeoxynucleotide probes were purchased from Oswel DNA
Services (Edinburgh) and later obtained from the UK Human Genome Mapping
Project Resource Centre free of charge. Oligodeoxynucleotide probes of 30 and 45
bases, that were complementary, and in the reverse orientation, to the region of the
target mRNA selected, were designed and synthesised to order. The published
cDNA sequence of the mRNA under investigation was scanned for an area of 30 or
45 nucleotides of which approximately 50% had guanine or cytosine bases. A higher
GC content increases the stability of the probe-mRNA hybrids and so increases the
required hybridisation and wash temperatures. Areas of the mRNA likely to encode
amino acid sequences shared with other functionally related proteins were avoided.
Sense oligodeoxynucleotide probes with an identical sequence of bases in the same
orientation as the target region of the mRNA species to be examined, were
synthesised to allow for correction of non-specific binding.
The proposed sense and antisense sequences were checked against the European
Molecular Biology Laboratory gene database to establish whether the same
nucleotide sequence, with up to 4 mismatches, existed in another published
sequence. Such a precaution does not, of course, exclude the possibility that another,
as yet unidentified mRNA exists with a similar nucleotide sequence to which the
probe might bind. If no homologies were found the oligodeoxynucleotide probe was
ordered. Where other considerations were pertinent to probe selection they are
discussed in the individual chapters.
The oligodeoxynucleotide probes were stored at a concentration of 2 pmoles/ql in 50
pi aliquots at -70°C until needed.
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2.6 Calculation of Melt Temperature
The stability of the oligodeoxynucleotide probe-mRNA hybrids depends on a number
of factors such as the number of GC as opposed to AT bonds maintaining the hybrid,
the degree of mismatch between the probe and the mRNA, the concentration of
sodium ions and the presence of destabilising agents, such as formamide, in the
hybridisation buffer, the length of the probe and the temperature at which
hybridisation and washing take place. The temperature at which 50% of the hybrids
spontaneously dissociate the 'melt temperature' (Tm) is calculated according to the
following formula (Davis et al, 1986):
Tm (°C) = 16.6 log[M] + 0.41 [Pgc] + 81.5 - Pm - B/L - 0.65[Pf]
Where:
M is the molar concentration of sodium ions to a maximum of 0.5. (0.5 for the
concentration of sodium ions during hybridisation and 0.195 for the concentration of
sodium ions during washing).
Pgc is the percentage of G and C nucleotides in the oligodeoxynucleotide probe
sequence.
Pm is the percentage of mismatches between the oligodeoxynucleotide probe and the
target mRNA.
Pf is the percentage of formamide in the buffer.
B is 675 for synthetic oligodeoxynucleotide probes of up to 100 bases.
L is the length of the oligodeoxynucleotide probe.
Temperatures of 15°C below the calculated hybridisation and wash temperatures
were found to give adequate specificity without loss of sensitivity.
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2.7 Preparation of 35s Labelled Oligodeoxynucleotide Probes
The antisense and sense oligodeoxynucleotide probes employed in this study were 3'
end labelled with [-'^SJdATP. Approximately 10 radioactively labelled
deoxyadenylate nucleotides, not themselves specific for the target sequence, were
added to each oligodeoxynucleotide probe. The oligodeoxynucleotide probes used
were prepared and purified using a commercially available kit (NEN/DuPont
oligonucleotide 3' end labelling system). Sterile gloves were worn throughout the
procedure and all plasticware used was autoclaved before use. 3' end labelling of the
probes with [^^S]dATP (NEN/DuPont) was carried out as detailed below.
The following reagents were added, in order, to a 1 ml sterile centrifuge tube:
7.5 pi pure water
5 pi oligodeoxynucleotide probe (2 pmol/pl)
2.5 pi cobalt chloride
12.5 pi terminal transferase reaction buffer
The tube was tapped to mix the reagents and then centrifuged for a few seconds.
Vortexing was avoided to prevent shearing of the oligodeoxynucleotide probe. 5 pi
of P^sjdATP (NEN/DuPont) was then added and the mixture tapped and
centrifuged as before. Finally, 2.5 pi of terminal deoxynucleotide transferase, stored
in a bench top freezer box, was added to the centrifuge tube. After mixing and
centrifugation the tube was placed in a water bath at 37°C for 1 hour. At the end of
the incubation period the reaction was stopped by the addition of 400 pi of Reagent
A (NEN/DuPont) and the tube was cooled on ice.
After labelling, the p^sjdATP labelled oligodeoxynucleotide probe was
chromatographically purified from any unincorporated nucleotides, excess salt and
low molecular weight materials using a commercially available nucleic acid
purification cartridge (NENSORB: NEN/DuPont). Gentle tapping concentrated the
sorbant in the bottom of the cartridge which was then clamped vertically. The
cartridge lid was replaced with an adapter that allowed an air-filled syringe to be
fitted to the top of the cartridge. The sorbant was then activated by the application of
2 ml of 100% methanol to the top of the sorbant. Gentle, constant pressure applied
to the air-filled syringe pushed the alcohol through the sorbant. Once the meniscus
reached the top of the sorbant, 2 ml of Reagent A (NEN/DuPont) was applied to the
top of the sorbant and likewise pushed through the cartridge. Care was taken to
ensure that the sorbant did not dry out at any stage in the procedure. The sample
containing the labelled probe was then applied to the top of the cartridge and pushed
through the sorbant. The effluent, containing any unincorporated nucleotides, was
collected in centrifuge tube number 1. Any excess salt, low molecular weight
materials and remaining unincorporated nucleotides were washed from the cartridge
by pushing through a further 2 ml of Reagent A (NEN/DuPont), which was collected
in centrifuge tubes 2 and 3. The radio-labelled probe was then eluted from the
sorbant with 1 ml of 50% ethanol. Three drops of the resulting effluent were
collected in tube 4, 14 drops in tube 5, 5 drops in tube 6 and the remainder was
collected in tube 7. Less than 30% of the radioactivity was expected to be in tubes 1
to 3 with most of the radioactivity being in tube 5.
The efficiency of the labelling was measured by mixing a 5 pi aliquot from each tube
with 1 ml of scintillant and measuring on a scintillation counter. The radioactivity,
in counts per minute, was calculated for tube 5 and used to determine what volume
of the purified, radio-labelled probe was required to give 10^ counts per minute. The
probe was stored at 4°C until use, which was always within 24 hours of purification.
Where several labelling reactions were required to produce sufficient labelled probe,
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the probes were pooled, mixed and re-measured to eliminate any differences
between the batches.
2.8 In situ Hybridisation Histochemistry with [35s]dATP
Oligodeoxynucleotide Probes
A stock solution of 20 x standard citrate solution (SSC) was prepared and autoclaved
before use. Deionised, purified water was incubated overnight with 1 ml of
diethylpyrocarbonate per litre before being autoclaved. Sections from each brain
were hybridised in triplicate with antisense probe. The selected tissue sections were
placed in lidded bioassay dishes (Nunc) lined with two layers of absorbent paper
(Whatman number 3MM) soaked in 4 x SSC. All sections were marked with the
name of the probe and appropriately labelled as sense or antisense for later
identification.
Hybridisation buffer was prepared in advance and stored at -20°C until required.
Before use, the hybridisation buffer was thawed, boiled for 10 minutes and then
quenched on ice. The final hybridisation solution per section consisted of the
volume of radio-labelled probe required to give 10^ counts per minute, 1 pi 1 molar
dithiothreitol (DTT) and sufficient hybridisation buffer to achieve a final volume of
100 pi. 100 pi of hybridisation solution was applied to each section and evenly
spread. Sections were then covered with a piece of laboratory film (Nescofilm) and
hybridised in an incubator for approximately 18 hours at the appropriate temperature
A bioassay dish of 4 x SSC was placed in the base of the incubator to ensure that the
atmosphere was kept moist.
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2.9 Experimental Controls for ISHH
The controls employed were designed to verify that any ISHH signal detected was as
a result of specific hybridisation of the chosen oligodeoxynucleotide probe to the
particular mRNA under investigation, and not from non-specific binding of the
oligodeoxynucleotide probe to other macromolecules, or its specific hybridisation to
another mRNA species.
The specificity of hybridisation in human brain for each of the oligodeoxynucleotide
probes employed in this thesis was determined by Northern blotting. The probes
were labelled with [32p]dATP and hybridised to 25 jug total RNA extracted from the
frontal cortex of a control subject. The number, size and abundance of the mRNAs
to which the labelled oligodeoxynucleotide probe hybridised was estimated by the
position and intensity of the band(s) on gel electrophoresis and compared with
published data. Northern blotting was performed by Drs. A.J. Barton, P.J. Harrison
and P.R. Heath solely to verify the specificity of the oligodeoxynucleotide probes.
In each ISHH experiment, concurrent hybridisation of a [^SjdATP labelled sense
oligodeoxynucleotide probe, identical in nucleotide sequence to the mRNA under
study, was used to assess the extent of non-specific hybridisation. The labelled sense
probe was applied to a sub-sample of the tissue sections to be examined. These
sense sections were then hybridised under identical conditions to the antisense
sections.
Abolition of ISHH signal was demonstrated by diluting labelled antisense probe
100-fold with unlabelled antisense probe. Where an antisense probe binds
specifically to a selected mRNA species, the number of binding sites is finite and an
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excess of cold, unlabelled antisense probe can monopolise available sites and
displace the radioactively labelled antisense probe.
The volume of purified, radio-labelled, antisense probe required to give 10^ counts
per minute per section was calculated and aliquotted into a separate centrifuge tube.
This volume was increased 100-fold by the addition of unlabelled antisense probe.
This diluted probe was then substituted for the normally radio-labelled probe in the
hybridisation solution which was prepared in the normal way. Hybridisation,
washing and detection of ISHH signal was performed as described. Concurrent
sections hybridised with normally prepared [^SjdATP labelled antisense probe
served as positive controls.
Finally, loss of ISHH signal was demonstrated on pre-treatment of a sub-sample of
tissue sections with a solution containing the ribonuclease, RNase A (Sigma). The
sections were incubated in the solution for 60 minutes at 37°C prior to the other
pre-treatment steps. (For preparation of ribonuclease pre-treatment solution see
appendix I.)
2.10 Post-Hybridisation Washing
After overnight incubation, the laboratory film (Nescofilm) covers were removed
from the sections, along with any unhybridised probe, by washing in a large volume
of 1 x SSC at room temperature. The slides were racked and stored in 1 x SSC at
room temperature in preparation for the high stringency washes. A wash
temperature 15°C lower than the calculated melt temperature was used. This
temperature, and the salt concentration of 1 x SSC, is believed to provide a
reasonable level of stringency. Care was taken to ensure that the sections did not dry
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out at any stage of the washing procedure as this can result in a significant increase
in background labelling.
The sections were washed in I x SSC at the calculated wash temperature for 15
minutes. This wash was repeated three further times. Two separate hour long
washes in 1 x SSC at room temperature followed. Finally, the sections were rinsed
briefly in distilled water to remove any salt residue and allowed to air dry.
2.11 Direct Autoradiography
Once dry, the slides were mounted on cardboard in lightsafe cassettes and opposed
against autoradiographic X-ray film (Hyperfilm-Pmax, Amersham) at room
temperature for an appropriate amount of time to generate autoradiograms.
Hyperfilm-Pmax (Amersham) is an X-ray film composed of a flexible plastic base
coated on one side with a photographic emulsion of high sensitivity protected by an
anti-scratch layer. This film type is designed for use in direct autoradiography in
which film and sample are in intimate contact, and it is relatively insensitive to the
blue and ultraviolet light produced in indirect autoradiography by the use of
fluor-impregnated substrates and intensifying screens (Amersham, 1992). Direct
autoradiography is suitable for the detection of -^^S, since the layer of photographic
emulsion overlying the sample absorbs most of the weak p particles emitted by this
radioisotope.
A photographic emulsion consists of numerous photosensitive silver halide, usually
silver bromide, crystals suspended in a clear solution composed mainly of gelatin.
Beta particles have the same mass and single negative charge as electrons, and are
ejected from radioactive nuclei in order to achieve stability (Rogers, 1979). Beta
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particles striking the silver halide crystals in the emulsion cause reduction of some of
the silver ions to atoms of metallic silver. This change produces what is known as a
latent image. On development of the film, these silver atoms catalyse the reduction
of the entire silver halide crystal in which they are located to a tiny particle or grain
of metallic silver. Since a single hit by a (3 particle is sufficient to convert an entire
silver halide crystal to a grain of silver on development of the film, the blackening of
an autoradiographic film is directly proportional to the amount of radioactivity
reaching it (Laskey, 1993). Silver halide crystals which remain unchanged are
washed away during the development process leaving the film transparent.
2.12 Development of Autoradiograms
One litre each of developer, stop solution and fixative, diluted to the appropriate
concentration with purified, deionised water, was required to develop two
autoradiographic films. The cassettes were opened in a dark room illuminated under
safe light conditions. The films were gently agitated in a solution of llford PQ
Universal Developer at a concentration of 1 part developer to 9 parts water for 5
minutes. The developer reduces silver ions to metallic silver in a self catalytic
process which is far faster in crystals already containing atomic silver (Rogers,
1979). The reaction was stopped by immersing the films in a 2% acetic acid solution
for 30 seconds and the films were then fixed by gently agitating them in a solution of
1 part Ilford Hypam Fixer in 4 parts water for 5 minutes. The lowered pH of the 2%
acetic acid solution stops the development of the film and slightly hardens the
gelatin. The fixative solution is designed to wash away any unchanged silver halide
crystals remaining in the emulsion. The films were then immersed in running tap
water for approximately 30 minutes before being hung up to air dry. Once dry, the
autoradiograms were labelled with a permanent marker and the films stored ready
for regional quantification of ISHH signal.
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2.13 Dipping of Slides for Autoradiography
For cellular localisation of hybridisation signal, the sections were removed from the
cardboard inserts lining the lightsafe cassettes under safe light conditions and
assembled in racks. An appropriate volume of Ilford K5 Photographic Emulsion was
melted in a water bath at 45°C and then mixed with an equal volume of distilled
water to which a drop of glycerol had been added. The solution was stirred gently to
mix and poured into a slide container set in a beaker of water in the water bath. A
number of blank slides were dipped in the emulsion to ensure that it was free of
bubbles and coated the slides evenly before the experimental slides were dipped.
Each slide was lowered into the emulsion for 5 seconds and then slowly and steadily
withdrawn. The emulsion was wiped from the back of each slide which was then
placed on a cold plate for 15 minutes to allow the photographic emulsion to gel.
Once set, the slides were laid out to dry at room temperature for approximately 3
hours. The dry slides were racked and placed in black plastic boxes sealed with
adhesive tape and wrapped in two layers of silver foil. A package of silica gel was
placed in each box as a drying agent. The boxes were sealed in black plastic bags
and stored in a refrigerator for the appropriate exposure time for the individual
probe; approximately two to three times the length of time required to generate
autoradiograms.
2.14 Development of Dipped Autoradiographic Sections
Under safe light conditions the dipped autoradiographic sections were allowed to
warm to room temperature. The adhesive tape sealing the black boxes was stripped
from all of them before any were opened, to prevent artefactual exposure of the
sections to sparks of light. The developer, stop solution and fixative used were
diluted with purified, deionised water. The slides were gently agitated in Ilford
Phenisol Developer, 1 part to 4 parts water, for 2 minutes and then transferred to a
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2% acetic acid solution for 30 seconds. The lowered pH of the acetic acid solution
halts the process of development while slightly hardening the gelatine in which the
silver bromide crystals of the emulsion are suspended. The slides were then
immersed in a fixative solution of 30% sodium thiosulphate for 5 minutes to dissolve
any silver bromide crystals remaining in the emulsion. Some of the silver
thiosulphate complexes produced during this process are light sensitive, thus safe
light conditions were maintained until the 30 minute wash in gently running tap
water, designed to wash the fixative out of the emulsion, was completed. The slides
were then briefly rinsed in purified, deionised water and allowed to dry.
The developed sections were counter-stained by immersion in a 0.1% cresyl violet
solution for 1-2 minutes and then dehydrated by passage through a series of alcohols
of increasing concentration. Once dehydrated, the sections were immersed in xylene
until coverslipped using DePeX (BDH Laboratory Supplies) as a mountant.
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2.15 The Calculation of Optical Density
Since the energy from a single P particle is sufficient to reduce an entire silver halide
crystal to a grain of metallic silver on subsequent development of the photographic
film, the local blackening of the film is directly proportional to the amount of
radioactivity reaching it (Laskey, 1993). Thus, the response of autoradiographic
X-ray film to exposure to ionising radiation is conventionally measured by
estimating the optical density of the developed film. Optical density is a measure of
the extent to which an object prevents light from passing through it and has been
confirmed by several workers as being proportional to the mass of silver per unit area
(See Mees, 1942 for review). Essentially, optical density is the ratio of the
transmitted to the incident light expressed as a logarithm to the base 10. Thus:
Since the transmitted light must always be less than, or equal to, the incident light
and the logarithm to the base 10 of a number between zero and 1 is always negative,
this logarithm is always either a negative number or zero. By convention, in
reporting optical densities, this negative sign is omitted since it conveys no useful
information.
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Where A = transmitted light and B = incident light, then:
Optical density = log 10
or
Optical density = log 10 A - log 10B
and
-Optical density = - log 10,4 +log 10#
therefore
- Optical density = log 10
or




The intensity of light transmitted through the autoradiographic films was measured
using one of two image analysis systems. Both systems, like most video based
systems, were calibrated to assign the amount of light transmitted through an object
of optical black to zero. Pure white light was registered by both systems as having a
value of 255 and shades of grey were linearly assigned to the numbers between zero
and 255. Incident light, presumed to be pure white light, is therefore a constant and
the calculation of negative optical density yields the positive number required by
convention. The final version of the equation is thus:
- Optical density = log 10
V transmitted lighty
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2.16 The Relationship Between Optical Density and Radioactive
Exposure
The optical density of a developed direct autoradiogram is linearly related, within
certain limits, to the exposure to radioactivity of the film (Laskey, 1993). A direct
plot of exposure against optical density with respect to ionising radiations yields a
straight line at low densities (Goldstein and Williams, 1971). This is in contrast to
the classical sigmoid Hurter-Driffield curve which is more suited to the study of
multi-hit processes such as characterises the response of photographic film to visible
light (Goldstein and Williams, 1979; Rogers, 1979). With intensive or prolonged
exposure to ionising radiation all of the available silver halide crystals in the
photographic emulsion are reduced to metallic silver and optical density reaches a
plateau. Accurate quantitation, therefore, requires exposure levels which do not
saturate the absorbance of the film (Laskey, 1993). Similarly, at low levels of
radioactivity the errors inherent to the system becomes so great in relation to the
response to be measured as to render optical density measurements inaccurate.
2.17 Problems Associated with the Measurement of Optical
Density
In practice the measurement of optical density is problematic. Each system
employed to measure optical density must be individually calibrated to ensure that it
does so accurately. The measurement of optical density, using the image analysis
systems employed in this study, required that the sample be illuminated using
monochromatic light and that those parts of the stabilised light source not directly
below the video camera were masked. Further, it was determined that optical black
was not precisely registered by either system as having an optical density of zero, and
it is known that such offsets in optical density may vary with time and temperature
(Aldridge, 1993). In view of these limitations the term 'approximate optical density'
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(AOD) is used throughout this study in acknowledgement of the inaccuracies
inherent in the system.
2.18 The Application of Radioactive Standards
The relationship between radioactive exposure and approximate optical density was
studied in my system using ^Carbon (^C) standards. Miller (1991) studied the
response of Hyperfilm (Amersham), a single coated autoradiographic film, to both
labelled standards and 35s labelled brain paste, and demonstrated a simple
linear relationship between the two. Further, the optical density obtained by
exposing autoradiographic film to 35s at various concentrations and for various
exposure times, covaried with the response of the film to the '^C labelled standards,
suggesting that the film responded similarly to the two isotopes. Miller concluded
that labelled standards provide a reliable means of calibrating the response of
autoradiographic film to 35s.
14c microscales (Codes RPA 504 and RPA 511, Amersham) were opposed to
autoradiographic film alongside specimen sections and analysed at the same time as
the related experiment and in the same way. These microscales are composed of
eight (RPA 504) or ten (RPA 511) individual sheets of 14c polymer sandwiched
between alternate layers of coloured, inactive, methacrylate polymer. An average
approximate optical density reading was obtained for each radioactive layer of the
polymer. This value was plotted against the tissue equivalent radioactivity of that
layer in qCi/g as supplied by the manufacturer. As predicted, a linear relationship
was demonstrated between the two at low optical density readings. Details of the
calibration of individual experiments is presented in the appropriate chapter.
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2.19 Quantification of Autoradiographic Film
Two similar image analysis systems were employed in the analysis of the
autoradiographic films produced during this study: Image Manager PC, Sight
Systems, Newbury and Seescan Pic, Cambridge. Image analysis systems allow rapid,
accurate and consistent estimation of greyness of autoradiographic films. Certain
precautions, however, are necessary to ensure the accuracy and reproducibility of
data.
The film was transilluminated on a stabilised light box and a charge coupled device
(CCD) camera employed to produce a computerised image of the specimen on a
video monitor. The camera aperture and magnification that afforded the clearest
representation on the video screen of the tissue section to be measured was
determined at the outset of analysis. These settings were then maintained without
change until the analysis of an individual experiment was complete.
The video signal provided by the camera is achieved by scanning the image
horizontally from top left to bottom right, dividing the screen into an array of 512
separate points or 'pixels' horizontally and 512 pixels vertically. The image at each
pixel is digitised and stored.
Before capturing on the video screen the image to be measured, a blank portion of
the same autoradiogram was analysed, to allow estimation of the extent to which the
film itself inhibited the passage of incident light. Since this varies slightly from film
to film, a blank portion of each new film was measured before analysis began.
During so called 'shade correction' the recorded intensity of light transmitted through
the image is adjusted pixel by pixel to take into account the effect of the barrier
presented by the film itself. In order for this adjustment to be valid, the incident light
63
and the configuration of the image capturing optics must remain constant between
measurement of the blank film and measurement of the image. For this reason the
use of a stabilised light box, which provides a constant, diffuse and even light,
constant ambient lighting and the avoidance of overhead glare are crucial. At the
start of each experiment an antisense specimen was chosen as a control and was
measured at the beginning of each session of image analysis and at frequent intervals
during sessions to ensure the reproducibility of the results. It became clear that the
apparatus required a minimum period to 'warm up' after which the grey levels
obtained were gratifyingly reliable.
2.20 Correction for Non-Specific Binding
Sense oligodeoxynucleotide probes, identical in nucleotide sequence to the mRNA
under study, were employed to assess the extent of non-specific binding. Initially,
sections from a subset of cases were hybridised with the sense probe and a mean
sense AOD reading obtained for each diagnostic category examined. However, the
diagnosis specific mean AOD for the sense sections were often identical, since sense
strand hybridisation tends to be uniform and virtually negligible, resulting in the
same value being subtracted from each antisense AOD. In some experiments a
suitable sense oligodeoxynucleotide probe was not available and the antisense
readings were therefore not corrected for non-specific binding. Ideally, an AOD
reading for the appropriate sense probe would be available for each case employed,
allowing the antisense readings for each individual case to be corrected for
non-specific binding. This was attempted with Series III (the OPTIMA series) where
an additional section was selected from each case and hybridised with the
appropriate sense probe. Subsequent careful scrutiny of the calibration curves
generated for these probes suggested that the very low sense AOD readings obtained
were often beyond the linear extent of the relationship between AOD and estimated
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tissue radioactivity. It was, therefore, decided that it was not meaningful to subtract
such sense AOD readings from the AOD readings obtained for the corresponding
antisense probe.
The problems inherent in correcting for non-specific binding and the methods chosen
to resolve them are discussed in the individual chapters.
2.21 Quantification of Autoradiographic Slides
Intensity of ISHH signal on dipped slides was estimated by counting the average
number of silver grains per unit area over specific cells using the semi-automated
image analysis systems described above. In addition to the principles discussed
above in relation to the quantification of autoradiograms, a number of other
considerations are important in quantifying ISHH signal over cells.
Quantification can only be carried out at a cellular level if the cells are sufficiently
dispersed to allow the signal derived from one cell to be clearly identifiable. The
system was first calibrated using a graticule and then optimised for the clear
visualisation of silver grains without the loss of cellular outlines. The threshold of
the image analysis system was optimised empirically to ensure that all of the silver
grains visible by eye were identified, and measured, by the system. The average area
of a silver grain was estimated by measurement of the total area of numerous clumps
of silver grains followed by counting by eye the number of silver grains in each
clump. The average area of a silver grain was then entered into the image analysis
equipment. Three sections labelled with antisense probe were available from each
case. Approximately 17 cells were selected from each of three fields of each section.
A final measure of silver grain counts per unit area of cell was obtained. The
average silver grain count over the sense sections was subtracted from the antisense
65
readings to eliminate the effect of background labelling. Since an approximately
linear relationship exists between number of silver grains and radiation dose
(Goldstein and Williams, 1971), it is not necessary to transform logarithmically the
readings obtained.
2.22 Statistical Analysis




The Application of the Quantitative Polymerase Chain
Reaction to Analysis of Reverse Transcribed Gsa mRNA
3.1 Introduction
3.1.1 The Heterotrimeric G-Proteins
The heterotrimeric G-proteins represent a family of highly homologous proteins
attached to the cytoplasmic leaflet of the plasma membrane that are involved in
signal transduction. Approximately eight out of ten neurotransmitters and hormones,
as well as many autocrine and paracrine factors, rely on the heterotrimeric
G-proteins to communicate with the interior of the cell (Birnbaumer et al., 1990).
Heterotrimeric G-proteins are composed of subunits of decreasing molecular weight
named a, (3 and y and bind guanosine phosphate moieties, hence their name. The a
subunit confers specificity of action on the G-protein, is hydrophilic (Graziano et aI.,
1987) and possesses weak, inherent guanosine triphosphatase (GTPase) activity
(Northup et al., 1980). The P and y subunits exist as dimers that are believed to
anchor the a subunit to the plasma wall (Sternweis, 1986; Graziano et al., 1987).
At rest, the heterotrimeric G-proteins exist predominantly as trimers with guanosine
diphosphate (GDP) attached to the a subunit (See Birnbaumer et al., 1990 and
Gilman, 1987 for review). Ligand occupancy of a G-protein linked receptor, results
in a conformational change in the receptor that allows it to attach to an appropriate
G-protein. Association of a ligand-bound receptor with a G-protein results in the
release of GDP from the a subunit and the binding of guanosine triphosphate (GTP).
The binding of GTP to the a subunit reduces the affinity of the ligand for the
receptor leading to an alteration in the equilibrium of bound to unbound first
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messenger. The [3y dimer dissociates from the activated a subumt that now has the
capacity to modify the activity of the downstream effector systems for which it is
specific. Within seconds, the inherent GTPase activity of the a subunit results in the
hydrolysis of GTP to GDP whereupon the G-protein is inactivated and the trimer
reassembles.
Two characteristic features of heterotrimeric G-protein-mediated signal transduction
are worthy of note. Firstly, it allows amplification of the first messenger borne
signal. Both the G-protein-coupled receptor and the G-protein itself can move freely
in the plasma membrane such that a ligand-bound receptor can activate numerous
G-proteins before the release of its bound ligand. Moreover, each activated
G-protein is capable of activating numerous downstream effectors before its bound
GTP is hydrolysed to GDP and it is returned to its inactive state. Secondly, since the
active conformation of a G-protein is intrinsically short-lived and persistent
activation is only possible in the continued presence of first messenger, the system is
supremely sensitive to alterations in the hormonal milieu.
Four groups of G-protein a subunits have been identified (Lyons, 1994). The first
group includes Gsa and the olfactory a subunits that are capable of activating adenyl
cyclase. The second group includes the inhibitory a subunits Gi 1, Gi2, Gi3, Go and
transducin. These inhibitory G-proteins are vulnerable to ADP-ribosylation by the
ATP dependent ADP-ribosyltransferase present in the neurotoxin released by the
bacteria Bordetella pertussis. The Gq group of a subunits activate phospholipase C
and are pertussis toxin insensitive. The fourth group includes G12 and G13; a
subunits that have been demonstrated by sequencing to be distinct from the other
three groups. The (3 and y subunits are tightly associated under non-denaturing
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conditions (Watson and Arkinstall, 1994). Five different (3 and seven different y
chains are known to exist (Watson and Arkinstall, 1994).
3.1.2 The a Subunit of Gs
Gs was first isolated by scientists working in Alfred G. Gilman's laboratory in 1980
(Northup et al., 1980). Three subunits of Gs, of molecular weights 52 000, 45 000
and 35 000, were identified on sodium dodecyl sulphate-polyacrylamide gel
electrophoresis. Subsequent purification and characterisation of Gs (Sternweis et al.,
1981; Codina et al., 1984) established that the 52 000 and 45 000 molecular weight
subunits of Gs were two forms of the Gsa protein. The large and small molecular
weight isoforms of Gsa protein, and the mRNAs on which they are encoded, are
designated Gsa-L and Gsa-S respectively. It has been established unequivocally that
Gs stimulates the catalytic subunit of adenyl cyclase (May et al., 1985), a
membrane-bound enzyme which displays strict Gs selectivity (Cooper et al., 1990).
Adenyl cyclase catalyses conversion of its physiological substrate magnesium-ATP,
into cAMP, and is inactive in the absence of Gs. Gs has also been implicated in the
regulation of magnesium ion transport across the plasma membrane (Maguire et al.,
1980) and in the inhibition of the calcium pump responsible for the extrusion of
ionic calcium in rat liver (Jouneaux et al., 1994). Yatani and co-workers (1987) used
excised membrane patches from guinea pig cardiac myocytes and bovine cardiac
sarcolemmal vesicles to demonstrate that Gs could activate voltage-gated calcium
channels directly. Three of the four isoforms of Gs were subsequently shown to
activate both adenyl cyclase and voltage-gated calcium channels (Mattera et al.,
1989). It is of interest that constitutive activation of the G-protein linked adenosine
A2 receptor in transgenic mice has been linked with chronic over-stimulation of the
cAMP cascade and ultimately oncogenesis.
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Stemweis and colleagues (1981) proposed that the 52 000 molecular weight species
of Gsa, Gsa-L, was more rapidly activated by GTP analogues, and was the more
efficient hormone-stimulated activator of adenyl cyclase, than the 42 000
polypeptide, Gsa-S. Initially, Graziano and his colleagues (1987) inserted
complementary DNAs encoding both forms into plasmid vectors in Escherichia coli
and found them to be equally active. However, in subsequent experiments Gilman's
team (Graziano et al., 1989) demonstrated that though the rate of GTP hydrolysis is
similar for both species, the rate of dissociation of GDP from Gsa-L is 2 to 3 fold
faster than the rate of GDP dissociation from Gsa-S.
Gsa undergoes dynamic palmitoylation which helps determine its subcellular
location (Mumby et al., 1994). The covalent attachment of the fatty acid palmitate
to the amino terminal cysteine residue of Gsa, through a labile thioester bond,
promotes stable association of Gsa with the plasma membrane (Wedegaertner and
Bourne, 1994). Activation of Gs is associated with the rapid depalmitoylation of its
a subunit and its translocation to the cytoplasm (Wedegaertner and Bourne, 1994).
Gsa is also a substrate for the ADP-ribosyltransferase contained in the toxin
produced by the bacteria Vibrio cholerae. ADP ribosylation of arginine 201 of Gsa
results in constitutive activation of the G-protein due to a marked reduction in its
GTPase activity (Weinstein and Shenker, 1993).
3.1.3 The Structure of the Human Gsa Gene
The Gsa gene has been analysed in rat (Itoh et al., 1986), cattle (Graziano et al.,
1987; Robinshaw et al., 1986a; Robinshaw et al., 1986b), rabbit (Graziano et al.,
1989) and man (Harris, 1988; Bray et al., 1986). Study of complementary DNAs and
human genomic DNA (Kozasa et al., 1988), indicates that four splice variants of Gsa
exist in humans generated by alternative splicing of a single gene located on
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chromosome 12. The Gsa gene is a split gene that spans approximately 20 kilobases
and is composed of 13 exons and 12 introns (Kozasa et al., 1988). It is probably the
most remote of the G-protein a subunits since it includes two large sequences not
seen in other G-proteins (Itoh et al., 1986). The four splice variants of Gsa mRNA
are generated by the inclusion or exclusion of a span of 45 nucleotides encoded on
exon 3, and by the use of a variable splice junction at the end of intron 3 (Kozasa et
al., 1988). The cDNA encoding Gsa-1 contains exon 3 alone while Gsa-2 contains
both exon 3 and 3 additional nucleotides, deoxycytidylate, deoxyadenylate and
deoxyguanylate (CAG) that are split between two codons and result in an additional
serine residue at position 87 (Bray et al., 1986). Gsa-3 contains neither exon 3 nor
the additional 3 nucleotides and Gsa-4 contains the 3 nucleotides only, and thus
contains an extra serine residue at position 72. The four isoforms of Gsa are
illustrated in figure 3.1. This splicing model implies the use of an unusual 3' splice
junction, TG-AG, instead of the usually strictly conserved sequence of GT-AG. The
variable splice junction at the end of intron 3 results in the three additional
nucleotides, CAG, being present in two of the four isoforms of Gsa. This serine
residue is a potential site of phosphorylation by protein kinase C (Kishimoto et al.,
1985), but not by cAMP-dependent protein kinase A (Bray et al., 1986). Exon 3 is
unique to Gsa and encodes a hydrophilic amino acid sequence located on the surface
of Gsa which is hypothesised to have a functional role in the regulation of adenyl
cyclase (Kozasa et al., 1988).
3.1.4 Studies of Gsa Messenger RNA
In screening a human brain cDNA library, Bray and colleagues (1986) detected four
types of Gsa cDNA that differed in nucleotide sequence in the region corresponding
to amino acid residues 71 to 88. The authors hypothesised that four types of Gsa




























of two splice variants of Gsa mRNA. Since the two long and two short forms of
Gsa mRNA differ by only 3 nucleotide residues, the authors suggest that these three
unpaired bases were not appreciably cleaved by S1 nuclease and hence could not be
demonstrated using this assay. Granneman and colleagues (1991) studied the pattern
of mRNA splicing of Gsa in human adult brain using a method based on the
polymerase chain reaction (PCR). Products of 285 and 325 base pairs were
generated and separated on gel electrophoresis on a 2 to 3% agarose gel containing
ethidium bromide. Gsa-L was found to account for 84% of total Gsa mRNA in the
hippocampus and cortex, but only 66% of total Gsa mRNA in the striatum. Since
the serine-encoding form of Gsa-S mRNA contains a BsmAl restriction site, it was
possible to determine the contribution of this form of Gsa-S to the total amount of
Gsa-S mRNA. Approximately 40% of Gsa-S mRNA is serine-encoding and no
regional variations were found in the amount of this splice variant. This method
relies heavily, however, on the complete digestion of Gsa-2. No such restriction site
could be identified in the exon 3-containing splice variants of Gsa which would
allow differentiation of the serine-encoding forms of Gsa-L from those containing
exon 3 alone. Therefore, attempts to quantify the relative contribution of these two
splice variants were unsuccessful.
Thyroid stimulating hormone (TSH) and forskolin have been shown to produce a
significant increase in Gsa mRNA, as measured by Northern blotting, and in Gsa
protein, in cultured pig thyroid cells (Dib et al., 1994). The up-regulation of Gsa
mRNA in response to TSH or forskolin could be prevented by long term exposure of
the cells to 12-o-tetradecanoylphorbol 13-acetate (TPA), an activator of protein
kinase C, suggesting that protein kinase C activation prevents the cAMP-dependent
up-regulation of Gsa mRNA and Gsa protein.
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Harrison and colleagues (1991c) have demonstrated a marked increase in the mRNA
encoding the a subunit of Gsa in the hippocampus of AD sufferers in comparison to
neurologically normal controls. This increase was not the result of a generalised
increase in mRNA expression, as the increase in Gsa mRNA remained even when
expressed as a proportion of total poly(A)+ mRNA levels in the same cell
populations. The magnitude of the increase in Gsa mRNA identified, implied that,
should rates of transcription and translation be unchanged, Gsa protein synthesis
would be enhanced.
3.1.5 Gsa Protein Levels
Gsa isoform levels appear to be developmentally regulated in the rat (Babila et ul.,
1992). Pineal levels of Gsa-L protein remain constant throughout life. Gsa-S
protein, however, is virtually absent from the rat pineal at birth, but increases
markedly in abundance thereafter. Moreover, the ratio between the long and short
forms of Gsa protein decreases from 11 in the newborn rat to approximately 2 in the
adult. The appearance of Gsa-S protein coincides with the development of the
cGMP response to adrenergic stimuli and to hydroxyindole-o-methyltransferase
activity, though is not necessarily functionally related to either (Babila et al., 1992).
In contrast to Granneman and Bannon (1991) findings regarding Gsa mRNA,
Cooper and co-workers (1990) found Gsa-S protein to be the predominant form of
Gsa protein in the striatum, while in the cerebellum Gsa-L was the most abundant
form of Gsa protein. The authors comment that at least two forms of adenyl cyclase
exist in the brain that differ in their sensitivity to ionic calcium/calmodulin. The
cerebellum is far richer in the calcium/calmodulin sensitive form of adenyl cyclase
than is the striatum. On the basis of the co-localisation of Gsa-S and the
calcium/calmodulin independent form of adenyl cyclase, the authors hypothesise that
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Gsa-S selectively associates with this form of adenyl cyclase, and that thus the
balance between Gsa-L and Gsa-S may be functionally important.
Protein studies in AD hippocampi have failed to identify any increase in Gsa
subunits in comparison with control tissue as would have been predicted from the
findings of Harrison and colleagues (1991c) regarding Gsa mRNA. Using
immunoblotting, McLaughlin and co-workers (1991) found no statistically
significant differences in the abundance of Gsa-L and Gsa-S protein, or in the levels
of the a subunits of Gil, Gi2 and Go between AD and control hippocampus,
cerebellum and frontal cortex. The tissue used was age-matched, but the PMI for the
control group was significantly longer than that for the AD group and agonal state
information was not provided. Similarly, O'Neill and colleagues (1994) examined
Gsa protein levels in crude synaptic membrane fractions from temporal cortex,
angular gyrus and hippocampus of control and AD brains matched for age, tissue pH
and gender. They found no statistically significant difference in the amounts of
Gsa-L or Gsa-S between control and AD tissue. However, the ratio of Gsa-L to
Gsa-S was found to be significantly increased in the hippocampi and angular gyri of
the AD cases when compared with the controls. Unfortunately, the PMI of the
control group, as in McLaughlin and co-workers (1991) study, was significantly
longer than the PMI of the AD group. O'Neill and colleagues (1994) found Gsa
stimulated adenyl cyclase activity to be impaired in AD hippocampus, although no
change was detected in G-protein mediated inhibition, or forskolin stimulated,
adenyl cyclase activity.
Li and colleagues (1996) examined Gsa protein levels in human pre-frontal cortex,
superior temporal gyrus and occipital cortex and found them to be equal to those in
age and PMI matched controls. Li and co-workers found Gsa protein levels to be
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remarkably stable over post-mortem intervals of between 5 and 21 hours though, as
the authors point out, these findings cannot necessarily be generated to other brain
regions. No assessment of agonal state was made in this study.
Cowburn and workers (1992) have identified a decrease in Gs stimulated adenyl
cyclase activity in the neocortex and cerebellum in AD in comparison to
non-demented controls in the presence of preserved basal and forskolin stimulated
adenyl cyclase activity. The authors postulate that the altered Gsa expression
documented by Harrison and colleagues (1991c) reflects a compensatory
up-regulation in Gsa expression in response to the functional impairment in adenyl
cyclase activation.
Paulssen and colleagues (1992) have investigated the effects of phospholipase C on
Gsa protein levels in cultured prolactin producing rat pituitary adenoma cells.
Pre-treatment of the cells with of l-oleoly-2-acetylglycerol (OAG), an activator of
protein kinase C, resulted in a decrease in Gsa protein levels and a slight decrease in
the responsiveness of adenyl cyclase to vasoactive intestinal peptide (VIP) and the
virtual abolition of responsiveness of adenyl cyclase to thyrotropin releasing
hormone (TRH). Ionomycin mobilises calcium from intracellular stores resulted in a
transient decrease in Gsa protein paralleled by a decrease in the responsiveness of
adenyl cyclase to both TRH and VIP. Thus, it would appear, that there is interplay
between G protein coupled second messenger systems and the phosphatidylinositol
4,5-biphosphate pathway and that first messengers can influence the abundance of G
protein subunits.
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3.1.6 The Polymerase Chain Reaction
The polymerase chain reaction (PCR), invented by Kary B. Mullis in 1985 (K.B.
Mullis, U.S. patent 4,683,195, July 1987; U.S. patent 4,683,202, July 1987; See
Mullis, 1994), is an ingenious and powerful means of amplifying DNA. James D.
Watson, in his foreword to The Polymerase Chain Reaction (1994), described this
rapid, exquisitely sensitive and specific molecular biology technique as
indispensable.
Primers are chosen whose base sequences are complementary, and in the reverse
orientation, to the base sequences flanking the area of DNA of interest. After
denaturation of the DNA template by heating, the primers are allowed to anneal to
the DNA under carefully optimised PCR conditions. Chain elongation is effected by
the heat stable Taq DNA polymerase and the newly formed duplexes are then
denatured by heating in preparation for another cycle of the PCR.
As few as 10 specific nucleic acid molecules in a background of hundreds of
millions can be reliably reproduced (Ferre et al., 1994) and PCR can even be started
from a single molecule of DNA (Hayashi, 1994). The PCR results in an exponential
increase in the products of the reaction as the amplicons produced with each cycle of
the chain reaction become the substrates for the next round of amplification (Siebert,
1993). In theory, the amount of product doubles with each PCR cycle according to
the equation An=A()2n where Aq represents the amount of starting material, n equals
the number of PCR cycles and An represents the amount of product after n cycles of
the PCR. Of course, this equation assumes that the PCR proceeds with 100%
efficiency whereas in reality an efficiency, R, of between 0.5 and 0.8 is more usual
(Salomon, 1995a). Logging the parameters of the equation, An=Ao(l+R)n, converts
it to a linear equation allowing the ideal PCR reaction to be represented graphically
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by a straight line. In reality, the exponential increase in the products of the PGR
begins to plateau after approximately 20 cycles (Salomon, 1995a) as a result of
diminishing amounts of reagents, enzyme and primers and competition for binding
sites with the increasing amounts of template. Thus, the amplification efficiency of
the reaction is constant only during the linear phase of product accumulation.
Unfortunately, however, the PCR is subject to unpredictable and perplexing
variations in yield (Salomon, 1995a). Significant tube-to-tube variation in the
products of a reaction has been documented even with precise control of PCR
conditions, such as when a reaction has been assembled as a master mix, divided into
individual tubes and amplified during the same run (Gilliland et al., 1990).
3.1.7 Coupling of Reverse Transcription to the Polymerase Chain Reaction
The adaptation of PCR, which allowed conversion of mRNA to complementary
DNA (cDNA) by the intermediate step of reverse transcription, (RT-PCR),
revolutionised the detection and quantitation of RNA. Prior to the application of
RT-PCR, ISHH was the most sensitive method for detecting mRNA, being capable
of detecting 10 to 100 molecules of mRNA in a single cell (Kawasaki, 1990).
However, ISHH is widely regarded as technically difficult and the technique is not
well suited to the processing of large numbers of samples. Other methods for
detecting RNA such as Northern blots, S-l nuclease protection assays and RNase A
protection studies require considerably higher concentrations of RNA at
approximately 10^ to 10^ target molecules (Kawasaki, 1990). RT-PCR, in contrast,
allows the detection of rare mRNAs and mRNAs from small numbers of cells or in
small quantities of tissue (Siebert, 1993). The reproducibility of the reverse
transcription reaction is, however, notoriously poor with reported efficiency rates for
cDNA synthesis of between 5 and 90% (Ferre et al., 1994) though some authors have
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argued that the major source of error in quantitation of RT-PCR is, in fact, the
difficulties inherent in the accurate measurement of the starting RNA and its variable
integrity (See Ferre et ai, 1994 for discussion).
The double-stranded starting point required by the enzyme reverse transcriptase can
be achieved in three ways (Salomon, 1995b). Oligo dT primers consist of a string of
deoxythymidylates capable of annealing to the poly (A) tail present on most mRNAs.
Where the RNA sample is degraded or the RNA sequence of interest is distant from
the poly (A) tail, however, the cDNA yield from oligo dT may be disappointing.
Like oligo dT, random oligodeoxynucleotide primers are capable of annealing to
potentially all mRNA species in the total RNA sample, but are less dependent on the
integrity of the mRNAs (Salomon, 1995b). Where oligodeoxynucleotide primers
specific for the mRNA species of interest are chosen, the cDNA generated cannot be
used to amplify any other target, though where a sample is likely to be significantly
degraded they are more useful than the other two primers.
3.1.8 Quantitative RT-PCR
Salomon (1995a) and Vandevyver and Raus (1995) warn that quantitative RT-PCR is
not a trivial undertaking. Though two successive enzymatic reactions immediately
present difficulties of quantitation, it is the unwieldy increase in the desired products
which is characteristic of PCR that presents the greatest challenge to the quantitative
assessment of PCR amplified RNA (Siebert, 1993). During the initial cycles of PCR,
the products of the reaction accumulate at an exponential rate and the efficiency of
the amplification reaction remains constant. During this period the amount of
product is directly related to the abundance of the cDNA of interest in the sample.
Where two different products are known to amplify with the same efficiency, the
relative abundance of the two amplicons can be compared. Of course, with
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increasing cycle number the amplification efficiency declines and the accumulated
product can no longer be directly related to the amount of starting material.
The efficiency of a PCR depends on factors such as the starting amount of DNA, the
presence of contaminants, the length and complexity of the sequence to be amplified
and the degree which optimisation of reagents has been achieved (Vandevyver and
Raus, 1995). It is obvious that when more than one product is to be amplified, they
might amplify with different efficiencies. Two primer pairs may exhibit marked
differences in amplification efficiency, such that the ratio between the products of
the RT-PCR of total RNA does not reflect the ratio between the two native species in
the original sample (Salomon, 1995a). Moreover, given the nature of PCR a minute
alteration in the starting number of template DNA molecules or a slight difference in
the amplification efficiency of the reaction can, over a number of PCR cycles, result
in dramatic differences in the amount of reaction product (Scheuermann and Bauer,
1993).
The quantitation of RT-PCR can be relative or absolute (Ferre el al., 1994). The
relative quantitation of RT-PCR involves comparison of the relative amounts of a
particular mRNA species between samples. Since modest differences between
samples can result in dramatic differences in product generated, the relative
quantitation of mRNA is problematic without the inclusion of internal or external
standards. RNA standards are generally preferred given that they can control for the
relatively inefficient and highly variable RT step (Ferre et al., 1994). The
co-amplified RNA is either an endogenous species, the abundance of which is not
believed to vary with cell cycle, or an exogenous mRNA. Co-amplification of an
endogenous RNA control provides data on the success of the extraction process.
Alternatively, the co-amplification of an external mRNA allows the amount of
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external standard added to be adjusted such that it is keeping with the concentration
of the target mRNA, given that quantitative RT-PCR is best performed with two
equally abundant templates. Further, if the exact amount of the external standard is
known, and the amplification efficiency of the two reactions is equal, the number of
starting molecules of the mRNA of interest can be estimated and absolute
quantitation attempted. Unhappily, the competing amplification of the standard may
interfere with the amplification of the desired template (Ferre et al., 1994). In any
event, it is acknowledged that the absolute quantitation of RT-PCR is extremely
difficult (Ferre et al., 1994).
3.1.9 Aims of the RT-PCR Study of Gsa mRNA
The Gsa gene is a member of the expansive heterotrimeric G protein gene family
crucial to cellular responsiveness (O'Neill et al., 1994) that appears to have diverged
from the others early in evolution (Kozasa et al., 1988). Gsa is believed to be the
most remote of the G proteins (Itoh et al., 1986) and one of the two large sequences
in Gsa not seen in other G-proteins (Itoh et al., 1986) is encoded on exon 3 (Bray et
al., 1986). The 15 amino acids encoded by exon 3 constitute a relatively
hydrophilic, negatively charged region present in two of the four known isoforms of
Gsa protein (Bray et al., 1986) and may have a role in the control of adenyl cyclase
(Kozasa et al., 1988). An additional serine residue, that is a potential
phosphorylation site, is also present in this region in Gsa isoforms Gsa-2 and Gsa-4
(Bray et al., 1986). Though most tissues contain both Gsa-S and Gsa-L, the
functional importance of the different isoforms is unknown (Robinshaw et al.,
1986b).
Using an SI nuclease protection assay, Bray and colleagues (1986) identified Gsa-S
and Gsa-L but were unable to differentiate between the serine encoding and serine
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lacking isoforms of Gsa mRNA. Granneman and Bannon (1991), using a PGR based
technique, were able to explore the relative contribution of Gsa-3 mRNA and Gsa-4
mRNA to Gsa-S mRNA by virtue of a Bsmkl restriction site in Gsa-4 mRNA, but
the of relative abundance of the two splice variants of Gsa-L mRNA remains
elusive.
Harrison and colleagues (1991c) have established that Gsa mRNA is increased in the
hippocampus in AD, while studies of Gsa protein suggest that it is unchanged
(O'Neill et al., 1994; McLaughlin et al., 1991; Li et al., 1996). The AD and control
cases used by Li and colleagues (1996) in their examination of Gsa protein levels
were matched for PMI. However, unlike O'Neill and co-workers (1994), Li and
colleagues did not control for agonal state factors, and the variable effect of tissue
acidosis on protein is well documented (Yates et al., 1990), and they did not examine
hippocampus. In contrast, both O'Neill and co-workers (1994) and McLaughlin and
colleagues (1991), in their examination of Gsa protein levels in AD hippocampus,
employed control tissue with significantly longer PMIs than those of their AD cases.
However, the G proteins appear to be relatively resistant to post-mortem delay (Li et
al., 1996), further, there is no real possibility that extended PMIs in the control cases
would result in an increase in Gsa protein. Thus, the discrepancy in length of PMI
between the AD and control cases would be predicted to enhance, rather than
diminish, the probability of identifying an increase in Gsa protein in the AD cases.
Therefore, while there is no conclusive evidence that Gsa protein levels in AD
hippocampus are equal to that in controls, the hypothesis that they are, and that it is
the impairment in adenyl cyclase stimulation that results in up-regulation of Gsa
expression, is intriguing (Cowburn et al., 1992).
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It was hoped that by using quantitative RT-PCR, it would be possible to generate
products of sufficiently small size that the predicted 3 residue difference between
Gsa-1 and Gsa-2 mRNA, and between Gsa-3 and Gsa-4 mRNA, would be sufficient
to allow their differentiation on subsequent electrophoresis. The technique could be
performed on minute quantities of tissue and would be rapid, allowing
characterisation of a large number of control samples before comparing the relative
abundance of the four isoforms in AD. A large and well characterised series ofbrain
tissue from AD sufferers and controls were available for this work.
3.2 Materials and Methods
3.2.1 Prevention of Contamination
Initial RT-PCR experiments were beleaguered by contamination. Gel
electrophoresis repeatedly demonstrated bands in template-free controls suggestive
of contamination with amplified DNA (Figure 3.2).
Careful consideration was given as to the likely source(s) of the contamination.
Vortexing, opening microcentrifuge tubes, pipetting and tip ejection can all generate
aerosol particles which may be as large as 20 gm in diameter or 4 x 10~6 p.1 in
volume. Since 24 000 copies of an amplified product may exist in such a volume
(Orrego, 1990), the prevention of aerosols was deemed crucial. A safety cabinet, in
an area of the laboratory geographically distant from where post amplification
procedures were carried out, was washed out with a 1% Virkon solution (Antec
International) before use and was reserved for all procedures up to, and including,
the setting up of PCR reactions. A set of conventional air-displacement
micropipettes, fitted with sterile aerosol resistant tips, were reserved for PCR set-up
and the procedures preceding it. All reagents were divided into single use volumes
in the PCR set-up area and stored in disposable, autoclaved plastic ware at -20°C.
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Reagent and sample tubes were spun briefly in a microcentrifuge before opening and
all non-sample PCR components were added to the reaction tube before the addition
of sample DNA. All plastic ware was autoclaved before use and all metal
instruments soaked in a 1% Virkon solution. Disposable gloves were worn for all
procedures and changed frequently.
3.2.2 Extraction of Total RNA from Frozen Human Brain Tissue
Total RNA was extracted from cryostat cut frozen brain tissue using TRIzol Reagent
(Gibco BRL). TRIzol isolation of RNA represents a modification of the one step
RNA isolation method developed by Chomczynski and Sacchi (1987). Successful
isolation of intact RNA requires that the tissue used is efficiently disrupted, that the
endogenous nucleases released from membrane bound organelles during this process
are immediately inactivated, that the nucleoprotein complexes are denatured and that
the isolated RNA is free of DNA and protein.
RNA isolation was performed at room temperature in the safety cabinet within the
laboratory area reserved for PCR preparation. Twelve 18 gm cryostat cut sections
were lowered into 40 jul of TRIzol in a sterile 1 ml microcentrifuge tube on ice, with
a pair of ice-cold plastic tweezers. The tissue was homogenised to smoothness with
a hand-held homogeniser and a further 360 pi of TRIzol mixed in. The reaction was
incubated at room temperature for 5 minutes to allow complete dissociation of the
nucleoprotein complexes. Eighty pi of chloroform was added, the microcentrifuge
tube firmly capped and the mixture shaken by hand for 15 seconds. The tube was
incubated at room temperature for 3 minutes and then spun at 12 000 x g for 15
minutes at 4°C. The colourless, aqueous, upper phase containing the RNA was
removed into a fresh, sterile, microcentrifuge tube taking care not to disturb the
interface with the lower organic phase. The RNA was precipitated from the aqueous
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phase by incubating the sample at room temperature for 10 minutes with 200 ml of
isopropanol and 1 pi of glycogen and spinning at 12 000 x g for 10 minutes at 4°C.
The pellet so formed was washed by vortexing with 75% ethanol in DEPC treated
water and spun at 7 500 x g for 5 minutes at 4°C. The pellet was then air-dried at
room temperature for 10 minutes and re-suspended in DEPC treated water by
passing the solution through a pipette tip several times and incubating for 10 minutes
at 55°C. Samples were stored under DEPC treated water at -70°C until required.
3.2.3 Measurement of Extracted RNA
The concentration and purity of the extracted RNA was assessed using a GeneQuant
spectrophotometer (Pharmacia Biotech). A dilution of 1 part sample to 19 parts
DEPC treated water in a total volume of 70 pi was placed in a cuvette. The ratio of
the absorbance reading at 260 qm (A26O) *° the absorbance reading at 280 qm
(A28O) °f Pure RNA is 2.0 but A26O/A28O ratios of between 1.7 and 2.0 were
accepted.
3.2.4 Reverse Transcription of Total RNA
Reverse transcription (RT) was performed by dissolving the required quantity of
total RNA (0.04 to 2.5 pg) in 11 pi of water and adding 1 pi of oligo d(T). The
reaction was incubated at 70°C for ten minutes, chilled on ice and pulsed briefly in a
microcentrifuge. The following reagents were added:
5 x first strand buffer 4 pi
purified, deionised water 0.75 pi
0.1 M DTT 2 pi
mixed dNTP stock 10 mmolar for each dNTP 0.25 pi
Superscript RNase H" Reverse Transcriptase (200 units/pl) 1 pi
85
The reaction was incubated at 42°C for one hour and then heated to 99°C for 5
minutes to denature the cDNA-RNA hybrids and inactivate the reverse transcriptase
enzyme. All RT reactions were performed in a Progene Thermal Cycler, (Techne).
Two control tubes accompanied each RT reaction. Reverse transcriptase enzyme
was omitted from one of the controls and in the other purified, deionised water
replaced the RNA template. On completion, the RT samples were stored at -20°C
until required. Two microlitres of the RT reaction volume was used in all PCR
experiments.
While the above protocol proved satisfactory for reverse transcription of control
human tissue (0.38-2.38 pg/pl), the yield obtained from AD tissue (0.22-0.58 pg/pl)
proved disappointing.
3.2.5 Primer Design
Two 16 base primers were designed by scanning exons 2 and 4 of the human Gsa
gene (Kozasa et al., 1988) for regions, as close to the variably spliced region as
possible, that had a GC content of 50%. Complementarity at the 3' ends of the
primers was avoided as far as possible. RT-PCR was predicted to generate four
products of 98 bases (Gsa-1), 95 bases (Gsa-2), 53 bases (Gsa-4) and 50 bases
(Gsa-3) in length. It was hoped that since the primers were designed to anneal to
different exons, the amplification of contaminating genomic DNA would be
inhibited (Kawasaki, 1990).
The selected primers were entered into the European Molecular Biology Laboratory
gene database to ascertain what known cDNA sequences, with a mismatch of 4
bases, were likely hybridise with the chosen primer sequences. When a primer pair
was identified that were not homologous to any known cDNA sequence, the primers
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were ordered from the Human Genome Mapping Resource Centre. The chosen
sequences were as follows:
Exon 2 Primer 5' C CTG CAT GTT AAT GGG 3'
Exon 4 Primer 5' C CTG CAC TTT GGT TGC 3'
The exon 2 stock primer was obtained at a concentration of4.2 mg/ml and the exon
4 stock primer at a concentration of 0.7 mg/ml. Diluted aliquots of the primers and
the stock primers were stored at -70°C in separate freezers until use.
3.2.6 Calculation of the Annealing Temperature
The annealing temperatures of the primers were calculated as follows:
Annealing Temperature = [(number of A+T) x 2°C + (number of G+C) x 4°C]
Using this formula, the annealing temperature of the exon 2 primer was calculated to
be 48°C and the annealing temperature of the exon 4 primer to be 50°C. Though
Taq DNA polymerase is active over a wide range of temperatures, optimal annealing
temperatures for the enzyme are between 55 and 72°C.
3.2.7 The PCR Protocol
A PCR programme was designed from first principles and optimised empirically
thereafter. A range of annealing temperatures ofbetween 40°C and 50°C were
employed in an effort to maximise the efficiency of amplification of the desired
products while minimising the generation of non-specific products. A permissive
annealing temperature of 40°C was chosen initially and gradually increased since
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low annealing temperatures facilitate incorrect annealing of primers and
misextension of incorrect nucleotides at their 3' ends.
The final PCR programme was as follows:
Initial denaturation 96 °C 5 minutes
35 cycles of PCR were performed according to the following temperature profile:
Denature 94 °C 1 minute
Anneal 49.5°C 30 seconds
Extend 72 °C 1 minute
Final Extension 72 °C 3 minutes
Latterly, it was concluded that the initial denaturation step was too long and
potentially damageing to the Taq DNA polymerase, therefore, it was reduced to 2
minutes without any detectable change in the products of the reaction.
A range of primer concentrations from 5 rig/50 pi reaction mix to 500 r|g/50 pi
reaction mix were employed in an effort to maximise the intensity of the desired
bands on gel electrophoresis while minimising primer-dimer formation and the
generation of non-specific products. Primer-dimer complexes are duplex PCR
products in which the extension added to one primer is the antiparallel complement
of the other primer (Innis and Gelfand, 1990). As such, primer-dimers represent a
template-independent artefact, which, like non-specific background products, can
themselves act as substrates in subsequent PCR cycles. Low annealing temperatures,
high enzyme and primer concentrations and complementarity between the 3' ends of
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primers enhance primer-dimer formation (Gelfand and White, 1990). Once present
such products are prone to amplify efficiently and therefore compete for reagents.
A primer concentration of between 30 and 50 r|g/50 pi of reaction mix proved the
most satisfactory. For ease of use, a primer concentration of 50 qg/50 pi
(10.1 pmoles/50 pi) of reaction mix was used in all subsequent experiments. This
resulted in a final molarity of primer of 0.2 pM: a figure within the range of 0.1 to
0.5 pM generally recommended (Innis and Gelfand, 1990).
Magnesium was added to the PCR as a 25 mM solution of magnesium chloride and a
range of magnesium concentrations was studied. The magnesium concentration in
the PCR mixture is crucial to the specificity, fidelity and yield of the reaction.
Magnesium levels affect enzyme fidelity and activity, primer annealing, the
temperature at which strand dissociation of both template and PCR products occurs,
the specificity of the reaction and the formation of primer-dimer complexes (Innis
and Gelfand, 1990). The addition of 4.5 pi of 25 mM magnesium chloride solution
to each 50 pi of reaction mixture resulted in the greatest intensity of the desired
bands on gel electrophoresis with a minimum of additional unwanted bands.
Care was taken to ensure that equal concentrations of the four dNTPs were added to
the reaction volume to minimise the risk of incorporation errors.
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The final PCR reaction mix consisted of the following reagents:
Thermo DNA Polymerase 10 times x reaction buffer 5 gil
mixed dNTP stock 10 mmolar for each dNTP 1 pi
25 mM MgCl2 solution 4.5 pi
Taq DNA Polymerase in Storage Buffer A (5 000 units/ml) 0.25 jul
H20 32.25 pi
Exon 2 Primer 50 r|g/pl 1 pi
Exon 4 Primer 50 r|g/pl 1 pi
Reverse Transcription mix 2 pi
The reaction volume was overlaid with 25 pi mineral oil. All PCR reactions were
carried out in the same Hybaid OmniGene PCR machine. The wells in the block
were used randomly.
3.2.8 Polyacrylamide Gel Electrophoresis
In view of the small size of 98, 95, 53 and 50 bases of the expected products, 20%
non-denaturing polyacrylamide gels, capable of resolving products of 6 to 100 bases,
were employed initially to crudely separate the products of the PCR on
electrophoresis.
Gels, 1 mm in thickness, were cast between glass plates of 100 x 82 and 100 x72
mm on a vertical gel casting and electrophoresis apparatus (Bio-Rad Mini Trans
Blot). The wells were created with a comb of 10 x 5 mm teeth. The glass plates,
spacer and comb were washed after each use in a solution of detergent in warm
water and rinsed in first tap water, and then distilled water, to remove any spots of
grease which might impair the performance of the gel. Immediately prior to use, the
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glass plates, spacer and comb were wiped over with absolute alcohol and allowed to
dry before assembly.
A stock solution of 30% acrylamide was prepared as follows in a fume hood and
stored in a dark bottle at room temperature until use. Twenty-nine grams of
acrylamide and 1 g of N,N'-methylenebisacrylamide were measured into a flask and
60 ml of water added. The chemicals were dissolved by heating at 37°C in the fume
hood and the solution was adjusted to a final volume of 100 ml and pH of 7.0.
Twenty % polyacrylamide gels were prepared from the 30% acrylamide stock as
follows: 8.7 ml of 30% acrylamide stock was combined with 1.7 ml of purified,
deionised water and 2.6 ml of 5 x tris borate EDTA buffer (TBE-see appendix I).
Polymerisation was achieved by the addition of 7 pi of
N,N,N',N'-tetramethyl-ethylenediamine (TEMED) and 70 pi of 25% ammonium
persulphate (0.25g/ml). The solution was swirled gently to mix and immediately
drawn into a disposable plastic pipette. The nozzle of the pipette was introduced
into the space between the glass plates and the acrylamide solution gently expelled.
The comb was gently lowered into the gel. Once set, the gel was removed from the
casting apparatus and fitted into the gel tank. The tank was filled with 1 x TBE and
the comb removed. The wells were immediately rinsed with 1 x TBE from the gel
tank to remove any unpolymerised acrylamide solution. Acrylamide gels were cast
in duplicate and after rinsing of the wells with 1 x TBE were stored at 4 °C under
1 x TBE until use. No impairment in the quality of the gels was apparent with
storage of up to one week.
Five microlitres of loading gel buffer (see appendix I) was added to each 50 pi PCR
reaction volume and, after mixing, 10 pi of each sample was loaded onto the gel.
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Gels were run at 120 volts until the dye front was three-quarters of the way down the
gel. Gels were stained in 5 pi of ethidium bromide in 200 ml of 1 x TBE for 20
minutes. Once stained, the gel was viewed by transillumination on an ultraviolet
light box and photographed with a 5" Polaroid camera.
3.2.9 Size Determination of the Reaction Products on Non-Denaturing
Polyacrylamide Gel Electrophoresis
A 0X174 DNA///wf I marker, prepared by digestion of 0X174 DNA to completion
with Hinf I, was used to aid in identification of the products of the PCR. 9X174
DNA/777«f I markers are composed of 20 DNA fragments varying in length from 726
to 24 base pairs. One pi of 0X174 DNA/7/mf I marker stock was added to 19 pi of
water and 2 pi of loading gel buffer. Initially, a 100 base ladder was loaded onto
each gel in addition to aid in identification of the products of the reaction.
Two bands of approximately 50 and 100 bases were clearly visible on
non-denaturing polyacrylamide gel electrophoresis, corresponding to the long and
short isoforms of Gsa, as well as a number of unexpected reaction products (Figure
3.2).
3.2.10 The Preparation and Purification of y32pATP Labelled Primer
Despite assiduous attempts at optimisation of the RT-PCR of the variable exon 2 to
exon 4 region of Gsa mRNA, it was not possible to eliminate a number of unwanted,
apparently non-specific, PCR products. Reducing the concentration of the primers
or, indeed, increasing the annealing temperature used, resulted in loss of both the
unwanted and the desired bands. These bands may result from cross reaction of the
primers with RNA species derived from other genes, conceivably as yet
undiscovered members of the G protein family that are highly homologous with Gsa,
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Figure 3.2 RT-PCR of Gsa from total RNA using [,2P]ATP labelled exon 2
primer run on a 20% non-denaturing polyacrylamide gel at 200 volts. Two bands of
approximately 50 and 100 kilobases, corresponding to the short and long splice
variants of Gsa mRNA, are clearly visible as well as a number of unexpected
reaction products. Gel electrophoresis, such as this, repeatedly demonstrated bands
in template free controls suggestive of contamination with amplified DNA.
In the extreme left hand lane of each gel is a 9X174 DNA/Z/wf I marker (base pairs).
Gel A
Lane 1 Positive control.
Lane 2 Newly reverse transcribed RNA.
Lane 3 Newly reverse transcribed RNA.
Lane 4 No RNA.
Lane 5 No reverse transcriptase enzyme.
Lane 6 No RNA.
Lane 7 No reverse transcriptase enzyme.
Lane 8 Empty lane.
Gel B
Lane 1 Starting total
Lane 2 Starting total
Lane 3 Starting total
Lane 4 Starting total
Lane 5 Starting total
Lane 6 Starting total
Lane 7 Starting total
Lane 8 Starting total
RNA of approximately 2.50 pg
RNA of approximately 1.25 pg
RNA of approximately 0.63 pg
RNA of approximately 0.31 pg
RNA of approximately 0.16 pg
RNA of approximately 0.08 pg
RNA of approximately 0.04 pg


















































or previously unrecognised alternative splice products of Gsa. The bands were too
small to be contaminating genomic DNA. Despite the presence of these additional,
unwanted bands it was decided to pursue RT-PCR of Gsa mRNA using the primers
already described.
To allow quantitation of the PCR products generated, the exon 2 Gsa primer was
labelled with y^phosphorus ATP (y32pATP). This radioisotope has a half-life of
14.2 days and is a high energy (1.6 MeV) |3 emitter, therefore, all experiments
involving y32pATP were conducted behind a 10 mm Perspex screen or within a
Perspex p station. Microcentrifuge tubes in use were racked within a lidded-Perspex
box, opened with a tube opener and closed with the aid of stainless steel forceps and
tweezers. Tips and eppendorfs were discarded into a 10 mm lidded Perspex box. A
solution of decontaminating fluid (Decon 90, BDH/Merck) was available throughout
the experiments and the area was regularly monitored with a Geiger counter. A
dosimeter badge and finger rings were worn throughout.
Five hundred pmoles (sufficient for approximately 49 reactions of 50 pi each) of the
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exon 2 primer were labelled with yJ~PATP. The following were assembled in a
sterile 1 ml eppendorf:
500 pmoles exon 2 primer 24.8 pi of 100 qg/pl concentration
DEPC treated water to final volume of 50 pi






The reaction was heated to 37°C for 10 minutes before the addition of 1 pi of rATP
(ribonucleoside ATP). A further 10 minute incubation at 37°C followed.
ProbeQuant G-50 Micro Columns (Pharmacia Biotech) were used to separate the
labelled probe from any unincorporated nucleotides. The Sephadex G-50 DNA
Grade F resin in the columns was re-suspended by vortexing. The cap was loosened
by a quarter of a turn and the bottom closure on the column was snapped off. The
column was supported in a 1 ml microcentrifuge tube and spun at 735 x g for 1
minute. The column was removed to a fresh supporting 1 ml microcentrifuge tube
and the 50 pi reaction volume was slowly applied to the top centre of the resin. The
column was spun at 735 x g for a further 2 minutes. A Geiger counter was held at a
standard distance from the tube and the intensity of radioactivity estimated. The
volume of the purified probe was measured and the tube capped, y PATP labelled
probes were stored in lead containers at -20°C until use, which was always within 10
days. A positive and three negative control reactions were performed to ensure that
the efficiency of the labelling was adequate for subsequent experiments and to
demonstrate that the labelled primer was free from DNA contamination.
3.2.11 The Preparation of y^pATP Labelled 9X174 DNA/f/i/if I Ladder
The 0X174 DNA/7/mf I ladder was dephosphorylated prior to y^2pATP labelling
since the addition ofy^2pATP groups to a dephosphorylated substrate proceeds more
efficiently than an exchange reaction. The 5' phosphate groups were removed by
incubating 10 jul of the 9X174 DNA////Af 1 ladder stock with 2 pi of calf intestinal
alkaline phosphatase at 37°C for 10 minutes. The enzyme was subsequently
denatured by heating at 85°C for 15 minutes.
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2.5 pi of the dephosphorylated ladder was then labelled as follows:
2.5 pi dephosphorylated 0X174 DNA/Z/bzf I ladder
10.5 pi water
4 pi 5 x kinase buffer
2 pi y32PATP
1 pi T4 polynucleotide kinase
The reaction was incubated at 37 °C for 10 minutes before the addition of 5 pi of
rATP followed by a further 10 minute incubation at 37°C. A final reaction volume
of 50 pi was achieved by the addition of 30 pi of autoclaved STE buffer (see
appendix I). The labelled ladder was purified using the ProbeQuant G-50 Micro
Columns (Pharmacia Biotech) described above. The volume of labelled ladder and
the intensity of the labelling were estimated as for the labelled primer. 1 pi of the
radioactively labelled ladder was combined with 1 pi of loading gel buffer and 8 pi
of water in preparation for loading on the 20% polyacrylamide gels.
3.2.12 Quantitative RT-PCR of Gsa Using y32PATP Labelled Exon 2
Primer
In order to establish the optimum cycle number for subsequent RT-PCR
amplifications, 40 pi of RT mixture from a single RT experiment with a starting
RNA of 1 pg/12 pi RT reaction mixture, was amplified over a range of between 22
and 33 reaction cycles. It is crucial that the PCR is stopped while the products are
continuing to accumulate exponentially and the starting amount of RNA can be
linearly related to the amount of product. Product accumulation such that the strands
reanneal or fail to denature at high temperature, diminution of required reagents,
inhibition by end products and competition for the reagents from unwanted
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non-specific products or primer-dimer, all impair the efficiency of the reaction (Innis
and Gelfand, 1990) and ultimately the amount of product reaches a plateau.
The approximate volume of y^PATP labelled exon 2 primer containing
10.1 pmoles of primer was calculated. A master mix sufficient for 20 reaction
volumes of 50 ql each containing all of the reagents required for the RT-PCR, with
the exception of the RT mixture, was assembled and mixed thoroughly. Three
aliquots of master mix were removed for the control reactions and an appropriate
amount of cDNA was added to the master tube and mixed. The solution was
aliquotted, overlaid with 25 ql of mineral oil and placed randomly in the wells of the
Hybaid OmniGene thermal cycler.
Once the reaction reached completion the samples were prepared and loaded on a
20% non-denaturing polyacrylamide gel as described above. The gel was not stained
in order to avoid introducing an unnecessary step, but was immediately fixed by
immersion in a combination of 10% methanol and 10% acetic acid in deionised
water for 20 minutes. The gel was then mounted on a piece of card, covered with
clingfilm and dried at 80°C for 1 hour on a gel dryer. Once dry the gel was taped to
a phosphoimageing cassette, covered with a sheet of screen guard and opposed
against the phosphoimageing screen for 1 hour. The screen was then loaded into a
scanner and the image analysed using the software package Molecular Analyst for
Windows on a dedicated personal computer. The bands of interest were outlined and
their volume, adjusted for background, was measured. This technique is far less
labour intensive than cutting out the radioactive bands and subjecting them to
scintillation counting.
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In only three lanes of the gel were product bands visible. Two product bands of the
appropriate size were seen in the lanes of the gel corresponding to 25, 28 and 32
cycles of the PCR. The experiment was reviewed and the possible sources of error
considered. On meticulous repetition of the experiment, the same pattern of
products was obtained. In some lanes two bands of clearly visible radioactivity,
corresponding to the RT-PCR of the long and short forms of Gsa mRNA, were
obtained. In other lanes a broad band of radioactivity, level with the end of the gel,
but no distinguishable product bands, was seen (Figure 3.3).
On review of the experiment it was clear that sufficient accumulation of product
occurred after 26 cycles of PCR for bands to be visible on non-denaturing
polyacrylamide gel electrophoresis. It was highly unlikely that the reaction had
reached a plateau by this stage and so the thermal cycler was programmed for 26
cycles of PCR only.
Having gauged the optimal number of PCR cycles, the starting quantity of extracted
total RNA at which the reaction was likely to progress most efficiently was
investigated. It was also necessary to demonstrate that the relationship between the
long and short forms of Gsa was resistant to variations in the amount of total RNA
added to the RT-PCR.
A dilution series was prepared from 5 pg of total RNA extracted from control frontal
cortex dissolved in 20 pi autoclaved, deionised water. Ten pi containing 2.5 pg total
RNA was removed to a fresh eppendorf and the remaining aliquot was diluted with a
further 10 pi of autoclaved, deoinised water. This procedure was repeated until the
final eppendorf contained 10 pi containing 1/64 of the initial 2.5 pg of total RNA.
Each tube was reverse transcribed as described above. A master mix, containing all
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Figure 3.3 RT-PCR of Gsa from total RNA using [32P]ATP labelled exon 2
primer run on a 20% non-denaturing polyacrylamide gel at 200 volts. Two product
bands of the appropriate size are seen in lanes representing 25, 28 and 32 cycles of
the PCR. No distinguishable product bands are visible in the other lanes.
Lane 15 No RNA.
Lane 14 No reverse transcriptase enzyme.
Lane 13 33 PCR cycles.
Lane 12 32 PCR cycles.
Lane 11 31 PCR cycles.
Lane 10 30 PCR cycles.
Lane 9 29 PCR cycles.
Lane 8 28 PCR cycles.
Lane 7 27 PCR cycles.
Lane 6 26 PCR cycles.
Lane 5 25 PCR cycles.
Lane 4 24 PCR cycles.
Lane 3 23 PCR cycles.
Lane 2 22 PCR cycles.
Lane 1 9X174 DNA/T/mf I marker.
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of the reagents required for PCR, including the yJ-PATP labelled exon 2 primer,
was assembled and aliquotted into a series of eppendorfs containing 2 ju.1 of each of
the RT reactions prepared from the RNA dilution series. The tubes were placed
randomly in the thermal cycler and following 26 cycles of PCR the reaction mixture
was prepared for loading on a 20% non-denaturing polyacrylamide gel. The gel
revealed poor amplification both at high (2.5 pg) and low (1/64 of 2.5 pg) starting
concentrations of RNA. The experiment was repeated with a fresh total RNA
dilution series employing a narrower range of starting total RNA from 1.25 pg/10 pi
to 0.4 pg/10 pi total RNA. Amplification was observed to proceed most efficiently
with an intermediate concentration of starting total RNA of approximately 0.6 pg/10
pi. Higher and lower concentrations of total RNA resulted in less efficient
amplification (Figure 3.4).
Since the variable efficiency of the RT-PCR might reasonably have been predicted to
affect both products equally, the ratio between the volumes, adjusted for background
radioactivity, of the two bands corresponding to Gsa-S and Gsa-L was calculated.
An approximately two-fold variation in this ratio was observed over a range of
starting total RNA of 0.04 pg to 1.25 pg (Table 3.1). When a narrower range of
starting total RNA from 0.4 pg to 1.25 pg was employed, there was no appreciable
improvement in this ratio.
3.3 Discussion
3.3.1 Overview of the Study
In retrospect, this study was extremely ambitious given the universally
acknowledged technical difficulty of the work (Salomon, 1995a; Vandevyver and
Raus, 1995), my lack of experience with RT-PCR and, perhaps, the failure of other
groups to answer this research question (Bray et al., 1986; Granneman and Bannon,
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Figure 3.4 RT-PCR of Gsa from total RNA using [32P]ATP labelled exon 2
primer run on a 20% non-denaturing polyacrylamide gel at 200 volts.
A dilution series of total RNA was prepared ranging from approximately 1.25 to 0.4
pg of total RNA/10 pi. Amplification was observed to proceed most efficiently with
an intermediate amount of starting total RNA of approximately 0.6 pg/10 pi.
Lane 1 9X174 DNAJHinf I marker.
Lane 2 1.25 pg starting total RNA/10 pi.
Lane 3 1.0 pg starting total RNA/10 pi.
Lane 4 0.8 pg starting total RNA/10 pi.
Lane 5 0.6 pg starting total RNA/10 pi.
Lane 6 0.4 pg starting total RNA/10 pi.
Lane 7 No reverse transcriptase enzyme.
Lane 8 No RNA.
































1991). However, it was possible to co-amplify two products corresponding in size to
Gsa-S and Gsa-L using the technique and to explore systematically, identify and
eradicate the persistent contamination which hampered early optimisation
experiments. Radioactive labelling of the exon 2 primer with yJ-PATP was
successful and the resulting images could be transformed and analysed satisfactorily
with the phosphoimageing equipment. Nonetheless, it proved impossible to answer
the three main scientific questions that the study was designed to address namely:
What is the relationship between all four known isoforms of Gsa in the hippocampus
of neurologically normal controls? Is overall Gsa expression altered in homogenised
hippocampus in AD and if so, changes in which isoform(s) of Gsa is/are responsible
for this overall effect? Latterly, a judgement had to be made as to whether
continuing to persevere with this study was a measure of my tenacity and
perseverance or, alternatively, simply obsessional and imprudent.
3.3.2 Technical Problems Inherent to the Design of the Study
The study's basic design generated a number of technical problems. Firstly, the exon
2 and exon 4 primers were deliberately abbreviated in an attempt to ensure that the
size difference between the various isoforms of Gsa was as great a proportion of the
total length of the synthesised products as possible. However, primers of 18 to 22
bases in length (Kawasaki, 1990) are generally recommended for PCR and a 16 base
primer with a 50% GC content necessitates an annealing temperature of49.5°C,
when a temperature of greater than 55°C is advised (Innis and Gelfand, 1990).
Secondly, y-^PATP labelled primers were chosen because of the speed and
sensitivity with which radioactively labelled bands can be detected on subsequent gel
electrophoresis of reaction products. The optimisation of cycle number and RNA
concentration, however, required significant quantities of radioactively labelled
primer and the short half-life of 14.2 days of y^2 necessitated that fresh primer be
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prepared frequently. Aside from the hazards posed by intensive exposure to yJ~, the
shielding required is cumbersome, especially where large numbers of samples are
being prepared and clearing up following radioactive work is laborious and
necessarily meticulous. A non-radioactive detection method would have been more
agreeable and might ultimately have proved less time consuming. Finally, the use of
only one set of primers to generate all four desired products eliminated differences in
amplification efficiency between primer sets (Singer-Sam and Riggs, 1993).
However, had primer sets been chosen which allowed me to examine the RT-PCR of
Gsa-L and Gsa-S separately it would have been possible to optimise the two
reactions independently and determine whether their co-amplification was
theoretically probable. Differences in the lengths of the template cDNA sequences
to be amplified can affect primer/template hybridisation (Singer-Sam and Riggs,
1993). Further, variations in the secondary structure or sequence of target species
between their identical priming sites can cause differences in amplification
efficiency even with the same primer set (Scheuermann and Bauer, 1993).
3.3.3 Aspects of the Study Which Could Have Been Improved
A number of other aspects of the study could have been improved. The initially
intractable problem of contamination, eventually eradicated, made for an exhausting
and vexing start to the study. Further attention should have been paid to the dNTP
concentration since it is conceivable that it was too high. Plentiful dNTPs make
mispriming at non-target sites and the extension of misincorporated nucleotides
more likely and an attempt should have been made to ensure that the dNTP
concentration in the reaction mixture was thoroughly optimised. Further, the rate of
errors produced by Taq DNA polymerase is increased at high dNTP concentrations
(Hayashi, 1994). The final yield of amplified product might have been improved had
random hexamers been used for first strand synthesis, since they are believed to
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afford the most efficient and consistent results and the greatest final yield of
amplified product (Kawasaki, 1990). Their use minimises the effects of mRNA
secondary structure and sequence complexity. They are particularly useful when the
+
mRNA sequence of interest is at a distance from the poly(A) tail and especially
when samples are likely to contain partially degraded mRNAs (Noonan and
Roninson, 1988). Since this study hoped to employ total RNA from diseased human
tissue, exploration of this method of first strand synthesis might have been
worthwhile. Finally, Ferre and colleagues (1994) warn that variations in the purity of
RNA obtained from the one step RNA extraction method employed in this study may
prevent the precise quantitation of mRNA by impairing the efficiency of RT-PCR
(Ferre et a/., 1994).
3.3.4 Analysis of the Outcome of This Study
The results, generated using the phosphoimageing software, of the RT-PCR of Gsa
over a variable number of cycles of PCR, appeared at first to be inexplicable. The
reagents were assembled as a master mix and clearly some of the tubes had
amplified successfully effectively ruling out the possibility of reagent or template
omission or their failure. That the RNA used was of poor quality was rejected on
subsequent RT-PCR of the same aliquot of RNA. The possibility remained that the
RT mixture had been inadequately mixed into the master mix thus the experiment
was repeated with assiduous attention to detail resulting in a similar pattern of
intermittent amplification with successive cycle numbers of PCR. This particular
experiment was unusual in that it required a large number of sample tubes, which
were placed randomly in the wells of the Hybaid GeneQuant thermal cycler, to be
processed simultaneously. Thus, wells of the heating block not required in earlier
optimisation experiments were pressed into service and it is conceivable that some of
these were faulty. There is support for this view in the literature, since Orrego
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(1990) studied two commonly employed thermal cyclers and concluded that
temperature gradients across heating blocks were frequent when short step times are
used. He specifically advises using the central wells in PCR heating blocks. Hoof
and co-workers (1991) regard the thermocycler as an important source of variability
in PCR and indeed Salomon (1995a) attributes the large increase in researchers
successfully engaged in quantitative PCR, in part, to the development of
thermocyclers that exhibit minimal well-to-well variability in cycle parameters.
Alternatively, it is possible that the contact between the microcentifuge tubes
employed and the wells of the PCR machine was poor, since, for reasons of
economy, they were not those specified for use in the Hybaid GeneQuant Thermal
Cycler. Hybaid do manufacture a range of thin walled PCR tubes which precisely fit
their thermal cyclers and ensure maximal surface contact between the tubes and the
block for optimal thermal transfer and in retrospect it would have been a wise
investment to purchase these. The optimisation of vessel/heating block contact
during design and manufacture makes for good tube fit which is critical for efficient
thermal transfer (Newton, 1997). Ultimately, this economy may have proved costly.
The experimental design of the RT-PCR of Gsa obviated the need for an internal
standard. Rather than attempt to measure the absolute amount of Gsa mRNA, it was
the relationship between the four isoforms of Gsa in normal hippocampus, and the
amount of Gsa generated from a fixed quantity of total RNA from AD versus control
tissue, that was to be studied. The true relationship between the four isoforms of
Gsa can only be discerned, however, if all four forms amplify with equal efficiency
under the RT-PCR conditions employed. Further, alterations in the reaction
conditions, such as might realistically occur experimentally, should influence the
efficiency of the RT-PCR of all four isoforms equally. In reality, Gsa-S and Gsa-L
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appeared to be differentially affected by changes in the reaction conditions and this
was especially true for the starting amount of total RNA.
It is recognised that the amplification of individual species of cDNA can be
differentially affected by reaction conditions such as RNA concentration or quality
or the presence of contaminants. Reagents left over from RNA preparation or one or
more components of the cDNA reaction mixture can inhibit amplification of cDNA
species in a non-uniform way by, for example, impairing the activity of Taq DNA
polymerase, competing for binding sites or altering the conformation of the template
DNA (Siebert, 1993). It proved impossible to eliminate a number of unwanted bands
visible on non-denaturing polyacrylamide gel electrophoresis and it is conceivable
that they too might differentially affect accumulation of the different isoforms of
Gsa and interfere with the dynamics of the reaction. Scheuermann and Bauer (1993)
have demonstrated that an alteration in the reaction conditions of an experiment can
result in the same RNA molecules amplifying with a different efficiency. Crucially,
in quantitative RT-PCR any differences in the amplification efficiencies of the
reaction products can, with repeated cycles of PCR, result in dramatic differences in
the final results (Scheuermann and Bauer, 1993).
The efficiency of the reaction peaked at a starting concentration of RNA of 0.6 pg of
total RNA per 12 pi of RT reaction, but at lower and higher concentrations fell away
steeply. It appeared that the reaction was not robust and that relatively minor
variations in the reaction conditions further impaired template amplification. Minor
pipetting errors are to be expected in RT-PCR, even when pipettes are regularly
serviced and calibrated and used with care. It was clear that variations in the amount
of starting RNA could lead to pronounced loss of product. It was possible, however,
that though the RT-PCR was less efficient, that all four isoforms of Gsa were
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equally disadvantaged and that the relationship between them in native tissue would
be maintained. Therefore, the ratio between Gsa-L and Gsa-S was calculated for the
range of RNA concentrations studied. It became clear that the amplification of
Gsa-S and Gsa-L were differentially affected by alterations in the starting
concentration of RNA, since modest, and experimentally probable, alterations in the
concentration of RNA extracted from a single control brain resulted in a two-fold
change in the ratio between Gsa-L and Gsa-S. It was concluded that the relationship
between Gsa-L and Gsa-S could not be meaningfully examined by their
co-amplification by RT-PCR under the experimental conditions chosen.
3.3.5 Implications
By using ISHH, Harrison and co-workers (1991c) were able to examine Gsa mRNA
levels in a neuronally rich sub-population of hippocampal cells demonstrating a
marked increase in Gsa mRNA in AD tissue compared to controls. In contrast, both
McLaughlin and colleagues (1991) and O'Neill and co-workers (1994) examined
Gsa protein levels in homogenised hippocampal tissue. Studies of a mixed
population of cells do not, of course, exclude the possibility of a neuronally specific
increase in Gsa protein in hippocampus in keeping with Harrison and co-workers
(1991c) mRNA findings. Indeed, should an exclusively neuronal increase in Gsa
protein levels occur in AD, this increase is likely to be obscured by the large
numbers of other cell types present in a tissue homogenate. This would be especially
true of tissue from AD sufferers given the prominence of gliosis in the
pathophysiology of the disease. It would be interesting to compare Harrison and
colleagues (1991c) results with the analysis of a multi-cellular pre-selected area of
hippocampus that had been subjected to ISHH with the same Gsa probe employed
by Harrison and co-workers (1991c). This would provide an estimate of Gsa mRNA
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in a mixed population of hippocampal cells that could be more meaningfully
compared with the Gsa protein studies discussed above.
3.3.6 Future Work
Further study of the mRNAs encoding the various isoforms of Gsa in AD is a crucial
follow up to the work of Harrison and colleagues (1991c). It would be
experimentally feasible, using ISHH, to quantify separately the mRNA levels of Gsa-
S and Gsa-L in the hippocampus of AD and control tissue. ISHH, performed with a
35S labelled oligodeoxynucleotide probe specific for exon 3 of Gsa mRNA, would
allow selective analysis of Gsa-L. A second oligodeoxynucleotide probe, designed
to hybridise to those bases found at either end of exon 3, would allow the detection
of isoforms of GSa in which these bases were continuous, and therefore only to
Gsa-S. Thus, the contribution of these two forms of Gsa mRNA to the increase in
total Gsa mRNA identified in AD hippocampus in comparison to control
hippocampus could be discerned.
Exon 3 encodes a 45 nucleotide insert which is present in the large isoforms of Gsa
mRNA. The region of the large isoforms of Gsa protein encoded by exon 3, is a
hydrophilic section hypothesised to interact with adenyl cyclase. A Gsa-mediated
increase in the activity of adenyl cyclase resulting in higher levels of cAMP,
increased protein kinase activity and ultimately increased phosphorylation, would be
of enormous interest in AD.
Both an SI nuclease protection assay and a PCR based technique have failed to
disentangle the contribution of the four known isoforms of Gsa mRNA to the overall
increase in Gsa mRNA identified in AD hippocampus. Had it been possible to
establish the robust amplification of two RNA species corresponding in molecular
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weight to Gsoc-L and Gsa-S, an alternative way of quantifying the relative
contribution of each of the four isoforms of Gsa to overall levels of Gsa mRNA
might have been feasible. Single nucleotide primer extension (SNuPE) (Singer-Sam
and Riggs, 1993) has been used to quantify the relative abundance of two mRNA
species that differ by only a single base. This technique could be applied to the study
of Gsa mRNA levels as follows. Non-radioactive RT-PCR of the variably spliced
exon 3 region of Gsa mRNA could be performed, the products gel purified and the
two bands, corresponding to Gsa-L and Gsa-S, excised. The band containing Gsa-L
could then be incubated with Taq polymerase for one round of extension with a
primer, the SNuPE primer, whose 3' end is just 5' to the adenine residue of the
variably included 'CAG' nucleotide sequence. The sample could then be incubated in
separate tubes with either y32 dCTP or y^2 dTTP and the products of the two
reactions subject to denaturing polyacrylamide gel electrophoresis. The amount of
radioactivity in the appropriately sized bands could be measured and the ratio
between Gs-a-1 and Gsa-2 mRNA calculated. A similar procedure could be
performed on the excised band containing Gsa-S to examine the relative
contribution of Gsa-3 and Gsa-4 mRNA to Gsa-S mRNA.
The central role of Gsa in cellular responsiveness merits the application of such
techniques and renders its further investigation essential.
Chapter 4
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Goa mRNA Levels are Decreased in the Dentate Gyrus in
Alzheimer's Disease and are Correlated with Total Amyloid
Precursor Protein mRNA Levels in this Region
4.1 Introduction
APP is a glycosylated transmembrane protein (Kang et al., 1987) from which
(3-amyloid, the major protein constituent of the plaque and meningovascular amyloid
deposits which characterise AD, is cleaved (Glenner and Wong, 1984; Masters et al.,
1985a). APP has characteristics reminiscent of a cell surface receptor (Kang et al.,
1987). It is located in cellular membranes, including at the cell surface, possesses a
single membrane spanning domain and bears a consensus sequence on its
cytoplasmic tail that is thought to be necessary for ligand dependent internalisation in
a clathrin coated pit (Chen et al., 1990). No receptor function has yet been ascribed
to APP, but Nishimoto and colleagues (1993) hypothesise that APP is a receptor
linked to Go, a member of the signal-transducing, heterotrimeric G protein family,
believed to regulate phospholipase C dependent phosphoinositide hydrolysis
(Moriarty et al., 1990) and control neuronal calcium and potassium channels (Ewald
et al., 1988; Hescheler et al., 1987; Kleuss et al., 1991; VanDongen et al., 1988).
Nishimoto and co-workers (1993) have demonstrated that Go forms a complex with
APP, and that the His657-Lys676 domain in the cytoplasmic sequence of APP is
necessary for formation of this complex and activation of Go (Nishimoto et al.,
1993). The authors propose that, in AD, Go is constitutively activated by APP.
Go interaction with dopamine D2 (Lledo et al., 1992), muscarinic m2 and m4
(Matesic et al., 1991), somatostatin (Law et al., 1993) and opioid p. and 5 receptors
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(Roerig et al., 1992; Laugwitz et al., 1993) has been demonstrated in native
membranes. As well as its hypothesised role in APP signal transduction, Go is
postulated to activate effector systems in response to other novel factors such as the
intracellular growth associated protein GAP-43 (Strittmatter et al., 1990, 1991). Go
has been demonstrated to inhibit adenyl cyclase in JEG-3 cells on muscarinic
receptor activation and on constitutive activation of Goa (Migeon et al., 1994); the
apoptosis and negative transactivation ofcAMP response element, documented to
occur in response to mutated forms of APP in COS-NK1 cells, is also hypothesised
to be mediated through Go (Yamatsuji et al., 1996a; Ikezu et al., 1996).
Go, or the 'other' GTP-binding protein as it was labelled by Sternweis and
Robinshaw in 1984, is a member of the G protein family that is preferentially
expressed in the central nervous system (Price et al., 1989). Go accounts for
approximately 0.5 to 1% of membrane protein in the brain (Bertrand et al., 1990). It
is generally highly concentrated in synaptic-nch neuropil and absent from neuronal
cell bodies (Worley et al., 1986). At least three mRNAs, of 5.7, 4.2 and 3.2
kilobases, code for Goa in brain. All three mRNAs encoding Goa are spliced from a
single gene (Bertrand et al., 1990) that exhibits 45% gene homology with Gsa (Itoh
et al., 1986). Two 354 amino acid isoforms of Goa exist in brain, labelled Goal and
Goa2, which differ in 26 of their 106 carboxyl terminal amino acids (Hsu et al.,
1990). Spicher and co-workers (1992) have investigated the existence of a third
form of Goa in mammalian brain which is electrophoretically distinct from the other
two, but it is unclear whether the protein identified is indeed a hitherto undiscovered
product of the Goa gene, or merely the result of alternative co- or post-translational
processing of one of the already identified forms. Goa is both myristoylated and
palmitoylated and both acylations contribute to the association of Goa with the
membrane (Mumby et al., 1994).
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Gs, as was discussed in chapter three, is a specific G protein known to stimulate the
catalytic subunit of adenyl cyclase (May et al., 1985) and to activate voltage-gated
calcium channels in cardiac and skeletal muscle (Yatani et al., 1987; Mattera et al.,
1989). The mRNA encoding Gsa has been shown to be significantly increased in
hippocampal fields CA1, CAS and CA4 and in the dentate gyrus in AD brain in
comparison to neurologically normal controls (Harrison et al., 1991c). This increase
was not the result of a generalised increase in mRNA expression, as the increase in
+
Gsa mRNA remained even when expressed as a proportion of total poly(A) mRNA
levels in the same cell populations. McLaughlin and colleagues (1991) and O'Neill
and co-workers (1994) failed to demonstrate a concomitant increase in Gsa protein
in hippocampus in AD in using immunoblotting, though O'Neill and colleagues
found that the ratio of large to small molecular weight isoforms of Gsa was
significantly increased in the hippocampus and angular gyrus of AD brains in
comparison to controls.
Thus, Go represents an incompletely investigated member of a family of proteins
common to many of the neurotransmitter systems known to be abnormal in AD.
Elucidation of the extent of G protein a subunit mRNA abnormalities in AD is
crucial to the interpretation of functional neurotransmitter deficits in the disease.
Further, the success of therapeutic strategies involving provision of neurotransmitter
precursors, direct agonists or inhibitors of neurotransmitter metabolism depend on
the functional integrity of associated signal transduction mechanisms. To assume
that these are intact may be erroneous, since abnormalities in signal transduction in
AD have been documented at numerous stages of the signal transduction cascade
(See Fowler et al., 1992 for review).
Goa mRNA expression was investigated in the hippocampi of a series of AD brains
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and age matched neurologically normal controls. The aims of the study were
twofold. Firstly, to explore whether the documented increase in Gsa mRNA in AD
is a gene specific abnormality, or whether other members of the G protein family
also exhibit increased mRNA levels. Secondly, given the functional association
postulated to exist between Go and APP by Nishimoto and colleagues (1993), to
determine whether any correlation exists between hippocampal Goa and APP gene
expression in the same series of brains.
4.2 Materials and Methods
4.2.1 Introduction
This experiment was performed with the assistance of Dr. A.J.L. Barton on brains
from series I. The clinical and demographic details of these cases, along with
information relating to agonal state scores, PMI, storage time as a block and storage
time as cryostat cut sections, is presented in appendix II. Summarised information
relating to the cases included in series I is presented in table 4.1. The brains were
prepared and hybridised as described in chapter 2.
4.2.2 Oligodeoxynucleotide Probe Selection
The Goa antisense probe consisted of a 45 base oligodeoxynucleotide (Oswell DNA
Services) directed against bases 1-45 of the coding region of the human genomic
clone (Lavu et al., 1988). Total APP mRNA was detected by combining two 30 base
probes, the APP-insert oligodeoxynucleotide probe and the APP-junction
oligodeoxynucleotide probe, and applying them to the sections. The APP-insert
antisense oligodeoxynucleotide probe is directed at bases 1047 to 1076 of the
APP-751 cDNA sequence published by Ponte and co-workers (1988) and
theoretically detects APP mRNA isoforms APP-751, APP-770, APP-563 and
APP-365. The APP-junction antisense oligodeoxynucleotide probe is directed
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against bases 975 to 989 and 1158 to 1172 of the APP-751 cDNA sequence
published by Ponte and colleagues (1988) and therefore only hybridises to APP
isoforms in which the flanking regions of the KPI domain are contiguous, as in
APP-695 alone (see Harrison et al, 1994). Goa and APP-j unction sense
oligodeoxynucleotide probes were employed to control for the effects of non-specific
binding.
4.2.3 Experimental Controls
Dr. A.J. Barton demonstrated the specificity of the Goa oligodeoxynucleotide probe
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using Northern blotting with a [ P]-dATP-labelled probe hybridised to 20 pg total
RNA extracted from the frontal cortex of a control subject (Figure 4.1). The
specificity of the APP-insert and APP-j unction oligodeoxynucleotide probes has
been demonstrated in our laboratory by Dr. P.J. Harrison by Northern blotting of
RNA extracted from frontal cortex. The APP-insert probe detects a single band of
3.4 kb and the APP-junction probe detects a single band of 3.3 kb (Harrison et al.,
1994). Concurrent hybridisation of adjacent sections under identical conditions with
the complementary sense strand oligodeoxynucleotide probe was also performed.
4.2.4 In Situ Hybridisation Histochemistry
The total APP probe was prepared by combining the APP-junction probe with the
APP-insert probe such that 0.57 million counts per minute of each probe in a total
volume of 100 pi was applied to the sections. The hybridised sections were
incubated for approximately 18 hours, at 40°C for the Goa probe, and at 27°C for the
total APP probe. The slides were then washed in 1 x SSC (4*15 minute washes) at
60°C for the Goa probe, and at 52.5°C for the total APP probe. These washes were
then followed by 2 x 60 minute washes at room temperature. Once dry, the
hybridised sections were placed against film (Hyperfilm-(3max, Amersham) at room
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Figure 4.1 Northern blot provided by Dr. A.J.L. Barton demonstrating the
specificity of the Goa oligodeoxynucleotide probe. The oligodeoxynucleotide probe
was labelled with [32P]-dATP and hybridised to 20 pg of total RNA extracted from
the frontal cortex of a neurologically normal control. A major band of Goa mRNA





temperature for 46 days to generate autoradiograms (Figure 4.2).
4.2.5 Detection of Polyadenylated Messenger RNA
Where available, additional hippocampal sections from each case were hybridised
with a sense and antisense probe directed against the poly(A) tail of polyadenylated
mRNAs in order to correct, at least partially, for the differences in overall mRNA
content between individual brains and diagnostic groups (Flarrison el al., 1991b,
1993). The antisense probe comprised a strand 30 thymine deoxynucleotides, while
the sense probe consisted of a strand of 30 adenine deoxynucleotides. The
specificity of the poly(dT) oligodeoxynucleotide probe was demonstrated by
incubation of a subset of hippocampal sections with an excess of unlabelled poly(dT)
probe resulting in the abolition of signal. Similarly, pre-treatment of a subset of
hippocampal sections with ribonuclease abolished hybridisation of the labelled
oligodeoxynucleotide probe. The autoradiograms generated by the above cold
displacement and ribonuclease pre-treatment were completely blank. The standard
ISHH protocol, as detailed in the Materials and Methods chapter, was modified for
this experiment. Briefly, the hybridisation buffer was prepared with 2 x SSC, rather
than 20 * SSC, and 20%, rather than 50%, of formamide was added to the solution.
+
The sections hybridised with the poly(A) antisense and sense probes were incubated
for approximately 18 hours at 25°C and washed at 35°C. The hybridised sections
were exposed to autoradiographic film for 40 minutes to generate autoradiograms
(Figure 4.3). The strength of ISHH signal was analysed over dentate gyrus only for
each case.
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Figure 4.2 In situ hybridisation histochemistry using [35S]dATP labelled
oligodeoxynucleotide probes performed on hippocampal sections from the same
control case from series I. The images presented are direct photographs of
transilluminated autoradiograms generated from this single case and hybridised with
the following oligodeoxynucleotide probes. The blacker the image of the
autoradiogram the greater was the exposure of the autoradiographic film to
radioactivity and the more intensely labelled was the section.
A Goa antisense oligodeoxynucleotide probe.
B Goa sense oligodeoxynucleotide probe.
C Total APP antisense oligodeoxynucleotide probe
D Total APP sense oligodeoxynucleotide probe.
DG dentate gyrus
CA1 cornu Ammonis subfield 1
CA3 cornu Ammonis subfield 3
* cornu Ammonis subfield 4
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Figure 4.3 Autoradiogram of a hippocampal section from an AD case from
series I hybridised with the [35S]dTTP labelled poly(dT) oligodeoxynucleotide probe.
The autoradiogram of the corresponding sense section was completely blank.
This image was obtained by direct photography of the transilluminated
autoradiogram. Thus, the blacker the image of the autoradiogram the greater was the




4.2.6 Quantification of ISHH Signal
Quantitative assessment of ISHH signal, reflecting relative abundance of Goa and
total APP mRNAs, was made on the autoradiograms using an image analysis system
(Image Manager PC, Sight Systems, Newbury). Grain counting over individual
neurons was not possible in this series given the histological quality of the tissue.
Mean grey density was calculated, blind to case details, over the stratum granulosum
of the dentate gyrus and over the stratum pyramidale of hippocampal fields CA3 and
CA4. The mean value from each set of triplicates was used for subsequent
calculations. AOD readings, obtained by dividing 255 by the mean grey density,
adjusted for background, and logging the result, were used in all statistical analyses.
Mean grey density over hippocampus was calculated for the Goa and APP-junction
sense oligodeoxynucleotide probes. The AOD of each of the sense probes,
representing non-specific binding, was calculated as above. The AOD of the Goa
sense probe in both the AD and control groups was 0.020, while the AOD of the
APP-junction sense probe was 0.023 in both groups. These AOD readings were
subtracted from the AOD readings calculated for the appropriate antisense probe
prior to statistical analysis.
4.2.7 The Relationship between Radioactivity and Approximate Optical
Density
14C microscales (Codes RPA 504 and RPA 511, Amersham) were opposed to the
autoradiographic film alongside the specimen sections and analysed with them and in
the same way. An average AOD reading was obtained for each radioactive layer of
the polymer. This value was plotted against the tissue equivalent radioactivity of that
layer in nCi/g as supplied by the manufacturer (Figure 4.4). A linear relationship
was demonstrated between the AOD and tissue equivalent radioactivity at AOD
readings of less than 1.33. Since no AOD readings pertaining to this experiment
Figure4.4TissuEquivalentRad o ctivityinCi/gAgainstApproximatO t c lDens yfor1 C MicroscalesAcc mpanyingGoalphaExperi ent ApproximateO ticalDensity
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were obtained which were in excess of this level, all readings fell within the linear
portion of the graph.
The equation of the line of best fit for the plot of AOD against tissue equivalent
radioactivity for the l4C microscales was calculated to be:
y = 239x - 9.29
Computation of the F statistic for this line revealed a figure of 2018 suggesting that
the probability that the straight line fit of this data occurred by chance was p < 0.001.
Thus, the straight line fit of this data is highly significant.
4.2.8 Statistical Analysis
All statistical analysis was performed using SPSS for Windows version 6.0. A
two-tailed Student's t test was used to compare the control and AD group of cases.
Where Levene's test for homogeneity of variance was not significant, it was assumed
that the requirements of the Student's / test had been met. Where Levene's test was
significant, it was assumed that the requirements for the parametric test had been
violated and the data was examined using the non-parametric Mann-Whitney U.
Correlation matrices were constructed using both Pearson's correlation coefficient
and Spearman's rank correlation coefficient. When the two tests were in agreement,
the result was accepted, when a discrepancy was observed, the data was analysed
further, as detailed in the text.
4.3 Results
The Goa antisense probe has been demonstrated to hybridise to a major band of
3.4 kb on a Northern blot performed on RNA extracted from frontal cortex from a
neurologically normal control (Figure 4.1). The specificity of the APP-insert and
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APP-j unction antisense probes has been demonstrated by Northern blotting of RNA
extracted from frontal cortex; the oligodeoxynucleotide probes detect single bands of
3.4 and 3.3 kb respectively, and do not cross-hybridise to each other's target APP
mRNA isoforms (Harrison et al., 1991 d, 1994).
No statistically significant differences were found between the control and AD group
of cases in terms of age, agonal state score, PMI or storage duration of the tissue, as a
block or as cryostat cut sections, using a two-tailed Student's t test. No significant
4-
difference was observed in poly(A) mRNA levels between the control and AD
group of cases using a two-tailed Student's / test (Figure 4.5).
Comparison of Goa mRNA ISHH signal between the control group of cases (control
and age-related change cases) and the AD group of cases ( AD, borderline AD, mixed
AD and Parkinson's disease and mixed AD and multi-infarct dementia cases),
revealed that Goa mRNA signal was reduced in the dentate gyrus of the AD group in
comparison to the control group (two-tailed Student's t test p = 0.001). No
statistically significant difference in Goa mRNA levels was found, however,
between the two groups in fields CA3 or CA4 of the hippocampus (Figure 4.6).
Total APP mRNA levels were also found to be statistically significantly lower in the
AD group of cases when compared with the control group of cases in the dentate
gyrus (Mann-Whitney U two tailed corrected for ties p < 0.001). No statistically
significant difference between the groups in total APP mRNA level was apparent
over hippocampal fields CA3 or CA4 using a two-tailed Student's t test (Figure 4.7).
Nishimoto and colleagues (1993) have shown that APP forms a complex with Go
657 676
and have identified a cytoplasmic sequence, the His -Lys domain, in APP which
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is necessary for complex formation. Thus, we were curious as to whether APP and
Go mRNA levels might be correlated if studied in the same series of brains (Table
4.2). Pearson's correlation coefficient relating Goa and APP mRNAs in the dentate
gyrus of all cases yielded a correlation coefficient of 0.825 (p < 0.001). The mRNA
levels of Goa and total APP were not statistically significantly correlated in either
CA3 or CA4 of the hippocampus. No statistically significant correlation was found
+
between Goa mRNA and poly(A) mRNA levels or between total APP mRNA and
poly(A) mRNA levels in dentate gyrus using Pearson's correlation coefficient
(Table 4.2).
Total APP mRNA levels in CA4 were found to be negatively correlated with agonal
state with a Pearson's correlation coefficient of-0.466 (p = 0.022). Agonal state was
not correlated with total APP mRNA levels in CA3 or CA4 and did not correlate
•+*
with poly(A) or Goa mRNA levels in any of the regions measured (Table 4.2).
+
No correlations were found between total APP or poly(A) mRNA levels and age,
PMI or storage duration of the tissue, as a block or as cryostat cut sections. Goa
mRNA levels were not correlated with age, PMI or storage duration of the tissue as
cryostat cut sections. However, Goa mRNA levels were negatively correlated with
the duration of storage of the tissue as a block in CA3 with a Pearson's correlation
coefficient of-0.415 (p = 0.049). Spearman's rank correlation coefficient was not
significant (-0.355; p = 0.096), but the p value was sufficiently low to suggest that
the non-parametric test merely lacked the statistical power to demonstrate the
relationship between the two parameters (Table 4.2).
4.4 Discussion
A statistically significant reduction in Goa and total APP mRNA levels in the
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dentate gyri of the AD group of cases compared to the control group of cases was
demonstrated in this study. Further, Goa and total APP mRNA levels were
correlated in the dentate gyri of this series of brains irrespective of diagnosis.
Since both Goa and total APP mRNA levels were found to be statistically
significantly decreased in the dentate gyri of the AD group of cases in comparison
with the control group of cases, it was possible that the positive linear correlation
found between Go and total APP mRNA levels in the dentate gyrus was spurious.
Indiscriminate destruction of all mRNAs in the dentate gyri of the diseased tissue
might result in an artefactual correlation between the two mRNA species when all of
the cases were considered together. However, this correlation remained in dentate
gyrus on analysis of the control group of cases alone and a scatter plot of all cases
revealed that the subjects of both groups were evenly scattered about the line of best
fit (Figure 4.8), suggesting that the correlation found between these two mRNA
species is genuine. Further, this particular series of brains has been extensively
studied in Professor Pearson's laboratory and is well characterised. In 1991,
Makridimitri and colleagues found no significant difference in synaptophysin mRNA
in the dentate gyrus or CA1, CA3 and CA4 hippocampal fields of Alzheimer's
diseased brains in comparison to neurologically normal controls. Importantly, this
series included nineteen of the cases used in the present study suggesting that there is
preservation of selected mRNAs in the hippocampi of this series of brains. However,
the most compelling evidence in support of a real correlation between Goa and total
APP mRNA levels in the dentate gyri of this series of brains is the fact that the
mRNA levels of both species appear insensitive to the level of poly(A) mRNA in
this region, suggesting that both are uninfluenced by total mRNA levels.
Gs and Go are members of a multi-gene family, the heterotrimeric G proteins, whose
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subunits exhibit approximately 45% gene homology. In contrast to previous ISHH
work examining Gsa mRNA (Harrison et al., 1991c), this study demonstrates a
significant decrease in Goa mRNA in dentate gyrus, and unchanged levels of Goa
mRNA in the other hippocampal fields examined, in AD cases in comparison to
neurologically normal controls. Despite the decline in total mRNA documented in
the hippocampal CAS field in AD (Harrison et al., 1991b), and the involvement of
the hippocampus at an early stage in the pathophysiology of the disease (Braak and
Braak, 1991), perusal of studies of specific hippocampal mRNA species in AD
reveals mixed results. The APP-insert probe, which hybridises to APP mRNA
isoforms 751 and 770, is increased in CAS, but unchanged elsewhere in the
hippocampus (Pearson et al., 1992). The APP-junction probe, which hybridises to
APP isoform 695, is increased in the CAS field and dentate gyrus when expressed as
a proportion of total polyadenylated mRNA, but unchanged elsewhere (Pearson et
al., 1992). Palmert and co-workers (1988), using ISHH, found no change in total
APP gene expression or in expression of APP-insert containing isoforms of APP in
subicular hippocampal neurons in AD. Johnson and colleagues (1989), in a Northern
blotting study, found APP-695 mRNA to be greatly decreased in the hippocampus in
AD: a decrease which the authors believe cannot be solely accounted for by the
extensive neuronal loss expected in the subiculum and CA1 fields in AD.
Li and colleagues (1996) examined Goa protein levels in human prefrontal cortex
and demonstrated a statistically significant decline in Goa protein with increased
PMI, and a loss of this protein of approximately 4% per ten years of ageing in this
region. However, the authors found no statistically significant alteration in Goa
protein in the prefrontal cortex, superior temporal gyrus or occipital cortex of AD
brains in comparison with age and PMI matched controls. The mRNA findings in
fields CA3 and CA4 of the hippocampi in this series are in keeping with studies
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showing no difference in Goa protein levels, as measured by Western blotting,
between the hippocampi of AD and control brains (O'Neill et al., 1994; McLaughlin
et al., 1991). O'Neill and colleagues (1994), however, used crude synaptic
membrane fractions prepared from mid hippocampal tissue, including CA1, dentate
gyrus and a small piece of entorhinal cortex, while McLaughlin and co-workers
(1991), performed their immunoblot analysis of G-protein levels in the hippocampus
on tissue homogenates. It is conceivable, that a decrease in Goa subunits in dentate
gyrus, corresponding to the decreased Goa mRNA levels identified in dentate gyrus
in our study, is masked when Goa protein levels are examined in the hippocampus as
a whole.
Evidence suggests that the genes for all of the G-protein a subunits have evolved
from a common ancestral gene (Matsuoka el al., 1990). However, despite the
considerable sequence conservation in the coding regions of the G protein a subunit
genes, there is little sequence homology in the promoter regions and untranslated 5'
regions of different classes of these genes (Raport el al., 1989), and different
transcription factors appear to regulate the various G protein a subunits (Valerio el
al., 1993). It is likely that controls at the level of transcription are important in
determining levels of at least some of the G-proteins (Muller et al., 1993). There is
evidence, for example, that upregulation of the Gi-2a gene depends on the integrity
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of cAMP dependent protein kinase A , and that the Gi-2a gene contains consensus
sequences suggestive of a cAMP response element which the Gsa gene does not
have (Muller et al., 1993). Further evidence for the differential control of different
G-proteins comes from an ISHH study of chronically morphine-treated rats, who
exhibited significant increases in both Gsa and Goa mRNA in brain when compared
with control rats, in contrast to brain Gi-2a mRNA levels which were unchanged
(Parolaro el al., 1993). Gsa mRNA levels, however, were significantly increased
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only in the hypothalamic paraventricular nucleus of the morphine-tolerant rats, while
Goa mRNA was significantly increased only in the claustrum and endopiriform
nucleus of such animals (Parolaro et al., 1993). Differential effects of isoprenaline
on G protein a subunit transcription have also been demonstrated in rat heart, with a
40% increase in the transcriptional activity of the Gi-2a gene in response to the drug,
in contrast to the activity of the Gsa gene, which was unchanged (Muller et al.,
1993). Studies of G protein expression in failing human hearts have demonstrated a
significant increase in steady state levels of Gsa and Gi-3a mRNA, but no
significant alteration in Goa mRNA levels, when compared with non-failing human
hearts (Feldman et al., 1989). While it is conceivable that pre-mortem factors might
increase expression of Gsa mRNA in AD selectively, this seems unlikely as
Harrison and co-workers (1991c), in examining the expression of Gsa in human
brain, found no correlation between Gsa mRNA levels and agonal state.
Worley and colleagues (1986) have demonstrated that Go is widely but unevenly
distributed in brain. They found a selective enrichment of Go in the synaptic zones
of rat brain using a selective polyclonal antiserum to the a39 subunit of Go, and
Strittmatter and co-workers (1990) found Go to be one of the main components of
the growth cone membrane. It is clear, therefore, that Go is not uniformly distributed
in brain either at a regional or an intracellular level. In this study Goa mRNA was
measured in the dentate gyrus and CA3 and CA4 fields of the hippocampus in human
brain. It is conceivable that regional quantification has masked differential
alterations in Goa expression in subgroups of hippocampal neurons. The Goa
mRNA levels observed might be composed of an increase in expression of this
particular mRNA at the growth cone of surviving neurons undergoing aberrant
sprouting, but decreased expression elsewhere. Of course, levels of Goa mRNA
comparable to those found in neurologically normal brains does not guarantee that
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the mRNA is normally transcribed, or that the encoded protein is functionally active
and correctly coupled to effector systems.
Goa and total APP mRNA levels were found to be positively correlated in the
dentate gyri of this series of brains. If, as Nishimoto and colleagues (1993) predict,
APP is abnormally cleaved in AD such that it binds tonically to Go and
constitutively activates it, one would expect levels of Goa mRNA to fluctuate in
accordance with the requirement for Goa subunits. It is recognised that chronic
exposure of cells to agonists which rely on G-proteins for signal transduction can
lead to alterations in their G-protein levels (Mullaney et ai, 1993). Of course, it is
conceivable that Goa might only bind to specific isoforms of APP and, thus, that any
correlation between Goa and APP mRNAs might be weakened by looking at
estimates of total APP mRNA levels.
Migeon and colleagues (1994), investigated the properties of Goa using a luciferase
reporter gene under the transcriptional control of a cAMP response element in JEG-3
cells. This system is sensitive to small, physiologically relevant, increases in the
intracellular second messenger cAMP, the abundance of which is determined by
receptor mediated activation or inhibition of adenyl cyclase. JEG-3 cells express
Gila and Gi3a, but not Gi2a or Goa. The authors demonstrated that wild type Goa
can couple the m4 muscarinic receptor to inhibition of adenyl cyclase in JEG-3 cells
and that mutated, constitutively activated Goa can inhibit forskolin-stimulated
luciferase activity in these cells.
Cyclic AMP is centrally involved in learning and memory (Yin et a/., 1994).
Intracellular cAMP exerts its effects primarily through activation of the regulatory
subunit of protein kinase A, which allows translocation of the catalytic subunit of
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protein kinase A to the nucleus (Bonkale, 1996). Protein kinase A is capable of
transferring the terminal phosphate group of ATP to the serine, threonine or tyrosine
residues of substrate proteins. The transcription factor cAMP response element
binding protein (CREB) (Montminy et al., 1987) is regulated by translocated cAMP
dependent protein kinase A induced phosphorylation at serine 133 (Gonzalez and
Montminy, 1989). CREB, and its role in memory, has been highly conserved
through evolution (Frank and Greenberg, 1994). Activated CREB binds to the
cAMP response element found in the upstream control region of many cAMP
responsive genes. Long term memory, in contrast to short term memory, relies on
the synthesis of new RNA and protein (Huang el al., 1994). Long term potentiation
refers to the activity dependent increase in synaptic strength in neurons of the
hippocampus that occurs in response to brief, high frequency bursts of action
potentials (Huang et al., 1994), and hippocampal long term potentiation is believed
to contribute to memory storage. The late phase of long term potentiation is
stimulated by cAMP in all three of the major hippocampal synaptic relays identified,
namely the perforant, mossy fibre and Schaffer collateral pathways (Huang et a/.,
1994). Induction of expression of a dominant negative member of the fly CREB
family in Drosophila results in a loss of long term memory in the presence of
preserved short term memory and learning (Yin et al., 1994). This observation was
extended to mammals with the discovery that mice with targeted disruptions of the a
and 8 isoforms of CREB were profoundly deficient in long term memory
(Bourtchuladze et al., 1994). Go mediated regulation of the cAMP response element
has been studied in NK1 cells; naturally occurring transformants of COS cells which
express endogenous Goa. COS-NK1 cells transfected with mutated forms of
APP-695, in which the valine at position 642 had been converted to glycine,
isoleucine or phenylalanine (V642I/G/F), induced negative regulation of the cAMP
response element while wild-type APP-695 did not (Ikezu et al., 1996). Such
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V642I/G/F mutations are highly correlated with AD phenotype in humans. The
possibility that disrupted cAMP dependent phosphorylation of CREB, as a
consequence of constitutively activated Go, might underlie the memory loss which is
one of the earliest manifestations of AD (Ikezu et al., 1996), is intriguing.
Transfection with APP-695 mutants associated with familial AD have also been
reported to induce neuronal DNA fragmentation in F11 cells; hybrids of a primary rat
dorsal root ganglion neuron and a mouse neuroblastoma cell line that exhibits
neuronal traits (Yamatsuji et al., 1996b). This effect is critically dependent on the
His6:>7-Lys676 domain of APP-695, and is believed to be Go mediated. Yamatsuji and
co-workers (1996a) have demonstrated that COS-NFC 1 cells transfected with
V642I/G/F mutations of APP-695, undergo typical bcl-2 sensitive apoptosis, and that
the His6y7-Lys676 domain of APP-695 is necessary for this effect. A single point
mutation within codon 642 of APP-695 can result in conversion of valine to one of
six other amino acids. Only substitutions of valine with glycine, isoleucine or
phenylalanine have been associated with the familial AD phenotype, while point
mutations which result in conversion of amino acid 642 to leucine, alanine or
aspartic acid have not. Similarly, in vitro mutations of APP-695 incorporating
leucine, alanine or aspartic acid in place of valine at codon 642, do not result in a
significant increase in apoptosis in the COS-NK1 model system. The congruence
between in vivo and in vitro studies suggests that V642I/G/F induced, Go mediated
apoptosis may be fundamental to the pathology of this form of FAD (Yamatsuji et
al., 1996a). While it is likely that the cytotoxic effects of mutated APP-695 are
induced via direct activation of Go (Yamatsuji et al., 1996a), it should be noted that
cells transfected with V642I/G/F mutations secrete more (3-amyloid(l-42) and less
|3-amyloid(l-40) than cells transfected with wild type APP-695 (Suzuki et al., 1994).
Importantly, (3-amyloid(l-42) has been identified to adopt a toxic, aggregated state
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following an incubation of several days while the 1-40 amino acid form of (3-amyloid
does not (Pike et al., 1991a). Furthermore, immunochemical studies of brain tissue
from sufferers of sporadic AD suggests that the initial P-amyloid species deposited in
plaques is P-amyloid(l-42) and not P-amyloid( 1-40) (Iwatsubo et al., 1994).
However, Yamatsuji and co-workers (1996b) demonstrated that neuronal DNA
fragmentation was not induced by incubating the F11 cells in 50 M synthetic
P-amyloid(l-42), or in conditioned media from transfected cells themselves
undergoing DNA fragmentation, or following incubation in conditioned media from
cells undergoing DNA fragmentation combined with 50 M synthetic
P-amyloid(l-42). Nor could any significant apoptosis be induced in COS-NK1 cells
in response to incubation with 50 M synthetic P-amyloid( 1-42), or with conditioned
media from transfected cells supplemented with 50 M synthetic p-amyloid( 1-42)
(Yamatsuji et al., 1996a). Significantly, both of these studies imply that the
cytotoxic effects examined are mediated by V642I/G/F APP-695 mutations in a
manner independent of P-amyloid.
Lassmann and colleagues (1995), using terminal deoxynucleotide transferase
mediated deoxyuridine triphosphate nick end labelling (TUNEL), in which the
3'-OH termini of DNA strand breaks generated during DNA fragmentation are
labelled with a digoxigenin or biotin tagged dUTP, estimated that the number of cells
undergoing DNA fragmentation in AD brains was approximately thirty times that of
control brains. Cotman and Anderson (1995) employing the same technique
observed several features they believe to be suggestive of apoptosis in AD brain.
Profound cellular consequences of a point mutation in the transmembrane domain of
a cell surface molecule has previously been described for the receptor like protein,
pi 85, a product of the rat Neu gene (Bargmann and Weinberg, 1988). Conversion of
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the 664 valine of this protein to a glutamine or glutamic acid residue results in its
unregulated activation. The similarities between the transforming effect of a point
mutation in the Neu gene and the apoptotic effect of such a mutation in the APP gene
are obvious.
Previously, the distinct a subunits were thought to bind to a common pool of Py
dimers but recent work has demonstrated that the activity of the a subunit, and its
susceptibility to adenosine triphosphate (ADP) ribosylation by pertussis toxin, is
modulated by the subtype of v subunit to which the a subunit is bound (Sohma et al.,
1993). Further, Kleuss and co-workers (Kleuss et al., 1993) have shown that the y
subtype, y3, is required for mediation of somatostatin stimulated inhibition of
voltage-sensitive calcium channels through Go, whereas y4 is required for coupling
of m4 muscarinic receptors through Go to the same effector. Dissociated (3y dimers
are thought to inhibit the action of the a subunits by binding to them as a result of a
mass action effect (Katada et al., 1984), and may also interact with effectors directly
(Enomoto and Asakawa, 1986). Katada and colleagues (1984) hypothesise that the
Gi mediated inhibition of the catalytic subunit of adenyl cyclase results from the
mass action effect of the Py dimers liberated by the dissociation of Gi, binding to
Gsa and restoring it to its heterotrimeric and inactive conformation (Katada et al.,
1984). Since the Py dimers constitute a common pool and appear to be important in
specifying the receptor-effector specificity of the a subunits, it is tempting to
speculate on the impact of increased Gsa on the availability of Py dimers to associate
with a subunits of the other G proteins.
The present data suggests that one aspect of the G protein system, expression of Goa
mRNA, is selectively down-regulated in the dentate gyrus in AD. This is in contrast
to the increase in Gsa mRNA in hippocampus documented to occur in the disease.
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Elucidation of the mRNA levels of other a subunits of the G protein family are
needed in order to establish whether the alterations identified are shared by other a
subunits of the G protein family which are more highly homologous than Goa and
Gsa or whether these effects are in fact gene specific. The possible relationship of
Goa with APP, indicated by the correlation of Goa and APP mRNA abundance,




The Messenger RNA Encoding Amyloid Precursor Protein
5.1 Introduction
5.1.1 Amyloid Precursor Protein
The major proteinaceous component of the plaque and meningovascular amyloid
deposits which characterise AD is (3-amyloid, a 39 to 43 amino acid peptide (Glenner
and Wong, 1984; Masters et al., 1985a) identified as being the cleavage product of a
larger precursor protein known as APP (Kang et al., 1987; Tanzi et al., 1987). In
1987, Kang and colleagues identified the first APP cDNA clone and predicted APP
to be a 695 amino acid protein with characteristics reminiscent of a glycosylated
cell-surface receptor. Now at least six isofonns of APP of 365, 563, 695, 714, 751
and 770 amino acids are known to exist in humans.
APP (Figure 5.1) is composed of a short cytoplasmic domain, a single membrane
spanning region and a long extracellular domain. The p-amyloid sequence lies at the
junction of the extracellular and transmembrane domains of APP, extending 28
amino acids into the extracellular region and between 11 and 15 amino acids into the
transmembranous portion. The forty-three-residue form of p-amyloid terminates at,
and the forty-two-residue form tenninates just before, the first of the two threonine
residues found in the membrane spanning domain (Kang et al., 1987).
Figure5.1The770AminocidIsoformfmyloidPre ursorr tein (Drawntoscale1cm=35aminoidresidues)

















APP mRNAs are spliced from a single gene on chromosome 21 (Tanzi et al., 1987)
that is composed of 19 exons (Konig et al., 1992). Northern blotting of total RNA
from normal, adult, human cortex reveals APP mRNA transcripts of 3.4 and 3.2
kilobases (Kang et al., 1987) and APP mRNA has been detected in a wide variety of
human tissues including brain, liver, spleen, skeletal muscle, pancreas, kidney,
adrenal gland and small intestine (Tanzi et al., 1987). The confinement of
p-amyloid deposition to brain, despite the virtually ubiquitous distribution of its
precursor, is unexplained (Weidemann et al., 1989). An increase in APP mRNA has
been identified in brain tissue from Down's syndrome foetuses aborted at nineteen
weeks gestation when compared with brain tissue from normal foetuses aborted at
this time (Tanzi et al., 1987), in keeping with the 50% increase in APP gene dosage
associated with trisomy 21.
APP is synthesised as an immature N-glycosylated protein (Oltersdorf et al., 1990),
that undergoes extensive post-translational modification, to become a
tyrosine-sulfated and N- and O-gylcosylated membrane glycoprotein (Weidemann et
al., 1989; Oltersdorf et al., 1990; Moya et al., 1994). In keeping with the proposed
function of APP as a cell-surface receptor, a consensus sequence required for coated
pit-mediated internalisation, the NPXY domain, has been found in the cytoplasmic
domain of APP (Chen et al., 1990). In addition, APP has been demonstrated to bind
and activate the heterotrimeric GTP binding protein, Go, in a ligand-dependent and
ligand-specific manner (Okamoto et al., 1995), via a cytoplasmic binding domain.
149
The p-amyloid sequence is encoded by nucleotides from exons 16 and 17. The
multiple splice variants of APP identified arise from alternative splicing of exons 7,
8 and 15. Exon 7 consists of 168 nucleotides that encode a 56 amino acid domain,
the KPI domain, that is highly homologous with a Kunitz-type serine protease
inhibitor (Tanzi et al., 1988; Kitaguchi et al., 1988; Ponte et al., 1988). Such
inhibitors exhibit specificity for serine proteases such as trypsin, chymotrypsin,
elastase, plasmin and cathepsin G. In 1989, Oltersdorf and colleagues established
that the sequence of a secreted, KPI domain-containing derivative of APP was
identical to that of a cell-secreted protease inhibitor known as protease nexin II.
Protease nexin II forms inhibitory complexes with trypsin and is capable of
inhibiting factors IXa and XIa of the coagulation cascade.
Exon 8 encodes a 19 amino acid domain that exhibits 47% homology with the MRC
OX-2 antigen, a cell surface glycoprotein with an overall structure similar to an
immunoglobulin light chain or the T cell receptor p chain (Clark et al., 1985). Exon
15 is composed of 54 nucleotides and encodes 18 amino acids that precede the
amino terminus of the P-amyloid sequence by 16 amino acids.
The three major isoforms of APP in neuronal and non-neuronal cells, designated
according to their length in amino acids, are APP-695, APP-751 and APP-770
(Weidemann et al., 1989). APP-695 mRNA lacks both exon 7 and exon 8, APP-751
mRNA lacks exon 8 and APP-770 mRNA contains all 18 exons. The APP-714
mRNA isoform lacks exon 7 and represents a small proportion of total APP mRNA
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in brain (Harrison et al., 1996). Indeed, Jacobsen and colleagues (1991) found that
APP-714 consistently represented less than 1% of total APP mRNA in human
post-mortem brain samples from both AD and control donors. APP-563 mRNA (de
Sauvage and Octave, 1989) lacks exons 16, 17 and 18 and APP-365 mRNA
(Jacobsen et al., 1991) lacks exons 8 to 18. These two isoforms of APP are carboxyl
terminal-truncated forms that lack the cell-anchoring transmembrane domain and
thus do not contain the p-amyloid sequence. APP-563 contains the KPI domain and
is believed to be a secreted form of APP-751 in which the terminal 208 amino acids
of the peptide are replaced with 20 amino acids with homology to the consensus
repeat recognition sequence for the restriction enzyme Alul (de Sauvage and Octave,
1989).
APP mRNA transcripts which lack exon 15 were first discovered in peripheral
leucocytes and immunocompetent cells of the brain and are thus known as
leucocyte-derived APP (L-APP) mRNAs (Konig et al., 1992). Cleavage of exon 15
and fusion of exons 14 and 16 creates the sequence Glu-Xaa-Ser-Gly, a consensus
sequence for xylosyltransferase mediated attachment of a chondroitin sulfate side
chain (Pangalos et al., 1996). The side chain is attached to serine 619 of L-APP, 16
amino acids upstream from the p-amyloid sequence, and the resulting proteoglycan
is known as appican (Pangalos et al., 1996). Proteoglycan molecules are highly ionic
and the chondroitin sulfate proteoglycan form of L-APP is proposed by Pangalos and
co-workers (1996) to be a strong cell adhesion molecule. L-APP transcripts are not
expressed in neurons (Sandbrink et al., 1994a; Sandbrink el al., 1997), but are
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otherwise ubiquitous (Sandbrink et al., 1994a) and all four possible exon 15 lacking
transcripts of APP, L-APP-752, L-APP-733, L-APP-696 and L-APP-677, are known
to exist.
5.1.2 Human Homologues of Amyloid Precursor Protein
APP is a member of an evolutionarily conserved multigene family that includes
amyloid precursor-like protein 1 (APLP1) and amyloid precursor-like protein 2
(APLP2). The overall structures of APLP1 and APLP2 are strikingly similar to that
of APP, since all consist of a short cytoplasmic domain, a single membrane spanning
region and a large extracellular domain. However, APLP1 and APLP2 both lack the
P-amyloid sequence. APLP1 was first identified in the mouse (Wasco et al., 1992),
followed swiftly by the identification of its human homologue (Wasco et al., 1993).
APLP1 is a 653 amino acid protein that is 42% identical, and 64% similar, to
APP-695. It has been mapped by Wasco and colleagues to chromosome 19 (1992b).
Human APLP2 was isolated and characterised by Wasco and colleagues in 1993,
who demonstrated that the expression of APLP2 in the brain and periphery was
strikingly similar to that of APP. APLP2 maps to chromosome 11 and is a 752
amino acid protein predicted to be 52% identical, and 71% similar, to APP-751
(Wasco et al., 1993). It is expressed in a wide variety of human tissues including
brain, placenta, heart, lung, liver and kidney (Sprecher et al., 1993). Two
alternatively spliced inserts have been identified in APLP2: a KPI encoding region
highly homologous to exon 7 of the APP gene and a 12 amino acid sequence
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embedded in the region of APLP2 that exhibits the greatest divergence in sequence
from APP (Sandbrink et al., 1994b). Interestingly, splicing out of the 12 amino acid
encoding exon creates the same xylosyltransferase signal motif as exists in exon
15-lacking L-APP isoforms. In the rat, the 12 amino acid domain is present in the
majority of intraneuronal transcripts of APLP2, but is present in only a minority of
peripheral forms of APLP2 (Sandbrink et al., 1997). Thus, it appears that regulation
of L-APP and APLP2 glycosylation occurs partly at the level of mRNA splicing
(Sandbrink et al., 1997). APLP2 matures, like APP, through a secretory pathway,
and secreted, soluble, carboxyl terminal-truncated derivatives of APLP2 have been
identified in the conditioned media of Chinese hamster ovary cells transfected with a
cDNA encoding mouse APLP2 (Slunt et al., 1994). Webster and colleagues (1995)
identified soluble, secreted, truncated forms of APLP2 in human CSF, suggesting
that this pathway also exists in vivo. Like APP, APLP2 harbours a consensus
sequence in its cytoplasmic domain predicted to bind to the heterotrimeric
GTP-binding protein Go (Wasco et al., 1993).
5.1.3 Control of Amyloid Precursor Protein Expression
The promoter of the APP gene was cloned and characterised by Salbaum and
colleagues in 1988 and strongly resembles that of a housekeeping gene consistent
with the virtually universal expression of APP mRNA (Tanzi et al., 1987). At least
five mechanisms exist by which APP expression might be controlled at the level of
transcription. The APP gene promoter contains four potential regulatory elements: a
stress-inducible heat shock control element, a sequence resembling the consensus
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binding site for the transcription factor AP-1 and the oncogene products v-jun and
c-fos, a region with a high frequency of CpG dinucleotides capable of DNA
methylation, a known mechanism of gene expression control, and, lastly, a potential
binding site at a GC-rich element between positions -200 and -100 (Salbaum et al.,
1988). Gegelashvili and co-workers (1996) draw a further parallel between APP
transcription and the transcription of heat shock protein genes, in demonstrating that
upregulation of APP mRNA in a glioma cell line occurs in response to cAMP.
APP mRNA's contain multiple UTR AUUUA motifs encoded in the untranslated
3-region of the gene that are hypothesised to destabilise the mRNA and prevent its
accumulation. Such recognition sites are frequently identified in mRNA species
subject to rapid cytoplasmic decay (Shaw and Kamen, 1986). The stability of APP
mRNA, as studied in neuronal tumour cell lines and peripheral blood mononuclear
cells, is regulated by a 29 base element in the 3'-untranslated region of APP mRNA
approximately 200 bases from the stop codon (Zaidi et al., 1994). In resting, normal
cells this 29 base region appears to function in cis to destabilise APP mRNA. On
cellular activation APP mRNA-binding proteins are induced which attach to this 29
base region and stabilise APP mRNA (Zaidi and Malter, 1994).
The abundance of another glycoprotein, the major myelin glycoprotein, has been
demonstrated in Schwann cells to be partly controlled by post-translational
catabolism of the nascent protein (Brunden et al., 1990). The protein is processed at
least as far as the medial Golgi before its efficient transfer to lysosomes where it is
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rapidly degraded. APP has been localised to secondary lysosomes in cultured,
human, neuronal cell lines (Cole et al., 1989) and to neuronal secondary lysosomes
in both normal and AD diseased brains (Benowitz et al., 1989). Steady state levels
of APP in cultured cells have been observed to rise in the presence of lysosomal
inhibitors (Cole et al., 1989). C6 glioma cell lines, transfected with secreted
placental alkaline phosphatase-tagged fusion recombinant APP proteins, exhibit
intracytoplasmic accumulation of APP on heat shock (Pappolla et al., 1995). The
promoter employed was not heat shock inducible and the intracytoplasmic
accumulation of APP, demonstrated on cytochemistry, was Golgi-like. Thus, it is
conceivable that APP expression might be controlled by post-translational
catabolism (Pappolla et al., 1995).
5.1.4 Processing of Amyloid Precursor Protein
5.1.4.1 Introduction
A number of physiological functions have been ascribed to APP, though its definitive
role in human brain remains unknown (Adams, 1997). APP is hypothesised to be
processed in at least two major ways: a secretory pathway, in which APP is cleaved
intracellularly, or at the cell membrane, in preparation for its secretion from the cell,
and an endosomal-lysosomal route which involves targeting of APP, either from the
Golgi or the cell membrane, to endosomes-lysosomes. Early attempts to delineate
the processing of APP envisioned a simple scheme whereby P-amyloid was the
pathological product of the endososomal-lysosomal processing of APP (Haass et al.,
1992a). Secretory processing was assumed to cleave APP at one location within the
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P-amyloid domain and thus to be non-amyloidogenic (Sisodia et al., 1990). The
complexity of APP processing has since become obvious. It would seem unwise to
assume that current opinions about APP metabolism are wholly accurate and entirely
applicable in vivo.
5.1.4.2 Processing of Amyloid Precursor Protein by the Secretory Pathway
In 1988, Selkoe and colleagues, using two antibodies to the carboxyl terminus of
APP, identified APP immunochemically in various membrane-rich, sub-cellular
fractions of brain and non-neural human tissues. The APP forms identified were
heterogeneous, ranging from 110 to 135 kDa, and the authors postulated that
variations in the glycosylated side-chains attached to the extracellular domain of
APP, or proteolytic cleavage of the full length form, might be responsible for the
variability observed. Sisodia (1992) demonstrated cleavage of mature,
membrane-bound APP within the P-amyloid domain in cultured cells by a
membrane-bound endoprotease dubbed a secretase. Cleavage by this enzyme is
predicted to take place at the Lysl6-Leul7 bond of the p-amyloid sequence and
therefore precludes the formation of p-amyloid (Sisodia, 1992). Alpha secretase
exhibits a relaxed sequence specificity: the primary determinants of cleavage are the
presence of an a helical conformation and a distance of 12 to 13 amino acids of the
hydrolysed bond from the plasma membrane (Sisodia, 1992). Cleavage at this site
releases a soluble, amino terminal fragment of APP into the extracellular space,
leaving a truncated, carboxyl terminal derivative of APP, known as plO, embedded
in the membrane. It now appears likely that a secretase cleavage can occur both at
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the cell membrane, with fully matured APP as a substrate, and intracellular^',
probably in secretory vesicles or in the trans-Golgi network or late trans-Golgi
compartment (See Checler, 1995 for review). The secretory and membrane-bound
forms of the protein are likely to follow the same route, being separated after
N-glycosylation in the endoplasmic reticulum at the earliest (Weidemann et al,
1989). Weidemann and co-workers (1989) have identified carboxyl terminal and
transmembrane domain-lacking secretory products of APP-695, APP-751 and
APP-770 in the CSF of both AD sufferers and normal controls.
Golde and colleagues (1992) analysed the amino terminal derivatives of APP
secreted into the conditioned media of human embryonic kidney cells. They
concluded that such derivatives arose as the result of cleavage at a single a secretase
site generating one secreted derivative and one carboxyl terminal fragment.
However, in 1993 Seubert and co-workers identified another, far rarer, soluble amino
terminal derivative of APP in the conditioned media of human mixed brain cultures,
suggesting that a further APP processing route existed. This derivative arose from
cleavage of APP between Met 596 and Asp 597, the bond precisely at the amino
terminus of the p-amyloid sequence. Seubert and colleagues (1993) proposed that
the membrane-bound secreting system responsible for cleavage at this site be
referred to as P secretase. Beta secretase cleavage occurs at a privileged peptide
bond corresponding to the bond between Met671 and Asp672 of the APP-770
sequence and may be the rate limiting step in the release of soluble P-amyloid
(Maruyama et al, 1994). Cleavage at the P secretase site yields a soluble, amino
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terminal derivative of APP and a membrane-bound derivative that contains the whole
of the P-amyloid sequence at, or near to, its amino terminus. The discovery of P
secretase cleaved APP derivatives in CSF (Seubert et al., 1993) confirmed the
existence of this pathway in vivo. The identification, by Estus and colleagues
(1992), of a complex set of carboxyl terminal APP fragments in human brain, some
of them large enough to contain the entire P-amyloid sequence, confirmed that this
pathway was potentially amyloidogenic in vivo.
A further, alternative, cleavage site was documented by Kametani and colleagues
(1994) in Down's syndrome brain, whereby soluble P-amyloid is generated by
secretory processing of carboxyl terminal fragments by cleavage at Glu-7-lle-6 and
Glu-4-Val-3.
To generate P-amyloid APP must also be cleaved at the carboxyl terminal of
p-amyloid: a site that lies within the transmembrane domain of APP. An enzyme,
dubbed y secretase, is postulated to effect this cleavage, though how it might occur
remains obscure (Checler, 1995). A soluble, amino terminal derivative of APP, that
reacts with a polyclonal antiserum directed against residues Ala21 to Lys28 of the
p-amyloid sequence, has been identified in the culture medium of human kidney 293
cells (Anderson et al., 1992), suggesting that y secretase cleavage can indeed occur
in vivo. The exact site of y secretase cleavage is clearly variable, since the
P-amyloid peptide exhibits a range of lengths from 39 to 43 amino acids, (Checler,
1995). Cleavage of plO at the y secretase site yields a membrane-bound fragment,
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p7 and the carboxyl terminal fragment of P-amyloid, p3. It is noteworthy, that the a,
p and y proteases responsible for the cleavage of APP have not, as yet, been isolated
or cloned (Reaume et al., 1996).
Interference with both a and p secretase activity by the KPI domain of APP has been
proposed. Ho and co-workers (1996) have documented impaired a secretase
cleavage of APP in cells transfected with human APP-751 in comparison to those
transfected with human APP-695. While Ho and colleagues (1996) data are
consistent with direct inhibition of a secretase by the KPI domain, it is also possible
that the protein conformation of KPI containing isoforms of APP render them less
vulnerable to a secretase cleavage or, alternatively, that intracellular trafficking of
such forms removes them from the site of action of this protease (Ho et al., 1996).
Lymphoblasts derived from individuals with early onset familial AD exhibit slow
processing and cytosolic accumulation of P-amyloid (Matsumoto and Matsumoto,
1994). They also express large amounts of a calcium dependent, 68 kDa, serine
protease of the chymotrypsin type hypothesised to cleave APP at the amino terminus
of p-amyloid (Matsumoto, 1994). This serine protease has been demonstrated to
form SDS-stable, heat-labile, complexes with the KPI domain of APP (Matsumoto,
1994). Matsumoto (1994) proposes that KPI containing isoforms of APP may be
able to trap and inactivate potentially proteolytic peptides and thus alter the spectrum
of proteases available to cleave APP.
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Reaume and colleagues (1996) studied gene-targeted mice bearing the Swedish
mutation K670N/M671L and a humanised P-amyloid sequence. The authors
demonstrated enhanced, accurate P secretase cleavage, and depressed
non-amyloidogenic cleavage, of the mutated APP. Importantly, this model
demonstrates that amyloidogenic and non-amyloidogenic pathways of APP
metabolism are linked in vivo and that the production of p-amyloid can be enhanced
without an increase in APP synthesis.
5.1.4,3 Processing of Amyloid Precursor Protein by the
Endosomal-Lysosomal Pathway
The non-amyloidogenic nature of the a secretase pathway, and the inaccessible
membranous location of the y secretase cleavage site, prompted researchers to search
for another mechanism by which P-amyloid could be generated from APP. In 1989,
Cole and colleagues observed a rapid and dramatic increase in steady state levels of
immunochemically detectable APP in a neuronal cell line in response to inhibitors of
lysosomal proteolysis and proposed that APP is normally degraded in lysosomes.
Examination of the swollen, dystrophic neurites of senile plaques, has shown them to
be filled with acid phosphatase-positive dense bodies thought to be of lysosomal
origin (Suzuki and Terry, 1967) and APP in neurons (Cole et al., 1989), and in the
dystrophic neurites of senile plaques (Cole et al., 1989; Shoji et al., 1990), has been
localised immunochemically to membrane bound organelles believed to be
secondary lysosomes. In 1989, Neve's laboratory (Benowitz et al., 1989)
demonstrated punctate concentrations of immunochemically labelled APP in
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neocortical pyramidal cells, especially in associative regions, in normal brain.
Intense immunochemical staining for APP was also found in the pyramidal cells of
hippocampal subfield CA1 in normal brain. In AD, abnormally dense concentrations
of APP were observed in hippocampal subfield CA1, along with severe atrophy of
the pyramidal cells in this region. Benowitz and co-workers (1989) hypothesise that
APP accumulates in secondary lysosomes in AD, leading to proteolytic events that
form p-amyloid. The presence of the consensus sequence, NPXY, on the
cytoplasmic tail of APP (Chen et al., 1990) suggests that it is internalised in
clathrin-coated pits, and, further, the internalisation of full length APP and its
targeting to endosomes-lysosomes has been demonstrated (Haass et al., 1992a).
Golde and colleagues (1992) analysed the products of endosomal-lysosomal
processing of APP in human embryonic kidney 293 cells transfected with cDNA
encoding APP-695. They identified a complex set of carboxyl terminal APP
derivatives of between 8 and 12 kDa in size, some of which were long enough to
contain the entire P-amyloid sequence at their amino termini Both Ieupeptin, an
inhibitor of serine and cysteine proteases, and ammonium chloride, a weak base
amine that is concentrated in acidic compartments and inhibits lysosomes by
increasing their pH, inhibited the production of these carboxyl derivatives of APP.
Haass and co-workers (1992a) incubated living human endothelial cells with
antibody to the extramembranous portion of APP and demonstrated the uptake of
APP-antibody complexes into lysosomes. Subsequent purification of the lysosomes
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revealed full length APP and an extensive array of P-amyloid containing proteolytic
products. In addition, lysosomes extracted from leupeptin treated cells were
enriched with full length APP and carboxyl terminal derivatives of APP of 10 kDa
and longer, indicating that carboxyl terminal derivatives of APP, like APP itself, are
stabilised by inhibitors of lysosomal proteolysis. This work confirmed that
re-internalisation of fully matured, membrane-associated APP occurs and established
that p-amyloid bearing substrates are available to lysosomal proteases. Haass and
colleagues (1992a) noted, however, that their findings did not preclude the targeting
of APP directly from the late trans-Golgi network to lysosomes.
Hayashi and colleagues (1992) transfected human APP cDNAs into a glioma cell
line and examined the effect of lysosomal inhibitors on the metabolism of APP. The
protease inhibitors, leupeptin and E-64, led to the accumulation of aberrant,
potentially amyloidogenic fragments of APP in lysosome-like organelles in the
transfected cells. Whereas chloroquine caused little degenerative change in the
untransfected control cells, the transfected cells exhibited cellular degeneration in
response to chloroquine. The cytotoxic effects of chloroquine were potentiated by
pre-treatment of the transfected cells with the protease inhibitors, leupeptin and
E-64, suggesting that lysosomal inhibition results in the accumulation of cytotoxic
fragments of APP.
Fraser and colleagues (1996) have demonstrated that carboxyl terminal p-amyloid
containing derivatives of APP are extremely potent inducers of non-selective ion
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currents in Xenopus oocytes, a model system widely used to investigate
electrophysiological aspects of signalling. The induction of such currents implies
that carboxyl terminal (3-amyloid containing derivatives of APP may be involved in
the neural toxicity characteristic of AD.
5.1.4.4 Soluble (3-amyloid is a Product ofNormal Cellular Metabolism
The belief that P-amyloid is the product of aberrant cellular metabolism was
challenged by Haass and colleagues (1992b), who identified soluble p-amyloid in the
media of cultured human kidney 293 cells stably transfected with cDNA encoding
APP-695 and grown under normal conditions. Shoji and co-workers (1992)
independently identified soluble p-amyloid in the culture medium of human
mononuclear leukemic cells stably transfected with a carboxyl terminal (3-amyloid
bearing APP-derived construct, confirming that soluble (3-amyloid was the product of
normal cellular metabolism in these cells. Further, the same authors (Shoji et al.,
1992) demonstrated that the production of soluble (3-amyloid could be reduced by
the addition to the culture medium of lysosomotropic agents capable of increasing
the pH of acidic intracellular compartments. Thus, it appears that soluble P-amyloid
is produced, at least in part, in lysosomes.
Soluble P-amyloid has since been identified in human plasma, CSF obtained at
autopsy (Seubert et al., 1992) and CSF obtained during life (Shoji et al., 1992),
confirming the existence of this pathway in vivo (Seubert et al., 1992). Considerable
overlap has been found between AD and control groups in the abundance of this
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peptide (Tabaton et a/., 1994). Van Gool and co-workers (1994) observed a
significant, positive correlation between soluble P-amyloid levels detected in CSF
and age in subjects free of neurodegenerative disease. Kalaria and colleagues
(1996b) have demonstrated that soluble P-amyloid is constitutively produced by
meningeal vessels, large and small cerebral microvessels and the choroid plexus in
human brain. Soluble P-amyloid can be identified intracellularly, in a
membrane-associated form, or free in the extracellular space. Further, the authors
found soluble p-amyloid levels to be increased in vascular tissue from AD subjects
in comparison to that from age-matched controls
5.1.4.5 Regulation ofAmyloid Precursor Protein Processing
The control of APP processing in vivo is currently the focus of intense research
activity. Cell culture studies suggest that amyloidogenic and non-amyloidogenic
pathways of APP metabolism are stoichiometrically coupled (Nitsch, 1996),
probably through competition for substrate (Gandy and Greengard, 1994), and
evidence regarding control of the metabolic fate of APP is emerging. Stimulation of
m 1 and m3 muscarinic acetylcholine receptors in human embryonic kidney cell lines
transfected with human brain muscarinic acetylcholine receptors results in the rapid
release of soluble amino terminal derivatives of APP (Nitsch et al., 1992). The time
course of the appearance of these cleavage products suggests that cell surface
receptor stimulation enhances the secretory cleavage of pre-existing APP. Buxbaum
and colleagues (1992) independently demonstrated muscarinic acetylcholine receptor
regulated APP processing in human glioma and neuroblastoma cells, and, in
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addition, showed that interleukin-1 stimulates secretory processing of APP in human
endothelial and glioma cells. Metabotropic glutamate (Lee et al., 1995), 5-HT2a and
5-HT2c receptors (Nitsch et al., 1996) have also been shown in vitro to enhance a
secretase cleavage of APP and inhibit the production of P-amyloid. The
neuropeptides, vasopressin and bradykinin, have been demonstrated to increase
secretion of amino terminal derivatives (Nitsch, 1996), as has electrical stimulation
of rat brain hippocampal slices (Nitsch et al., 1997). Neurotransmitter
receptor-mediated cleavage and release of soluble amino terminal derivatives of APP
is insensitive to colchicine, suggesting that the cleaved substrate is either at the
plasma membrane or is transported to the membrane in colchicine-insensitive
secretory vesicles (Nitsch et al., 1997).
It is of note, that muscarinic ml and m3 receptors, like the bradykinin receptor, are
linked through two homologous heterotrimer G proteins, Gq and G11, to activation
of phospholipase C. Phospholipase C is responsible for the cleavage of
phosphatidylinositol 4,5-biphosphate to inositol 1,4,5-triphosphate and
1,2-diacylglycerol. Along with intracellular ionic calcium, 1,2-diacylglycerol helps
activate protein kinase C (PKC), while inositol 1,4,5-triphosphate regulates the
release of calcium from intracellular stores.
Nitsch and colleagues (1992) hypothesise that the neural control of APP processing
is mediated by protein kinases, possibly PKC (Nitsch et al., 1997; Nitsch et al.,
1992), since staurosporine, an inhibitor of protein kinase, blocks the effect of ml and
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m3 acetylcholine receptor stimulated release of soluble APP derivatives.
Intracellular ionic calcium enhances ml and m3 acetylcholine receptor-mediated
release of soluble APP derivatives (Nitsch et al., 1997), though it is not necessary for
this effect. Calcium alone is unable to mediate the release of soluble APP
derivatives (Nitsch et al., 1997).
Buxbaum and colleagues (1994) have identified another phospholipase C-dependent
mechanism by which the secretion of soluble APP derivatives is enhanced, and the
production of P-amyloid usually decreased, which relies on increased intracellular
calcium, but which is independent of PKC.
Further evidence implicating PKC, which is proposed to have a general role in
membrane trafficking (Luini and De Matteis, 1993), in the regulation of APP
processing, comes from study of the effects of phorbol esters on the secretion of
soluble amino terminal derivatives of APP. Phorbol esters usually alter the
intracellular distribution and trafficking of proteins by phosphorylation, either of the
protein itself or an ancillary protein, through stimulation of PKC (Efthimiopoulos et
al., 1994). Phorbol ester treatment of a rat C6 glioma cell line resulted in an increase
in the production and secretion of the 110 to 125 kDa soluble ectodomain of APP
and a decrease in the production of P-amyloid (Efthimiopoulos et al., 1994),
suggesting the P-amyloid levels can be manipulated pharmacologically. While the
membrane-anchoring domain and site of a secretase cleavage were necessary for the
effect, the ectodomain was not (Efthimiopoulos et al., 1994). Further, while the
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cytoplasmic domain was not required for phorbol induced modulation of APP
processing, the cytoplasmic sequence 707 to 719 did affect the magnitude of the
response. The authors hypothesise that removal of this cytoplasmic sequence
enhanced the effect of phorbol esters either because its absence precluded entry into
pathways other than the a secretase one or because this mutant proved a better
substrate for the a secretase enzyme. Thus, it appears that the cytoplasmic tail plays
little, if any, role in the regulation of a secretase cleavage of APP (Gandy and
Greengard, 1994).
The effect of phorbol esters in the above system appears to be modulated by a
cholera toxin sensitive heterotrimeric G protein (Efthimiopoulos et a/., 1994) and is
independent of substrate phosphorylation (Jacobsen et ai, 1994). Okadaic acid,
which inhibits protein phosphatases 1 and 2A, and tyrosine phosphorylation can also
accelerate processing and secretion of a cleaved APP in a receptor-mediated fashion
(Kingsbury et a/., 1995).
Significantly, the ml muscarinic acetylcholine receptor is largely expressed in the
CNS, unlike m2, m3 or m4 receptors that are widely distributed in peripheral tissues.
Further, preliminary studies suggest that ml agonists are safe and relatively free of
troublesome side effects and that they slow the rate of progression of AD (Nitsch,
1996).
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5.1.5 The Proposed Functions of Amyloid Precursor Protein
The physiological function of APP remains unknown (Adams, 1997), though a wide
variety of potential roles for APP, its soluble, amino terminal truncated derivatives
and residual carboxyl terminal fragments and P-amyloid are currently being
explored.
After its synthesis in neurons, APP is transported by fast, anterograde, axonal
transport. Indeed, APP can be seen to accumulate within three hours of neuronal
injury as a consequence of cytoskeletal breakdown (Sherriff et al., 1994). The
various isoforms of APP are differentially expressed and their expression appears to
be tightly regulated, suggesting they may have different actions (Moya et al., 1994).
Furthermore, their cellular effects may depend on the developmental stage of the
cells exposed to them (Shea, 1994). APP is hypothesised to be a cell surface
receptor linked to the heterotrimeric G protein, Go, and has been shown to bind to
and activate Go in a ligand specific and ligand dependent manner (Okamoto et al.,
1995). It is probable that a naturally occurring ligand exists for this putative APP
receptor, though none, as yet, has been identified (Okamoto et al., 1995).
Small quantities of full-length, soluble forms of APP have been identified in the
soluble fraction of PC 12 cell extracts and in the conditioned media of these cells
(Ripellino et al, 1994). Incubation of the membrane fraction of these cells at 37°C
results in solubilisation of a full-length, mature form of APP. Though representative
of a small fraction of the total APP in PC 12 cells, the authors comment that this form
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of APP is free of the plasma membrane and, therefore, accessible to proteolytic
enzymes. In this model, release of soluble APP from the cell membrane was blocked
by certain serine protease inhibitors and was inhibited by the presence of specific
metal cations. It was also temperature and pH sensitive, all of which suggests the
involvement of a serine protease in the process.
Severe degeneration has been described in post-mitotic neurons over-expressing APP
(Yoshikawa et al., 1992). Murine embryonal carcinoma P19 cells that differentiate
into neurons and astrocytes on exposure to retinoic acid were transfected with cDNA
for full-length human APP. Severe degenerative changes were identified in the
neurons, which contain large amounts of carboxyl terminal fi-amyloid containing
peptides.
By analogy with the secreted, soluble derivatives of other proteins, the soluble,
carboxyl truncated forms of APP are likely to be functionally important (Palmert et
al., 1989). Soluble, a secretase cleaved, APP-695 (APP-695S) is believed to be
neuroprotective in vitro, since conditioned medium from cells overproducing
APP-695 has been shown to promote neurite extension in a clonal CNS neuronal cell
line, B103 (Jin et al., 1994). A 17 amino acid region of APP-695S, from AIa319 to
Met335, a domain known as the Kang sequence, has been identified as being
responsible for this effect. The Kang sequence binds to specific and saturable cell
surface binding sites and neither the KP1 domain and nor the p-amyloid sequence is
necessary for it to exert its effects. A shorter, five amino acid sequence known as the
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RERMS sequence that spans amino acids 328 to 332 of APP-695S, was identified as
the active site crucial for such binding, though its effects were less potent than those
of the Kang sequence. A role for APP-695S in synaptic integrity has, therefore, been
proposed (Jin et al., 1994). The Kang sequence is also capable of inducing the
accumulation of inositol polyphosphates, suggesting that this sequence is involved in
the activation of inositol phospholipid signal transduction systems (Jin et al., 1994).
Evidence of a specific cell surface receptor for the soluble, carboxyl terminal
truncated forms of APP comes from Johnson-Wood and colleagues (1994). They
have identified a specific binding site for APP-75 ls, the a secretase cleaved
APP-751 isoform of APP that is identical to protease nexin II (Oltersdorf et al.,
1989), in cultured fibroblasts. The identified binding sites constituted a single class
of high affinity sites that were saturable and to which binding was reversible. The
identity of these binding sites remains unknown, but it is postulated to be either a
cell surface receptor or a cell adhesion molecule. It is conceivable that such binding
is the basis for the biological activities ascribed to APP-75 ls (Johnson-Wood et a/.}
1994).
A role as a cell adhesion molecule in the CNS has been postulated for APP as a
result of both in vitro (Ho et al., 1994) and in vivo (Moya et al., 1994) evidence. Ho
and colleagues (1994) have demonstrated that purified APP-770 is a substrate for
tissue transglutaminase, an enzyme responsible for the calcium dependent
intermolecular cross-linking of proteins via glutamine and lysine residues. Ho and
co-workers conclude from their work and that of others that the secreted form of
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APP-770 is an essential component of the extracellular matrix and that it contributes
to the supporting infrastructure of the cell.
The neuroprotective effects of APP-695S and APP-75 ls in vivo have been studied by
Smith-Swintosky and colleagues (1994), who administered these proteins
intracerebroventricularly to rats within ten minutes of a period of cerebral ischaemia.
The survival of neurons in the CA1 field of rat hippocampus was increased in rats
that had been injected with APP-695S and APP-75 ls. The surviving neurons were
both structurally and functionally intact and, in addition, APP-75 ls partially
prevented the decrease in microtubule-associated protein 2 (MAP-2)
immunoreactivity that usually accompanies cerebral ischaemia, suggesting dendritic
preservation. Bowes and colleagues (1994) employed a rabbit model of focal
cerebral ischaemia to examine the effects of the 17 amino acid Kang sequence when
administered intrathecally. They demonstrated a significant increase in the duration
of the period of ischaemia required to produce permanent neurological damage when
the Kang sequence was administered prior to, and for three days following, the
period of ischaemia. Since the effect of this peptide was evident 4 days, but not 18
hours, post-ischaemia, Bowes and co-workers suggest that its function is restorative
rather than protective. Thus, it would appear that the Kang sequence has a role in
cellular stress management.
In an unusual study, Wagner and colleagues (1994) examined soluble amino terminal
derivatives of APP, mostly the result of a secretase cleavage, in the CSF of three
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pairs of monozygous twins. Lower levels of soluble, amino terminal derivatives of
APP were found in the CSF of the AD subjects in comparison with the level found in
the CSF of their normal or less affected twin.
5.1.6 The Neurotrophic and Neurotoxic Actions of P-amyloid
Yanker and colleagues (1990) exposed cultures of embryonic, rat, hippocampal
neurons to (3-amyloid and observed that low concentrations of this peptide had a
neurotrophic effect on undifferentiated neurons. In contrast, higher concentrations
of (3-amyloid were neurotoxic to mature neurons. Substance P proved the most
potent mammalian inhibitor of both the neurotoxic and neurotrophic actions of
(3-amyloid, implying that a substance P receptor might be involved in these
phenomena. Yankner's team (Kowall et al., 1991) went on to demonstrate that the
forty-residue form of (3-amyloid ((3-amyloid(l-40)) was toxic in vivo by injecting rats
intracerebrally with this form of the peptide.
In 1991, Pike and co-workers (Pike et al., 1991a; 1991b) demonstrated that the
forty-two-residue form of (3-amyloid ((3-amyloid(l-42)) adopts an aggregated
conformation following several days incubation and is toxic to cultured, rat,
hippocampal neurons. A twenty-eight-residue form of P-amyloid (P-amyloid(l-28)),
however, did not aggregate under similar conditions and was not toxic to such
neurons. Exposure of rat, hippocampal cultures to aggregated deposits of P-amyloid
resulted in dystrophic neuronal processes (Pike et al., 1992), yet, once in contact
with deposits of aggregated P-amyloid the neuronal processes grew extensively over
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them and rarely extended beyond them. Scanning electron microscopy confirmed
that neurites in contact with aggregated P-amyloid deposits degenerated, that they
appeared orientated towards the deposits and that they tended not to leave the
deposits once they had established contact with them. Processes not in physical
contact with the deposits remained normal, even when other processes from the same
neuron were in contact with aggregated P-amyloid deposits and were degenerating.
Cotman and colleagues (1993), studied the neurotrophic effects of (3-amyloid using
2
vulnerable, low density, neuronal cultures of 7 000 cells/cm . These cultures
degenerate unless supplied with trophic factors and, thus, are sensitive to the effects
of trophic stimuli. Soluble P-amyloid( 1-40) and soluble P-amyloid( 1-42) were
shown to increase the survival of these cultured, rat, hippocampal neurons. Further,
when supplied with newly solublised and non-aggregated p-amyloid(l-42) they
exhibited significant axonal elongation and dendritic arborisation.
P-amyloid is a self-aggregating peptide (Pike et al., 1992). When a concentrated
solution of p-amyloid(l-42) is incubated at a slightly acidic pH it forms sheet-like
aggregates in solution visible on light microscopy (Cotman et al., 1993). Further,
reducing gel electrophoresis of incubated P-amyloid(l-42), reveals not only a band at
the predicted monomeric molecular weight, but other higher order bands suggestive
of aggregation. Such aggregates exhibit the tinctorial and optical properties that
characterise the P-amyloid of senile plaque cores (Cotman et al., 1993). Barrow and
Zagorski (1991) established that the hydrophobic, carboxyl domains of P-amyloid,
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represented by residues 29-42, exist in solution solely in an oligomeric p pleated
sheet conformation, irrespective of the pH and temperature of the solution or the
solvent used. The authors suggest that it is this highly aggregable domain that directs
folding of the P-amyloid(l-42) peptide. The toxic effects of aggregated
p-amyloid(l-40) on cultured rat pheochromocytoma PC 12 cells can be significantly
reduced by ageing the peptide in the presence of the rifampicin (Tomiyama et al.,
1994), an antibiotic that has been shown in vitro to inhibit the aggregation of
p-amyloid(l-40) in a dose-dependent manner. The aggregation of P-amyloid( 1-42)
is known to occur under physiological conditions (Pike et al., 1991a). Cotman and
co-workers (1993) conclude that aged, aggregated p-amyloid(l-42) is toxic and that
P-amyloid(l-28), which lacks a hydrophobic domain and does not aggregate on
incubation, is not.
However, it has been postulated that soluble P-amyloid does have toxic effects. A
type of potassium channel dysfunction documented to occur in AD fibroblasts has
been ascribed to soluble P-amyloid (Etcheberrigaray et al., 1994) and soluble
P-amyloid(l-42), while not toxic to mature, healthy, neuronal cultures, appears to
render the cells exposed to it more vulnerable to other insults (Cotman et al., 1992).
Glucose deprivation, glutamate excitotoxicity and exposure to nerve growth factor
are among such insults (Cotman et al., 1993). Binding of nerve growth factor to low
affinity receptors inhibits p-amyloid toxicity, while binding to high affinity nerve
growth factor receptors potentates p-amyloid induced neurotoxicity (Rabizadeh et
al., 1994). Protease nexin II, the secreted form of KPI-containing APP, has been
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shown to form complexes with the gamma subunit of nerve growth factor (Oltersdorf
et al., 1989), though whether this might enhance or diminish the toxicity of nerve
growth factor is unclear.
The spontaneous polymerisation of P-amyloid displays nucleation-dependent
kinetics (Jarrett et al., 1993). The formation of a nidus or seed is thermodynamically
unfavourable and slow, but once formed, further, ordered protein polymerisation of a
supersaturated solution is thermodynamically favourable and rapid. Thus, it is
conceivable that a small amount of highly aggregable, hydrophobic P-amyloid(l-42)
or the forty-three-residue form of P-amyloid (P-amyloid(l-43)) could serve as the
seed around which P-amyloid(l-40) could readily aggregate. Growth of this nucleus
could be sustained by p-amyloid(l-40), which Maness and colleagues (1994) attest
could come from the periphery, since P-amyloid(l-40) administered intravenously to
mice crossed the blood-brain barrier and accumulated intact in brain by a
non-saturable mechanism. It would appear that it is the carboxyl terminal of
P-amyloid which is critical and the relative concentration of P-amyloid(l-42) that is
important, rather than the total concentration of P-amyloid (Jarrett et al., 1993).
Furthermore, Wisniewski and co-workers (1994) have shown that the s4 allele of
apolipoprotein E accelerates p-amyloid fibril formation in the presence of a high
concentration of P-amyloid.
Citron and colleagues (1992) studied P-amyloid production in cultured human
kidney 293 cells transfected with APP bearing the double mutation found in a
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Swedish family with FAD (Mullan et al, 1992). They demonstrated a six to eight
fold increase in p-amyloid production in cells transfected with the mutated APP
compared with cells transfected with wild type APP, implying that increased
(3-amyloid production is fundamental to the disease. Suzuki and co-workers (1994)
provided further evidence for the crucial role of the long forms of (3-amyloid in
P-amyloid-induced neurotoxicity. They transfected human neuroblastoma cells with
wild-type human APP or APP mutated at the 717 position from valine to isoleucine,
glycine or phenylalanine. The wild-type transfectants expressed primarily, though
not exclusively, P-amyloid(l-40), while the APP717 mutants exhibited a 1.5 to 1.9
fold increase in the percentage of highly amyloidogenic P-amyloid(l-42) and
P-amyloid(l-43) forms expressed.
5,1.7 The Deposition of P-amyloid In Vivo
Yang and colleagues (1994) found abundant p-amyloid(l-42) in all of the diffuse
plaques, senile plaque cores and vascular amyloid deposits they identified in AD
frontal cortex, while only a subset were positive for P-amyloid(l-40). The same
workers concluded that p-amyloid( 1-42) is the earliest form of p-amyloid deposited
in the AD brain and hypothesised that region specific metabolism of P-amyloid
might account for the characteristic distribution of pathology in AD (Mak et al.,
1994). In support of this, the authors demonstrated only weak, or non-specific
staining, of diffuse plaques in response to antibodies directed against
P-amyloid(l-40) or p-amyloid(l-42) in the striatum in AD brain, an area relatively
spared in the disease.
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On immunochemical analysis, Iwatsubo and co-workers (1994) found all senile
plaques identified in AD cortex to be positive for (3-amyloid( 1-42) or
p-amyloid(l-43), but found that only a third were positive for p-amyloid(l-40).
Moreover, diffuse plaques were labelled exclusively with P-amyloid(l-42) or
p-amyloid(l-43) and were negative for P-amyloid(l-40). A strong correlation was
found between mature plaques and p-amyloid( 1-40) positivity. The cases of FAD
examined were distinctive in that p-amyloid(l-42) and p-amyloid(l-43) positive and
P-amyloid(l-40) negative plaques predominated. Thus, in keeping with in vitro
evidence, plaque formation in vivo appears to begin with the deposition of highly
amyloidogenic forms of P-amyloid. LaFerla and co-workers (1995) examined the
effects of the selective overexpression of the p-amyloid peptide in mice by
introducing a strong, neuron-specific promoter to drive the intracellular expression
of the murine homologue of human p-amyloid. The overexpression of P-amyloid in
the brains of these transgenic mice was not uniform, being extensive throughout the
cortex and hippocampus, regions that are significantly affected in AD. Extensive
neuronal degeneration and evidence of apoptotic cell death was apparent in the
brains of the transgenic mice. Thus, in conclusion, it appears that neurons are
vulnerable to overexpression of P-amyloid containing APP fragments, P-amyloid
itself, and impaired degradation of APP.
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5.1.8 Potential Mechanisms of (3-amyloid Toxicity
While there is consensus that aggregated P-amyloid is neurotoxic, there is no one,
unifying theory as to how this toxicity might occur and, as yet, no formally proven
mechanism (Rogers et al., 1992).
It is conceivable, that the toxic effects of P-amyloid are mediated by changes in
protein tyrosine phosphorylation (Zhang et al., 1994), since aggregated P-amyloid is
associated with a significant increase in the level of tyrosine phosphorylation of focal
adhesion kinase in cells of neuronal lineage. Signal transduction via tyrosine
phosphorylation participates in functions such as cell adhesion, axonogenesis,
cytoskeletal organisation, gene expression, mitosis and apoptosis (Zhang et al.,
1994), some of which have been ascribed to P-amyloid.
Two broad mechanisms of cell death exist: necrosis and apoptosis. Necrosis is
accompanied by inflammation, damage to surrounding cells and the random
degradation of cellular DNA visible as a smear on gel electrophoresis. In contrast,
apoptosis, a form of programmed cell death in which the cell itself participates in its
own demise, induces a minimal amount of inflammation and is associated with
activation of nuclear endonucleases which cleave DNA into 180 base pair fragments
visible as a ladder on gel electrophoresis (Lassmann et al., 1995). Aggregated
P-amyloid has been shown to induce apoptotic cell death in cultured neurons
(Cotman and Anderson, 1995).
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The immediate early genes, some of which have transcriptional capabilities, have
been implicated in the control of apoptosis (Cotman and Anderson, 1995). Such an
arrangement would seem logical given the involvement of the immediate early genes
in manageing cellular stress and the need to remove irretrievable damaged cells with
the minimum of disruption to surrounding tissues. Cotman and Anderson (1995)
report increased immunochemically detectable Jun-related proteins in cultures of
young and mature primary hippocampal neurons exposed to p-amyloid.
Interestingly, GABA neurons, which are resistant to apoptosis in both culture and in
vivo in AD, show no evidence of induction of Jun proteins in response to P-amyloid
(Cotman and Anderson, 1995).
Another potential molecular mechanism by which P-amyloid might be neurotoxic is
in the generation of reactive oxygen species (Davis, 1996). The inhibition of
hydrogen peroxide accumulation and prevention of cell death, in response to
antioxidants and inhibitors of the enzymes superoxide dismutase and superoxide, are
compelling evidence for the role of reactive oxygen species in p-amyloid induced
toxicity. Further, oxidative injury has been shown to induce apoptotic cell death in
vitro (Cotman and Anderson, 1995).
The P-amyloid peptide is known to bind and activate the Clq component of CI of
the classical complement cascade that results ultimately in the formation of the
membrane attack complex (MAC). MAC exerts its cytotoxic effects by inserting a
lytic plug in nearby cell membranes. The conventional mechanism by which the
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classical complement cascade is activated is through Clq binding to the Fc region of
immunoglobulins. While immunoglobulins do not co-localise with senile plaques in
AD, antibody-independent activation of complement activation is a recognised
phenomenon (Rogers et ai, 1992). When Clq is inappropriately bound to a
non-immunoglobulin substrate mechanisms exist whereby it can be disarmed.
Rogers and colleagues postulate, however, that since P-amyloid is insoluble in the
fluid phase, it is able to evade both cellular defence mechanisms and fluid phase
inhibitors and stimulate inappropriate activation of the complement cascade.
5.1.9 Amyloid Precursor Protein mRNA Expression
Koo and colleagues (1990) conclude, from their work in human and primate brains,
that APP mRNA levels are developmentally regulated. They found APP-695 mRNA
is three times more abundant than KPI-containing transcripts of APP mRNA in
human foetal brain, while in young adults the expression of APP-695 mRNA and
KPI-containing transcripts of APP mRNA was approximately equal. In aged controls
and AD sufferers, however, KPI-containing transcripts of APP mRNA predominated
over APP-695 mRNA, though the change in the ratio between KPI-containing APP
mRNA transcripts and APP-695 mRNA was similar in both groups (Koo et al.,
1990).
Levels of APP-695 mRNA in hippocampal neurons have been shown to decline with
age in female, but not male, rats and hippocampal APP-695 mRNA expression is
enhanced in young, ovarectomised, female rats on exposure to oestrogen and
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progesterone (Chao el al., 1994). Chao and colleagues (1994) proposed that a
decrease in APP-695 mRNA expression in the hippocampus, particularly the CA1
field, as a consequence of a decline in sex steroid levels with age, may contribute to
the neuronal degeneration seen in elderly, female rats.
Weidemann and colleagues (1989) established the presence of the three major
protein isoforms of APP, APP-695, APP-751 and APP-770, in neuronal and
non-neuronal cells. Extracts of RNA from pure cultures of rat neurons suggest that
APP-695 mRNA is the predominant form of APP mRNA in neurons, representing
95% or more of APP mRNA transcripts (Sandbrink et al., 1997). However, Moya
and colleagues (1994) have demonstrated intraneuronal synthesis of KPI-containing
isoforms of APP in vivo. Rat neuronal cells are virtually devoid of L-APP
transcripts, though such transcripts represent almost half of the APP transcripts in rat
astrocytes and microglia (Sandbrink et al., 1997). Only subtle regional variations in
the pattern of APP mRNA isoform expression have been identified in rat on analysis
of cultured neurons extracted from the hippocampus, cortex and striatum (Sandbrink
et al., 1997). Sandbrink and colleagues (1997) used RT-PCR and DNA extracted
from the parietal cortex of a single, aged, human control to study L-APP mRNA
expression in humans. The results obtained from examination of this subject were
representative of a larger number of brains studied. The authors found that L-APP
transcripts represented a significantly lower proportion of total APP mRNA
transcripts, while L-APLP2 transcripts represented a greater proportion of total
APLP2 mRNA transcripts than in rat cerebral cortex.
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Ebstein and co-workers (1996) have examined the effects of age and disease on
APP-751 and APP-770 mRNA levels in lymphocytes in the belief that they may
reflect changes in brain APP mRNA expression pertinent to AD. Using quantitative
RT-PCR, the authors demonstrated that APP-751 mRNA expression was positively
correlated with age in 64 cognitively intact individuals ranging from 20 to 91 years
of age. The nineteen AD subjects studied exhibited APP-751 mRNA levels
equivalent to that found in the age-matched control group. The ratio of APP-751 to
APP-770 mRNA transcripts, however, was lower in the AD group than in the group
of age-matched control subjects over 55 years. The authors attribute this finding to
the average 31% increase in APP-770 mRNA transcripts in lymphocytes from AD
subjects compared with an average 12% increase in this isoform in the lymphocytes
of control subjects over the age of 55 years.
Johnston and colleagues (1996b) have developed a sensitive, reproducible assay for
specific mRNA species based on solution hybridisation with an RNA antisense
probe, followed by degradation of non-hybridised RNA with a ribonuclease enzyme.
The assay is capable of detecting subtle, physiologically relevant, alterations in
mRNA expression, can detect as little as 1 pg of RNA and has low inter and intra
assay variability. A standard curve can be constructed for a particular mRNA
species if the solution hybridisation experiment is carried out using known quantities
of in vitro transcribed sense RNA. Absolute quantification of the mRNA species
under investigation can then be achieved by reference to the standard curve. Like
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PCR, this assay does not require that the mRNA species to be examined is intact and
it can be performed on small fragments of RNA.
Johnston and co-workers (1996b) examined cortical and cerebellar levels of APP and
APLP2 mRNA in homogenised, post-mortem, human brain tissue from 3 control
subjects matched for age and PMI, but not for agonal state. The expression of both
APP and APLP2 mRNA was highest in the temporal cortex, lowest in cerebellum
and intermediate in the frontal and occipital cortices. The ratio of APP:APLP2 was
1:0.3 in neocortex and 1:0.8 in cerebellum. Levels of KPI-containing APP mRNA
transcripts were highest in the frontal and temporal cortices, lowest in cerebellum
and intermediate in the occipital cortex. Johnston and co-workers (1996b) data
suggests that regional differences in the levels of APP and APLP2 mRNA, and in
APP splicing, do exist in control, post-mortem, human brain. Further, APP and
APLP2 mRNA expression and levels of KPI-containing transcripts of APP reflect the
pattern of pathological involvement in AD being highest in the temporal cortex,
intermediate in the occipital cortex and low in the relatively spared cerebellum.
Astrocytes do not normally contain either APP or APP mRNA, but rat astrocytes
accumulate large amounts of immunochemically detectable APP following neuronal
damage (Siman et al., 1989). Damage to rat hippocampal neurons results in the
accumulation of APP in glial fibrillary acidic protein-positive astrocytes immediately
adjacent to the injury (Siman et al., 1989). Glial fibrillary acidic protein mRNA is
also increased in AD (Robinson et al., 1994). The mechanism responsible for this
increase, and the specific isofonns of APP present in the reactive astrocytes, is
unknown.
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In 1989, in a study of 17 individuals suffering from Down's syndrome, Rumble and
colleagues established that the serum concentrations of APP in these subjects were
1.5 fold higher than those found in control subjects. Patients with AD had similar
serum APP levels to the controls. Triplication of the APP gene on chromosome 21
was hypothesised to result in overexpression of APP and subsequently amyloid
deposition in individuals with trisomy 21 (Rumble et al., 1989). Examination of
%
APP mRNA extracted from the brain tissue of aborted Down's syndrome foetuses,
suggests that APP mRNA is increased in the brains of these foetuses in comparison
to levels found in control foetal brains (Tanzi et al., 1987). Querfurth and colleagues
(1995) identified a 1.8 fold increase in APP mRNA levels in fibroblast cell lines
from individuals with Down's syndrome relative to age-matched normal controls.
This increase was not significant, but when the cells were grown under conditions of
stress in 0.5% serum, a significant, 2 fold increase in APP mRNA levels was
observed in the fibroblast cell lines obtained from Down's syndrome individuals.
Querfurth and co-workers (1995) have also demonstrated an apparent increase in
transcription of APP in fibroblast cell lines from a Canadian pedigree with FAD that
shows strong linkage to chromosome 14. A 1.6 fold increase in APP mRNA was
identified in fibroblast cell lines from affected members of the Canadian FAD
pedigree in comparison with fibroblast cell lines from unaffected members of the
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pedigree. This rose to a 1.9 fold increase in APP mRNA in fibroblasts from affected
probands stressed by serum free conditions of growth and was accompanied by a 2
fold increase in levels of the APP protein and a 2.5 fold increase in the (3-amyloid
peptide in these fibroblasts. Transient transfection of fibroblast cell lines from
affected members of the Canadian FAD pedigree with a reporter gene driven by the
APP promoter, revealed a four-fold increase in APP promoter activity in these cell
lines, suggesting that the increase in APP mRNA is not attributable to an increase in
mRNA stability. Querfurth and co-workers (1995) conclude that their results are
most consistent with an alteration in the amount or function of a nuclear, regulatory-
transcription factor for the APP gene in the Canadian FAD pedigree. Fibroblast cell
lines from another FAD pedigree of Italian origin with linkage to chromosome 14 did
not exhibit any increase in APP expression (Querfurth et al., 1995).
Harrison and colleagues (199Id) examined brain APP mRNA levels in FAD using
ISHH. Four brain regions were examined in three FAD and three control cases. The
authors found no difference in the distribution or quantity of either KPI-containing or
non-KPI splice variants of APP in the FAD cases compared to the controls.
However, further evidence that increased APP mRNA levels may be important in the
pathophysiology of AD in some subjects comes from Rockenstein and co-workers
(1995). Rockenstein and colleagues observed AD-type pathology in a transgenic
mouse model in which neuronal expression of an alternatively spliced minigene
encoding human APP was driven by a platelet-derived growth factor promoter. A
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substantial increase in total, and transfected human, APP mRNA levels were
observed in the transgenic mice. Elevated APP mRNA levels were not found in
other transgenic mouse lines that did not exhibit AD-like pathology. Thus, high
levels of APP mRNA expression appear to be necessary for the production of robust
AD-like pathology in these transgenic mouse lines (Rockenstein et ai, 1995). The
same workers (Rockenstein et al., 1995), examined APP mRNA levels in human
frontal cortex and identified a subtle increase in the relative amounts of APP-751 and
APP-563 mRNA transcripts, but no increase in total APP mRNA levels, in AD
compared to control brain. PMI was less than eight hours for all samples, but
pre-mortem factors were not analysed in this study and only four AD cases and five
control cases, selected for their relatively good preservation of RNA, were examined.
Cohen and co-workers (1988) examined APP mRNA transcripts containing the
[3-amyloid sequence in the cerebral cortex and nucleus basalis of five AD and five
control brains using ISHH. The brains were matched for age and PMI, but
pre-mortem factors were not assessed. The authors demonstrated an increase in APP
mRNA expression in the nucleus basalis in AD, but APP mRNA expression in the
cerebral cortex was unchanged. No ISHH labelling was observed over glia or
endothelial cells.
Palmert and co-workers (1988) examined total and KPI-containing APP mRNA
transcripts in eleven AD and seven control subjects using ISHH. The subjects were
matched for age and PMI, but no information on pre-mortem course was presented.
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No differences between the AD and control brains were observed in the basis pontis,
occipital cortex or hippocampal subicular neurons. However, total APP mRNA
levels were increased two fold in the nucleus basalis of Meynert and the locus
ceruleus of the AD brains in comparison to the control brains. The level of
KPI-containing APP mRNA transcripts remained unchanged in these areas. The
authors propose that the increase observed in total APP is exclusively accounted for
by an increase in non-KPI containing transcripts: presumably APP-695, though
conceivably APP-714. No labelling of glial or endothelial cells was seen with either
probe. Since fewer specific grains were detected over tangle-bearing neurons than
over tangle-free neurons, the authors suggest that increased APP mRNA expression
is a compensatory response in surviving neurons.
Goedert (1987) found little variation in APP RNA levels in different cortical areas of
normal control brains by Northern blotting. In particular, no difference was evident
between areas severely involved in AD, such as the temporal and frontal cortex, and
areas typically spared, such as the thalamus and the striatum. Northern blotting of
four AD cases and four control cases demonstrated a decrease in APP mRNA in the
frontal cortex in AD. Goedert (1987) complemented his Northern blotting work with
an ISHH study of AD and control brains. Four AD and three control cases, all aged
more than 65 years and with PMI of less than 4 hours, were examined. No
information was presented on the pre-mortem course of any of the patients whose
brains were examined. Specific labelling was detected over cortical pyramidal cells
and over pyramidal and granule cells in the hippocampus. No specific labelling of
glial or endothelial cells was observed. No disease specific differences in APP
mRNA expression were identified using ISHH in this study.
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Johnson and colleagues (1989) applied a complementary methodology, RNA gel blot
analysis using single-stranded cRNA probes, to the study of APP mRNA transcripts
in nine AD and ten control subjects. The cases were matched for age and PMI, but
not for pre-mortem factors. The results of this study are not comparable with those
of the ISHH studies, since the cells examined are heterogeneous in type. Using
powdered, frozen tissue from neocortex, hippocampus and cerebellum, Johnson and
co-workers examined APP-751 and APP-695 mRNA levels. They found APP-751
mRNA to be essentially unchanged in all of the regions they examined in AD in
comparison to control tissue, but APP-695 mRNA was reduced in the hippocampus
and neocortex in AD. The ratio between APP-751 and APP-695 mRNA levels,
however, was increased two fold in AD hippocampus in comparison to control
hippocampus. The APP-75 l/APP-695 ratio was found to be six fold lower in
cerebellum than in hippocampus or neocortex and to be unaltered in AD. Johnson
and colleagues (1990) went on to confirm that the APP-75 l/APP-695 ratio was
increased in hippocampal neurons in AD in comparison with non-AD hippocampal
neurons, using ISHH. The group compared tissue from seven cases of
neuropathologically confirmed AD with four non-AD cases. One of these cases was
a normal control subject, one had suffered from mixed multi-infarct dementia and
Parkinson's disease during life and two had suffered from Parkinson's disease alone.
Though the subjects in the two groups were matched for age, no information was
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presented on PMI or the pre-mortem course of the patients' illnesses. The study
found the pyramidal cell APP-751/APP-695 mRNA ratio to be positively correlated
with hippocampal and entorhinal plaque density. Crucially, however, this study
demonstrated an increase in APP-751 mRNA in the hippocampus and the authors
attributed the increased APP-751/APP-695 mRNA ratio to this, rather than to a
decrease in APP-695 mRNA as they had previously reported.
Koo and co-workers (1990) were unable to identify any disease-specific alterations
in the ratio between APP695 and KPI-containing transcripts of APP mRNA in a
study of seven AD and seven control cases unmatched for age, PMI or pre-mortem
course.
Neve and colleagues (1990) probed RNA extracted from six brain areas from AD
and control subjects with probes specific for APP-563, APP-695, APP-751 and
APP-770, using RNA slot blots. The RNA extracted from all five control and five
AD cases was intact, as assessed by Northern blotting, and the cases were matched
for age. No information was presented, however, regarding pre-mortem factors or
PMI. No changes were observed in the splice variants examined in the primary
visual cortex, basal ganglia or hippocampal formation in AD. However, a significant
and specific increase in APP-563 RNA was detected in the nucleus basalis,
occipitotemporal cortex and parahippocampal gyrus in AD. In the nucleus basalis
alone, the authors used ISHH and PCR to confirm that APP-563 mRNA was
increased. Increased expression of APP-563 mRNA in AD was evident in the
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magnocellular neurons of the nucleus basalis, but also in smaller cells in this region,
possibly glia, which appeared to be a new population of cells recruited in AD. All
other APP mRNA transcripts were unchanged in the nucleus basalis in AD, implying
that the change detected in APP-563 was not a simply a reflection of altered mRNA
expression in general. In AD, APP-695 mRNA was decreased in the
parahippocampal gyrus and APP-751 mRNA was slightly increased in the
occipotemporal cortex. Neve and co-workers ascribe the latter finding to
cross-hybridisation of the APP-751 oligonucleotide probe with APP563 mRNA.
In 1993, Tanzi and colleagues investigated the cellular localisation of APP-695 and
APP-751 mRNA in eleven AD and nine control hippocampi. The cases were
matched for age and PMI, but no information on pre-mortem factors was presented.
The authors concluded that APP-695 and APP-751 mRNA were both expressed in
neurons, that their cellular specificity, and regional distribution, was similar and that
both were unaltered in AD brain in comparison to control brain. In contrast, glial
cells exhibited little or no APP-695 or APP-751 mRNA, even in AD brains
displaying marked gliosis.
Jacobsen and colleagues (1991) used an SI nuclease protection assay to examine
mRNA levels of the individual APP transcripts: APP-365, APP-695, APP-751 and
APP-770 in the frontal, temporal, occipital and parietal cortices of sixteen AD and
nine control brains. The authors concluded, by comparing young and old
sub-populations of their normal control group and age-matched AD and control
sub-populations, that age has no effect on APP mRNA levels. Since PMI and
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pre-mortem factors were not taken into account in the analysis, the decision not to
age-match the AD and control groups appears presumptuous. Nevertheless,
Jacobsen and co-workers (1991) treatment of the data is interesting. Significant
increases were observed in APP-695 and APP-770 mRNA levels when expressed
relative to cyclophilin mRNA in AD subjects in comparison to controls. However,
total APP mRNA levels when expressed relative to cyclophilin mRNA levels were
unchanged in the frontal, temporal, parietal or occipital cortex in the AD subjects in
comparison to the controls. When total APP mRNA levels were expressed relative
to the mRNA levels of microtubule associated protein 2 (MAP-2), a largely neuron
specific mRNA, total APP mRNA levels were found to be increased in the AD
subjects in comparison to the controls in all of the cortical regions examined.
Moreover, the total APP/MAP-2 ratios in AD were greater in the temporal and
frontal cortices than in the parietal and occipital cortices. In normal subjects MAP-2
mRNA levels were 2.4 fold that of cyclophilin mRNA levels, while in the AD
subjects MAP-2 mRNA levels were half that of cyclophilin mRNA levels. The
authors surmise that in AD MAP-2 mRNA is decreased, cyclophilin mRNA is
increased, or alterations occur in both mRNA species. The authors preferred
explanation of their findings is that MAP-2 mRNA levels are decreased in AD.
Assuming that this is so, and that cyclophilin mRNA levels are unchanged in AD,
Jacobsen and co-workers (1991) findings regarding overall levels of APP mRNA can
be interpreted in several ways. APP mRNA levels in AD might be truly unchanged;
alternatively, increased amounts of APP mRNA might be produced by less cells, or
less produced by more cells. Further, selected transcripts of APP mRNA might be
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increased while others were decreased and this balanced change need not occur
within individual cells.
The authors state explicitly that there is no significant increase in total APP mRNA,
when expressed relative to cyclophilin mRNA, in AD cases in comparison to
controls. However, mRNA levels of the individual transcripts of APP, when
expressed relative to cyclophilin mRNA levels, are altered in AD, though show no
discernible link with amyloid pathology in the disease. When individual APP
isoform mRNA levels are expressed as a fraction of total APP mRNA, however,
these can be related to AD pathology. In the frontal and temporal cortices in AD, the
cortical regions most heavily involved in the disease process, the fraction of total
APP mRNA attributable to APP-695 mRNA was increased and that attributable to
APP-751 and APP-365 mRNA decreased. In addition, a small, but significant,
increase in the APP-770 mRNA fraction of total APP mRNA was observed in all of
the cortical areas measured in AD. The individual transcripts of APP mRNA when
expressed as a proportion of total APP mRNA are related to pathology, yet no such
association is apparent when the individual APP mRNA transcripts are related to
cyclophilin mRNA levels. The significance of this finding is not discussed.
Robinson and co-workers (1994) demonstrated a marked decrease in APP-695, and a
moderate decrease in KPI-containing transcripts of APP mRNA, in AD tissue from
the superior and middle pre-frontal cortex in comparison to age-matched control
tissue, using Northern blotting. Forty-two AD cases and thirteen control cases were
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selected for their fair or excellent RNA content on agarose formaldehyde gel
electrophoresis. The cases were not matched for agonal state or PMI. The ratio
between KPI-containing transcripts of APP mRNA and APP-695 mRNA was 1.12
for the AD cases and 0.73 for the control cases: a difference that is statistically
significant.
In an important paper in 1994, Harrison and colleagues investigated the effects of
AD, other dementing illnesses and pre-mortem course on APP mRNA, using ISHH
performed on frontal cortex obtained at rapid autopsy. Eleven AD cases, four
controls and six cases of non-AD dementia, on whom data was available regarding
age, PMI and pre-mortem course, were examined. APP mRNA abundance was
found to correlate strongly with GAD activity and was reduced in association with
terminal pyrexia. Both KPI-containing and non-KPI transcripts of APP mRNA,
normalised to levels of polyadenylated mRNA, were reduced in the AD cases in
comparison to the control or non-AD dementia cases. This study demonstrated that
APP mRNA levels are susceptible to pre-mortem influences such as coma and
pyrexia and established that potentially confounding agonal state factors should be
taken into account when interpreting changes in APP mRNA levels in human brain.
In a review of the published literature, Harrison and co-workers (1996) concluded
that no unequivocal, specific abnormality in APP mRNA expression has been
documented in AD. Preliminary data from Harrison and colleagues (1996) study of
brain tissue from seven control subjects, ten AD subjects and six subjects with
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non-AD dementia did not demonstrate any significant differences in APP-695 or
KPI-containing transcripts of APP mRNA between the diagnostic groups. The tissue
was obtained from the Oxford Study to Investigate Memory in Ageing (OPTIMA)
and was matched for age, sex, PMI and agonal state. Further, no significant
differences in the ratio of KPI-encoding to KPI-lacking splice variants of APP
mRNA was observed between the groups and no relationship was found between this
ratio and the age of the subjects.
Johnston and colleagues (1996a) demonstrated a decrease in APP and APLP2 mRNA
in the mid-temporal cortex, but not in the superior frontal cortex, in AD tissue in
comparison to normal control and non-AD neurologically diseased tissue. Fourteen
AD cases, nine control cases and five cases with non-AD neurological diseases,
matched for age and tissue pH, were included in the study. Information on PMI was
available for each case. Messenger RNA levels were measured using solution
hybndisation-RNase protection assay on samples of total nucleic acid and were
expressed as a function of total RNA levels. APP mRNA was present at three-fold
the level of APLP2 mRNA in the control cases and KPI-containing transcripts of
APP constituted 70% of total APP mRNA. A significant increase in KPI-containing
transcripts was found in both regions examined in AD. Johnston and colleagues
(1996a) postulate that the decreases in APP and APLP2 mRNA are confined to the
mid-temporal cortex in response to the characteristically more severe pathology
observed in this region compared to the frontal cortex in AD. It is conceivable that,
in employing homogenised tissue, Johnston and colleagues (1996a) have masked the
neuronal decreases in KPI-contaimng and non-KPI transcripts of APP mRNA
identified by Harrison and colleagues (1994) using ISHH.
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5.2 Materials and Methods
5.2.1 Selection of Tissue
5.2.1.1 Series II Tissue
This series comprised the visual cortices of thirty-two cases, collected mainly from
Oxford, but also from London, and included twelve normal control subjects,
seventeen subjects with definite AD, two subjects with borderline AD and one
subject with a mixed AD and multi-infarct dementia. Brain tissue from seventeen
male and fifteen female subjects were included in the study. Details of all of the
series II cases are presented in appendix II.
5.2.1.2 Series III Tissue - The Oxford Study to Investigate Memory in Ageing
(The OPTIMA Study) Tissue
The OPTIMA Study was established in 1988, under the directorship of Dr. A.D.
Smith with the aim of assembling a cohort of intensively, prospectively assessed
individuals willing to be involved in research into ageing. The study of individuals
recruited into OPTIMA has resulted in publications on clinical aspects of dementia,
such as the use of neuroimaging in early AD (Smith et al, 1996a) and the predictive
value of apolipoprotein E genotyping (Smith et ul, 1996b). In addition, post-mortem
tissue collected through OPTIMA has been used for mRNA studies (Harrison et al,
1996). In total, approximately 200 individuals have been enrolled in the OPTIMA
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study. At the time of the request for tissue, approximately 90 individuals had died
and in 70 of these cases frozen brain tissue was available for study.
Subjects with dementia enrolled into the OPTIMA study are assessed on the
CAMDEX, a rating scale designed to measure cognitive abilities and global
functioning, and receive annual haematological and biochemical screening, lumbar
puncture and CT scan. The apolipoprotein E genotype is determined for all subjects.
In some cases, the spouses of cognitively impaired subjects are recruited as controls,
but many controls are obtained independently. To date, a remarkable 98% of
individuals enrolled in the study have agreed to autopsy. Quantitative
neuropathological data is available for a subset of the brains examined at autopsy.
Brain tissue from fourteen individuals with AD, eight control subjects, five
individuals with borderline AD, six individuals with non-AD neurodegenerative
diseases and six individuals with non-neurodegenerative conditions was selected by
Dr. P.J. Harrison, Reader in Psychiatry at the University of Oxford for study in
Sheffield. Blocks of tissue were collected on cork discs from the mid-hippocampus
and visual cortex (Brodmann area 17) and sent to Sheffield on dry ice. No
information was supplied regarding the clinical history or pathological diagnosis of
the supplied tissue until the experiments and image analysis were complete.
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The value of a positive control group in elucidating changes in mRNA expression
specific to AD from those secondary to chronic neurological disease has been
underlined by Harrison and colleagues (1994).
Unfortunately, the brains were not dissected by the same neuropathologist, nor were
they all frozen according to the same protocol. The collection of frozen blocks of
tissue on cork discs has both advantages and disadvantages. The tissue is exposed
and unsupported on its cork disc, unlike tissue embedding in OCT. It is therefore
more vulnerable to damage during freezer storage and thaws quickly once removed.
The cork discs used were approximately 2.5 cm in diameter and thus it was difficult
to record the case number and brain region legibly on the base. A number of blocks
were difficult to identify for this reason.
The series III (the OPTIMA series) blocks were cut into eighteen gm thick sections
on a Bright cryostat at -20°C with appreciable assistance from Mr. M.W. Sanders
and Miss J.M. Heffernan. The histological quality of several of the tissue blocks was
noted to be poor. The cryostat cut tissue was prepared as detailed in chapter 2.
Details of all of the cases included in this series are presented in appendix II.
5.2.1.3 Series IV Tissue
Series IV comprised cases from both series II and the series III (the OPTIMA series)
as well as cases investigated in our laboratory by two independent investigators, Dr.
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A.J.L. Barton and Dr. M.H. Griffiths. Details of the series IV cases are presented in
appendix II.
5.2.2 Oiigodeoxynucleotide Probe Selection
Three oligodeoxynucleotide probes, APP-770, APP-insert and APP-junction were
selected to examine APP expression (Figures 5.2 and 5.3). The APP-770
oligodeoxynucleotide antisense probe was directed against bases 1033 to 1089 of the
cDNA sequence published by Kitaguchi and co-workers (1988) and theoretically
detects APP transcripts APP-770 and APP-714. The APP-insert
oligodeoxynucleotide antisense probe was directed against bases 1047 to 1076 of the
APP-751 cDNA sequence published by Ponte and co-workers (1988) and
theoretically detects APP mRNA transcripts APP-751, APP-770, APP-563 and
APP-365. The APP-junction probe was directed against bases 975 to 989 and 1158
to 1172 of the APP-751 cDNA sequence published by Ponte and colleagues (1988).
The APP-j unction probe, therefore, only hybridises to APP splice variants in which
the flanking regions of the KPI domain are contiguous; as in APP-695 alone (see
Harrison el al, 1994). A sense oligodeoxynucleotide probe with the same sequence
and orientation as the putative sequence of APP-695 mRNA was used to correct for
non-specific binding of the APP-j unction oligodeoxynucleotide antisense probe.
However, when this probe was employed in series III (the OPTIMA series)
hippocampus an intense signal was observed. The APP-junction sense probe when
hybridised against series I and series II tissue resulted in a consistently weak signal,
at the limits of detection of the system, that exhibited little variation in intensity.
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Further, it was an order of magnitude lower in intensity than the antisense
oligodeoxynucleotide probe. It was decided that the results of the APP-j unction
sense oligodeoxynucleotide probe should be omitted from the analysis of series III
(the OPTIMA series) visual cortex. Since no sense oligodeoxynucleotide probe was
available for either the APP-770 or the APP-insert oligodeoxynucleotide probes,
none of the APP oligodeoxynucleotide probes employed in the study of the series III
(the OPTIMA series) had a corresponding sense strand to allow for correction of the
effects of non-specific binding.
5.2.3 Experimental Controls
The specificity of the APP-insert and APP-junction oligodeoxynucleotide probes has
been demonstrated in our laboratory by Dr. P.J. Harrison by Northern blotting of
RNA extracted from frontal cortex. The APP-insert probe detects a single band of
3.4 kb and the APP-junction probe detects a single band of 3.3 kb (Harrison et al.,
1994). The specificity of the APP-770 oligodeoxynucleotide probe has also been
verified by Northern blotting in Professor Pearson's laboratory.
APLP2 mRNA has been demonstrated on Northern blotting to be approximately 4 kb
in length, though weaker bands at approximately 3 kb and 2 kb, suggestive of
cross-hybridisation with other members of the APP family, have also been described
(Wasco et al., 1993). Thus, it would appear that the oligodeoxynucleotide probes
employed in this study do not detect APLP2. However, Northern blotting of L-APP
mRNA transcripts reveals a major band of 3.4 kb (Konig et al., 1992), suggesting
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that L-APP mRNA transcripts lacking the 54 bases of exon 15 are indistinguishable
on a Northern blot from APP mRNA transcripts. Thus, it is conceivable that the
probes employed may not only detect the desired APP mRNA transcript, but also
detect the corresponding L-APP mRNA.
5.2.4 In Situ Hybridisation Histochemistry
Hybridised sections were incubated for approximately 18 hours, at 36.6°C for the
APP-770 oligodeoxynucleotide probe, 27°C for the APP-insert oligodeoxynucleotide
probe and 27°C for the APP-junction oligodeoxynucleotide probe. The slides were
then washed in I x SSC (4x15 minute washes) at 62.3°C for the APP-770 probe,
52.5°C for the APP-insert probe, and 52.5°C for the APP-junction probe. These
washes were then followed by two hour long washes at room temperature, as
detailed in chapter 2. Once dry, the hybridised sections were placed against film
(Hyperfilm-pmax, Amersham) at room temperature for 28 days to generate
autoradiograms (Figures 5.4 and 5.5). All slides were dipped in photographic
emulsion (Ilford), as detailed in chapter 2, to allow cellular localisation of the ISHH
signal.
5.2.5 Detection of Polyadenylated Messenger RNA in Series III (The
OPTIMA Series)
Poly(A)+ mRNA was measured in all of the series III (the OPTIMA series) brains for
which tissue from visual cortex was available, thirty-four cases in all, in order to
correct, at least partially, for differences in overall mRNA expression between the
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Figure 5.4 In situ hybridisation histochemistry using [33S]dATP labelled
oligodeoxynucleotide probes performed on sections of visual cortex from the same
non-AD dementia case from series III (the OPTIMA series). The images presented
are direct photographs of transilluminated autoradiograms generated from this single
case and hybridised with the following oligodeoxynucleotide probes. The blacker
the image of the autoradiogram the greater was the exposure of the autoradiographic
film to radioactivity and the more intensely labelled was the section.
A APP-junction oligodeoxynucleotide probe.
B APP-insert oligodeoxynucleotide probe.
C APP-770 oligodeoxynucleotide probe.
D Poly (dT) oligodeoxynucleotide probe.
I
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Figure 5.5 In situ hybridisation histochemistry using [33S]dATP labelled
oligodeoxynucleotide probes performed on hippocampal sections from the same
non-AD dementia case from series III (the OPTIMA series). The images presented
are direct photographs of transilluminated autoradiograms generated from this single
case and hybridised with the following oligodeoxynucleotide probes. The blacker
the image of the autoradiogram the greater was the exposure of the autoradiographic
film to radioactivity and the more intensely labelled was the section.
A APP-junction oligodeoxynucleotide probe.
B APP-insert oligodeoxynucleotide probe.
C APP-770 oligodeoxynucleotide probe.
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individual brains examined (Harrison et ah, 1991b, 1993). The
oligodeoxynucleotide antisense probe for the detection of polyadenylated tails, the
poly(dT) probe, consists of 30 thymidylate residues. A sense oligodeoxynucleotide
probe, consisting of 30 adenylate residues, was synthesised to correct for
non-specific binding. Ten pmoles of the poly(dT) probe was 3' labelled with 50
pmoles of [35S]dTTP, since had [33S]dATP been employed the radioactively
labelled tail would have hybridised to the probe itself. The sense probe was 3'
labelled with [^^sjdATP according to the standard protocol outlined in chapter 2.
Each brain was hybridised in triplicate with the poly(dT) probe. The hybridisation
buffer was modified for the poly(dT) experiment as described by Harrison and
colleagues (1991b). Specifically, in order to lower the required wash temperature,
20%, instead of 50%, of deionised formamide was added to the hybridisation buffer,
and a 2 x SSC solution, rather than 20 x SSC solution, was employed. The sections
were incubated at 25°C for 18 hours and washed, according to the standard protocol,
at 35°C. Once dry, the sections were placed against film (Hyperfilm-Pmax,
Amersham) for 10 minutes to generate autoradiograms (Figure 5.4).
The specificity of the poly(dT) oligodeoxynucleotide probe was demonstrated by
incubation of a subset of sections from visual cortex with an excess of unlabelled
poly(dT) probe resulting in the abolition of signal. Similarly, pre-treatment of a
subset of sections of visual cortex with ribonuclease abolished hybridisation of the
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labelled oligodeoxynucleotide probe. The autoradiograms generated by the above
cold displacement and ribonuclease pre-treatment were completely blank.
5.2.6 Quantification of ISHH Signal
The ISHH signal in hippocampus was assessed by outlining the stratum granulosum
of the dentate gyrus and the stratum pyramidale of hippocampal fields CA1, CA3,
and CA4. To analyse the ISHH signal in visual cortex, a strip of grey matter
perpendicular to the cortical surface was outlined. For each section, the average
intensity of light transmitted through the corresponding autoradiogram per unit area
of the delineated portion of the film was obtained. The mean value of each set of
three sections was then calculated and used in all subsequent calculations. The
AOD, corrected where possible for non-specific binding, was calculated for each
probe in the mid-hippocampus and visual cortex as described in chapter 2.
5.2.7 The Relationship between Radioactivity and Approximate Optical
Density in Analysis of Series III (The OPTIMA Series)
In order to delineate the relationship between AOD and radioactivity in this system,
14c microscales (Codes RPA 504 and RPA 511, Amersham) were opposed to
autoradiographic film for 28 days alongside all of the oligodeoxynucleotide probes
against series III (the OPTIMA series) tissue, except the poly(dT) probe against
visual cortex and APP-junction probe against hippocampus. A linear relationship
was demonstrated between the tissue equivalent radioactivity of the standards and
AOD readings of 0.62 and below. All of the AOD readings pertaining to the
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APP-770, APP-insert and APP-junction probes on series III (the OPTIMA series)
tissue were within the linear range of the system. At more intense radioactive
exposures the curve shouldered and then reached a plateau.
5.2.8 Statistical Analysis
All statistical analysis was performed using SPSS for Windows version 6.0. Where
two groups were to be compared, a Student's t test was used, so long as Levene's test
for homogeneity of variance was not significant (p > 0.050). Where Levene's test
was significant, it was assumed that the requirements of the parametric test had been
violated and the data was analysed using the non-parametric Mann-Whitney U.
Where the means of three or more groups were to be compared, a one way analysis
of variance (ANOVA) was used. Where Levene's test for homogeneity of variance
was significant, however, it was assumed that the requirements of the parametric test
had not been met and the non-parametric Kruskal-Wallis one way ANOVA was used
instead.
Correlation matrices, when used, were constructed using both Pearson's correlation
coefficient and Spearman's rank correlation coefficient for comparison. When the
results of the two tests concurred, the result was accepted. When a discrepancy was
observed between the results of the two tests, the data was analysed further as




The results in this chapter are presented in three sections corresponding to the three
series of tissue employed in this part of the study. Series II comprised the visual
cortices of thirty-two cases in which were examined mRNA transcripts detected by
the APP-junction and APP-insert oligodeoxynucleotide probes and the ratio between
KPI-encoding and KPI-lacking splice variants of APP mRNA (the insert:junction
ratio). Series III (the OPTIMA series) consisted of tissue from the visual cortex and
hippocampus of thirty-nine cases in which were examined mRNA transcripts
detected by the poly(dT) (visual cortex only), APP-junction, APP-insert and APP-770
oligodeoxynucleotide probes and the insert junction ratio. Series IV represented a
combined data set generated specifically to allow exploration of the effect of
diagnosis and the conduct of individual experiments on the insert junction ratio.
The statistical analysis of the series III (the OPTIMA series) and series IV data was
complex and performed following exhaustive consultation with biomedical
statistician Miss J.M. Russell. The results of this labour are presented in detail and
without apology, though many of the results generated were not significant.
The results are presented in the following order. Firstly, data relating to the
APP-junction and APP-insert oligodeoxynucleotide probes and the insert junction
ratio in series II is presented, followed by the results of the correlation statistics
performed on this series. Secondly, data relating to series III (the OPTIMA series) is
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presented. Throughout this section, results pertaining to the visual cortex are
presented first, followed by results for the dentate gyrus and hippocampal subfields
CA4, CA3 and CA1, in that order. Results for poly(dT) (visual cortex only),
APP-junction, APP-insert and APP-770 oligodeoxynucleotide probes are presented
first, along with, where applicable, an analysis of APP-junction, APP-insert and
APP-770 oligodeoxynucleotide probes when expressed as a proportion of the
poly(dT) oligodeoxynucleotide probe. Data relating to the insertj unction ratio is
presented along with the results of the individual oligodeoxynucleotide probes. The
correlation statistics relating to series III (the OPTIMA series) are presented in the
following order. Correlations between the ages and mini-mental state scores of the
subjects, and neuropathology, are presented first, followed by correlations relating to
the individual oligodeoxynucleotide probes and neuropathology. Next, correlations
between the various oligodeoxynucleotide probes measured and tissue and
demographic details are presented and finally the inter-relationships between the
various oligodeoxynucleotide probes are described. Thirdly, and finally, the results
of analysis of the insertj unction ratio in series IV visual cortex is presented,
followed by analysis of the insertj unction ratio in the dentate gyrus and hippocampal
subfields CA4, CA3 and CA1.
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5.3.2 Summary of the Significant Positive, and Important Negative,
Results of the Analysis of APP mRNA Expression in Tissue from
Series II, III and IV
A summary of the positive findings and important negative findings is presented
briefly here as a prelude to the more detailed presentation below. No effect of
diagnosis on the abundance of APP-695 mRNA or that of KPI-containing transcripts
of APP mRNA was apparent from analysis of series II. No effect of diagnosis on the
abundance of APP-695 mRNA, KPI-containing transcripts of APP mRNA or
APP-770 mRNA was apparent from analysis of series III (the OPTIMA series). The
ratio between KPI-containing transcripts of APP mRNA and APP-695 mRNA, the
insert.junction ratio, was also estimated for the visual cortices examined in series II,
III and IV and no effect of diagnosis on this parameter was apparent.
+
The abundance of poly(A) mRNA was examined in the visual cortices of series III
(the OPTIMA series) and no significant difference in this parameter was identified
between the four diagnostic categories examined. APP-junction, APP-insert and
APP-770 mRNA levels in visual cortex were then expressed as a proportion of
poly(A) mRNA in this region and again no significant differences between the
diagnostic groups was apparent.
A significant reduction in APP-695 mRNA in AD in comparison to control brains
and unchanged levels of KPI-containing APP mRNA transcripts and APP-770
mRNA was identified in the dentate gyrus of scries III brains (the OPTIMA series).
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A significant reduction in APP-695 mRNA in the AD brains in comparison to the
control or BAD brains was also found in the CA4 hippocampal subfield in series III
(the OPTIMA series) in the presence of unchanged levels of the other APP
transcripts measured. No effect of diagnosis on the insert junction ratio was
apparent from examination of the hippocampi in series III or IV.
Analysis of the correlation matrices prepared in the course of this study can be
summarised as follows. No significant correlations were identified on analysis of
series II. On analysis of series III (the OPTIMA series) a negative correlation was
established between the mini-mental state score and the mean hippocampal and
neocortical NFT density, the mean neocortical neuritic plaque density, the Braak
score and the maximum CERAD plaque frequency. The mini-mental state score was
also negatively correlated with the poly(dT) oligodeoxynucleotide probe in visual
cortex. The poly(dT) probe was positively correlated with the Braak score, the mean
hippocampal amyloid plaque frequency, the maximum CERAD plaque frequency,
the mean neocortical neuritic plaque frequency and the mean neocortical NFT
density. Both the APP-insert and APP-junction oligodeoxynucleotide probes when
expressed as a proportion of the poly(dT) probe were positively correlated with the
mini-mental state score. The APP-insert and APP-junction probes, when expressed
as a proportion of the poly(dT) oligodeoxynucleotide probe were both negatively
correlated with the mean hippocampal NFT density.
In series III (the OPTIMA series) visual cortex the APP-insert and APP-770
oligodeoxynucleotide probes were positively correlated, as were the APP-insert and
APP-junction probes.
In the dentate gyrus and hippocampal subfield CA1 of series III (the OPTIMA series)
the APP-insert and APP-junction oligodeoxynucleotide probes were correlated, as
were the APP-insert and APP-770 oligodeoxynucleotide probes. In hippocampal
subfields CA3 and CA4, however, no associations were found between the APP
oligodeoxynucleotide probes.
In the visual cortex, but not in any of the other regions studied, both the APP-insert
and the APP-junction oligodeoxynucleotide probes were positively correlated with
tissue pH. In series II and series III (the OPTIMA series) no correlation was found
between the age of the subjects and the insert junction ratio.
Although no effect of diagnosis on the insert junction ratio was apparent from
examination of the tissue in series IV, the age of the subjects and the prosecution of
the individual experiments, in visual cortex alone, did significantly affect the
insert junction ratio.
5.3.3 Series II
Since this series comprised the visual cortices from thirty-two cases, including
twelve normal control subjects, seventeen subjects with definite AD, two subjects
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with borderline AD and one subject with a mixed AD and multi-infarct dementia, the
comparison of four diagnostic categories was possible. However, this analysis would
have resulted in a significant loss of power, since there were only two borderline AD
subjects and one subject with a neurological disease in addition to AD. Therefore,
the borderline AD cases and the mixed AD and multi-infarct dementia case, were
excluded from the analysis and a Students t test was used to compare the control
subjects with the AD subjects. Details of all of the series II cases are presented in
appendix II and are summarised in tables 5.1 and 5.2.
The cases used in this study have been examined previously and the results have
been published (Wighton-Benn et al., 1995). However, since publication of this
work, it has become clear that one of the control cases included in the original study
was unsuitable by virtue of co-existing neurological disease. This case has therefore
been excluded from the analysis.
The APP-junction and APP-insert antisense oligodeoxynucleotide probes were used
to examine this series. The APP-770 oligodeoxynucleotide antisense probe was not
available at the time this series was examined. The mean AOD of the APP-junction
sense oligodeoxynucleotide probe proved to be 0.01 for both the AD and control
cases examined. In view of the reassuringly uniform and universally low signal
attributable to this probe, this value was not subtracted from the AOD of the

























































cases. Autoradiograms generated from the analysis of series II visual cortex are not
presented.
No significant difference in age was identified between the two diagnostic groups
using the non-parametric two-tailed Mann-Whitney U test corrected for ties. Using a
students t test, no significant differences were found between the two groups in terms
of agonal state score, PMI, storage of the tissue as a block, storage of the tissue as
cryostat cut sections or total tissue storage time. No significant differences were
observed between the two groups in the AOD of either the APP-j unction or
APP-insert probes using a Student's t test (Figure 5.6). The ratio of the AOD of the
APP-j unction probe to the AOD of the APP-insert probe, the insert:j unction ratio,
was not significantly different between the two groups using a students t test (Figure
5.7).
All thirty-two cases were included in a correlation matrix comprising twenty-one
cells, of which two cells yielded statistically significant Pearson's correlation
coefficients (p < 0.050) (Table 5.3). A Pearson's correlation coefficient of p = 0.050
was obtained in a third cell. An identical Spearman's correlation matrix was
performed for comparison.
A significant, positive correlation was identified between the AOD of the APP-insert
probe and the insert:junction ratio using both parametric (p < 0.001) and
non-parametric (p < 0.001) tests. A weaker, negative, Pearson's correlation






































































































































coefficient was obtained between the AOD of the APP-j unction probe and the
insert junction ratio (p = 0.027), though non-parametric analysis was not significant
(p = 0.073). Scatter diagrams of the AOD of the APP-junction probe and the AOD
of the APP-insert probe plotted against the insert junction ratio confirmed that this
ratio is more heavily influenced by the AOD of the APP-insert probe than that of the
APP-junction probe (Figures 5.8 and 5.9).
Finally, the insertjunction ratio was correlated with the age of the subjects in the
visual cortex of series II using Pearson's correlation coefficient (p = 0.050), but not
using Spearman's rank correlation (p = 0.133). A scatter diagram confirmed the
positive correlation between these two parameters implying that the non-parametric
test merely lacked the statistical power to demonstrate this correlation (Figure 5.10).
However, since in a matrix of twenty-four cells a minimum of four significant
findings would be expected if the variables were meaningfully related, two
significant cells are no more than would be predicted to occur by chance.
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5.3.4 Series III - The OPTIMA Series
5.3.4.1 Introduction
Series III (the OPTIMA series) comprised tissue representative of five diagnostic
categories: normal controls, definite AD, borderline AD, non-AD neurodegenerative
dementias and non-neurodegenerative dementias. Details of all of the series III cases
are presented in the appendix II. The demographic, clinical and storage details of
this tissue is presented in table 5.4. The data set comprised thirty-nine cases in all,
twenty-one female and eighteen male subjects. Female subjects were
over-represented in the non-AD neurodegenerative disease group (five female
subjects and one male) and under-represented in the control group (three female
subjects and five male). Otherwise the sex ratio of the diagnostic groups was
acceptable. The neuropathological details available for series III cases are presented
in table 5.5.
The borderline AD grouping represents the smallest number of cases: three male and
two female subjects. The possibility of combing this group with the AD group was
rejected, however, following examination of a series of boxplots depicting the
neuropathological measures made on these cases (Figures 5.11 to 5.15). Boxplots of
the mean neocortical and mean hippocampal neuritic plaque density, the mean
neocortical and mean hippocampal neurofibrillary tangle density and the maximum
CERAD plaque frequency suggested that the fourteen definite AD and five
borderline AD cases were from different populations. A decision was therefore
made to retain the distinction between the AD and borderline AD cases.
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Figure 5.11 Boxplot Depicting the Mean Neocortical Neuritic Plaque Frequency
































Figure 5.12 Boxplot Depicting the Mean Hippocampal Neuritic Plaque
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Figure 5.13 Boxplot Depicting the Mean Neocortical Neurofibrillary Tangle




























Figure 5.14 Boxplot Depicting the Mean Hippocampal Neurofibrillary Tangle
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Figure 5.15 Boxplot Depicting the Maximum CERAD Plaque Frequency (0-5)
for the Four Diagnostic Groups Examined in Series III (OPTIMA)
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The six non-AD neurodegenerative dementia cases comprised brains from
individuals who had suffered from Parkinson's disease, Pick's disease, Huntington's
chorea and progressive supranuclear palsy. The six non-neurodegenerative dementia
cases comprised brains from individuals who had suffered from multi-infarct
dementia and glioma. These latter two diagnostic categories were small, and since
data on any specific probe was not always available for all of the cases in the series,
the number of cases from these groups, for any one probe, was sometimes reduced
further. Moreover, both groups were heterogeneous and included in order to provide
information from a positive control group about the non-specific effects of a
dementing illness. It was decided that combining these two groups would serve this
aim equally well and, importantly, would improve the power of the analysis. The
loss of data would be minimal, since the groups did not represent pure diagnostic
categories and, further, on examination of the available demographic and
neuropathological data for the two groups, no significant differences were identified.
The non-AD neurodegenerative and non-neurodegenerative dementia groups were,
therefore, amalgamated into a non-AD dementia group for all subsequent analysis of
the data.
No statistically significant differences were found between the four diagnostic
categories in terms of age, PMI, freezer storage of the tissue in years or brain pH,
using a one way ANOVA (p > 0.050).
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5.3.4.2 Analysis ofPolyadenylated Messenger RNA in Series III (The
OPTIMA Series) Visual Cortex
The AOD of the poly(dT) oligodeoxynucleotide probe was measured in the visual
cortex of series III (the OPTIMA series) tissue. No significant differences in the
AOD of this probe were identified between the four diagnostic groups using a one
way ANOVA.
5.3.4.3 Analysis of the APP-Junction, APP-Insert and A PP- 770
Oligodeoxynucleotide Probes in Series III (The OPTIMA Series)
Visual Cortex
The AOD of the probes were calculated and used in all subsequent analysis. No
significant differences were observed between the four diagnostic groups in the AOD
of the APP-junction probe in visual cortex using a one way analysis of variance
(ANOVA) (Figure 5.16). However, Levene's test for homogeneity of variance was
significant (p = 0.026) implying that the requirements of the one way ANOVA had
not been met. Consequently, a Kruskal-Wallis one way ANOVA was performed
which did not reveal any significant differences in the AOD of the APP-junction
oligodeoxynucleotide probe between the four diagnostic groups.
No significant differences were found between the four diagnostic categories in the
AOD of the APP-insert or APP-770 oligodeoxynucleotide probes in visual cortex
using a one way ANOVA (Figure 5.16).








































For each case, the AOD of the APP-junction, APP-insert and APP-770 probes, in
visual cortex, was expressed as a proportion of the AOD of the poly(dT) probe in this
region (Figure 5.17). Using a one way ANOVA, no significant differences were
observed, between the four diagnostic categories, when the APP-770
oligodeoxynucleotide probe or the APP-junction oligodeoxynucleotide were
expressed in this way. However, Levene's test for homogeneity of variance revealed
that the requirements of the one way ANOVA were not met for the AOD of the
APP-insert oligodeoxynucleotide probe when expressed as a proportion of the AOD
of the poly(dT) probe and a Kruskal-Wallis one way ANOVA was performed,
confirming that there were no statistically significant differences in the APP-insert to
poly(dT) ratio between the four diagnostic groups.
No significant differences were found, using a one way ANOVA, between the four
diagnostic groups, in the insert junction ratio, in the visual cortex, of series III (the
OPTIMA series) brains (Figure 5.18).
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5.3.4.4 Analysis of the APP-Junction, APP-Insert and APP-770
Oligodeoxynucleotide Probes in Series III (The OPTIMA Series)
Hippocampus
5.3.4.4.1 The APP- 770 Oligodeoxynucleotide Probe in Series III (The OPTIMA
Series) Hippocampus
The boundaries of the dentate gyrus and the hippocampal CA subfields could not be
identified using the APP-770 oligodeoxynucleotide probe and a global measure of
the AOD of this probe, in the hippocampus overall, was made. No significant
differences between the four diagnostic groups in the AOD of the APP-770
oligodeoxynucleotide probe in the hippocampus were observed using a
Kruskal-Wallis one way ANOVA (Figure 5.19).
5.3.4.4.2 The APP-Junction Olisodeoxynucleotide Probe in Series III (The
OPTIMA Series) Hippocampus
The APP-junction oligodeoxynucleotide probe was measured over the dentate gyrus
and CA4, CA3 and CA1 subfields of the hippocampus. The AOD of this probe
varied significantly between the four diagnostic groups in the dentate gyrus
(p = 0.034) and CA4 (p = 0.016), but not in CA3 or CA1, using a one way ANOVA
(Figure 5.20). Tukey's Honestly Significant Difference test (significance level
p = 0.050) was used to determine where the differences, identified between the
diagnostic groups in dentate gyrus and CA4, lay. In the dentate gyrus the AOD of the
APP-junction oligodeoxynucleotide probe was significantly higher in the control
rams; ♦I+K+X+ ♦T+T+T+T+m iSRESgW&S» mv^
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subjects in comparison to the AD subjects, while in CA4, the AOD of the
APP-junction oligodeoxynucleotide probe was significantly higher in the control and
borderline subjects, than in the AD subjects.
5.3.4.4.3 The APP-Insert Olisodeoxynucleotide Probe in Series III (The
OPTIMA Series) Hippocampus
No significant differences between the four diagnostic groups in the CA4, CA3 or
CA1 hippocampal fields was detected for the APP-insert oligodeoxynucleotide probe
using a one way ANOVA (Figure 5.21). The non-parametric Kruskal-Wallis one
way ANOVA was required to establish that there were no significant differences
between the four diagnostic groups in the AOD of the APP-insert
oligodeoxynucleotide probe in the dentate gyrus.
5.3.4.4.4 The Insert to Junction Ratio in Series III (The OPTIMA Series)
Hippocampus
Finally, the insert junction ratio was calculated, as above, for the dentate gyrus and
hippocampal fields CA4, CA3 and CA1 of series III (the OPTIMA series) tissue. No
significant differences were identified between the diagnostic groups in the
insert:j unction ratio in any of the regions analysed using one way ANOVA (Figure
5.22).
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5.3.4.5 Significant Correlations Identified on Analysis ofSeries III (The
OPTIMA Series) Data
5.3.4.5.1 Introduction
A series of correlation matrices were constructed to examine the series III (the
OPTIMA series) data. In each case, a Pearson's correlation matrix and a Spearman's
rank correlation matrix were prepared, and the two compared. Where p values are
presented in the text they relate to the Pearson's correlation matrix, unless otherwise
stated.
5.3.4.5.2 Correlations Identified Between the Age and Mini-Mental State Scores
of the Subjects and Neuropathology
A Pearson's correlation matrix, consisting of 14 cells, was constructed to examine
the relationship(s), if any, between the age and mini-mental state scores of the
subjects and the 7 neuropathological parameters examined for each case (Table 5.6).
Six significant correlations, (p < 0.050), were identified. Since the probability of
generating three, or more, significant findings in a matrix of 15 cells by chance is
p = 0.036, the association between the above variables is likely to be a real one. All
but one of the significant correlations identified in the Pearson's correlation matrix,
were confirmed on non-parametric analysis of the data.
Five of the six significant correlations identified on parametric analysis (four of
which had p values less than 0.010) related to correlations between the score on
mini-mental state examination and neuropathological findings. The mean
Table5.6Pe rson'sCorrelationCo fficientsf rSe i sIII(OPT MA)Dat Maximum CERAD Plaque FrequencyBraak ScoreMeanHC Amyloid Plaque FrequencyMeanHC Neuritic Plaque Frequency
Mean HC NFT Density
Mean Neocortical NFT Density












































neocortical neuritic plaque density, the mean neocortical neurofibrillary tangle
density, the maximum CERAD plaque frequency and the Braak score, were all
negatively correlated with the score on mini-mental state examination with a p value
of less than 0.010. The mean hippocampal neurofibrillary tangle density was
correlated with the score on mini-mental state examination with a p value of 0.026.
The mean hippocampal neuritic and amyloid plaque frequencies, however, were not
correlated with the mini-mental state scores.
The final significant correlation was between age and mean neocortical
neurofibrillary tangle density (-0.366; p = 0.047). Unlike all of the other significant
findings in the Pearson's correlation matrix, this correlation could not be replicated
on non-parametric analysis of the data and, moreover, suggested that as the included
subjects increased in age their mean neocortical neurofibrillary tangle density fell. A
scatter plot (Figure 5.23) revealed two outlying values as likely to be responsible for
the parametric correlation between these two variables and, thus, this significant
finding was disregarded.
No significant correlations were identified between the ages and mini-mental state
scores of the subjects or between the pH, PMI and duration of storage of the tissue
using either parametric or non-parametric tests. (Correlation matrices not
presented.)
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5.3.4.5.3 Correlations Between the APP-Insert, APP-Junction, APP-770 and
Polv(dT) Oligodeoxxnucleotide Probes in the Visual Cortex and
Neuropathology
Data on correlations between the APP and poly(dT) probes in visual cortex and
neuropathology, were sought using a Pearson's correlation matrix comprising 56
cells, of which three were significant (Table 5.7; pages 247 and 248). The
Spearman's correlation matrix is presented for comparison, since three entirely
different cells proved significant on non-parametric analysis (Table 5.8; pages 249
and 250).
On parametric analysis, the first significant finding related to the AOD of the
APP-junction probe in visual cortex, which was correlated with the mean
hippocampal neuritic plaque frequency, with a value of 0.551 and a probability of
p = 0.027. This correlation was not confirmed using Spearman's rank correlation,
and it became apparent on examination of a scatter diagram that it was likely that a
single massively outlying value was responsible for the significant correlation
identified using the parametric test (Figure 5.24). This correlation was, therefore,
regarded as spurious.
The second significant correlation on parametric analysis related to the
insert:poly(dT) ratio in visual cortex, which was negatively correlated (-0.544) with
the mean hippocampal neurofibrillary tangle density with a p value of 0.036.
Spearman's rank correlation revealed a correlation coefficient of-0.504 and a p
Table5.7Pearson'sCorrelationefficie tf rS i sIII(OPT MA)Visualort xD t Maximum CERAD Plaque FrequencyBraak ScoreMeanHC Amyloid Plaque FrequencyMeanHC Neuritic Plaque FrequencyMean
HC NFT Density
Mean Neocortical NFT Density
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Figure 5.23 Age Plotted Against the Mean Neocortical Neurofibrillary Tangle
Density for Series III (OPTIMA) Cases
Figure 5.24 The Approximate Optical Density of the APP-Junction
Oligodeoxynucleotide Probe in the Visual Cortex Plotted Against the Mean
Hippocampal Neuritic Plaque Frequency for Series III (OPTIMA) Cases
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value of 0.055, suggesting that the non-parametric test simply lacked the power to
identify the correlation between these two variables.
Finally, the third significant correlation on parametric analysis related to the
junction.poly(dT) ratio in visual cortex, which was also negatively correlated
(-0.520) with the mean hippocampal neurofibrillary tangle density with a p value of
0.047. Non-parametric analysis revealed a negative correlation of -0.497 with a p
value of 0.059, suggesting that, again, Spearman's rank correlation lacked the power
to identify the correlation between these two variables.
Non-parametric analysis of the data revealed that the AOD of the poly(dT) probe in
visual cortex was correlated with the maximum CERAD plaque frequency, mean
neocortical neuritic plaque density and mean neocortical neurofibrillary tangle
density. These findings were not confirmed on parametric analysis of the data.
However, scrutiny of the data revealed two extreme values for the AOD of the
poly(dT) oligodeoxynucleotide probe. When these two outlying values were
removed, the CERAD plaque frequency was found to be correlated with the AOD of
the poly(dT) probe using both tests with a p value of less than 0.010 for both,
suggesting that these extreme values had masked the parametric correlation between
these two variables. Further, exclusion of these two values revealed a correlation
between the AOD of the poly(dT) probe and the mean neocortical neuritic plaque
density with a p value of 0.003 for the parametric test and 0.002 for the
non-parametric test. Similarly, on the removal of these two values, the mean
neocortical neurofibrillary tangle density and AOD of the poly(dT) probe were
correlated with a p value of 0.005 on the parametric test and a p value of 0.002 on
the non-parametric test.
As a precaution, parametric and non-parametric analysis of the relationship between
the AOD of the poly(dT) probe and the remaining neuropathological parameters was
repeated following exclusion of these two extreme values for the AOD of the
poly(dT) oligodeoxynucleotide probe. The correlation between the Braak score and
the AOD of the poly(dT) probe then became significant, (p < 0.030), using both
parametric and non-parametric tests. The mean hippocampal amyloid plaque
frequency and the mean hippocampal neuritic plaque frequency were also
significantly correlated with the AOD of the poly(dT) probe (p < 0.030) by
parametric analysis alone. Examination of a scatter diagram (Figure 5.25) of the
mean hippocampal amyloid plaque frequency and the AOD of the poly(dT) probe
suggested that the two were indeed correlated but that Spearman's rank correlation
(p = 0.108) simply lacked the power to establish the relationship. The mean
hippocampal neuritic plaque frequency, however, did not appear to be correlated
with the AOD of the poly(dT) probe on scrutiny of a scatter diagram (Figure 5.26).
In conclusion, 3 significant Pearson's correlation coefficient's in a total matrix of 56
cells is less than would have been predicted to occur by chance and, overall, a
significant relationship, between the AOD of the probes measured and
neuropathology would appear unlikely. However, 3 of the 7 neuropathological
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Figure 5.25 The Approximate Optical Density of the Poly(dT)
Oligodeoxynucleotide Probe in the Visual Cortex Plotted Against the Mean
Hippocampal Amyloid Plaque Frequency for Series III (OPTIMA) Cases
Figure 5.26 The Approximate Optical Density of the Poly(dT)
Oligodeoxynucleotide Probe in the Visual Cortex Plotted Against the Mean
Hippocampal Neuritic Plaque Frequency for Series III (OPTIMA) Cases
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parameters measured, were positively correlated with the AOD of the poly(dT) probe
on a Spearman's correlation matrix. Parametric statistical techniques are notoriously
sensitive to extreme values, and when two outlying values for the AOD of the
poly(dT) probe were excluded from the analysis, parametric testing of the above
relationships became significant in concordance with the non-parametric analysis
and a fourth correlation, significant on both parametric and non-parametric testing,
was revealed. Moreover, the clustering of significant findings in a matrix of 56 cells
+
suggests that the abundance of poly(A) mRNA in visual cortex in AD and normal
control brains, is meaningfully related to the severity of both neocortical and
hippocampal pathology, as measured in this study. Removal of the outlying values
for the AOD of the poly(dT) oligodeoxynucleotide probe results in the identification
of eight significant cells in the parametric matrix of 56 cells. It is noteworthy that
the probability of generating 8 significant cells in a matrix of 70 cells is p = 0.023. It
is also curious that the AOD of both the insert and junction probes in visual cortex
when expressed as a proportion of the AOD of poly(dT) probe, were negatively
correlated with the average hippocampal neurofibrillary tangle density, suggesting
that these ratios may reflect, indirectly, hippocampal neuritic pathology.
5.3.4.5.4 Correlations Between the APP-Insert, APP-Junction and APP-770
Oligodeoxynucleotide Probes in the Dentate Gyrus and
Neuropathology
A Pearson's correlation matrix of 28 cells (Table 5.9), prepared to examine the
relationship between the APP oligodeoxynucleotide probes in dentate gyrus and
Table5.9Pe rson'sCorrelationefficie tf rS i sIII(OPT MA)HippocampalD nt e GyrusData Maximum CERAD Plaque FrequencyBraak ScoreMeanHC Amyloid Plaque FrequencyMeanHC Neuritic Plaque FrequencyMean HC NFT Density
Mean Neocortical NFT Density




















































































neuropathology, revealed only one significant finding. The AOD of the
APP-junction probe in dentate gyrus was negatively correlated with the mean
neocortical neuritic plaque density (-0.488), with a p value of 0.040, using the
parametric test. Spearman's rank correlation resulted in a correlation coefficient of
-0.424 and a p value of 0.080, for the same two variables, suggesting that the
non-parametric test lacked the power to establish this correlation.
However, one significant finding out of 28 cells is less than would have been
predicted to occur by chance, implying that the abundance of the mRNA species
detected by the APP-insert, APP-junction and APP-770 oligodeoxynucleotide probes
in dentate gyrus, or the insert junction ratio, are unrelated to neuropathological
severity as measured in this study.
5.3.4.5.5 Correlations Between the APP-Insert, APP-Junction and APP-770
Olisodeoxynucleotide Probes in CA4 and Neuropathology
A Pearson's correlation matrix of 21 cells was used to examine the relationship
between the APP probes and neuropathology in CA4 (Table 5.10). Both parametric
and non-parametric tests concurred and the only significant finding was a negative
correlation between the AOD of the APP-junction oligodeoxynucleotide probe and
the maximum CERAD plaque frequency (p = 0.014). One significant finding is less
than would have been predicted to occur by chance, suggesting that neither the
abundance of the APP mRNA species measured in CA4, nor the insert junction ratio,
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5.3.4.5.6 Correlations Between the A PP-Insert, APP-Junction and 1PP- 770
Oligodeoxynucleotide Probes in CA3 and Neuropathology
No significant correlations were observed, between the neuropathological parameters
measured and the APP probes and insert:junction ratio in CA3, on a Pearson's
correlation matrix of 21 cells (Table 5.11). However, the non-parametric matrix
suggested a correlation between the insert:junction ratio and the maximum CERAD
plaque frequency of -0.586 (p = 0.035). Examination of a scatter diagram (Figure
5.27) did not support this correlation and it was, thus, disregarded. It would appear
that, in CA3, neither the abundance of the APP mRNA species measured, nor the
insert junction ratio, are meaningfully related to the severity of neuropathology as
assessed in this study.
5.3.4.5.7 Correlations Between the APP-Insert, APP-Junction and APP-770
Oligodeoxynucleotide Probes in CA1 and Neuropathology
No significant correlations were observed, using either the parametric or
non-parametric tests, between the neuropathological parameters measured and the
abundance of mRNA species identified by the APP-insert, APP-junction or APP-770
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5.3.4.5.8 Correlations Between the A PP-Insert. A PP-Junction, A PP- 770 and
Poly(dT) Olisodeoxynucleotide Probes and Demographic and Tissue
Details i/t Visual Cortex
A Pearson's correlation matrix of forty cells was prepared to examine the
relationship(s), if any, between the APP and poly(dT) oligodeoxynucleotide probes,
and the age and mini-mental state scores of the subjects, and the pH, PMI and
storage of the tissue (Table 5.13). This matrix generated five significant correlations
(p < 0.050). The probability of generating five significant correlations from forty
cells is p = 0.048, therefore, a real relationship between the parameters measured and
the oligodeoxynucleotide probes analysed is likely.
The Pearson's correlation matrix identified two significant correlations that related
to the pH of the tissue used. Tissue pH was correlated with both the AOD of the
APP-junction oligodeoxynucleotide probe (p = 0.003) and AOD of the APP-insert
oligodeoxynucleotide probe (p = 0.001) measured in the visual cortex.
Non-parametric analysis confirmed both of these relationships. No correlation was
observed between the insert junction ratio in visual cortex and the tissue pH.
The three remaining significant Pearson's correlations related to the scores on
mini-mental state examination. Firstly, the AOD of the APP-junction
oligodeoxynucleotide probe was found to be positively correlated with the
mini-mental state score, on parametric analysis alone (p = 0.047). A scatter diagram
(Figure 5.28) of the data revealed two outlying values that when removed resulted in
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Table 5.13 Pearson's Correlation Coefficients for Series III






























































































































































Figure 5.27 The Insert:Junction Ratio in Hippocampal Subfield CA3 Plotted























AOD APP-Junction Probe in Visual Cortex
.30
Figure 5.28 The Approximate Optical Density of the APP-Junction
Oligodeoxynucleotide Probe in the Visual Cortex Plotted Against the
Mini-Mental State Examination Score for Series III (OPTIMA) Cases
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a loss of significance of the parametric test. Secondly, the insert:poly(dT) ratio was
positively correlated with the mini-mental state score using both parametric
(p = 0.011) and non parametric (p = 0.009) tests. The third significant Pearson's
correlation related to the junction:poly(dT) ratio, which was positively correlated
with the mini-mental state score on parametric analysis of the data only (p = 0.018).
Since Spearman's correlation coefficient was found to be approaching significance
(p = 0.054), it is likely that the non-parametric test merely lacked the power to
demonstrate this relationship definitively.
On non-parametric analysis only, the AOD of the poly(dT) probe was negatively
correlated with the mini-mental state score (p = 0.014). Analysis of a scatter
diagram (Figure 5.29) suggested that an outlying value was responsible for the lack
of significance of the parametric result (p = 0.065) and it was, therefore, concluded
that the AOD of the poly(dT) probe was correlated with the mini-mental state score
in the visual cortex. It is likely that the correlations identified between the
insert:poly(dT) ratio and junction:poly(dT) ratio, and the mini-mental state score, in
reality reflects the negative correlation established between the AOD of the poly(dT)
probe in visual cortex and the score on mini-mental state examination.
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5.3.4.5.9 Correlations Between the A PP-Insert, 1PP-Junction and A PP- 770
Oligodeoxynucleotide Probes and Demographic and Tissue Details in
Dentate Gyrus and Hippocampal Fields CA4, CA3 and CA1
A Pearson's correlation matrix of 20 cells was prepared examining the
relationship(s) between the above probes in the dentate gyrus and the age,
mini-mental state score, tissue pH, PMI and tissue storage of the cases used (Table
5.14). Only one significant finding was obtained. The AOD of the APP-junction
probe was correlated with the mini-mental state score (p=0.042). Spearman's rank
correlation did not achieve significance (p=0.073), but was, however, close enough
to suggest that the two variables were indeed correlated but that the non-parametric
test lacked the power to demonstrate this association.
No significant correlations were found, using either parametric or non-parametric
tests, between the age and mini-mental state of the subjects or the pH, PMI or storage
of the tissue, and the above probes, in CA4 (Table 5.15). In CA3 (Table 5.16), the
AOD of the APP-junction probe was correlated with the mini-mental state score
using Spearman's rank correlation (p=0.041). The parametric test, however, did not
achieve significance (p=0.055). Examination of a scatter diagram (Figure 5.30) of
these two variables suggested a correlation between the two that was masked by an
outlying value distorting the parametric test. No significant correlations were found
in CA1 between the APP probes and the age, mini-mental state scores of the subjects
or the pH, PMI or storage of the tissue (Table 5.17).
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Table 5.14 Pearson's Correlation Coefficients for Series III
(OPTIMA)
























































































































































Table 5.16 Pearson's Correlation Coeffici
(OPTIMA) Hippocampal CA3


































































Table 5.17 Pearson's Correlation Coeffic
(OPTIMA) Hippocampal CA1
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Figure 5.29 The Approximate Optical Density of the Poly(dT)
Oligodeoxynucleotide Probe in the Visual Cortex Plotted Against the
Mini-Mental State Examination Score for Series III (OPTIMA) Cases
Figure 5.30 The Approximate Optical Density of the APP-Junction
Oligodeoxynucleotide Probe in Hippocampal Subfield CA3 and the
Mini-Mental State Examination Score for Series III (OPTIMA) Cases
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In total, a Pearson's correlation matrix of 65 cells was generated, to examine the
relationship between the APP probes and the age and mini-mental state scores of the
subjects and the pH, PMI and storage of the tissue, in the dentate gyrus and
hippocampal fields CA4, CA3 and CA1. Only one significant finding was observed:
less than would have been predicted to occur by chance. It would appear that the
abundance of the mRNA species detected by the APP probes used in this study in the
dentate gyrus, CA4, CAS or CA1 are not significantly affected by the age or
mini-mental state scores of the subjects studied, or by the pH, PMI or duration of
storage of the tissue.
5.3.4.5.10 Correlations Between the A PP-Insert, APP-Junction, APP- 770 and
PolyfdT) Olisodeoxynucleotide Probes in Visual Cortex
A Pearson's correlation matrix of 28 cells (Table 5.18), constructed to examine the
inter-relationship(s), if any, between the APP-insert, APP-junction and APP-770
oligodeoxynucleotide probes and the poly(dT) probe, in the visual cortex, generated
fifteen significant correlations (p < 0.050). The relationship between the probes is
unlikely to be due to chance, since the probability of obtaining 5 significant
correlations in a matrix of 30 cells is p = 0.016.
The most striking finding in the visual cortex is the correlation between the AOD of
the APP-insert oligodeoxynucleotide probe and the AOD of the APP-junction
oligodeoxynucleotide probe with a Pearson's correlation coefficient of 0.905 and a p
value of < 0.001. Non-parametric analysis resulted in a p value of < 0.001 also. The
Table5.18Pe rson'sCorrelationefficie tf rS i sIII(OPT MA)Visualo t xD t APP-Insert ProbeAPP- Junction ProbeAPP-770 ProbeInsert: Junction RatioPoIy(dT) Probe
APP-Insert Probe: Poly(dT) Probe
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AOD of the APP-insert probe was also positively correlated with the AOD of the
APP-770 probe on both parametric (p = 0.016), and non-parametric (p < 0.001),
analysis. The AOD of the APP-junction oligodeoxynucleotide probe was
significantly correlated with the AOD of the APP-770 oligodeoxynucleotide probe by
non-parametric analysis only (p = 0.003). Parametric analysis revealed a p value of
0.095 and examination of a scatter diagram (Figure 5.31) suggested that two outlying
values were responsible for the non-significance of the Pearson's correlation
coefficient.
The AOD of the APP-junction probe was negatively correlated with the
insert junction ratio by both parametric (-0.678; p < 0.001) and non-parametric
(-0.653; p < 0.001) analysis. The AOD of the APP-insert oligodeoxynucleotide
probe was significantly negatively correlated to the insert junction ratio by
parametric analysis alone (-0.376; p = 0.028). Non-parametric analysis revealed a p
value of 0.099 suggesting that Spearman's rank correlation lacked the statistical
power to identify this correlation. Thus, it would appear that in visual cortex the
APP-junction oligodeoxynucleotide probe influences the insert junction ratio to a
greater degree than does the APP-insert oligodeoxynucleotide probe. Further, since
these two probes are highly correlated, an increase in the AOD of the APP-insert
oligodeoxynucleotide probe is associated with an increase in the AOD of the
APP-junction oligodeoxynucleotide probe and a lowering of the insert junction ratio,
hence the negative correlation between the AOD of the APP-insert probe and the
insert junction ratio.
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The AOD of the APP-insert oligodeoxynucleotide probe was correlated with the
AOD of the poly(dT) probe by parametric analysis alone (0.352; p = 0.045).
Non-parametric analysis of this correlation revealed a p value of 0.112, suggesting
that the non-parametric test lacked the power to establish this correlation.
Both the AOD of the APP-insert oligodeoxynucleotide probe (0.449; p = 0.009) and
the AOD of the poly(dT) oligodeoxynucleotide probe (-0.581; p < 0.001) were
correlated with the insert:poly(dT) ratio. Non-parametric analysis confirmed both of
these results. Both of these probes would appear to influence the ratio between them
to approximately the same degree.
The AOD of the APP-insert oligodeoxynucleotide probe (0.686; p < 0.001) and the
AOD of the APP-junction oligodeoxynucleotide probe (0.790; p < 0.001) are both
correlated with the junction:poly(dT) ratio. The Spearman's rank correlation matrix
confirmed the above two results. The strong correlation between the AOD of the
APP-insert and APP-junction ohgodeoxynucleotide probes probably accounts for the
correlation between the AOD of the APP-insert oligodeoxynucleotide probe with the
junction:poly(dT) ratio. The AOD of the poly(dT) probe correlates with the
APP-770:poly(dT) ratio on both parametric (-0.672; p < 0.001), and non-parametric
(-0.810; p < 0.001) analysis, suggesting that the AOD of the poly(dT) probe is the
major determinant of the ratio. The AOD of the APP-770 oligodeoxynucleotide
probe, was correlated with the APP-770:poly(dT) ratio on parametric analysis alone
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Figure 5.31 The Approximate Optical Density of the APP-770
Oligodeoxynucleotide Probe Plotted Against the Approximate Optical Density
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Figure 5.32 The Approximate Optical Density of the APP-770
Oligodeoxynucleotide Probe Plotted Against the Approximate Optical Density
of the APP-770 Oligodeoxynucleotide Probe Expressed as a Proportion of the
Approximate Optical Density of the Poly(dT) Oligodeoxynucleotide Probe in
Series III (OPTIMA) Visual Cortex
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outlying values as being responsible for the parametric correlation and the finding
was disregarded.
The insert:poly(dT) ratio was positively correlated with both the junction:poly(dT)
ratio and the APP-770:poly(dT) ratio on both parametric (p <0.001) and
non-parametric (p <0.001) analysis, probably as a result of the common denominator
of the AOD of poly(dT) probe and the correlations between the AOD of the
APP-insert, APP-junction and APP-770 probes.
The junction:poly(dT) ratio was negatively correlated with both the insert junction
ratio (-0.555; p = 0.001) and the AOD of the poly(dT) probe (-0.371; p = 0.036).
Non-parametric analysis confirmed the above two observations (p = 0.002 for each).
Finally, the APP-770:poly(dT) ratio was positively correlated with the
junction:poly(dT) ratio by non-parametric analysis alone (p = 0.006). Parametric
analysis revealed a p value of 0.160 and examination of a scatter diagram (Figure
5.33) suggested that two outlying values were responsible for the non-significance of
the parametric test. Again the common denominator of the AOD of the poly(dT)
probe and the correlation between the AOD of the APP-j unction and APP-770 probes
is likely to be responsible for this finding.
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5.3.4.5.11 Correlations Between the APP-Insert, APP-Junction and APP-770
Olieodeoxynucleotide Probes in Dentate Gyrus
A Pearson's correlation matrix of 6 cells was constructed to examine the
inter-relationship(s), if any, between the APP-insert, APP-j unction and APP-770
oligodeoxynucleotide probes in the dentate gyrus (Table 5.19).
The AOD of the APP-insert oligodeoxynucleotide probe was highly correlated with
the AOD of the APP-junction oligodeoxynucleotide probe in this region, using both
parametric and non-parametric tests (p = 0.001). The AOD of the APP-insert
oligodeoxynucleotide probe was also highly correlated with the AOD of the APP-770
oligodeoxynucleotide probe using both parametric (p = 0.006), and non-parametric
(p = 0.003), tests. Finally, the AOD of the APP-insert oligodeoxynucleotide probe
was highly correlated with the insert:junction ratio using both parametric (p < 0.001)
and non-parametric (p = 0.004) tests. In contrast to the visual cortex, the AOD of the
APP-junction probe was not correlated with the insert junction ratio suggesting that
in the dentate gyrus the AOD of the APP-insert oligodeoxynucleotide probe
dominates this ratio. Further, since the probability of obtaining 3 significant findings
in a sample of 10 cells is p = 0.012, the correlations identified, between the APP
oligodeoxynucleotide probes and the insert junction ratio in the dentate gyrus, is
unlikely to be due to chance.
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Table 5.19 Pearson's Correlation Coefficients for Series III (OPTIMA)




































































5.3.4.5.12 Correlations Between the APP-insert, APP-Junction and APP-770
Olisodeoxxnucleotide Probes in CA4
A Pearson's correlation matrix of 6 cells was constructed to examine the
inter-relationship(s), if any, between the APP-insert, APP-j unction and APP-770
oligodeoxynucleotide probes and the insert:junction ratio in CA4 (Table 5.20). The
Pearson's correlation matrix revealed two significant correlations. The AOD of the
APP-insert oligodeoxynucleotide probe was positively correlated (0.813; p < 0.001),
and the AOD of the APP-junction oligodeoxynucleotide probe was negatively
correlated (-0.627; p = 0.001), with the insert:junction ratio. Both correlations were
confirmed using the non-parametric test. The APP-junction and APP-insert
oligodeoxynucleotide probes would appear to influence the insert:junction ratio to
approximately the same degree.
Since the probability of generating 2 significant findings in a sample of 5 cells, is
p = 0.023, the associations identified between the APP probes and the insert junction
ratio is likely to be significant.
5.3.4.5.13 Correlations Between the APP-insert, APP-Junction and APP-770
Olieodeoxxnucleotide Probes in CA3
A Pearson's correlation matrix of 6 cells was constructed to examine the
inter-relationship(s), if any, between the APP-insert, APP-junction and APP-770
oligodeoxynucleotide probes and the insert junction ratio in CA3 (Table 5.21). Only
one significant finding was observed in the Pearson's correlation matrix: the AOD of
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the APP-insert oligodeoxynucleotide probe was positively correlated with the
insert:]unction ratio (p = 0.001). The result was confirmed by non-parametric
analysis of the data.
The Spearman's rank correlation matrix, identified a further significant correlation:
the AOD of the APP-j unction probe was significantly negatively correlated with the
insert:junction ratio (p = 0.023). Examination of a scatter diagram (Figure 5.34) did
not support a correlation between these two variables.
In conclusion, it would appear that no significant inter-relationships exist between
the APP oligodeoxynucleotide probes examined and the insert:junction ratio in
hippocampal field CA3.
5.3.4.5.14 Correlations Between the APP-lnsert, APP-Junction and A PP- 770
Oligodeoxynucleotide Probes in CA1
A Pearson's correlation matrix of 6 cells was constructed to examine the
inter-relationship(s), if any, between the APP-insert, APP-j unction and APP-770
oligodeoxynucleotide probes and the insert]unction ratio in CA1 (Table 5.22). Four
significant correlations were identified, suggesting that the abundance of the mRNA
species identified by the APP-insert, APP-junction and APP-770 probes, and the
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Figure 5.33 The Approximate Optical Density of the APP-Junction
Oligodeoxynucleotide Probe when Expressed as a Proportion of the
Approximate Optical Density of the Poly(dT) Oligodeoxynucleotide Probe
Plotted Against the Approximate Optical Density of the APP-770
Oligodeoxynucleotide Probe when Expressed as a Proportion of the
Approximate Optical Density of the PoIy(dT) Oligodeoxynucleotide Probe in
Series III (OPTIMA) Visual Cortex
Figure 5.34 The Insert:Junction Ratio Plotted Against the Approximate Optical
Density of the APP-Junction Oligodeoxynucleotide Probe in Hippocampal
Subfield CA3 for Series III (OPTIMA) Cases
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Table 5.22 Pearson's Correlation Coeffic
Hippocampai CA1





































































The AOD of the APP-insert oligodeoxynucleotide probe was positively correlated
with the AOD of the APP-junction oligodeoxynucleotide probe (p = 0.018).
Non-parametric analysis revealed a p value of 0.111, suggesting that the
non-parametric test lacked the power to establish this correlation. The AOD of the
APP-insert oligodeoxynucleotide probe was also positively correlated with the AOD
of the APP-770 probe (p = 0.028) and this result was confirmed on non-parametric
analysis (p = 0.020).
The AOD of the APP-insert oligodeoxynucleotide probe was positively correlated
with the insert:junction ratio (0.009) and this finding was confirmed on
non-parametric analysis of the data. The AOD of the APP-770 oligodeoxynucleotide
probe was positively correlated with the insert junction ratio by parametric analysis
alone (p = 0.030) and examination of a scatter diagram (Figure 5.35) revealed two
outlying values as the likely source of the parametric correlation.
The AOD of the APP-junction oligodeoxynucleotide probe was negatively correlated
with the insert junction ratio on non-parametric analysis alone: examination of a
scatter diagram (Figure 5.36) suggested that the two were not, in fact, correlated.
Thus, in hippocampal field CA1, as in the dentate gyrus, the AOD of the APP-insert
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Figure 5.35 The InsertrJunction Ratio Plotted Against the Approximate Optical
Density of the APP-770 Oligodeoxynucleotide Probe in Hippocampal Subfield
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Figure 5.36 The InsertrJunction Ratio Plotted Against the Approximate Optical
Density of the APP-Junction Oligodeoxynucleotide Probe in Hippocampal




Analysis of series III (the OPTIMA series) led to the conclusion that the AOD of
both the APP-insert and APP-junction oligodeoxynucleotide probes were correlated
with agonal state. The insert:junction ratio, however, did not correlate with agonal
state, implying that these two probes are equally affected by agonal state factors.
This finding suggested that the insert:junction ratio could be of use where
information regarding agonal state was absent, or inadequate.
Data generated by two other scientists, Dr. A.J.L. Barton and Dr. M.H. Griffiths, was
combined with the data already generated during the course of this study to allow
analysis of the insert junction ratio in the visual cortex, dentate gyrus and
hippocampal fields CA4, CAS and CA1 of a larger number of normal and Alzheimer
diseased brains.
A simple, two way ANOVA study, was designed, which would allow examination of
the relative importance of diagnosis and the conduct of the individual experiments in
determining the insert junction ratio. To accommodate this study design, cases
belonging to ambiguous diagnostic categories were removed from the four different
data sets used, generating two groups of subjects: normal control subjects and
subjects with unequivocal AD. To simplify interpretation of the results, an equal
number of matched control and AD cases were selected from each data set for each
brain area to be studied.
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Control and AD cases where the insert junction ratio had been measured in multiple
brain areas were preferred, since they minimised inconsistency of case mix across
the brain areas analysed. Similarly, as far as was possible, the cases selected from
each individual data set were held constant across the different brain areas. Where a
raw data set included an unequal number of control and AD subjects for a particular
brain area, those where demographic details or information about PMI were missing,
were excluded. If necessary, cases were then excluded with a view to matching the
control and AD cases selected from each data set for sex, age and PMI. When it was
no longer possible to exclude cases by these criteria, and the numbers of control and
AD subjects remained unequal, subjects were randomly removed from the analysis.
Demographic details, PMI and diagnosis of all of the cases included in this analysis,
labelled series IV, are presented in appendix II. For each brain region the effects of
diagnosis and experiment number on the insert:junction ratio was assessed.
Subsequently, the age and sex of the subjects, and the PMI of the tissue employed,
were included in the analysis and any discrepancies between the two analytical
models analysed. However, since the control and AD cases included in this analysis
were matched for age and PMI, extreme values of these variables tended to be
excluded from the analysis. It was, therefore, impossible to assess the effects of age
and PMI on the insert junction ratio. Further, the total number of cases that could be
analysed in this way remained relatively small. In order to increase the power of the
analysis and examine the effects of age and PMI, the remaining control and AD
cases belonging to the four series were included in a second statistical analysis
effectively widening the range of ages and tissue post-mortem delay analysed. The
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cases included in this second, unmatched analysis are listed under the appropriate
brain area and marked with an asterisk.
The effect of age on the insert junction ratio was of particular interest since a
previous study conducted in Professor Pearson's laboratory (Heffernan, 1996) had
demonstrated a significant positive relationship between the insert junction ratio and
age in a series of thirteen neurologically normal individuals whose ages varied from
eighteen to ninety-three years.
The unmatched series were examined using a customised, sequential, two way
ANOVA. The order of entry of the terms in the model was determined in advance
and was fixed. Previous, thorough analysis suggested that the insert junction ratio in
the visual cortex and hippocampus was unlikely to be significantly affected by
diagnosis, therefore, terms including the variables age, experiment number, PMI and
sex were included before terms including the variable diagnosis. This model
effectively excluded the effects of all other variables on the insert junction ratio
before considering the effects of diagnosis and lowered the probability of
demonstrating a significant effect of diagnosis on the insert junction ratio: a
premeditated bias in the conduct of the analysis. Information on PMI was
unavailable for some of the cases included in the unmatched series and where this
occurred this variable was excluded from the analysis initially and then included to
observe any alteration in the results.
290
5.4.4.2 Insert:Junction Ratio in Series IV Visual Cortex
Data from three independent experiments was combined to provide data on the
insert junction ratio in normal and Alzheimer diseased visual cortex. Fourteen cases
from Dr. Barton's experiment, fourteen series III (the OPTIMA series) cases and
twenty cases from series II, forty-eight cases in all, were included in the analysis
(Table 5.23). Summarised demographic and post-mortem details of these cases are
presented in table 5.24. Those cases marked with an asterisk represent those cases
excluded from the matched series and subsequently included in the unmatched
series.
The matched series was analysed first. Dr. Barton's control cases were significantly
younger than her AD cases (p = 0.010), though there was no significant difference in
PMI between her two diagnostic categories. No significant differences were
identified between the control and AD cases selected from series II in terms of age
and PMI, nor were any such differences identified between the control and AD cases
selected from series III (the OPTIMA series).
The Cochran test for non-homogeneity of variance performed on the combined data
set in visual cortex was significant (p < 0.050), suggesting that the requirements of
the two way ANOVA had not been met. The data was transformed by raising the
insert junction ratio in visual cortex to the power of 0.1, whereupon the Cochran test
became non-significant. A two way ANOVA performed on the combined,
transformed data set revealed a significant effect of experiment number (p = 0.011),
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Table 5.23 Series IV Visual Cortex





























Denotes cases added to series for unmatched analysis only.
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Table 5.24 Series IV Visual Cortex - Matched Cases

















































Demographic and Post-Mortem Details of Cases Selected from Series

























but no effect of diagnosis (p = 0.050), on the insert)unction ratio (Figure 5.37). The
ages of the subjects and the PMI of the tissue were then added to the model as
covariates and the sex of the subjects included in the model as a factor. Only
forty-five cases were analysed, since PMI data was absent for three cases. The
Cochran test was non-significant. A significant effect was demonstrated for
experiment number (p = 0.013), but not for diagnosis (p = 0.259), on the
insert)unction ratio in visual cortex. A significant interaction was also demonstrated
between diagnosis and sex (p = 0.029) for the transformed insert)unction ratio.
Analysis of the data revealed that the mean, transformed insertjunction ratio was
0.98 for both the thirteen male AD and sixteen male control cases and, moreover, the
dispersion of the insert) unction ratio was similar in these two groups (standard
deviations of 0.04 and 0.05 respectively). However, the mean, transformed
insert) unction ratio of the eleven female AD cases was 1.02 with a standard
deviation of 0.06, whereas the mean, transformed insert) unction ratio of the eight
female control cases was 0.94 with a standard deviation of 0.05. Thus, though there
is no significant effect of sex or diagnosis alone on the transformed insert)unction
ratio, female AD and control cases do behave differently from their male
counterparts in terms of transformed insert)unction ratio, for reasons that are
unclear. Understandably, the effect of age and PMI in predicting the insert) unction
ratio was not significant in this carefully matched series.
Data on the insert)unction ratio in the visual cortex of six additional cases from





































































added to the series. No additional cases were available from Dr. A.J.L. Barton's
series. These cases are marked by an asterisk in table 5.23.
The insert:junction ratio was examined in the visual cortex of the fifty-nine
unmatched series IV cases using the customised, sequential, two way ANOVA.
However, the Cochran test for non-homogeneity of variance was significant
suggesting that the requirements of the two way ANOVA had not been met.
Therefore, the data was transformed, as above, by raising the insert junction ratio to
the power of 0.1, whereupon the Cochran test became non-significant. The covariate
PMI was excluded from the analysis initially, since this information was not
available for five of the cases included in the study. A significant effect on the
transformed insertj unction ratio was demonstrated for age (p < 0.001) and
experiment number (p = 0.008), but not for diagnosis (p = 0.229). The terms 'age
and diagnosis' (p = 0.047), 'diagnosis and sex' (p = 0.014) and 'age, diagnosis and sex'
(p = 0.013), also had significant effects on the transformed insert junction ratio. In
the unmatched series the AD cases tended to be older (mean ± standard
deviation = 81.7 ± 8.4 years) than the controls (mean ± standard deviation = 73.9 ±
10.1 years) and, of course, age is strongly positively correlated with the transformed
insert junction ratio. Analysis of the cohort by diagnosis and sex revealed that,
inexplicably, while the male AD cases were older (mean ± standard deviation = 78.5
± 7.0 years) than the male controls (mean ± standard deviation = 72.4 ± 10.6 years)
the mean, transformed insert junction ratio of the two groups was equal (0.98) and
their dispersion was similar (standard deviation of control cases = 0.05; standard
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deviation of AD cases = 0.04). The female AD cases were also older (mean ±
standard deviation = 83.7 ± 9.0 years) than the female control cases (mean ±
standard deviation = 77.0 ± 9.0 years) however, the mean, transformed
insertj unction ratio differed between the two groups (mean ± standard deviation of
AD cases = 1.02 ± 0.05; mean ± standard deviation of control cases = 0.94 ± 0.05).
Thus, females with AD behave differently in terms of transformed insert junction
ratio than do males with AD, for reasons that are unclear. When the analysis was
repeated including PMI in the model, only the terms 'age' (p < 0.000), 'trial'
(p = 0.011) and 'age and sex' (p = 0.027) were significant. The Cochran test was not
significant.
5.4.4.3 Insert:Junction Ratio in Series IVHippocampus
5.4.4.3.1 Insert:Junction Ratio in Series IVDentate Gyrus
A total of thirty-eight cases were used to analyse the effect of diagnosis and
experiment number on the insertj unction ratio in the dentate gyrus. The cases
comprised fourteen cases from Dr. Barton's series, twelve cases from series III (the
OPTIMA series) and twelve cases from Dr. Griffiths's series (Table 5.25).
Summarised demographic and post-mortem details of the cases used are presented in
table 5.26. Those cases marked with an asterisk represent those cases excluded from
the matched series and subsequently included in the unmatched series. The cases
selected from each series for the matched analysis did not differ significantly in
terms of age or PMI.
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Table 5.25 Series IV Dentate Gyrus




















Denotes cases added to series for unmatched analysis only.
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Table 5.26 Series IV Dentate Gyrus - Matched Cases


















































Demographic and Post-Mortem Details of Cases Selected from Series

























The Cochran test for used to analyse the matched series for non-homogeneity of
variance and was not significant (p = 0.910). A two way ANOVA did not
demonstrate any significant effects of diagnosis or experiment number, nor any
interaction between the two, on the insert:junction ratio in the dentate gyrus of series
IV (Figure 5.38). The inclusion of sex, as a factor, and age and PMI, as covariates,
did not alter the conclusions of the two way ANOVA in the dentate gyrus.
Three cases from Dr. Barton's series, one case from Dr. Griffiths's series and two
cases from series III (the OPTIMA series) were added to examine the effects of age
and PMI on the insert:junction ratio in dentate gyrus. The customised, sequential,
two way ANOVA was used to examine the forty-four cases unmatched cases. The
covariate PMI was not included initially since this data was not available for one
case. The Cochran test was not significant. The term 'age and diagnosis' was the
only one to achieve significance (p = 0.010). The procedure was then repeated
including PMI as a covariate. The Cochran test for non-homogeneity of variance
was not significant and the terms 'age and diagnosis' and 'age, diagnosis and trial'
achieved significance (p = 0.017 and p = 0.037 respectively). On a scatter diagram
(Figure 5.39) it was clear that the youngest controls tended to have the lowest
insert junction ratios and the AD cases tended to be older (mean ± standard
deviation = 78.3 ± 7.98 years) than the controls (mean ± standard deviation = 73.6 ±
11.1 years). Furthermore, in this unmatched series the youngest subgroup represents
the control subjects in Dr. Barton's experiment (mean ± standard deviation = 70.8 ±
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Figure 5.41 Age Plotted Against the APP-Insert to APP-Junction Ratio in
Hippocampal Subfield CA4 of Series IV Alzheimer Diseased and Control Brains
(Unmatched Series)
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12.9 years), while the oldest subgroup is the AD subjects in Dr. Griffiths's
experiment (mean ± standard deviation = 80.2 ± 4.8 years). It is likely that it is this
discrepancy in ages between the subgroups that is responsible for the significant
effect of'age, diagnosis and trial1 on the insert junction ratio.
5.4.4.3.2 Insert:Junction Ratio in Series IVHippocampal CA4 Field
The insert junction ratio in CA4 was analysed using fourteen cases from Dr. Barton's
series, twelve cases from series III (the OPTIMA series) and ten cases from Dr.
Griffiths's series, a total of thirty-six cases (Table 5.27). Summarised demographic
and post-mortem details of these cases are presented in table 5.28. Those cases
marked with an asterisk represent those cases excluded from the matched series and
subsequently included in the unmatched series. The cases selected from each series
for the matched analysis did not differ significantly in terms of age or PMI.
On analysis of the matched series the Cochran test was significant (p < 0.001),
suggesting that the requirements of the two way ANOVA were not met. The
insert junction ratio in CA4 was transformed by raising each value to the power of
negative 0.7. The Cochran test on the transformed data was not significant (p >
0.082). No significant effect of diagnosis (Figure 5.40) or experiment number on the
transformed insert junction ratio in CA4, nor any significant interaction between the
two, was demonstrated using the two way ANOVA. The inclusion of sex, as a
factor, and age and PMI, as covariates, resulted in the term 'sex, diagnosis and
experiment number' achieving significance (p = 0.044). Analysing the transformed
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Table 5.27 Series IV Hippocampal CA4




















Denotes cases added to series for unmatched analysis only.
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Table 5.28 Series IV Hippocampal CA4 - Matched Cases


















































Demographic and Post-Mortem Details of Cases Selected from Series





























insertJunction ratio by experiment number, diagnosis and sex revealed that the
subgroup with the highest transformed insertJunction ratio was the female AD
subjects in Dr. Barton's experiment (mean ± standard deviation = 1.40 ± 0.30), while
the subgroup with the lowest transformed insertJ unction ratio was the female control
subjects in the series III (the OPTIMA series) experiment (mean ± standard
deviation = 0.54 ± 0.12). The term 'sex, diagnosis and experiment number' resulted
in subgroups of subjects that behave differently from one another in terms of
transformed insert junction ratio.
Three cases were added from Dr. Barton's series, two cases from series III (the
OPTIMA series) and two cases from Dr. Griffiths's series in order to examine the
effect of age and PMI on the insert junction ratio in CA4. This unmatched series of
forty-three cases were analysed using the customised, sequential, two way ANOVA.
PMI was excluded from the model initially since this would have resulted in the loss
of one case for which no data on PMI was available. The Cochran test was
significant for the insert junction ratio in CA4 and the insert junction ratio was
therefore transformed by raising each value to the power of negative 0.7: the same
transformation as was performed on the matched series. Unfortunately, the Cochran
test remained significant for the insert junction ratio transformed in this way.
Examination of a scatter diagram of the insert junction ratio in CA4 plotted against
age revealed a massively outlying value for the insertjunction ratio among Dr.
Barton's cases (Figure 5.41). On exclusion of this case, transforming the remaining
insertjunction ratios in CA4 by logging to the base 10 resulted in homogeneity of
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variance as analysed by the Cochran test. PMI was excluded from the analysis
initially, since this information was not available for one case. Using the
customised, sequential, two way ANOVA none of the variables examined had a
significant effect on the transformed insert junction ratio in CA4. When PMI was
added to the model as a covariate, two terms, 'PMI and experiment number' and 'age,
diagnosis and experiment number', achieved significance (p = 0.022 and p = 0.026
respectively). While the mean PMI was similar for all three experiments, Dr.
Barton's experiment showed the greatest dispersion in PMI exhibiting both the
longest and shortest PMIs in the series and the lowest mean transformed
insert:junction ratio. The mean PMI of series III (the OPTIMA series) (mean ±
standard deviation = 38.00 ± 15.18) was similar to that of Dr. Griffiths's series (mean
± standard deviation = 34.58 ± 17.52) and the dispersion of PMIs was similar in
both. The mean transformed insert junction ratios calculated for these two series,
however, were very different (series III (the OPTIMA series) mean ± standard
deviation = 0.22 ±0.18; Dr. Griffiths's series mean ± standard deviation = 0.12 ±
0.30). Thus, similar values for PMI are associated with different transformed
insert junction ratios in experiments carried out by different researchers.
The significance of the term 'age, diagnosis and experiment number' was examined
in the unmatched series. The transformed insert junction ratio in CA4 of AD series
III (OPTIMA) cases was higher than that for control series III cases. In contrast, in
Dr. Barton and Dr. Griffiths's experiments, the transformed insert junction ratio was
lower in the AD cases than the controls. Further, the AD and control cases included
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in series III (the OPTIMA series) are well matched in terms of age, while in the other
two experiments the AD cases are older than the controls. Thus, in series III (the
OPTIMA series), cases of similar ages, but different diagnostic groups, differ in their
transformed insert junction ratio, unlike cases of a similar age in either of the other
two experiments.
5.4.4.3.3 Insert:Junction Ratio in Series IVHippocampal CA3 Field
A total of thirty-two cases were processed in a two way ANOVA to examine the
insert:j unction ratio in CA3. Fourteen cases from Dr. Barton's Series, eight cases
from series III (the OPTIMA series) and ten Cases from Dr. Griffiths's series were
included. The case numbers of the brains selected from each series are presented in
table 5.29 and the demographic and post-mortem details of the cases used are
summarised in table 5.30. Those cases marked with an asterisk represent those cases
excluded from the matched series and subsequently included in the unmatched
series. The matched control and AD cases, selected from each series, did not differ
significantly in age or PMI.
The Cochran test was not significant for the insert:junction ratio of this matched
series, suggesting that the requirements of the two way ANOVA were satisfied. No
significant effects of diagnosis (Figure 5.42) or experiment number could be
demonstrated on the insert:junction ratio in CA3, nor any significant interaction
between these factors, using this test. The inclusion of the age of the subjects, their
309
Table 5.29 Series IV Hippocampal CA3



















Denotes cases added to series for unmatched analysis only.
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Table 5.30 Series IV Hippocampal CA3 - Matched Cases
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sex, and the tissue PMI, in analysing the insert junction ratio in CA3 did not alter the
conclusions of the two way ANOVA.
Two cases were added from Dr. Barton's series, one case from Dr. Griffiths's series
and two cases from series III (the OPTIMA series) in order to examine the effects of
age and PMI on an unmatched series. The Cochran test was not significant. A
complete data set was available for all thirty-seven cases and therefore the
customised, sequential two way ANOVA was performed to examine the effects of
age, experiment number, sex, PMI and diagnosis, or any interaction between these
variables, on the insert:junction ratio in CA3. The only term to achieve significance
was 'age and diagnosis' (p = 0.042). On closer inspection of the data, it appeared that
the older AD subjects tended to have lower insert junction ratios than younger AD
subjects but this was not true for the control subjects for whom no pattern in relation
to age could be discerned. Thus, for reasons that are unclear, elderly AD and control
subjects appear to behave differently in terms of their insert junction ratio.
5.4.4.3.4 Insert:Junction Ratio in Series IV Hippocampal CA1 Field
The insert junction ratio in CA1 was analysed in twenty-six cases in total, eight cases
from Dr. Barton's series, eight cases from series III (the OPTIMA series) and ten
cases from Dr. Griffiths's series. The case numbers of the brains selected from each
series are presented in table 5.31 and the demographic and post-mortem details of
the cases used are summarised in table 5.32. Those cases marked with an asterisk
represent those cases excluded from the matched series and subsequently included in
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Table 5.31 Series IV Hippocampal CA1















Denotes cases added to series for unmatched analysis only.
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Table 5.32 Series IV Hippocampal CA1 - Matched Series


















































Demographic and Post-Mortem Details of Cases Selected from Series

























the unmatched series. The control and AD cases selected from each series did not
differ significantly in terms of age or PMI.
On analysis of the matched series, the Cochran test for homogeneity of variance was
significant (p < 0.05) for the insert junction ratio in CA1, suggesting that the
requirements of the two way ANOVA were not met. The log 10 of the
insert junction ratio in CA1 was calculated in an attempt to compress the scale and
normalise the data. The Cochran test performed on the log 10 (insertjunction ratio)
was not significant, and a two way ANOVA did not demonstrate any significant
effects of diagnosis (Figure 5.43) or experiment number on the insertj unction ratio
in CA1, nor any significant interaction between the two. The inclusion of the age of
the subjects, their sex, or the PMI of the tissue did not alter the findings, using this
model, in CAT
Three cases were added from Dr. Barton's series, two cases from series III (the
OPTIMA series) and two cases from Dr. Griffiths's series and a customised,
sequential two way ANOVA was performed on the thirty-three unmatched cases
with data for the insert junction ratio in CA1. The Cochran test was significant
(p = 0.001) therefore the insert junction ratio in CA1 was transformed according to
the formula 1/insertjunction ratio. The Cochran test performed on the transformed
data was non-significant and no significant effects of age, sex, experiment number,
PMI or diagnosis on the transformed insertjunction ratio were apparent using this
model in this region.
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The importance of APP to the pathogenesis of AD is undisputed: a number of
mutations in the APP gene are associated with FAD (Goate el al., 1991;
Chartier-Harlin et al., 1991; Murrell et al., 1991; Mullan el al., 1992; Hendriks el al.,
1992). FAD is generally associated with an early age of onset, but only 5 to 10% of
all AD cases present below the age of 60 years (Sandbrink et al., 1996). Clearly,
therefore, since the above mutations represent a minority of FAD, mutations in the
APP gene explain a minute proportion of all AD cases. Of course, it is not the
abnormality in the APP gene per se, but an increase in the production of P-amyloid,
the major protein constituent of the plaque and meningovascular amyloid deposits
which characterise AD, that is believed to be fundamental to the development of AD
(Citron et al., 1992). Clearly, there are other mechanisms by which P-amyloid levels
might be increased. The abundance or stability of APP mRNA might be enhanced,
for example, or the efficiency with which APP mRNA is translated might be
increased. Abnormalities in the APP peptide which promote its amyloidogenic
cleavage or aberrant processing of normal APP, or any combination of the above,
might result in the increased levels of p-amyloid assumed to be necessary for the
development of AD.
APP mRNA levels are increased in Down's syndrome consistent with the 50%
increase in gene dosage associated with trisomy 21 (Tanzi el al., 1987) and are
believed to be responsible for the early appearance of the pathological stigmata of
AD in patients with this condition. There is other evidence that increased APP
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mRNA levels are toxic. Fibroblast cell lines derived from affected members of a
Canadian FAD pedigree that shows strong linkage to chromosome 14, exhibit an
increase in APP mRNA (Querfurth et al., 1995) and elevated APP mRNA levels are
observed in transgenic mice exhibiting AD-like pathology (Rockenstein et al., 1995).
Further, severe degeneration of post-mitotic murine embryonal carcinoma PC 12
neurons that exhibit increased APP mRNA and peptide has been demonstrated
(Yoshikawa et al., 1992). Thus, the hypothesis that the neuropathology of AD
originated from a modest, protracted, increase in APP mRNA levels was compelling,
since it was both biologically plausible (Jacobsen, 1991) and experimentally testable.
Crucial to the analysis of APP mRNA expression in AD, is the determination of the
upper and lower limits of APP mRNA in normal human brain, since it is conceivable
that subtle alterations in APP mRNA expression over decades might be implicated in
the pathophysiology of the disease (Jacobsen et al., 1991). Unfortunately, APP
mRNA levels appear to be extremely variable in normal human brain. Oyama and
co-workers (1993) studied thirty-seven brains obtained at autopsy from elderly
individuals, four of whom were diagnosed as suffering from AD diagnosed as typical
on clinical and pathological grounds. The authors noted a marked individual
variability in APP mRNA levels among the brains examined, for reasons they were
unable to fully explain. Harrison and colleagues (1994) have also commented on the
marked brain to brain variability in APP mRNA and hence the difficulty in
identifying disease related alterations in the expression of these mRNA species.
Ebstein and co-workers (1996), in their study of lymphocytes harvested from
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sixty-four cognitively intact subjects ranging from twenty to ninety-one years of age,
provide indirect evidence in support of the variability of brain APP mRNA
expression in normal brain. The authors documented a ten fold variation in
individual APP-751 mRNA levels in subjects less than fifty-five years old. Thus,
given the wide variation in normal APP mRNA levels, large numbers of control
subjects are needed to generate statistically meaningful results and to avoid
generating false positive and false negative findings (Harrison et al., 1996).
However, despite this, APP mRNA expression has generally been studied in normal,
post-mortem, human brain using small numbers of cases. For example, Cohen and
colleagues (1988), Goedert (1987), Neve and co-workers (1990), Harrison and
co-workers (199Id; 1994), Rockenstein and co-workers (1995) and Johnston and
colleagues (1996b) all employed five or less control subjects in their analysis.
Further, any differences in APP mRNA expression between diseased and normal
brain tissue are likely to be modest, necessitating the recruitment and investigation of
large numbers of diseased as well as control subjects. While Robinson and
colleagues (1994) employed forty-two AD cases in a Northern blotting study, most
studies employ far less cases (Cohen et al., 1988; Goedert 1987; Neve et al., 1990;
Harrison et al., 199Id; Rockenstein et al., 1995). In addition, though the importance
of controlling for pre-mortem variables (Harrison et al., 1994) and post-mortem
handling (Burke et ah, 1991) when analysing APP mRNA levels has been
demonstrated, not all studies take agonal state (Robinson et al., 1994) or PMI
(Robinson et al., 1994) into account.
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Other challenges to the accurate assessment of APP mRNA levels in AD present
themselves. Firstly, studies employing human post-mortem brain tissue encompass
subjects at varying stages of AD, a disease that occupies a neuropathological
spectrum (Braak and Braak, 1991). Rarely is the severity of disease of included
subjects known, nor is it likely that they represent a homogeneous group of equally
affected individuals, such that studies may vary greatly in their case mix. Further,
accurate diagnosis of AD depends on the adequate exclusion of complicating
pathologies, the application of recognised diagnostic criteria and neuropathological
precision. Secondly, the value of the concomitant use of a measure of overall gene
expression to help identify those mRNA species differentially affected by the disease
process, as opposed to those that are simply altered in tandem with changes in total
gene expression, have been underlined by Flarrison and co-workers (1991b). Ideally,
ISHH studies of specific mRNAs should be complemented by an assessment of the
abundance of polyadenylated mRNA.
Thirdly, the effect of age on APP mRNA expression remains controversial. Some
workers have attempted to study the effects of age on the individual splice variants
of APP mRNA. Harrison and colleagues (1994) found no association between age
and APP mRNA expression in the frontal cortex of eleven AD and four control
subjects on whom data was available regarding age, PMI and pre-mortem course.
Similarly, Jacobsen and co-workers (1991) failed to establish any effect of age on
APP mRNA expression. However, though these workers did include an internal
control to allow better comparison of tissue derived from different samples, they did
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not control for the effects of PMI or agonal state. Robinson and co-workers (1994)
documented a trend for neuronal transcription of the neurofilament light subunit and
major transcripts of APP to decline with age in both AD and control subjects: a
finding that was most significant and consistent for APP-695. Robinson and
colleagues (1994), however, did not take agonal state factors into account in their
analysis.
Other workers have examined the relationship between KPI-encoding and
KPl-lacking splice variants of APP mRNA with age. Koo and colleagues (1990)
demonstrated that KPI-encoding APP mRNA species predominated over non-KPl
APP mRNA species in aged controls and AD sufferers, while in young adult controls
the abundance of KPI-containing and non-KPI APP mRNA transcripts was
approximately equal. Tanaka and co-workers (1992) demonstrated an increase in the
ratio of KPI-encoding to KPI-lacking splice variants of APP mRNA with age in the
frontal cortex of eight AD and seven control subjects, though the AD subjects
exhibited this change in ratio at an earlier age than the control subjects. These
workers also documented a positive correlation between age and this ratio in grey
matter from control, but not AD, frontal cortex (Tanaka et al., 1993). However,
tissue from only six control and five AD subjects were examined in this study.
Heffernan (1996) examined the relationship between KPI-encoding and KPI-lacking
splice variants of APP mRNA in the hippocampus, temporal cortex and visual cortex
of a series of normal human post-mortem brains from thirteen individuals aged
between eighteen and ninety-three years at death. The ratio between KPI-encoding
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and KPI-lacking splice variants of APP mRNA was positively correlated with age in
the visual cortex only. Harrison and colleagues (1994) found no association between
the ratio of KPI-encoding and KPI-lacking splice variants of APP mRNA and age in
their 1SHH study of frontal cortex. Ebstein and co-workers (1996), in their analysis
of lymphocytes from AD and control donors, found APP-751 mRNA to be positively
correlated with age in their sixty-four control subjects aged twenty-one to ninety-one
years. APP-751 mRNA levels in their nineteen AD cases were equivalent to those in
an age-matched control group. The ratio of APP-751 to APP-770 mRNA in the AD
subjects, however, was lower than that in the age matched controls due to an
increase in APP-770 mRNA in AD over and above that seen in the age matched
control subjects. Thus, Ebstein and colleagues (1996) conclude that KPI-containing
transcripts of APP mRNA increase with age. In conclusion, it would appear wise to
age-match control and diseased subjects to eliminate the potentially confounding
effect of age on APP mRNA levels.
The fourth consideration concerns the cerebral region studied. Clearly, APP mRNA
expression studies that employ different brain areas are not comparable. The brain
has been described as a multi-organ organ (Wisniewski, 1993), limiting the extent to
which the findings in one brain area can be extrapolated to another. The extent of
neuronal loss in AD is variable and may be region-specific, altering the ratio of
neuronal to non-neuronal cells in the disease (Neve e( a/., 1990). Of course, cellular
composition is crucial to the interpretation of APP mRNA expression studies.
L-APP transcripts, for example, are not expressed in neurons (Sandbrink el aL,
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1994a; Sandbrink et al., 1997), but are otherwise ubiquitous (Sandbrink et al.,
1994b). Techniques that employ homogenised tissue may include reactive
astrocytes, microglia and endothelial cells as well as varying numbers and types of
neurons. Therefore, studies may not be comparing like with like when they examine
equal volumes of AD and control brain tissue, as in the 1993 study of Oyama and
co-workers, for example. Further, neurons may not themselves be uniform in their
expression of the alternative splice forms of APP (Jacobsen et al., 1991).
Fifthly, are technical considerations such as the availability of suitable tissue and its
appropriate processing and storage. Human, post-mortem brain tissue is precious: it
requires the co-operation and goodwill of the donor and their family and its handling,
storage and processing represents a considerable investment in time and money.
Experimental variables, such as the efficiency of oligodeoxynucleotide probe
labelling, render it impossible to compare the intensity of 1SHH between cerebral
regions directly, making statistical analysis imperative. Exclusion of the
non-specific effects of a dementing illness requires the analysis of a positive control
group of non-AD dementia sufferers, the value of which has been discussed by
Harrison and co-workers (1994). Ideally these individuals should be a homogeneous
group of non-AD dementia sufferers (Pearson et al., 1992). Finally, the importance
of the application of complementary techniques that examine individual or
sub-populations of cells in reaching a comprehensive understanding of APP mRNA
expression is obvious. Indeed, the study of selected types of neurons, such as
olfactory neuroblasts (Wolozin et al., 1993), as well as non-neuronal cells (Ebstein et
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al., 1996), from AD donors, has contributed to AD research in this way. In addition
primate and rat brains (Koo et al., 1990; Chao el al., 1994;) and human (Querfurth el
a/., 1995) and rat (Sandbrink et al., 1997) cell lines have been studied in an attempt
to further our understanding of the pathophysiological processes underlying AD.
The neuropathological stigmata of AD are not uniformly distributed in brain
(Pearson and Powell, 1989), and the particular vulnerability of certain brain areas to
the pathological changes characteristic of the disease is unexplained, hence the
interest in regional variations in APP mRNA expression in health and disease.
Goedert (1987) observed little regional variation in APP mRNA expression in his
study of human, control brains. Johnston and co-workers (1996a), however,
observed regional differences in the levels of APP and APLP2 mRNA, and in APP
splicing, in their study of three control, post-mortem, human brains. Their data
suggests that APP, APLP2 and KPI-containing APP mRNA transcripts are most
abundantly expressed in the temporal cortex, are intermediately expressed in the
occipital cortex and are least abundant in the cerebellum; an area relatively spared
from the ravages of AD. Johnson and colleagues (1989) analysed APP-751 and
APP-695 mRNA expression in the neocortex, hippocampus and cerebellum of nine
AD and ten control subjects. They found APP-751 mRNA to be unchanged in the
disease while APP-695 mRNA was decreased selectively in the hippocampus and
neocortex in AD. However, none of the three studies described above (Goedert,
1987; Johnston et al., 1996a; Johnson et al., 1989) included tissue obtained from
individuals whose pre-mortem condition was known. It is conceivable that in some
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cerebral regions mRNA is more vulnerable to the effects of a poor agonal state than
it is in other brain areas (Harrison et a/., 1995).
Numerous studies have examined the abundance of individual splice variants of APP
mRNA in AD. However, few satisfactorily control for all of the confounding
variables now known to influence APP mRNA levels. Two studies, superior in their
prosecution, are worthy of note. Harrison and co-workers (1994) examined the
frontal cortex in eleven AD, four control and six non-AD dementia subjects using
1SHH. They normalised KPI-containing and non-KPI APP mRNA levels to the
abundance of polyadenylated mRNA is this region and documented a decrease in
both in comparison to the control and non-AD dementia subjects. This study
attended partially to potentially confounding agonal state factors and the tissue
specimens were obtained at rapid autopsy; however, by the authors' admission the
control group was small.
The impressive study of Johnston and co-workers (1996a) employs a novel solution
hybridisation-RNase protection assay and represents an attempt to control for all of
the factors now known to influence APP mRNA levels. Fourteen AD, nine control
subjects and five individuals afflicted with non-AD neurological diseases were
included in the analysis. The cases were matched for both pH and age, and
information was available regarding PMI. Total APP and APLP2 mRNA levels were
reduced in the mid-temporal, but not superior frontal, cortex in AD tissue in
comparison to the other two groups examined. However, the proportion of APP
326
mRNA that was KPI-encoding was increased in both cortical areas in AD. There are
two important caveats regarding interpretation of this study. Firstly, this study
represents the findings in a heterogeneous cellular mix and, thus, is not directly
comparable with the study by Harrison and co-workers (1994). Secondly, the mRNA
species measured are expressed as a proportion of total RNA levels, rather than as a
proportion of all polyadenylated mRNA species as in Harrison and colleagues (1994)
study. Since mRNA represents between only three and five per cent of all cellular
RNA, Johnston and co-workers (1996a) method may have been less sensitive and,
thus, unable to detect the reduction in APP mRNA levels in frontal cortex identified
by Harrison and co-workers (1994). Alternatively, the frontal cortices in the cases
studied by Johnston and colleagues (1996a) may have been less severely diseased
than those employed by Harrison and co-workers (1994). However, crucially, neither
of these studies support the hypothesis that APP mRNA levels are elevated in AD.
In this thesis a consistent picture of APP mRNA expression in AD, BAD and
non-AD dementia brains, in comparison to control brains, emerges, and suggests that
the hippocampus and neocortex are differentially affected by the disease processes
studied. Therefore, as suspected, it appears inadvisable to extrapolate the findings
obtained from the study of one cerebral area to another.
The examination of series II control and AD visual cortices failed to find any effect
of diagnosis on the abundance of APP-695 mRNA or that of KPI-containing
transcripts of APP mRNA. This finding was reproduced on examination of the
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visual cortices in series III (the OPTIMA series), that included not only AD and
control brains, but those from individuals who had suffered from BAD and non-AD
dementias during life. The analysis of APP mRNA expression was extended in
series III to include examination of APP-770 mRNA expression, which was also
unaffected by diagnostic group. The ratio between KPl-containing transcripts of
APP mRNA and non-KPI APP mRNA, the insert:junction ratio, was also estimated
for the visual cortices examined in series II and III, and in neither study was there
any effect of diagnosis on this parameter. The insert junction ratio was also
examined in series IV visual cortices in AD brains in comparison to control brains
and no significant effect of diagnosis on the insertjunction ratio was apparent.
+
The abundance of poly(A) mRNA was examined in the visual cortices of series III
(the OPTIMA series) and no significant difference in this parameter was identified
between the four diagnostic categories. The APP-junction, APP-insert and APP-770
oligodeoxynucleotide probes in visual cortex were then expressed as a proportion of
poly(A) mRNA in this region and again no significant differences between the
diagnostic groups was apparent.
APP mRNA expression in the hippocampus in AD in comparison to control brain
tissue was examined in series I brains (see chapter 4). Total APP mRNA was
significantly reduced in the dentate gyrus of AD hippocampus in comparison with
control hippocampus in the presence of unchanged levels of poly(A) mRNA in this
region. No significant differences in total APP mRNA expression were identified in
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the CA4 and CA3 subfields of the hippocampi studied in series I. A reduction in
total APP mRNA expression was confirmed in the dentate gyrus of series III brains
(the OPTIMA series) in the form of a significant reduction in APP-695 mRNA in AD
in comparison to control brains and unchanged levels of KPI-containing APP and
APP-770 mRNA. A significant reduction in APP-695 mRNA in the AD brains in
comparison to the control or BAD brains was also found in the CA4 hippocampal
subfield in series III in the presence of unchanged levels of the other APP mRNA
transcripts measured. No effect of diagnosis on the insert:j unction ratio was
apparent from examination of the hippocampi in series I, III or IV. Thus, it can be
concluded unequivocally from this study that, though increased APP mRNA levels
are associated with the neuropathological stigmata of AD (Tanzi et al., 1987),
increased APP mRNA levels are not a feature of Alzheimer diseased visual cortex or
hippocampus. Indeed, in the dentate gyrus and hippocampal subfield CA4, APP-695
mRNA was reduced in AD tissue in comparison to tissue from control, BAD or
non-AD dementia subjects.
*
Analysis of the correlation matrices prepared in the course of this study can be
summarised as follows. No significant correlations were identified on analysis of
series II, since two significant findings (p < 0.050) and one finding of p = 0.050 is
less than would have been predicted to occur by chance. However, it is noteworthy
that one of the two significant findings identified on examination of series II had a p
value of less than 0.001. On consultation with biomedical statistician, Miss J.M.
Russell, the determination of the statistical significance of this finding, a complex
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and inexact undertaking, was deemed beyond the scope of this thesis. No correlation
statistics were performed on series IV, since this series was compiled specifically to
examine the effects of diagnosis and experimental variables on the insert junction
ratio. Thus, further statistical analysis of this data set was not appropriate. Series III
(the OPTIMA series) benefited from the inclusion of tissue from cerebral areas
differentially involved in the disease processes studied and from the unparalleled
demographic, neuropathological and tissue details available. A previous study of
OPTIMA derived tissue (Nagy et a/., 1995) documented a highly positive correlation
between the extent of cognitive decline and the severity of neuropathological change.
This finding was replicated in series III (the OPTIMA series). A negative correlation
was established between the mini-mental state score and the mean hippocampal and
neocortical NFT density, the mean neocortical neuritic plaque density, the Braak
score and the maximum CERAD plaque frequency. Thus, despite the relatively
crude nature of the mini-mental state examination, the score does appear to reflect
the degree of underlying pathology.
The mini-mental state score was also negatively correlated with the AOD of the
poly(dT) oligodeoxynucleotide probe in visual cortex, suggesting that the more
plentiful were polyadenylated species of mRNA in this region the poorer was
cognitive function. The abundance of polyadenylated mRNA in visual cortex was
also correlated with both neocortical and hippocampal pathological severity, since
the AOD of the poly(dT) probe was positively correlated with the Braak score, the
mean hippocampal amyloid plaque frequency, the maximum CERAD plaque
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frequency, the mean neocortical neuritic plaque frequency and the mean neocortical
NFT density. In contrast, when the AOD of the APP-insert and APP-j unction
oligodeoxynucleotide probes were expressed as a proportion of the AOD of the
poly(dT) probe both were positively correlated with the mini-mental state score.
This correlation cannot be explained simply as a result of the negative correlation
identified between the mini-mental state score and the AOD of the poly(dT)
oligodeoxynucleotide probe, since in both cases the correlation is slightly stronger
than that between the mini-mental state score and the AOD of the poly(dT)
oligodeoxynucleotide probe, and of considerably more compelling significance. It
would appear that the greater the proportion of polyadenylated mRNA in visual
cortex that is detected by the APP-insert and APP-junction oligodeoxynucleotide
probes then the more robust is cognitive function. In further support of this
contention is the negative correlation between the AOD of the APP-insert and
APP-junction oligodeoxynucleotide probes, when expressed as a proportion of the
AOD of the poly(dT) oligodeoxynucleotide probe, and the mean hippocampal NFT
density. It would appear that the greater the proportion of the polyadenylated mRNA
in visual cortex that is detected by the APP-insert and APP-junction
oligodeoxynucleotide probes then the less severe is hippocampal pathology. It
would appear that increasing pathological severity is associated with up-regulation of
some mRNAs, but not the major APP mRNA transcripts of APP-695, APP-751 and
APP-770. Indeed, it is noteworthy that the abundance of the mRNA species
identified by the APP-insert, APP-junction and APP-770 oligodeoxynucleotide
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probes alone was unhelpful in predicting pathological severity as measured by the
seven parameters employed in this study in any of the cerebral regions examined.
Initially, the above cohesive cluster of results in the visual cortex proved perplexing,
however, on closer scrutiny a plausible explanation of these findings emerged.
Polyadenylated mRNA would be expected to be increased in AD, despite neuronal
losses, consequent upon the gliosis that is characteristic of the disease (Frederickson,
1992). It is likely that the AOD of the poly(dT) oligodeoxynucleotide probe is a
measure, in part, of the extent of gliosis and hence disease progression. The
proportion of polyadenylated mRNA that is APP-695 mRNA, in contrast, would be
expected to fall in AD, since this splice variant of APP is the predominant form in
neurons (Sandbrink et al., 1997). Thus, a smaller ratio between the AOD of the
APP-junction and poly(dT) oligodeoxynucleotide probes would be expected to be
associated with increased pathology and poorer cognitive function. In health, the
ratio between the AOD of the APP-junction and poly(dT) oligodeoxynucleotide
probes would be predicted to be larger, since APP-695 mRNA should be more
abundant and polyadenylated mRNA less so. Of course, in the visual cortex the
AOD of the APP-junction and APP-insert oligodeoxynucleotide probes are highly
correlated, hence the association between the AOD of the APP-insert
oligodeoxynucleotide probe, when expressed as a proportion of the AOD of the
poly(dT) oligodeoxynucleotide probe, and pathology and cognitive function. No
significant differences in the AOD of the poly(dT) oligodeoxynucleotide probe were
identified between the four diagnostic groups studied, yet this parameter proved
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positively correlated with five of the seven neuropathological measures employed in
this study. It is likely that diagnostic group is too crude an approximation of
pathology and, in addition, twenty-seven cases were available in which to study the
association between the AOD of the poly(dT) oligodeoxynucleotide and pathology, a
marked increase in the power of the analysis when compared to identifying a
relationship between the AOD of this oligodeoxynucleotide probe and diagnostic
group.
The association between the APP-insert and APP-770 oligodeoxynucleotide probes
in visual cortex is understandable given that the APP-770 probe theoretically detects
APP-714 and APP-770 mRNAs, while the APP-insert probe detects APP-770,
APP-751, APP-563 and APP-365 mRNAs. However, the strong correlation between
the APP-insert and APP-junction probes in this region cannot be dismissed so easily.
It would appear that in healthy and diseased visual cortex the abundance of the APP
mRNA species detected by the APP-j unction and APP-insert oligodeoxynucleotide
probes are highly inter-dependent. Further, since the two are positively correlated,
changes in the relative abundance of the mRNA species identified by the
APP-j unction and APP-insert oligodeoxynucleotide probes must result from
alterations in transcription and/or mRNA degradation and not from alternative
splicing of heterogeneous nuclear APP RNA.
In the dentate gyrus and hippocampal subfield CA1, as in the visual cortex of this
series, the APP-insert and APP-junction oligodeoxynucleotide probes were
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correlated, as were the APP-insert and APP-770 oligodeoxynucleotide probes. In
hippocampal subfields CAS and CA4, however, no associations were found between
the AOD of the APP oligodeoxynucleotide probes examined.
In the visual cortex, but not in any of the other regions studied, both the APP-insert
and the APP-junction oligodeoxynucleotide probes were positively correlated with
tissue pH, and to a similar degree (0.573; p = 0.001 and 0.540; p = 0.003
respectively). It is unclear why in the visual cortex alone these two APP
oligodeoxynucleotide probes would appear sensitive to pH. However, this
association underlines the need to control for agonal state factors when measuring
APP mRNA levels and probably explains, in part, the highly variable nature of APP
mRNA levels (Oyama et al., 1993; Harrison el al., 1994; Ebstein el al., 1996). In
contrast, the use of the insert:j unction ratio is supported by this study, since as both
probes are equally affected by pH the resulting ratio is immune to its effects.
A ratio is a dimensionless pure number whose units are immaterial (Bland and
Altman, 1996). On analysis of series III the APP-j unction oligodeoxynucleotide
probe was negatively correlated with the insert junction ratio in the visual cortex
with a value of -0.678 and a p value of p < 0.001. The APP-insert
oligodeoxynucleotide probe was also negatively correlated with the insert:junction
ratio with a value of -0.376 and a p value of p = 0.028 in this region. Thus, it would
appear that in the visual cortex the value of the insert) unction ratio in health and
disease is dominated by the value of the APP-junction oligodeoxynucleotide probe.
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Conversely, in the dentate gyrus and hippocampal subfield CA1, areas particularly
susceptible to the pathological changes characteristic of AD, the insert junction ratio
appears to be dominated, in health and disease, by the value of the APP-insert
oligodeoxynucleotide probe. In hippocampal subfield CA4, the APP-insert
oligodeoxynucleotide probe was positively correlated (0.813; p < 0.001) and the
APP-junction oligodeoxynucleotide probe negatively correlated (-0.627; p=0.001)
with the insert junction ratio. Thus, it would appear that both oligodeoxynucleotide
probes influence the value of the insert junction ratio to the same degree in this
region. In hippocampal subfield CA3 no relationships were found between the value
of any of the APP oligodeoxynucleotide probes measured and the insert junction
ratio. Therefore, intriguingly, the major determinant of the insert junction ratio did
differ between the two cerebral regions studied. This finding implies that the
insert junction ratio in the visual cortex is relatively resistant to alterations in the
abundance of KPI-encoding transcripts of APP mRNA and vulnerable to changes in
APP-695 mRNA. The insert junction ratio in the dentate gyrus and hippocampal
subfield CA1, however, would be predicted to be selectively vulnerable to changes in
KPI-encoding APP mRNA levels and relatively impervious to changes in APP-695
mRNA.
No effect of diagnosis on the insert junction ratio could be discerned on examination
of the visual cortices in series II and III or the hippocampi in series I and III. Series
IV was compiled specifically to examine the relative importance of diagnosis and
experimental variables on the insert junction ratio in a larger series of brains. No
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significant differences, in terms of agonal state, were identified between the
diagnostic groups examined in series II and III, however, the data available on
pre-mortem course was inadequate for some of the cases included in series IV,
therefore, the insert:junction ratio alone was analysed. Experimental variables were
found to significantly influence the insert junction ratio in the visual cortex alone of
series IV. In none of the areas examined was the insert junction ratio correlated with
diagnosis.
In order to increase the power of the analysis of series IV, and to examine the effects
of age and PMI, the remaining cases in the series were included in a subsequent
unmatched analysis. The intention was to widen the range of ages over which the
insert junction ratio was examined and in this regard the analysis was successful.
Series II comprised cases aged from sixty-four to ninety-eight years and series III
(the OPTIMA series) comprised cases aged between sixty-two to ninety-one years.
The range of ages of the subjects studied in series IV was similar for all cerebral
areas, fifty-one to ninety-eight years for the visual cortex and fifty-one to ninety-six
for the other regions studied. In the visual cortex of series IV (Figure 5.44), but not
the dentate gyrus or hippocampal subfields CA4, CA3 or CA1, the insert junction
ratio was correlated with the age of the examined subjects. The identification of this
correlation in visual cortex alone is unexplained, but replicates the findings of
Heffernan (1996) who established this correlation in the visual cortex, but not the
hippocampus, in a series of normal controls aged between eighteen and ninety-three
years. However, the visual cortex data set comprised the largest number of cases,
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fifty-nine, while the number of cases studied in the dentate gyrus and hippocampal
subfields CA4, CA3 and CA1 was forty-four, forty-three, thirty-seven and
thirty-three respectively. In any event, the increase identified in the insert:junction
ratio in the visual cortex with age implies that KPI-encoding and non-KPI APP
mRNA transcripts must either both decrease or both increase in this region with age,
since in visual cortex the mRNA species detected by the APP-junction and
APP-insert oligodeoxynucleotide probes are positively correlated in healthy and
diseased tissue. Thus, the increase documented in the insert:junction ratio with age
in the visual cortices of series IV may be due to an increase in the mRNA species
detected by both the APP-insert and the APP-junction oligodeoxynucleotide probes
that is far more significant for the APP-insert oligodeoxynucleotide probe or,
alternatively, to a decrease in the mRNA species detected by both probes that is far
more marked for the species detected by the APP-junction oligodeoxynucleotide
probe. Since information on pre-mortem course was incomplete for the series it was
not possible to analyse the individual transcripts of APP mRNA. However, the
finding that KPI-encoding splice variants of APP mRNA increase relative to non-KPI
APP mRNA transcripts with age hints that this predominance of KPI-encoding APP
mRNA is amyloidogenic, since age is a risk factor for AD. It may be that the
balance between these two forms of APP mRNA is crucially altered with age in
favour of amyloidogenesis.
Clearly the use of age-matched controls in the study of AD is to be applauded,
however, this does artificially truncate the age range over which APP mRNA levels
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are studied and may be, in part, responsible for the failure to identify the correlation
between the insert:junction ratio and age in some studies. This is likely to be
consolidated by the small numbers of cases employed by most workers.
This thesis represents the analysis of a large series of human post-mortem brains: a
total of one hundred and thirty-nine cases were examined in the course of the work
on APP mRNA expression, and thirty-nine cases were included in the series III (the
OPTIMA series) study alone. Thus, it represents a large and comprehensive analysis
of APP mRNA in human brain. The diagnosis of AD was made on clinical history
and was confirmed neuropathologically. Further, all of the experiments described in
this thesis were performed at a single centre, in a blind and uniform manner, and
variables known to confound the measurement of APP mRNA, such as age of the
individual at death, tissue pH and PMI, were matched. Where possible,
polyadenylated mRNA was estimated as a measure of overall gene expression in
order to identify gene specific effects. The analysis of the ISHH experiments was
conducted with particular care: microscales were used to demonstrate that the
hybridisation signal generated could be meaningfully analysed and the image
analysis system employed was dedicated to the analysis of a single experiment until
its completion. The statistical analysis of the data was thorough and achieved with
the extensive assistance of a professional biomedical statistician. Nevertheless, a
number of deficiencies in the design and prosecution of this study remain. Firstly,
the tissue employed in this thesis was obtained, fortuitously, from a restricted
number of sources and was handled by relatively few neuropathologists; even so, not
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all of the tissue was dealt with identically. For example, tissue blocks from series I
and II were fully embedded in OCT embedding compound on a dry ice and alcohol
slurry, while tissue blocks from series III (the OPTIMA series) were mounted
unsupported on cork discs with the embedding compound. The series III tissue was,
thus, less well protected during storage and more vulnerable to thawing. Secondly,
while the inclusion of a positive control group for comparison in series III is an
advance, the group was non-homogeneous. Thirdly, the choice of cortical areas
examined obviously restricts the applicability of the findings of this study. However,
the consistent nature of the findings is reassuring and suggests that the two cerebral
areas studied are differentially affected by the disease processes examined.
The APP gene bears a stress-inducible heat shock control element in its promoter
region (Salbaum et at., 1988) and, like the heat shock genes, its expression is
up-regulated in response to cAMP (Gegelashvili et ah, 1996). APP is known to be
induced in response to stress in vitro (Abe et a/., 1991a) and in vivo (Siman et a/.,
1989). Indeed, APP synthesis and turnover increases rapidly in response to brain
injury and it is postulated that its function is either to protect or repair damaged
neurons (Bowes et al., 1994). Since the abnormal intracellular proteins that
characterise AD are a known stimulus to the heat shock proteins, it is curious that
APP is not up-regulated in AD. However, Abe and co-workers (1991b) have
demonstrated that the induction of APP in response to stress is not absolute,
confirming the complexity of the control of APP expression. Indeed, Harrison and
colleagues (1994) demonstrated a negative correlation between the abundance of
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APP-695 mRNA and that of a stress-inducible 70 kDa heat shock protein mRNA
(hsx70 mRNA) in the frontal cortex of control, AD and non-AD dementia brains.
Wolozin and colleagues (1993) studied olfactory neuroblasts from AD donors and
controls and found good agreement between APP mRNA and protein levels and no
significant disease-related differences in levels of APP mRNA or protein between
the two groups. These findings imply that, in AD, APP mRNA is translated with an
efficiency typical of that in normal cells, however, generalisation of these in vitro
conclusions may be unwise. Olfactory neuroblasts do express many neuronal
proteins, but, unlike neurons, synthesise predominantly APP-770 and APP-751
mRNA and protein, rather than APP-695 mRNA and protein. The authors do,
however, conclude that APP mRNA levels are less important in the pathophysiology
of AD than was originally thought and with this I would concur.
The fact that brain APP mRNA levels are unaltered in AD, does not, of course,
guarantee that translation of all of the splice variants of APP mRNA is accurate in
AD and proceeds with an efficiency equal to that in control tissue. Nor does it
ensure that the resulting peptide is delivered to the correct intracellular compartment
in the disease. Abundant APP, as a result of improved efficiency of translation of
APP mRNA or depressed post-translational catabolism of the nascent protein, might
lead to the enhanced production of toxic carboxyl terminal P-amyloid containing
derivatives of APP and P-amyloid (Fraser et al., 1996; Yoshikawa et al., 1992;
Rogers et al., 1992). It is clear, however, that P-amyloid production can be enhanced
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without such an increase in the APP peptide (Reaume et al., 1996). The
amyloidogenic and non-amyloidogenic processing pathways of APP are linked in
vivo (Reaume et al., 1996), probably through competition for substrate (Gandy and
Greengard, 1994). Thus, alterations in the metabolic fate of a normal amount of
APP peptide could conceivably result in an increase in the production of (3-amyloid.
Abnormal trafficking of the APP peptide, for example, such that exposure to the
usual spectrum of proteases does not occur, failure of one or more of the components
of the usual degradative pathway or the use of an alternative, or usually little used,
processing pathway might all increase P-amyloid synthesis. Alternatively,
abnormalities in the APP peptide itself might lead to the production of metabolically
disruptive metabolites (Nixon and Cataldo, 1994), as well as interfering with the
hypothesised functions of APP, such as its role in the cell membrane (Okamoto et
al., 1995) and in cell adhesion (Moya et al., 1994).
There is evidence that the balance between KPI-containing and KPl-lacking isoforms
of the APP peptide is disrupted in AD in the form of an increase in the proportion of
KPI-containing forms. Further, there is reason to believe that this disturbance might
promote amyloidogenesis. Moir and co-workers (1998) have documented a
significant increase in the proportion of KPI-containing isoforms of APP in APP
purified from the soluble subcellular fraction of AD brains in comparison to control
brains. Transgenic mice that exhibit a selective, moderate, neuronal over-expression
of APP-751 mRNA and protein develop hippocampal and cortical extracellular
p-amyloid immunoreactive deposits (Quon et al., 1991). In contrast, preliminary
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data suggests that such mice over-expressing the APP-695 mRNA and protein do not
exhibit such pathology (Quon et al., 1991). KPI-containing isoforms of the APP
peptide have been documented to impair a secretase cleavage of APP (Ho et al.,
1996) and to form complexes with proteolytic peptides, thus potentially altering the
spectrum of proteases available to cleave APP. A metabolically relevant interaction
between KPI-containing isoforms of APP and lysosomal enzymes has also been
proposed (Benowitz et al., 1989). Of course, a relative deficiency of non-KPI APP
protein species might also interfere with the neuroprotective functions proposed for
a secretase cleaved APP-695 protein (Jin et al., 1994).
An alteration in the ratio of KPI-encoding to non-KPI APP mRNA species might
underlie any change in the ratio of KPI-containing to KPI-lacking APP isoforms in
AD. However, this study does not support an alteration in the ratio of
KPI-containing transcripts of APP mRNA relative to non-KPI APP mRNA in the
disease. KPI-encoding APP mRNA transcripts do, however, increase relative to
APP-695 mRNA transcripts with age in the visual cortex. This increase in ratio
might be one mechanism whereby age predisposes to AD and further supports the
belief that an increase in KPI-containing APP isoforms is a risk factor for AD. In
addition, a relative increase in KPI-containing APP mRNA would be predicted to
selectively alter the insert junction ratio in the dentate gyrus and hippocampal
subfield CA1, the insert junction ratio in the visual cortex being resistant to such
changes. Thus, the dentate gyrus and hippocampal subfield CA1, would be expected
to exhibit greater pathology than the visual cortex should the balance of
KPI-containing to KPI-lacking isoforms of APP be important in the pathophysiology
of AD, and indeed they do.
The genetic abnormalities underlying the majority, if not all, of the forms of AD
inherited in an autosomal dominant fashion with complete penetrance have now
been identified (Sandbrink et a/., 1996). Given the evidence, exploration of APP
mRNA levels in AD was an obvious and compelling research topic, however, this
study implies that further investigation of APP transcription in AD is likely to prove
fruitless and would be ill advised. In AD it would appear that abnormalities at the
level of the efficiency of translation of KPI-encoding transcripts of APP mRNA, at
the earliest, result in the proposed increase in KPI-containing isoforms of the APP
peptide hypothesised to be crucial to enhanced P-amyloid production. The most
profitable avenues for future research in AD would seem to be determination of the
abundance of KPI-containing and non-KPI isoforms of the APP peptide in neuron's
and investigation of the cellular handling of these nascent APP forms.
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Chapter 6
Ubiquitin-Dependent Non-Lysosomal Proteolysis is not
Enhanced in Established Alzheimer's Disease
6.1 Introduction
Ubiquitin is a seventy-six amino acid polypeptide first identified during the isolation
and characterisation of thymopoietin I and II from bovine thymus (Goldstein et al.,
1975). The newly discovered polypeptide was originally labelled ubiquitous
immunopoietic polypeptide, since it was capable of inducing differentiation of not
only pro-thymocytes, but also B cells, and appeared to be universally represented in
living cells. Ubiquitin is found not only in all animal cells, but also in yeast, bacteria
and higher plants (Goldstein et al., 1975), and, indeed, has been shown to be fully
conserved between the two orders of mammals from cattle to man (Schlesinger and
Goldstein, 1975). The rigorous conservation of ubiquitin over this immense
evolutionary time span hints at its vital role within cells (Goldstein et al., 1975; St
John et al., 1986). In evolutionary terms, the appearance of ubiquitin antedates even
such early developments as karyon formation that occurred far in advance of the
regulation of cells by nerve networks and endocrine signals (Goldstein et al., 1975).
Ubiquitin is found in the cytoplasm and the nucleus (Lund et al., 1985) and has been
implicated in both lysosomal and non-lysosomal proteolysis (Gropper et al., 1991;
Ciechanover et al., 1984a). Within eukaryotic cell nuclei 10% of histone H2A and
1-2% of histone H2B are ubiquitinated at a defined lysine residue (Morimoto et al.,
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1993). Ubiquitinated histones are preferentially associated with transcribed genes,
implying that ubiquitin-mediated proteolysis of chromosomal proteins may be
involved in the regulation of gene expression (Ciechanover et al., 1984a), though this
remains controversial (Morimoto et al., 1993). Indeed, the slow turnover of histones
suggests that the function of ubiquitin conjugation of histones may be unrelated to
proteolysis (Finley et al., 1984). Cytoplasmic ubiquitin is part of the ATP-dependent
ubiquitin/25S proteasome system that is the major means of disposing of abnormal
and short-lived intracellular protein (Ciechanover el al., 1984a). A functional
ubiquitin conjugating system also appears to be necessary for lysosomal biogenesis
and maturation (Lenk et al., 1992; Low et al., 1993) and for the enhanced
degradation of endogenous long-lived proteins by lysosomal autophagy that is
induced in response to cellular stress (Gropper et al., 1991).
The efficient removal of abnormal and expired proteins is crucial to cellular survival,
especially so for post-mitotic, terminally differentiated cells like neurons that cannot
dilute out unwanted proteins through division and replication. The intracellular
precipitation of abnormal proteins could conceivably interfere with protein synthesis,
intracellular transport and the assembly of ribosomes and other macromolecular
complexes (Bond and Schlesinger, 1985), and embarrass dynamic fibrous structures
such as chromatin and the cytoskeleton (Finley et al., 1984). Of course,
immunochemical and histochemical studies have demonstrated that neurons are rich
in lysosomes and lysosomal enzymes (Nixon et al., 1992) whose constitutive
function is proteolysis (Ciechanover et al., 1984a). However, it is only under
conditions of nutritional deprivation that significant degradation of short-lived and
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abnormal proteins is carried out by these organelles (Ciechanover et al., 1984a).
Under basal metabolic conditions it is clear that the degradation of the majority of
such proteins is non-lysosomal (Ciechanover et al., 1984b). Cells from the mouse
mammary cell line, ts85, that bear a mutant, thermolabile ubiquitin-activating
enzyme, fail to degrade abnormal and otherwise short-lived proteins at
non-permissive temperatures (Finley et al., 1984). Studies of this mutant imply that
the contribution of ubiquitin-independent proteolysis to the breakdown of short-lived
and aberrant proteins is no more than 10% and probably less (Ciechanover et al.,
1984b).
Ubiquitin is an essential component of non-lysosomal, ATP-dependent proteolysis.
The carboxyl terminal glycine residue of ubiquitin is conjugated to a wide variety of
substrate proteins through an isopeptide bond with the s-amino groups of lysine
residues in the substrate (Ciechanover el al., 1984a). St John and co-workers (1986)
hypothesise that the requirement that ubiquitin interact with many different proteins
has prohibited mutations which might interfere with this capacity, resulting in the
extreme amino acid conservation exhibited by ubiquitin. One or more ubiquitin
molecules may be conjugated to a single protein molecule in preparation for its
proteolytic degradation (Bond and Schlesinger 1985). This process has an absolute
requirement for metabolic energy (Ciechanover et al., 1984a). It is believed that
ATP is needed, not for what is essentially an exothermic reaction in thermodynamic
terms, but to fuel the precise nature of such protein degradation (Ciechanover et al.,
1984a). ATP is also required for the enzymatic degradation of the protein moiety of
the ubiquitin-protein conjugate (Hershko et al., 1984).
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Ubiquitin is a member of the multi-gene, heat shock protein family (Bond and
Schlesinger, 1985; Finley and Varshavsky, 1985; Nowak et al., 1990). The heat
shock proteins are produced by cells on exposure to thermal stress, and in response to
viral infection, amino acid analogues, DNA damage, ethanol and heavy metals
(Mosser et al., 1990; Ananthan et al., 1986). The cells react by increasing the
amount, or activity, of a transcription factor that is specific for the heat shock genes
and the metabolic effort of the cell is re-directed to the production of the heat shock
proteins (Bond and Schlesinger 1985). Kinouchi and colleagues (1993) draw
attention to the substantial body of evidence in support of a protective role for the
heat shock proteins in cellular injury (see also Kiang and Tsokos, 1996 for review).
Kiang and Tsokos (1996) favour the 70 kDa heat shock proteins (Hsp70) as the
likely mediators of this protective effect. Induction of Hsp70 heat shock proteins in
neurons is associated with the acquisition of tolerance against subsequent injury (see
Kiang and Tsokos, 1996 for review). However, the unique induction kinetics
demonstrated for different members of the heat shock protein family suggests that
other heat shock proteins are necessary for this effect (Higashi et al., 1994). It is
likely that several classes of heat shock proteins act in concert in response to cellular
stress (Kinouchi et a/., 1993; Higashi et al., 1994). Further, the profile of heat shock
protein induction may be organ specific following a comparable stress (Nowak et al.,
1990). The induction of ubiquitin in response to stresses as diverse as ischaemia and
hyperthermia occurs largely in concert with the induction of Hsp70 in vivo in rodent
brain, though Hsp70 is more readily detected than ubiquitin in this model in response
to hyperthermia (Nowak et al., 1990). The inclusion of the ubiquitin genes in the
heat shock regulon is not unexpected. Heat stress particularly, would be predicted to
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result in an increase in the production of misfolded and denatured proteins that
increase the demands on the proteolytic capacity of the cell (Bond and Schlesinger,
1985).
The final common pathway that results in activation of the heat shock genes appears
to be the accumulation of abnormal protein forms in response to an unphysiological
milieu (Ananthan et al., 1986). Ananthan and co-workers (1986) demonstrated that
denatured, but not native, proteins microinjected into Xenopus oocytes resulted in the
activation of transcription of the heat shock genes. The key regulatory protein in the
heat shock response is believed to be the heat shock factor (HSF) which binds to a
highly conserved c/.v-acting sequence, the heat shock element, that is present in the
promoters of heat-induced genes. This heat shock element is composed of three
repeats of a five base module nGAAn (See Wu et al., 1990 for review). HSF not
only pre-exists, but is pre-localised to the nucleus, thus minimising the delay in
initiating heat shock transcription in response to stress, though how HSF is directed
to, and maintained, in this cellular compartment is unknown (Westwood et al., 1991).
On heat shock, HSF undergoes oligomerisation from an inactive monomer to an
active multimer (Westwood et al., 1991). This transformation may be as a result of
heat-induced phosphorylation of HSF (Larson et al., 1988) or, alternatively, the
fourth leucine zipper motif, unique to mammalian HSF, could be involved in
intermolecular and intramolecular interactions that determine the oligomerisation
state of HSF (Westwood et al., 1991). It is conceivable that the oligomeric form of
HSF affords better contact with the triplicated nGAAn module of the heat shock
element than monomeric HSF (Westwood et a/., 1991). However, high levels of
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DNA-binding of HSF are insufficient to induce heat shock transcription and a
constitutive heat shock element binding factor also appears to be involved in the
regulation of heat shock transcription (Liu et al., 1993). Crucially, HSF also binds to
loci repressed during heat shock suggesting a role for this factor in the repression of
normal gene activity during heat shock (Westwood et al., 1991).
Evidence exists in support of four theories concerning the activation of cryptic,
monomeric non-DNA binding HSF, in response to an accumulation of abnormal
intracellular protein, that account for the homeostatic nature of the heat shock
response. Firstly, it is proposed that the unphysiological milieu alters the
conformation of HSF directly, resulting in its activation (Mosser et al., 1990).
Secondly, Ananthan and colleagues (1986) hypothesise that while HSF exists
predominantly in an inactive form in unstressed cells, the active form is present, but
is labile. On heat shock, denatured proteins amass and are degraded in preference to
the labile, active form of HSF, which accumulates and activates the heat shock
genes. Thirdly, it is suggested that HSF in unstressed cells may be prevented from
adopting its active, DNA-binding form because it is held in a complex with Hsp70
(Abravaya et al., 1992). On heat shock, a pool of denatured and malfolded proteins
accumulate and compete with HSF for binding to Hsp70 (Abravaya et al., 1992;
Mosser et al., 1990). The released HSF oligomerises and acquires DNA-binding and
transcriptional activity (Abravaya et al., 1992). Finally, Munro and Pelham (1985)
advance the theory that during heat shock the demands on the ubiquitin proteolytic
system are so great that there is a failure to ubiquitinate a critical factor, perhaps even
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HSF itself, and that this non-ubiquitinated factor promotes transcription of the heat
shock genes.
Abnormal protein conformations in the form of NFTs, amyloid plaques and
meningovascular amyloid characterise AD. In AD, antibodies directed against
ubiquitin strongly stain NFTs, the distended neurites associated with senile plaques
and a subset of neuronal processes, distinct from senile plaques or NFTs, suggesting
that these structures are highly ubiquitinated (Perry et al., 1987). Why such substrate
proteins are not subsequently degraded is unclear (Perry el al., 1987). Mori and
co-workers (1987) observe that tangle-bearing neurons are actively ubiquitinating
them and postulate that at some stage in the degenerating process such neurons
should exhibit expression of the heat shock proteins in response to the accumulation
of abnormal protein. Indeed, Harrison and co-workers (1993) documented an
increase in the mRNA of a specific 70 kDa heat shock protein, hsx70, in frontal
cortex white matter in AD and non-AD dementias. Importantly, the authors found no
correlation in this study between hsx70 mRNA levels and agonal state factors such as
coma and pyrexia (Harrison et al., 1993).
This study aimed to examine the expression of ubiquitin, using ISHH, in two brain
areas differentially affected by AD: the visual cortex and the hippocampus. It was
hypothesised that ubiquitin up-regulation would be an early feature of Alzheimer
diseased cells in response to the increase in aberrant protein forms that is
characteristic of the disease. AD progression, it was proposed, would be associated
with failure of the ATP-dependent non-lysosomal pathway and a fall in ubiquitin
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mRNA levels. It would appear likely that failure of a system that displays such
striking evolutionary' conservation as the ubiquitin proteolytic pathway, would
severely compromise the capacity of an organism to withstand cellular stress
(Heydari el al., 1993). Indeed, genetic evidence supports the view that an intact
ubiquitin conjugating system is essential for cellular survival (Wu et al., 1981).
6.2 Materials and Methods
6.2.1 Introduction
These experiments were performed with the assistance of Miss J.M. Heffernan and
Mr. M.W. Sanders on brains from series III (the OPTIMA series) as detailed in
chapter 2. Details of all of the cases used are presented in appendix II. Summarised
demographic and post-mortem information is presented in the tables relating to the
OPTIMA tissue, tables 5.4 and 5.5 on pages 226 and 227 respectively. The brains
were prepared and hybridised as described in chapter 2.
6.2.2 Oligodeoxynucleotide Probe Selection
The human genome contains numerous copies of the ubiquitin sequence (Wiborg et
al., 1985). Three bands, corresponding to splice variants of ubiquitin mRNA of 651,
1100 and 2500 nucleotides long, that are labelled ubiquitin A, ubiquitin B and
+
ubiquitin C respectively, are visible on Northern blotting of poly(A) mRNA
extracted from human brain (Wiborg et al., 1985; Lund et al., 1985). Ubiquitin A
encodes one, ubiquitin B three and ubiquitin C nine copies of ubiquitin. At least two
splice variants of ubiquitin A mRNA exist that code for a single sequence of
ubiquitin fused at its carboxyl terminus to a non-ubiquitin peptide sequence (Lund et
al., 1985; Salvesen et al., 1987). Lund and co-workers (1985) identified a 516 base
pair cDNA corresponding to amino acids five to seventy-six of the ubiquitin
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sequence, an eighty amino acid carboxyl terminal extension, a 3' untranslated region
+
and a poly(A) tail. This carboxyl tail extension is unique to ubiquitin A and
suggests that this isoform is synthesised as a precursor. Salvesen and colleagues
(1987) isolated a different, smaller cDNA clone encoding residues forty to
seventy-six of ubiquitin along with a carboxyl terminal extension. Salvesen and
co-workers (1987) sequence of ubiquitin A differs at only one base from a region of
the sequence, published by Wiborg and co-workers (1985), encoding the nomeric
form of ubiquitin, ubiquitin C. The ubiquitin C gene is highly unusual. Firstly, it
encodes a polypeptide containing nine direct repeats of the ubiquitin sequence,
uninterrupted by spacer sequences, and, secondly, there are no introns in the coding
region. Thus, for the first eight repeats of the ubiquitin sequence in ubiquitin C, the
terminal glycine of one sequence is followed immediately by the first amino acid,
methionine, of the next ubiquitin sequence. The ubiquitin B gene, containing three
head to tail repeats of the ubiquitin sequence, was isolated and characterised by
Baker and Board (1987a), along with two processed ubiquitin B pseudogenes. The
existence of a third ubiquitin B processed pseudogene (Baker and Board, 1987b) and
a ubiquitin B tetrameric non-processed pseudogene (Cowland el al, 1988) has been
demonstrated.
The region of maximum homology between the ubiquitin A sequence characterised
by Lund and co-workers (1985) and the other three ubiquitin sequences was
identified. However, since any thirty nucleotide sequence within this region
contained a minimum of six mismatches between this ubiquitin A sequence and the
other three splice variants of ubiquitin mRNA, it was necessary to design two
oligodeoxynucleotide probes to ensure that all known forms of human ubiquitin
mRNA were detected. A sense oligodeoxynucleotide probe, with a base sequence
identical to the mRNA region of interest and in the same orientation, was designed
for each of the antisense oligodeoxynucleotide probes.
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The main oligodeoxynucleotide probe, labelled ubiquitin C, was designed to
hybridise to ubiquitin mRNA of all three known molecular weights. The ubiquitin C
oligodeoxynucleotide probe was directed against bases 168 to 198 of the sequence
published by Wiborg and co-workers (1985) and, with two mismatches, to bases 168
to 198 of the sequence published by Baker and Board (1987a). The ubiquitin C
oligodeoxynucleotide probe also matched bases 53 to 82 of the ubiquitin A sequence
published by Salvesen and colleagues (1987) with one mismatch. The second
oligodeoxynucleotide probe, designed to hybridise to the ubiquitin A sequence of
Lund and colleagues (1985) alone, was directed against bases 136 to 165 of their
published sequence. This oligodeoxynucleotide probe was labelled ubiquitin A. The
two oligodeoxynucleotide probes were as follows:
Ubiquitin C Antisense GGT GGA CTC TTT CTG GAT GTT GTA GTC AGA
Ubiquitin A Antisense CTG GAA GAT GGA CTG ACT TTG TCT GAC TAC
6.2.3 Experimental Controls
Dr. P.R. Heath demonstrated the specificity of the ubiquitin C and ubiquitin A
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oligodeoxynucleotide probes using Northern blotting with a [ PjdATP-labelled
probe hybridised to 25 pg total RNA extracted from the frontal cortex of a control
subject (Figure 6.1). The ubiquitin C oligodeoxynucleotide probe detected three
bands of approximately 2.5, 1.35 and less than one kilobase, and the ubiquitin A
oligodeoxynucleotide probe detected a single band of less than one kilobase, in
keeping with published data (Wiborg et al., 1985; Lund et al., 1985).
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Figure 6.1 Northern blot performed by Dr. P.R. Heath demonstrating the
specificity of the ubiquitin C and ubiquitin A oligodeoxynucleotide probes. The
oligodeoxynucleotide probes were labelled with [32P]-dATP and hybridised to 25 pg
total RNA extracted from the frontal cortex of a neurologically normal control.
Lane 1 RNA molecular weight ladder (Gibco BRL).
Lane 2 Sample total RNA.
Lane 3 Sample total RNA.
Lane 4 [32P]-dATP labelled ubiquitin C oligodeoxynucleotide probe.
Lane 5 [":P]-dATP labelled ubiquitin C oligodeoxynucleotide probe.
Lane 6 [?2P]-dATP labelled ubiquitin A oligodeoxynucleotide probe.
Lane 7 [32P]-dATP labelled ubiquitin A oligodeoxynucleotide probe.
The open triangles on the right of the photograph indicate the position of the
observed bands.
The ubiquitin C oligodeoxynucleotide probe detected three bands of approximately
2.5, 1.35 and less than 1.35 kilobases.
The ubiquitin A oligodeoxynucleotide probe detected a single band of less than 1.35
kilobases.
1 2 3 4 5 6 7
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In situ hybridisation histochemistry of the series III (the OPTIMA series) visual
cortex and hippocampus with the ubiquitin C and ubiquitin A antisense
oligodeoxynucleotide probes was accompanied by concurrent hybridisation of
adjacent sections with the sense oligodeoxynucleotide probes for ubiquitin C (Figure
6.2) and ubiquitin A (Figure 6.3). The addition of 100-fold excess of unlabelled
probe and pre-treatment of sections with ribonuclease led, in both cases, to the
abolition of signal for the ubiquitin C and ubiquitin A antisense
oligodeoxynucleotide probes. The autoradiograms generated by the above cold
displacement and ribonuclease pre-treatment experiments were completely blank
(data not shown).
6.2.4 In Situ Hybridisation Histochemistry
The hybridised sections were incubated for approximately 18 hours at 26°C for both
the ubiquitin C and the ubiquitin A oligodeoxynucleotide probes. The slides were
then washed in 1 x SSC (4x15 minute washes) at 51.5°C for both
oligodeoxynucleotide probes. These washes were then followed by 2 x 60 minute
washes at room temperature. Once dry, the hybridised sections were placed against
film (Hyperfilm-Pmax, Amersham) at room temperature for between 52 and 79 days
to generate autoradiograms (Figures 6.2 and 6.3).
6.2.5 Quantification of ISHH Signal
Quantitative assessment of ISF1H signal, reflecting the abundance of the mRNAs
detected by the ubiquitin C and ubiquitin A oligodeoxynucleotide probes, was made
on the autoradiograms using an image analysis system (Seescan Pic, Cambridge).
Gram counting over individual neurons was not attempted. Mean grey density was
calculated, blind to case details, over the stratum granulosum of the dentate gyrus
and over the stratum pyramidale of hippocampal fields CA1, CA3 and CA4. In the
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Figure 6.2 In situ hybridisation histochemistry using [35S]dATP labelled
oligodeoxynucleotide probes performed on sections of visual cortex from the same
case of non-AD dementia from series III (the OPTIMA series). The images
presented are direct photographs of transilluminated autoradiograms generated from
this single case and hybridised with the following oligodeoxynucleotide probes. The
blacker the image of the autoradiogram the greater was the exposure of the
autoradiographic film to radioactivity and the more intensely labelled was the
section.
A Ubiquitin C antisense oligodeoxynucleotide probe.
B Ubiquitin C sense oligodeoxynucleotide probe.
C Ubiquitin A antisense oligodeoxynucleotide probe.
D Ubiquitin A sense oligodeoxynucleotide probe.
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Figure 6.3 In situ hybridisation histochemistry using [33S]dATP labelled
oligodeoxynucleotide probes performed on hippocampal sections from the same case
of borderline AD from series III (the OPTIMA series). The images presented are
direct photographs of transilluminated autoradiograms generated from this single
case and hybridised with the following oligodeoxynucleotide probes. The blacker
the image of the autoradiogram the greater was the exposure of the autoradiographic
film to radioactivity and the more intensely labelled was the section.
A Ubiquitin C antisense oligodeoxynucleotide probe.
B Ubiquitin C sense oligodeoxynucleotide probe.
C Ubiquitin A antisense oligodeoxynucleotide probe.
D Ubiquitin A sense oligodeoxynucleotide probe.
c D
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visual cortex a strip of tissue perpendicular to the cortical surface was selected for
measurement of the mean grey density. Areas of the tissue where the stria of
Gennari were visible were preferred. The mean value from each set of triplicates
was used for all subsequent calculations.
6.2.6 Statistical Analysis
All statistical analysis was performed using SPSS for Windows version 6.0. A one
way ANOVA was used to analyse the four diagnostic groups. Where Levene's test
for homogeneity of variance was not significant, it was assumed that the
requirements of the one way ANOVA had been met. Where Levene's test was
significant, it was assumed that the requirements for the parametric test had been
violated and the data was examined using the non-parametric Kruskal-Wallis one
way ANOVA.
Correlation matrices were constructed using both Pearson's correlation coefficient
and Spearman's rank correlation coefficient. When the two tests were in agreement,
the result was accepted, when a discrepancy was observed, the data was analysed
further, as detailed in the text.
6.2.7 The Relationship between Radioactive Exposure and Greyness of
Radiographic Film
14C microscales were opposed to the radiographic films alongside sections from all
four of the ubiquitin experiments performed in this study, allowing examination of
the relationship between exposure of the film to radioactivity and its resulting
greyness. The l4C microscales were supplied complete with information regarding
the absolute radioactivity contained withii each active layer of the polymer. The
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estimated tissue equivalent radioactivity (ETR) was also supplied for each active
layer of the polymer. This value is an estimate of the radioactivity inherent in an
apparently equally radioactive tissue sample, adjusted for the autoabsorptive nature
of tissue. A series of calibration curves were constructed depicting the relationship
between the radioactivity inherent in the 14C microscales and the corresponding
greyness of the exposed radiographic films. The ETR, rather than the absolute
radioactivity, of the l4C microscales was used to construct these curves, since it was
hoped that they might ultimately be used to estimate the radioactivity inherent in the
ISHH sections used in this study. Clearly, to use the absolute radioactivity to
construct the calibration curves would be to underestimate the radioactivity inherent
in the ISHH tissue sections.
Traditionally, the greyness of an autoradiographic film, as measured by specialised
image analysis equipment, has been converted to an optical density reading; the
optical density of a direct autoradiogram being linearly related to its exposure to
radioactivity over a limited range (Laskey, 1993). However, it was clear from the
calibration curves generated during this study that there was considerable spread of
the data about the line of best fit relating optical density to radioactive exposure. In
addition, at low levels of radioactive exposure, such as when tissue sections
hybridised with the sense oligodeoxynucleotide probes were opposed to radiographic
film, the relationship between optical density and radioactive exposure clearly ceased
to be linear.
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Using the traditional formula, the correction of antisense AOD readings for
non-specific binding using the AOD of the corresponding sense
oligodeoxynucleotide probe is also problematic. Since the difference between the
log of two numbers is the log of their ratio (Bland and Altman, 1996), the expanded
traditional formula for negative optical density, corrected for non-specific binding,
takes the following form:
Optical density = logl 0
255




mean grey level sense
Optical density = logl 0
^255/mean grey level antisense^
255/mean grey level sense
Optical density = log 10
^ 2 5 5 x mean grey level sense A
255 x mean grey level antisense
Optical density = log 10
/
mean grey level sense
mean grey level antisense
Optical density = logl 0(mean grey level sense) - logl 0(mean grey level antisense)
Thus, according to the above formula it appears that it is not necessary to calculate
the optical density of the sense and antisense oligodeoxynucleotide probes
individually.
364
6.2.8 An Improved Formula Relating Radioactive Exposure to Greyness
of Radiographic Film
In the course of this study an alternative formula was devised relating radioactive
exposure to the consequent greyness of radiographic film. In three out of the four
ubiquitin experiments performed this resulted in improved adherence of the data to
the line of best fit and in two increased the range over which radioactive exposure
and greyness of film were linearly related. The mean grey level obtained for each
radioactive layer of the polymer was subtracted from the mean grey level assigned to
incident light (assumed to be pure white light with a greyness of 255) and the
resulting value was logged to the base 10. A linear relationship was obtained
between this value and the loglO(ETR). Thus, the formula is as follows:
loglO(ETR) = log 10(255 - mean grey level)
Thus, the antilog of logl 0(255 - mean grey level) gives an estimate of the strength of
radioactivity found in each section, whether hybridised with a sense or antisense
oligodeoxynucleotide probe, and correction for non-specific binding using this
formula is accurate and intuitive.
The application of the alternative formula, and its comparison with the traditional
formula, to each of the ubiquitin experiments is detailed below.
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6.2.9 Application of the Alternative Formula to the Analysis of the
Ubiquitin Oligodeoxynucleotide Probes
6.2.9.1 The Ubiquitin C Oligodeoxynucleotide Probe in the Visual Cortex
Alongside the sections of visual cortex hybridised with the ubiquitin C
oligodeoxynucleotide probe were l4C microscales RPA 504 and RPA 511. Image
analysis of the autoradiogram generated by the 14C microscales resulted in a mean
grey level for each radioactive layer of the polymer from which was calculated its
corresponding AOD. The ETR for each layer of the polymer was plotted against the
AOD generating a straight line graph with the equation y = 189.38x + 3.97 (Figure
6.4). On inspection of the points plotted it was clear that there was considerable
spread of the data about this line of best fit and, at low AOD readings especially, the
points plotted fell sharply away from this line. The mean grey level for each layer of
the polymer was substituted into the alternative formula: log 10(255 - mean grey
level) and the resulting value plotted against the loglO(ETR). When transformed in
this way, the points adhered closely to a line of best fit with the equation y = 1,3x -
0.87 (Figure 6.5). The straight line fit of the data was highly significant (p < 0.001).
Further, R", a summary measure of goodness of fit, was larger (0.999) for the
alternative formula than for the traditional formula (0.987), confirming that the
alternative formula was superior. It was decided, therefore, to use the alternative
formula to convert the raw mean grey levels obtained for the ubiquitin C sense and
antisense oligodeoxynucleotide probes in the visual cortex to a loglO(ETR) reading.
The antilog of this value, giving an estimate of the radioactivity inherent in the
section, the ETR, was obtained for all of the sense and antisense mean grey levels.
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The antisense sections were then corrected for non-specific binding by subtracting
the sense ETR from the antisense ETR.
A problem was encountered in analysis of the ubiquitin C antisense
oligodeoxynucleotide probe in the visual cortex. Radioactive exposure eventually
saturates radiographic film so that further radioactive decay has no effect on its
greyness. A number of visual cortex sections hybridised with the ubiquitin C
antisensc oligodeoxynucleotide probe were so intensely radioactive as to lie beyond
the linear portion of the graph. Two control cases, two BAD, one AD and one
non-AD dementia case were in this category. The radioactivity of these sections
was, therefore, underestimated whichever formula was applied. However,
fortuitously, the cases to which this applied were representative of each of the
diagnostic groups studied.
6.2.9.2 The Ubiquitin C Oligodeoxynucleotide Probe in the Hippocampus
The raw mean grey levels obtained from the analysis of 14C microscales RPA 504
and RPA 511 opposed to autoradiographic film alongside the hippocampal sections
hybridised with the ubiquitin C oligodeoxynucleotide probe, were converted to AOD
readings and plotted against the corresponding ETR for each active layer of the
polymer, as above (Figure 6.6). Using this formula, the most intensely radioactive
layer of the microscales fell well beyond the portion of the graph in which
radioactive exposure and AOD were linearly related. Using the alternative formula,
however, this reading could be accommodated in the linear portion of the graph
(Figure 6.7). The AOD and logl0(255 - mean grey level) readings plotted,
















































corresponded to mean grey level values of between 0.08 and 228.85 in each case.
The equation for the line of best fit for the graph depicting the alternative formula
was y = 1.81 x-1.9 (Figure 6.7). R2 was 0.983 with a probability of p < 0.001. Thus,
the straight line fit of this data is highly significant. It would appear that the division
required by the traditional formula exaggerates small changes in mean grey level that
are minimised using the alternative formula in which the mean grey level is
subtracted from the incident light. It was decided that the alternative formula, given
its larger range, should be used in the analysis of the ubiquitin C
oligodeoxynucleotide probe in the hippocampus.
It should be noted, however, that using either formula, eleven of the available sense
readings fell beyond the linearity of the graph. It was, therefore, impossible to
correct accurately for non-specific binding using a case-specific sense strand. A
global reading for non-specific binding, calculated from the cases where the
logl 0(255 - mean grey level) of the sense section did fall within the linear part of the
graph, would have resulted in the same value being subtracted from each antisense
reading. As there appeared to be no merit in this, the ubiquitin C probe in
hippocampus was not corrected for non-specific binding. However, given that the
tissue sections hybridised with the sense ubiquitin C oligodeoxynucleotide probe
produced autoradiograms that were universally and uniformly pale, this was deemed
acceptable. In addition, despite the larger range of the alternative formula, one
hippocampal section hybridised with the ubiquitin C antisense oligodeoxynucleotide
probe remained too intensely stained to be accommodated within the linear portion
of the graph.
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6.2.9.3 The Ubiquitin A Oligodeoxynucleotide Probe in the Visual Cortex
Unfortunately, only the 14C microscale Code RPA 504, composed of layers of 14C
polymer of actual radioactivity of between 104 to 0.1 nCi/g, was available for the
ubiquitin A experiment in the visual cortex. A linear relationship was demonstrated
both between the AOD and the ETR using the traditional formula (Figure 6.8) and
between the logl0(255-mean grey level) and loglO(ETR) using the alternative
formula (Figure 6.9). The range over which these relationships remained linear was
similar for both formulae and all of the sense and antisense readings obtained from
the ubiquitin A experiment in visual cortex could be accommodated within the linear
portions of both graphs. However, using the traditional formula the equation of the
line was y = 136.15x + 5.36, R2 was 0.980 and the significance was p = 0.001. Using
the alternative formula, the equation of the line was y = 1.33x - 1.03, R" was 0.998
and the significance was p < 0.001. Thus, the alternative formula was judged to be
superior. The alternative formula was used to convert all of the antisense and sense
mean grey levels to logl 0(255 - mean grey level) and the antisense ETR readings
were then corrected for non-specific binding, as above.
6.2.9.4 The Ubiquitin A Oligodeoxynucleotide Probe in the Hippocampus
Plotting of AOD against ETR for the 14C microscales accompanying the UB A
experiment in the hippocampus generated a straight line with the equation y =
211.62x + 6.44 (Figure 6.10). R2for this line of best fit was 0.992 and the
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The value of logl0(255 - mean grey level) was plotted against loglO(ETR) and
generated a straight line graph with the equation y = 1.1 Ox - 0.04 (Figure 6.11). R2
for this line of best fit was 0.995 and the significance was p < 0.001, suggesting that
the alternative formula was superior. The linear portion of the two graphs covered an
equal range. The alternative formula was, therefore, used in the analysis of the
ubiquitin A oligodeoxynucleotide probe in the hippocampus.
One section labelled with the ubiquitin A sense oligodeoxynucleotide probe was too
pale to be accommodated within the linear portion of either scale and four cases
labelled with antisense probe did not have a section labelled with the corresponding
sense oligodeoxynucleotide probe. Therefore, an average mean grey level was
calculated for the sections hybridised with ubiquitin A sense oligodeoxynucleotide
probe. This value was used to correct for non-specific binding in those four cases
that lacked a corresponding sense section and the one case whose sense section was
too pale to be converted accurately to an ETR. In hippocampal subfield CA4, the
sense ETR was greater than the antisense ETR for four of the studied cases. In these
cases the antisense ETR was recorded as zero, since subtracting the sense ETR from
the antisense ETR would otherwise have resulted in a negative value for the ETR of
the sample sections. Three antisense readings, corrected for non-specific binding,
were too dark to be accommodated on the linear portion of the graph. These cases
included a control case, a BAD case and an AD case. Since only three cases were
involved and three of the four diagnostic groups represented, it was accepted that the
radioactivity inherent in these sections would be underestimated using either
formula.




















The ETR of the ubiquitin C and ubiquitin A oligodeoxynucleotide probes did not
vary significantly with the sex of the subjects.
6.3.2 Analysis of the Ubiquitin C and Ubiquitin A Oligodeoxynucleotide
Probes in the Visual Cortex
No significant differences in the ETR of the ubiquitin C oligodeoxynucleotide probe
were identified in visual cortex between the four diagnostic groups using a one way
ANOVA (Figure 6.12). The Levene test for homogeneity of variance was not
significant.
The ETR of the ubiquitin A oligodeoxynucleotide probe in visual cortex was
compared between the four diagnostic groups using a one way ANOVA. No
significant differences were observed between the groups (Figure 6.13). The Levene
test for homogeneity of variance was not significant.
6.3.3 Analysis of the Ubiquitin C and Ubiquitin A Oligodeoxynucleotide
Probes in the Hippocampus
A one way ANOVA was performed to examine the ETR of the ubiquitin C
oligodeoxynucleotide probe in the hippocampus (Figure 6.14). No significant
differences were observed between the four diagnostic groups in the ETR of this
oligodeoxynucleotide probe in hippocampal subfields CA4 and CA1. In the dentate
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gyrus and hippocampal subfield CAS, however, the Levene test for homogeneity of
variance was significant, suggesting that the requirements of the one way ANOVA
had not been met. In each case the non-parametric Kruskal-Wallis one way ANOVA
was not significant.
A one way ANOVA failed to demonstrate any significant differences between the
four diagnostic groups in the ETR of the ubiquitin A oligodeoxynucleotide probe in
the any of the hippocampal regions examined (Figure 6.15). The Levene test for
homogeneity of variance was not significant.
6.3.4 Analysis of the Ubiquitin C and Ubiquitin A Oligodeoxynucleotide
Probes in the Visual Cortex when Expressed as a Ratio with the
Poly(dT) Oligodeoxynucleotide Probe
The AOD of the poly(dT) oligodeoxynucleotide probe had been measured in series
III (the OPTIMA series) visual cortex and the ETR of the ubiquitin C and A
oligodeoxynucleotide probes in the visual cortex were expressed as a ratio of the
AOD of all polyadenylated mRNA in this region (Figure 6.16). It was considered
legitimate to do this, since though the units are different, the numerator was
consistently AOD units and the denominator was consistently ETR units, and the
ratio was not to be used in any subsequent calculations. The ubiquitin C/poly(dT)
ratio differed significantly between the four diagnostic groups (p = 0.035). The
Levene test for homogeneity of variance was not significant. Tukey's honestly
significant difference test was applied and indicated that the ubiquitin C/poly(dT)
ratio in the BAD cases was significantly higher than this ratio in the control or AD
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cases (Figure 6.16). The ubiquitin A/poly(dT) ratio, however, did not differ
significantly between the four diagnostic groups. The Levene test for homogeneity
of variance was not significant for the ubiquitin A/poly(dT) ratio in the visual cortex
(Figure 6.17).
6.3.5 Correlations Identified on Analysis of the Ubiquitin
Oligodeoxynucleotide Probes
6.3.5.1 Correlations Involving the Ubiquitin C and Ubiquitin A
Oligodeoxynucleotide Probes in the Visual Cortex
A correlation matrix comprising thirty-three cells was prepared to examine the
relationships, if any, between the ETR of the ubiquitin C and ubiquitin A
oligodeoxynucleotide probes in the visual cortex and the age and mini-mental state
scores of the subjects, the PMI, pH, storage and severity of neuropathology of the
tissue, and the abundance of mRNAs detected by the APP-695, APP-insert, APP-770
and poly(dT) oligodeoxynucleotide probes. A Spearman's rank correlation matrix
was prepared for comparison. Correlations, discussed below, were identified
between the ETR of the ubiquitin A oligodeoxynucleotide probe, in visual cortex,
and both tissue pH and mean hippocampal neuritic plaque frequency. However, no
significant correlations were identified between the ETR of the ubiquitin A or C
probes and the age and mini-mental state scores of the subjects or between these
probes and the PMI and storage of the tissue. No significant correlations were
identified between these probes and any neuropathological measure apart from that
with the mean hippocampal neuritic plaque frequency referred to above. Therefore,
correlation statistics relating only to associations between the various
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oligodeoxynucleotide probes measured are presented in tables 6.1 and 6.2. Data
regarding correlations between the ubiquitin C and ubiquitin A oligodeoxynucleotide
probes are presented in both correlation tables for ease of reference.
Both the parametric and non-parametric tests concurred that the ETR of the ubiquitin
C oligodeoxynucleotide probe was positively correlated with the AOD of the
APP-695 probe (0.813; p < 0.001), the AOD of the APP-insert probe (0.810;
p < 0.001) and the ETR of the ubiquitin A probe (0.868; p < 0.001). On
non-parametric analysis alone, the ETR of the ubiquitin C probe was positively
correlated with the AOD of the APP-770 probe (0.387; p = 0.029). Examination of a
scatter diagram suggested that these two probes were indeed correlated and that one
extreme value was responsible for the non-significance of the parametric test (Figure
6.18).
The parametric and non-parametric tests concurred that the ETR of the ubiquitin A
probe was positively correlated with the AOD of the APP-695 probe (0.865;
p < 0.001) and the AOD of the APP-insert probe (0.839; p < 0.001). Examination of
a scatter diagram suggested that the ETR of the ubiquitin A probe and the AOD of
the APP-770 probe were correlated and that three markedly outlying values were
responsible for the non-significance of the parametric test (Figure 6.19). On
parametric analysis alone, the ETR of the ubiquitin A probe in the visual cortex was
positively correlated with the pH of the tissue (0.400; p = 0.035). A scatter diagram
revealed that that two were indeed correlated and fnat fne non-significance of the
non-parametric test (0.348; p = 0.070) was probably due to the relative lack of power
Table 6.1 Pearson's Correlation Coefficients for Series
III (OPTIMA)



























































Table 6.2 Pearson's Correlation Coefficients for Series
III (OPTIMA)
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Figure 6.18 The Estimated Tissue Radioactivity of the Ubiquitin C
Oligodeoxynucleotide Probe Plotted Against the Approximate Optical Density
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Figure 6.19 The Estimated Tissue Radioactivity of the Ubiquitin A
Oligodeoxynucleotide Probe Plotted Against the Approximate Optical Density
of the APP-770 Oligodeoxynucleotide Probe in Series III (OPTIMA) Visual
Cortex
of this test (Figure 6.20). A correlation between the ETR of the ubiquitin A probe
and the mean hippocampal neuritic plaque frequency, on parametric analysis alone,
was disregarded on scrutiny of a scatter diagram (Figure 6.21). Seven cells were
significant in the matrix of thirty-three cells, a finding that is unlikely to be due to
chance, since the probability of obtaining five significant cells in a matrix of thirty
cells is p — 0.016.
6.3.5.2 Correlations Involving the Ubiquitin C and Ubiquitin A
Oligodeoxynucieotide Probes in the Hippocampus
A Pearson's correlation matrix comprising thirty-one cells was constructed to
examine the relationships, if any, between the ETR of the ubiquitin C and ubiquitin
A oligodeoxynucieotide probes in the dentate gyrus and the age and mini-mental
state scores of the subjects, the PMI, pH, storage and severity of neuropathology of
the tissue, and the abundance of the mRNAs detected by the APP-695, APP-insert
and APP-770 probes. An identical Spearman's rank correlation matrix was
constructed for comparison. Apart from a significant correlation, discussed below,
between the ETR of the ubiquitin C oligodeoxynucieotide probe, in dentate gyrus,
and the mean hippocampal NFT density, no other significant correlations were
identified between the ETR of the ubiquitin C and A probes in this region and the
age and mini-mental state scores of the subjects, the PMI, pH and storage of the
tissue or any other neuropathological parameter. Therefore, correlation statistics
relating only to associations between the various oligodeoxynucieotide probes
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Figure 6.20 The Estimated Tissue Radioactivity of the Ubiquitin A
Oligodeoxynucleotide Probe in the Visual Cortex Plotted Against Tissue pH for
Series III (OPTIMA) Cases
Figure 6.21 The Estimated Tissue Radioactivity of the Ubiquitin A
Oligodeoxynucleotide Probe in the Visual Cortex Plotted Against the Mean
Hippocampal Neuritic Plaque Frequency for Series III (OPTIMA) Cases
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the ubiquitin C and ubiquitin A oligodeoxynucleotide probes are presented in both
correlation tables for ease of reference.
Parametric and non-parametric tests concurred that the ETR of the ubiquitin C and
ubiquitin A oligodeoxynucleotide probes were positively correlated in the dentate
gyrus (p < 0.001). The ubiquitin C probe was correlated with both APP-695 (p <
0.001) and APP-insert (p = 0.001) oligodeoxynucleotide probes on both parametric
and non-parametric analysis. An additional significant parametric correlation
between the mean hippocampal NFT density and the ETR of the ubiquitin C
oligodeoxynucleotide probe in this region (Pearson's p = 0.020; Spearman's
p = 0.186) was discounted on examination of a scatter diagram (Figure 6.22). The
ubiquitin A oligodeoxynucleotide probe in the dentate gyrus positively correlated
with the abundance of APP-695 mRNA (p < 0.001) and APP-insert (p < 0.001) on
both parametric and non-parametric tests. Six significant findings in a correlation
matrix of thirty-one cells is likely to be significant, since the probability of obtaining
five significant cells in a matrix of thirty-five cells is p = 0.029.
A similar Pearson's correlation matrix and Spearman's rank correlation matrix were
prepared for hippocampal subfields CA4, CAS and CAE
No significant correlations were identified between the ETR of the ubiquitin C and A
oligodeoxynucleotide probes, in hippocampal subfields CA4, CA3 and CA1, and the
age and mini-mental state scores of the subjects or the PMI, pH, storage and severity
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of neuropathology of the tissue. Therefore, only correlation statistics relating to the
various oligodeoxynucleotide probes examined are presented in tables 6.1 and 6.2.
The ubiquitin C and ubiquitin A oligodeoxynucleotide probes were correlated on
both parametric and non-parametric tests in hippocampal subfields CA4, CAS and
CA1 (p < 0.020). In CA4 this was the only significant finding. Using both
parametric and non-parametric statistics the ETR of the ubiquitin C
oligodeoxynucleotide probe was positively correlated with the AOD of the
APP-insert probe (p = 0.018) in hippocampal subfield CA1, while in CA3 the
ubiquitin C probe was correlated with the APP-695 oligodeoxynucleotide probe (p <
0.001). Non-parametric analysis suggested that the ubiquitin C oligodeoxynucleotide
probe in CAS was also correlated with APP-insert (p = 0.016) though the parametric
test was not significant (p = 0.066). Examination of a scatter diagram suggested that
the two were indeed correlated and that a single outlying value was responsible for
the non-significance of the parametric test (Figure 6.23).
In hippocampal subfield CA1 the abundance of ubiquitin A mRNA was positively
correlated with the abundance of APP-695 mRNA (p < 0.001) and APP-insert
mRNA (p = 0.025) on both parametric and non-parametric analysis.
The correlation statistics relating to hippocampal subfields CA4, CAS and CA1
suggest that the number of significant cells are no more than would have been
expected to occur by chance.
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Figure 6.22 The Estimated Tissue Radioactivity of the Ubiquitin C
Oligodeoxynucleotide Probe in Dentate Gyrus Plotted Against the Mean
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Figure 6.23 The Estimated Tissue Radioactivity of the Ubiquitin C
Oligodeoxynucleotide Probe in Hippocampal Subfield CA3 Plotted Against the




The l4C microscales were used consistently during the analysis of ubiquitin mRNA
by ISHH in the visual cortex and hippocampus, allowing the relationship between
exposure of the films to radioactivity and their resulting greyness to be methodically
explored. Subsequently, the conversion of the mean grey levels to optical density
readings was abandoned in favour of a demonstrably superior alternative
transformation. The alternative formula used to generate an estimate of the
radioactivity inherent in the hybridised tissue sections involved transforming mean
grey levels as follows: logl0(255 - mean grey level). Mean grey levels transformed
in this way were linearly related to the loglO(ETR). Importantly, the range over
which the alternatively transformed mean grey levels were linearly related to the
logl O(ETR) was equal, or superior, to the range over which optical density was
linearly related to the ETR. Moreover, using the alternative formula scatter of the
data about the line of best fit relating logl 0(255 - mean grey level) to loglO(ETR)
was minimal. Obtaining the antilog of the logl O(ETR) was simple and allowed an
estimate of the radioactivity inherent in the section, the parameter of interest, to be
made directly, in contrast to the circuitous estimation of optical density. Further, the
radioactivity inherent in sections hybridised with antisense and sense
oligodeoxynucleotide probes could be estimated identically and correction for
non-specific binding was simple and intuitive. However, this promising, alternative
transformation needs to be tested further in order to establish its limitations and
wider applicability.
No significant differences were observed in the expression of ubiquitin mRNA in the
hippocampus or visual cortex of the control, BAD, AD and non-AD dementia cases
studied. However, when the ETR of the ubiquitin C oligodeoxynucleotide probe was
expressed as a proportion of all polyadenylated mRNA in the visual cortex, a
significantly higher proportion of the polyadenylated mRNA in the BAD cases was
accounted for by ubiquitin mRNA than in the AD or control cases. The ubiquitin C
probe detects ubiquitin mRNA of all three known molecular weights, though
theoretically not the alternative sequence for ubiquitin A published by Lund and
colleagues (1985). No significant differences in the ubiquitin A/poly(dT) ratio in the
visual cortex were observed between the diagnostic groups. Presumably the
ubiquitin A oligodeoxynucleotide probe detects such a small proportion of ubiquitin
mRNA that any change in relation to the abundance of all polyadenylated mRNA
would be negligible.
The BAD cases lack the definitive pathological stigmata of AD and in all probability
represent an early stage in the progression of the disease. Furthermore, the visual
cortex represents an area relatively spared in AD that would be expected to show far
less pathological involvement than the hippocampus at all stages of the disease.
Thus, it would appear that the up-regulation of the ubiquitin system in response to an
accumulation of abnormal protein is a feature of early AD: even in the visual cortex
in established disease ubiquitin mRNA has returned to control levels. Such
up-regulation of ubiquitin mRNA would be difficult to study, since the earliest,
pre-clinica! stages of AD rarely reach medical attention and a slight deterioration in
cognitive ability7, especially in individuals with a high pre-morbid intellect, is
notoriously difficult to document with certainty. The examination of the brains of
individuals who have suffered from Down's syndrome during life would afford an
opportunity to examine ubiquitin expression in at risk groups of neurons destined to
develop the pathological stigmata of AD. It would be of interest to investigate
whether other members of the heat shock regulon, including APP, are increased in
such cells. The increase in ubiquitin mRNA would appear to be occurring even
before a definitive neuropathological diagnosis of AD can be made, presumably in
response to an, as yet, invisible accumulation of abnormal intracellular protein. The
increase in ubiquitin mRNA relative to polyadenylated mRNA in the visual cortex
may signal the incipient failure of intracellular ATP-dependent proteolysis. Similar
subtle alterations have been identified in the parallel lysosomal proteolytic system in
apparently healthy neurons, a sign of metabolic dysfunction that is believed to signal
future cellular degeneration (Nixon el al., 1992).
The importance of a functional stress response to cellular survival is underlined by
Heydari and co-workers (1993) who examined the ability of hepatocytes isolated
from young and aged rats to express heat shock proteins in response to a thermal
stress. The authors documented an age-related decline in heat shock transcription as
a result of a decreased binding of HSF to the heat shock element. Caloric restriction
of the aged rats, a practice consistently demonstrated to retard the effects of ageing in
mammals, reversed this age-related decline in heat shock transcription. Further
evidence of the key role of the heat shock proteins, and ubiquitin in particular, in
neuronal survival, is the role of ubiquitin in isehaemic tolerance (Kato et al., 1993).
Survival of gerbil hippocampal neurons following ischaemia parallels the recovery of
ubiquitin immunoreactivity. Neurons in hippocampal subfield CA1 that are destined
to die following ischaemia, never recover ubiquitin immunoreactivity, whereas CA1
cells pre-treated with sub-lethal ischaemia recover ubiquitin immunoreactivity and
survive. Even more cogent is the fact that the toxic effects of [3-amyloid on rat
pheochromocytoma PC 12 cells can be attenuated by prior exposure of the cell
cultures to heat shock (Behl and Schubert, 1993).
The unusual genomic arrangement of ubiquitin C in which identical polypeptide
sequences are tandemly repeated in a single mRNA reading frame, suggests that
ubiquitin C is translated as a polyubiquitin precursor that is post-translationally
modified (Lund et al., 1985). Such a design allows for the rapid production of
ubiquitin in response to stress (Bond and Schlesinger, 1985). It is conceivable that
the primary product, polyubiquitin, may have a function distinct from the monomelic
form of ubiquitin in cellular metabolism (St John el al., 1986). Significantly, it was
not possible to employ a single oligodeoxynucleotide probe to detect all four known
splice variants of ubiquitin mRNA. Even the region of greatest homology in the
alternative ubiquitin A mRNA sequence detailed by Lund and co-workers (1985).
could not be accommodated by the probe chosen to detect the other three known
splice variants. Given the rigorous conservation to which the ubiquitin genes are
subject (Goldstein ei al., 1975) it is possible that the alternative ubiquitin A sequence
evolved at a slightly different stage of evolution. As such, it may serve a different
function and be subject to different transcriptional controls. Indeed, ubiquitin A is a
fusion protein (Lund et al., 1985; Salvesen et al., 1987) that may be biologically
active in its own right (Lund et al., 1985). There is evidence that the ubiquitin yeast
genes, UBI1, UBI2, UBI3 and UBI4, are differentially controlled. UBI4, the yeast
polyubiquitin gene, is dramatically induced in response to starvation, heat shock or
the DNA damageing agents, 4-nitroquinoline 1-oxide and methylmethane sulfonate,
but these stresses variably affect transcription of the other three ubiquitin genes
(Fraser et al., 1991). This study would support a functional distinction between
ubiquitin C and B and ubiquitin A, since only the ubiquitin mRNA identified by the
probe derived from the ubiquitin A sequence published by Lund and colleagues
(1985), in visual cortex, is significantly positively correlated with tissue pH.
The APP gene promoter contains a stress-inducible heat shock element (Salbaum et
al., 1988) and immunochemical studies of APP expression in rats following brain
damage by kainic acid injection, suggest that APP is a rapid reactive protein involved
in brain damage and repair (Kawarabayashi et al., 1991). The association
demonstrated between the APP and the ubiquitin C and ubiquitin A
oligodeoxynucleotide probes in the visual cortex and dentate gyrus in this study,
suggests that transcriptional control of these genes is intimately related and is further
evidence that APP is a member of the heat shock protein superfamlly.
Under normal metabolic conditions non-lysosomal ATP-dependent proteolysis is
responsible for the degradation of the majority of short-lived and abnormal proteins.
It is primarily when the cell is depleted of energy that a significant amount of
lysosomal degradation of intracellular protein takes place (Ciechanover et al.,
1984a). The central nervous system is particularly vulnerable to metabolic stress
given its high energy requirements (Tytell et al., 1993). Positron emission
tomography performed on patients suffering from clinically diagnosed AD has been
used to measure regional cerebral glucose metabolism, an index of neuronal activity,
and has demonstrated that it is significantly reduced in comparison to that of controls
(Foster et al., 1984). Posterior parietotemporal areas were primarily affected, though
medial temporal lobe structures were not assessed in this study. Marked metabolic
abnormalities were identified even in those patients with mild cognitive impairment,
suggesting that cortical metabolic dysfunction can be severe before it is clinically
evident (Foster et al., 1984). Analysis of oxygen metabolism in AD has revealed
similar evidence of hypometabolism. Reduced oxygen consumption is apparent in
the parietal and adjoining areas of the posterior temporal cortex and anterior occipital
cortex first, with involvement of the frontal cortex in advanced disease (Bench et al.,
1990). This progression of functional deficits, as identified by in vivo imagcing
techniques, mirrors the neuropathological advance of the disease as described by
Pearson and Powell (1989). Further, the efficiency of ubiquitination and
ubiquitin-mediated degradation of substrate proteins has been demonstrated to be
impaired by glycation, a common post-translational modification that increasingly
occurs in in vivo with advancing age (Takizawa el al., 1993). Thus, age may itself
predispose to a deterioration in ubiquitin dependent proteolysis.
The poverty of cellular energy that is a feature of AD (see Bowling and Beal, 1995
for review) may be compounded in the elderly by mitochondrial genome deletions: a
phenomenon that is particularly common in tissues, such as the nervous system, that
have high energy requirements (Cortopassi et al., 1992). Further, under conditions
of cellular stress, the metabolic effort of the cell is re-directed towards the production
of the products of the heat shock genes and the products of other genes are
suppressed, potentially compounding the metabolic embarrassment of the cell.
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There is evidence for early lysosomal dysfunction in AD. At-risk, but apparently
healthy, populations of neurons in the disease exhibit modest lysosomal
abnormalities in comparison with the advanced lysosomal disruption seen in overtly
abnormal neurons (Nixon et al., 1992). Lysosomes and lysosome-related organelles
have been observed to accumulate in at-risk pyramidal neurons of the neocortex and
hippocampus that are free of neurofibrillary pathology on thioflavin staining and
show no apparent atrophy or chromatolytic changes on Nissl staining (Nixon et al.,
1992), suggesting increased lysosomal activity. Further, Cataldo, Mann and Nixon
have observed alterations in the lysosomal system of at-risk neurons in the brains of
sufferers from Down's syndrome at a time when only diffuse deposits of p-amyloid
can be detected and neurofibrillary tangles are few (Nixon et al., 1992). The
pyramidal cells of the hippocampus and neocortex appear to be particularly
vulnerable to the accumulation of cellular debris, since they show the greatest
accumulation of lipofuscin during ageing (Cataldo et al.. 1994). Thus, the effects of
AD might be predicted to be most conspicuous in these cells (Cataldo et al., 1994).
Significantly, in diseases where the lysosomal system is involved at an early stage,
Nixon and Cataldo (1993) believe that the primary abnormality is frequently linked
either to lysosomal dysfunction or to the production of large quantities of a
digestion-resistant substrate that accumulates within lysosomes. Punctate
concentrations of APP have been demonstrated immunochemically in pyramidal
cells of the neocortex, especially those in associative regions, in normal brain
(Benowitz et a/., 1989). The pyramidal cells of hippocampal subfield CA1 also
show intense punctate concentrations of APP in normal brain (Benowitz et al., 1989).
Thus, the cerebral regions involved are those most vulnerable to the pathological
changes associated with AD. Further, electron microscopy has confirmed that these
dense concentrations of APP are contained within secondary lysosomes (Benowitz et
al., 1989). Mayer and co-workers (1992) have described the lysosome as a
bioreactor for the production of P-amyloid and lysosomal internalisation, partial
degradation and subsequent exocytosis of substrate has been indirectly demonstrated
in cell culture (Buktenica et al., 1987). Undoubtedly the hypometabolism that is
characteristic of AD (see Bowling and Beal, 1995 for review) compromises
ATP-dependent non-lysosomal proteolysis and results in increased reliance on
lysosomal degradation of intracellular proteins. Enhanced lysosomal activity might
be predicted to result in increased amyloidogenic processing of APP and potentially
to the extrusion of P-amyloid and (3-amyloid-containing peptides into the
extracellular space. The results of this study suggest that further investigation of
proteolytic mechanisms in AD would be worthwhile, especially since lysosomotropic
agents have been shown to reduce P-amyloid production in cell cultures, raising the
possibility of therapeutic intervention in the disease process (Shoji et al., 1992).
Concluding Remarks
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Any attempt to weave the findings of this thesis into a cohesive whole that underpins
AD is to overstate the significance of the data. The possibility that APP mRNA was
increased in AD was a biologically plausible and eminently testable hypothesis that
merited careful study. However, comprehensive analysis of APP mRNA levels in a
large, well-matched series, controlled for known confounding variables,
demonstrated that this hypothesis was false. The probable functional association
between the heterotrimeric G protein, Goa, and APP, and the tentative conclusion
that ubiquitin mRNA is up-regulated in pre-clinical AD, offer tantalising glimpses of
the pathophysiology of the disease, but do not significantly alter our understanding of
it, while the RT-PCR study proved wholly inconclusive. The relative poverty of
significant findings unearthed by this study is disappointing, though the definitive
exclusion of an up-regulation of APP mRNA in AD is a profoundly important
negative result.
This study illustrates that despite the proven ability of techniques like in situ
hybridisation histochemistry and the polymerase chain reaction to contribute to our
understanding of complex, multi-factorial diseases such as Alzheimer's disease, there
is no guarantee that a promising study, however meticulously prosecuted, will reveal
illuminating results. A genuine interest in the research question posed is helpful in
weathering such scientific disappointments.
The study of mRNA levels, especially APP mRNA levels, in AD has evolved to its
current level of sophistication. Early studies simply could not have anticipated the
capricious nature of APP mRNA levels or controlled for the variety of factors now
known to confound their measurement. Thus, the prosecution of this study benefited
from the insights generated by earlier studies of APP mRNA levels in human brain.
Further, the laboratory in which this research was performed is dedicated to the study
of human neuropsychiatric diseases using primarily post-mortem brain tissue and is
actively engaged in addressing the difficulties inherent in such work. Without large
numbers of superior tissue samples, expert neuropathological verification of
diagnosis, the availability of a positive control group and detailed clinical and
demographic information it would not have been possible to identity the increase in
ubiquitin C/poly(dT) mRNA levels in borderline AD. Similarly, it would not have
been possible to demonstrate that the insert junction ratio in the visual cortex is
relatively immune to the effects of agonal state without data on tissue pH.
At the beginning of a project such as this it is difficult to conceive of its scale and
complexity. Indeed, it would not have been possible, at the start, to envisage
abandoning the traditional method of quantifying autoradiographic greyness using
optical density. Moreover, basic laboratory skills can seem obvious to the
experienced and naturally inclined, but may appear obscure and unnecessarily
complicated to the novice, and the pace of laboratory research can seem slow,
painfully so initially, to the clinician ignorant of the complexity of the endeavour.
Further, the de-skilled clinician can be tempted to cling to tasks at which they are
competent, especially when they can be legitimised as pressing or urgent, and
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would appear prudent to reserve the analysis of such tissue, with all its attendant
difficulties, for the resolution of crucially important, highly specific and carefully




All chemicals employed in the preparation of the following solutions were of
molecular biology grade.
Agarose Gel Loading Buffer
A 6 x concentration of loading gel buffer was prepared by combining a solution of
30% glycerol in purified deionised water with 0.25% of bromophenol blue.
100% Deionised Formamide
Five grams of BioRad AG 501 - X8, 20 - 50 mesh ion exchange resin was added to
50 ml formamide. The solution was stirred for 30 minutes at room temperature and
then filtered twice through Whatman No 1 filter paper.
Denhardt's Solution
For 500 ml of a 50 * Denhardf s solution, 5 g ficoll, 5 g polyvinylpyrrolidone and 5 g
bovine serum albumin were dissolved in autoclaved, DEPC treated water to achieve
a final volume of 500 ml. The solution was then filtered through a disposable
Nalgene filter.
Disodium Ethylene Diamine Tetraacetate (EDTA)
For 1 litre of the solution, 37.22 g EDTA was dissolved in 800 ml autoclaved, DEPC
treated water with vigorous stirring. The pH was adjusted to 8.0 with solid pellets of
sodium hydroxide and autoclaved, DEPC treated water added to give a final volume
of 1 litre.
Gelatin/Chrome Alum Subbing Solution for Glass Slides
For 500 ml of a 1% gelatin and 0.05% chromic potassium sulphate subbing solution,
5g gelatin and 250 mg chrome alum were dissolved in 500 ml purified, deionised
water with gentle heat. When dissolved, the solution was filtered through Whatman
No 1 filter paper. When the solution was cool, racks of slides were dipped into the
subbing solution for a few seconds, removed, drained and blotted. The slides were
then dried in a 40°C oven overnight.
Hybridisation Buffer
For 50 ml:
10 ml 20 x SSC
1 ml 50 x Denhardt's solution
0.5 ml 0.1 M disodium ethylene diamine tetraacetate (EDTA)
1 ml denatured herring/salmon sperm DNA
5 mg yeast tRNA
5 mg poly A
25 ml deoinised formamide
5 g dextran sulphate
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The yeast tRNA and poly A are obtained commercially as salts (Sigma) and diluted
to a concentration of 10 mg/ml on arrival.
The above reagents, except the dextran sulphate, were combined. The dextran
sulphate was then gradually added, while stirring the solution over a gentle heat.
When dissolved, the solution was made up to 50 ml with 20 mM phosphate buffer.
Phosphate Buffered Saline
Tablets of phosphate buffered saline containing 137 mM sodium chloride, 2.7 mM
potassium chloride and 10 mM phosphate buffer were bought commercially (Sigma).
To produce 200 ml phosphate buffered saline one tablet was dissolved in 200 ml
purified, deionised water.
Ribonuclease Pre-Treatment Solution
Two hundred ml of ribonuclease solution was prepared as follows. Four hundred pi
RNase A solution (Sigma 10 mg/ml), 2 ml 1 M tris (hydroxymethyl) aminomethane
(tris) hydrochloride at a pH of 8.0, 1 ml 0.2 M EDTA at a pH of 8.0, 5.8 g sodium
chloride and 2 pi RNase T1 (Sigma 100 units/pl) were combined. The solution was
made up to a final volume of 200 ml with purified, autoclaved water. The tissue
sections were incubated in this solution for 60 minutes at 37°C and then pre-treated
and stored as usual.
Sodium Thiosulphate Fixative
For a 30% weight by volume solution of sodium thiosulphate, 300 g of sodium
thiosulphate was dissolved in purified, deionised water and made up to a final
volume of 1 litre.
Standard Citrate Saline (SSC)
To prepare 1 litre of SSC, 175.3 g sodium chloride and 88.2 g sodium citrate were
dissolved in 800 ml autoclaved, DEPC treated water. The pH was adjusted to 7.0
with hydrochloric acid. Autoclaved, DEPC treated water was then added to bring the
final volume to one litre.
STE Buffer
To prepare this buffer 0.1 M of sodium chloride, 10 mM of tris chloride and 1 mM of
EDTA were dissolved in purified, deionised water to a final volume of one litre.
Both of the latter solutions were at a pH of 8.0.
Triethanolamine Hydrochloride (TEA) with Acetic Anhydride
For 250 ml of TEA, 4.625 g TEA and 2.25 g sodium chloride were made up to 250
ml with purified, deionised water. The pH was adjusted to 8.0 with a 10 M solution
of sodium hydroxide. Finally, 0.625 ml of acetic anhydride was added immediately
prior to use.
Tris Borate EDTA Buffer (TBE)
For 1 litre of 5 x TBE buffer, 54 g tris, 27.5 g boric acid and 20 ml of 0.5 M EDTA



















SI Control Female 82 50 864 (84)
S4 AD Female 79 31 857 (84)
Sll AD Female 77 68 2 836(70)
S12 Control Male 68 21 3 768 (3)
S14 Control Female 93 873 (111)
S15 Control Male 94 27 2 884 (122)
S17 AD Male 89 29 3 879(128)
S20 AD Female 80 20 3 1011(248)
S23 Control Female 74 35 1 887(135)
S25 AD Female 86 18 1291 (539)
S27 AD Female 89 3 4 1032 (281)
S28 AD Male 83 17 2 859(471)
S29 BAD Female 71 43 800 (52)
S34 AD Female 80 17 793 (47)
S40 Control Female 65 24 669(306)
S41 AD Male 88 663 (330)
S42 AD Male 81 60 768 (430)
S44 AD Female 90 40 3 744 (406)
S46 AD Male 79 69 1 793(447)
S51 Control Male 74 34 525 (213)
S53 AD Female 90 46 4 752 (459)
S56 Control Female 74 662 (363)
S57 Control Male 89 675 (567)
S61 AD Male 78 45 3.5 783(499)
S65 AD Male 72 19 473 (190)
S66 AD Female 87 42 2 530(251)
S67 BAD Male 79 50 4 448 (174)
















S74 Control Female 67 25 1 516(248)
S78 AD Male 67 30 3.5 1355(1131)
S79 BAD Female 91 42 684 (462)
S80 AD Female 98 40 1 585(362)
S82 AD Male 81 36 2 545 (333)
S83 AD Female 84 48 3.5 587(374)
S89 AD+PD Female 98 58 3 731 (590)
S90 Control Male 81 362 (223)
S92 BAD Female 85 391 (287)
S96 Control Male 72 4 408 (215)
S100 AD Male 85 24 387 (202)
H12 AD Female 44 27 2 1557(147)
H53 AD Male 84 38 1 1458(106)
H71 Control Male 69 70 4 1333 (33)
H81 Control Male 64 60 1 1242 (48)
1194 AD+MID Male 83 16 4 1153 (80)
H95 AD Female 59 9 4 989 (21)
*The first figure denotes the total storage time of the tissue. The figure in brackets
represents the duration of storage of the tissue as an uncut block, the remaining days
















SI Control Female 82 50 1119
S12 Control Male 68 21 3 1023
S14 Control Female 93 1128
S15 Control Male 94 27 2 1039
S20 AD Female 80 20 3 1266
S23 Control Female 74 35 1 1142
S25 AD Female 86 18 1546
S27 AD Female 89 3 4 1287
S28 AD Male 83 17 2 1114
S40 Control Female 65 24 924
S41 AD Male 88 918
S42 AD Male 81 60 1023
S44 AD Female 90 40 3 999
S46 AD Male 79 69 1 1030
S51 Control Male 74 34 680
S53 AD Female 90 46 4 1007
S65 AD Male 72 19 728
S66 AD Female 87 42 2 785
S69 Control Male 93 22 2 1142
S74 Control Female 67 25 1 771
S78 AD Male 67 30 3.5 1610
S79 BAD Female 91 42 939
S80 AD Female 98 40 1 840
S82 AD Male 81 36 2 800
S83 AD Female 84 48 3.5 842
S90 Control Male 81 617
S92 BAD Female 85 646
S96 Control Male 72 4 663
Series II Cases
Case












S100 AD Male 85 24 642
H53 AD Female 84 38 1 1713
H81 Control Male 64 60 1 1497
H94 AD+MID Male 83 16 4 1408
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Series III - The OPTIMA Series
Case















Female 77 16 6










Female 67 22 6.76 5
C3970 AD Female 87 39 5





Female 88 14 6.79 5
C4295 AD Male 84 36 6.05 5
1026/90 AD Male 76 30 6.69 5
1123/91 BAD Male 73 38 6.57 4
1174/91 Control Female 81 78 6.57 4
1250/91 AD Female 74 30 6.81 4





Male 88 28 6.46 4










Female 83 13 7.06 3
1027/92 BAD Male 67 55 7.23 3
1125/92 AD Female 70 22 4
1274/92 Control Male 79 29 6.98 OJ
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Series III - The OPTIMA Series
Case











1309/92 Control Female 73 40 6.22 3
1436/92 BAD Female 89 24 6.48 3
1438/92 AD Male 74 39 6.53 3





Female 86 50 6.82 2





Female 86 41 6.89 2





Male 72 19 6.74 2
1034/94 BAD Male 89 16 6.78 1
1182/94 Control Female 80 37 6.47 1
1234/94 Control Male 82 43 6.26 1
1252/94 AD Male 62 34 7.01 1
1315/94 BAD Female 83 20 6.15 1





Female 83 68 6.30 1
1445/94 AD Female 91 1





Female 88 47 7.13 1
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Series IV Cases
Details of Cases Selected from Series II (Visual Cortex)




SI Control Female 82 50
S14 Control Female 93
S20 AD Female 80 20
S23 Control Female 74 35
S25 AD Female 86 18
S27 AD Female 89 3
S28 AD Male 83 17
S40 Control Female 65 24
S41 AD Male 88
S42 AD Male 81 60
S44 AD Female 90 40
S46 AD Male 79 69
S51 Control Male 74 34
S53 AD Female 90 46
S65 AD Male 72 19
S66 AD Female 87 42
S69 Control Male 93 22
S74 Control Female 67 25
S78 AD Male 67 30
S80 AD Female 98 40
S82 AD Male 81 36
S90 Control Male 81
S96 Control Male 72
S100 AD Male 85 24
H53 AD Male 84 38
H81 Control Male 64 60
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Series IV Cases
Details of Cases Selected from Series III (OPTIMA Series) (Visual
Cortex, Dentate Gyrus and Hippocampal Fields CA4, CA3 and CA1)




C3452 AD Female 83 29
C3970 AD Female 87 39
C4017 AD Male 82 36
C4295 AD Male 84 36
1174/91 Control Female 81 78
1250/91 AD Female 74 30
1313/91 AD Female 83 44
1381/91 AD Male 74 56
1125/92 AD Female 70 22
1438/92 AD Male 74 39
1127/93 Control Male 65 24
1165/93 Control Male 87 43
1306/93 AD Female 68 30
1182/94 Control Female 80 37
1234/94 Control Male 82 43
1252/94 AD Male 62 34
1274/94 Control Male 79 29
1340/94 Control Male 68 17
1445/94 AD Female 91
1004/95 AD Female 80 35
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Series IV Cases
Details of Cases Selected from Dr. A.J.L. Barton's Experiment (Visual
Cortex, Dentate Gyrus and Hippocampal Fields CA4, CA3 and CA1)




107 AD Female 92 11
109 AD Male 77 35
1011 AD Female 76 39
1013 AD Male 77 86
1016 AD Female 66 40
1028 AD Female 91 6
1043 Control Male 66 7
1045 Control Female 96 68
1053 AD Male 85 38
1058 AD Male 61 12
1063 AD Female 81 23
1066 Control Female 73 24
1072 Control Female 83 27
1073 Control Male 78 94
1074 Control Male 59 20
1078 Control Male 64 22
1079 Control Female 74 11
1080 Control Male 51 29
1081 Control Male 64 60
1084 Control Male 70 41
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Series IV Cases
Details of Cases Selected from Dr. M.H. Griffiths's Experiment (Dentate
Gyrus and Hippocampal Fields CA4, CA3 and CA1)




835 Control Male 77 48
986 Control Male 78 42
1010 Control Male 84 8
1015 AD Female 77 24
1022 Control Male 69 28
1029 AD Female 81 17
1050 AD Male 82 75
1289 AD Female 87 31
1419 Control Male 55 24
1590 AD Female 81 38
1639 Control Female 91 48
1790 AD Female 73 39
7292 Control Female 76 31
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As candidates for three seminal advances in
Alzheimer's disease (AD) research of the past twenty
years we would propose: the discovery of the cholin¬
ergic deficit (Bowen et al, 1976; Davies & Moloney,
1976; Perry et al., 1977), the sequencing of P-amyloid
(Glenner & Wong, 1984; Masters et al., 1985), and the
finding of a causative P-amyloid precursor protein
(APP) mutation (Goate et al., 1991). These discoveries
played critical roles in, respectively, the neurochemi¬
cal, neuropathological and genetic understanding of
AD.
Investigation of gene expression has helped inte¬
grate these research fields in several ways. Here we
focus upon studies of APP mRNAs and the informa¬
tion they have provided with regard to the involve¬
ment of APP in AD. We also review briefly the
expression of apolipoprotein E (apoE) and the prese-
nilins. The use of gene expression methodologies to
investigate other areas of AD and relevant experi¬
mental models is discussed in Harrison (1994,1995).
P-amyloid precursor protein (APP) mRNAs
Following the cloning of the human APP gene (Tanzi
et al., 1987) it became possible to examine the expres-
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sion of its mRNA. Two obvious questions arose. Which
tissues and cells express APP? Is the expression of APP
altered in AD? Both have proved surprisingly difficult
to answer unequivocally.
Distribution of amyloid precursor protein mRNAs
Initial blot hybridization studies showed that APP
mRNA is abundant in the brain (as well as other tis¬
sues) at all stages of life (Tanzi et al., 1987; Goedert,
1987), and cellular in situ hybridization histochem¬
istry (ISHH) showed that expression occurs primarily
(Bahmanyar et al., 1987) but not exclusively
(Schmechel et al., 1988) in neurons. Subsequently,
matters became more complicated with the
identification of multiple APP transcripts and the real¬
ization that the mRNAs are expressed differentially in
terms of localization and relative abundance (Neve
et al., 1988,1990; Palmert et al., 1988; Tanzi et al., 1988,
1993; Spillantini et al., 1989; Tanaka et al., 1989; Golde
et al., 1990; Kang & Muller-Hill, 1990). A simplified
summary is shown in Table 1 and illustrated in Figure
1. Some details, however, remain unclear, largely as a
result of three methodological issues. (1) Some
studies have used probes or conditions which detect
more than one isoform or which may cross-hybridize
to APP homologues. (2) Interpretation of findings
based upon homogenized tissue is hindered by uncer¬
tainty as to its composition with regard to the pro¬
portions of grey and white matter, meninges, etc. The
presence of leukocytes and microglia is relevant, since
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Table 1. Localization and relative abundance of APP mRNA isoforms in human brain8
Missing Abundance in brain Abundance in brain Main cell types expressing
Isoform exonsb relative to other organs relative to total APP mRNA the isoform in brain
APP695 7,8 + + + + + + + + Neurons >> other cells
APP714 7 + + + /- Meninges, glia, endothelia, ?neurons
APP751 8 + + + + Neurons > other cells
APP770 None + +(+) Glia, meninges, endothelia > neurons
L-APPC 15 - (+) Lymphocytes, microglia. Not in neurons
APP365d ?9-19 Unknown + Unknown
APP563d ?8—19 Unknown + Unknown
"The table is a consensus interpretation of the data.
bDerived from Yoshikai et al. (1990). (l-amyloid is encoded by parts of exons 16 and 17. Thus, all APP isoforms other than APP365 and APP563
are potential sources of p-amyloid.
'Several L-APP transcripts exist. They differ in whether they also skip exons 7 (L-APP696), 8 (L-APP733), neither (L-APP752) or both
(L-APP677).
dThese isoforms cannot be described purely in terms of missing APP exons, and both also contain non-APP sequences.
they express significant levels of some APP transcripts
(Table 1; Allen et al., 1991; Konig et al., 1992). (3) The
techniques differ in their sensitivities. In particular,
reverse transcriptase-PCR (Golde et al., 1990) analyses
of APP mRNA will detect transcripts present at
extremely low levels. In this instance, point (2)
becomes especially germane.
Notwithstanding these considerations, two conclu¬
sions regarding the distribution of APP expression
may be drawn. Firstly, APP mRNA expression is wide¬
spread and lifelong in the human brain. As such, APP
expression is not per se a pathological event, and no
extra-cerebral origin of the (3-amyloidosis of AD need
be postulated. Secondly, within the brain, APP is syn¬
thesized primarily in neurons. However, the occur¬
rence of some APP transcripts in non-neuronal cells
inside and outside the brain means that (3-amyloid
could still arise from these alternative sources.
Quantitative alterations of APP mRNAs in
Alzheimer's disease?
As well as examining where and in what proportions
APP transcripts are expressed in normal subjects,
research has attempted to ascertain whether these
parameters are altered in AD. In particular, it was a
plausible hypothesis that (3-amyloid deposition in AD
was caused by simple overexpression of APP, as is
thought to be the case in Down's syndrome. Although
this possibility was soon ruled out, a complete answer
to the question posed in the title above has proved elu¬
sive. This is due partly to the number and complex
distribution of transcripts, and partly to the method¬
ological and interpretational problems which affect
quantitative mRNA studies in human brain.
A number of changes have been reported in the
abundance of one or more APP mRNAs in one or more
regions of the AD brain (reviewed in Harrison (1994)
and Rockenstein et al. (1995)). However, the findings
overall have been inconsistent. An important reason
for this is that APP mRNA expression is now known
to be highly variable between brains (Koo et al., 1990;
Oyama et al., 1991,1993; Robinson et al., 1994). Oyama
et al. (1991,1993) studied 38 individuals and showed
a several-fold range in the abundance and proportions
of cortical APP mRNAs. The variation did not corre¬
late with age, post mortem interval or (1-amyloid depo¬
sition. In the light of this variability, the possibility of
false positive and false negative results from quanti¬
tative APP mRNA studies—which have often been
carried out on small (n < 8) numbers of cases—is clear.
Clues to the origin of APP expression variability
were provided by a study of brains collected by Drs
Andy Procter and David Bowen. The subjects, mostly
demented, had been prospectively assessed during the
days before death. Preservation of APP mRNA was
found to be affected by the duration of terminal coma
and by pyrexia, and it correlated strongly with the
activity of glutamic acid decarboxylase (GAD), an
enzyme known to be vulnerable to prolonged modes
of death (Harrison et al., 1994; Procter et al., 1994; see
also Burke et al., 1991). The finding that APP mRNAs
are affected by premortem course (agonal state) prob¬
ably explains much of the observed variation in brain
APP mRNA levels between individuals. Conversely,
post mortem interval does not (Harrison et al., 1994).
Premortem events are not, however, likely to be the
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Figure 1. Cellular expression of APP mRNAs in the normal human hippocampus
(CA3 field) using isoform-specific 35S-labelled oligonucleotide probes and liquid emul¬
sion autoradiography, (a) APP695 mRNA using an exon 6/9 junction probe, (b) APPins
mRNA, using a probe to a region within exon 7. (c) APP751 mRNA, using an exon 7/9
junction probe, (d) APP770 mRNA using a probe to a region within exon 8. Only neu¬
rons are seen to express APP695 and APP751 mRNAs, whereas APP770 mRNA is
absent from neurons and present at low levels in putative glia. Signal for APP770
mRNA, although weak, is specific, since sense strand hybridization produced no grain
clustering, and the APP770 oligonucleotide was validated in a northern blot. The sim¬
ilar images in B and C reflect the fact that most APPins mRNA in brain is APP751
mRNA.
412 P.J. Harrison et al.
sole cause of variability in APP expression since a sim¬
ilar phenomenon is observed in lymphocytes (Ebstein
et al., 1996), and to a lesser extent in brains of monkeys
(Koo et al., 1990) whose mode of death was presum¬
ably rapid and uniform.
Within the Procter/Bowen series, APP695 mRNA
was decreased in AD frontal cortex compared to con¬
trols (Harrison et al., 1994), as had been found in sev¬
eral earlier studies (see Rockenstein et al., 1995). We
also showed that the decrease was present relative to
total poly(A)+mRNA content, and that it distin¬
guished the AD cases from a mixed group of non-AD
dementias. APPins mRNAs were reduced to a similar
extent as APP695 mRNA; therefore we did not repli¬
cate an increase in the ratio of KPI-encoding to KPI-
lacking APP transcripts in AD cases reported
previously. The three comparison groups were rea¬
sonably matched for GAD activity and terminal coma,
thus reducing the likelihood of agonal state factors
confounding the results.
Recently we have examined APP mRNAs in mate¬
rial from the Oxford Study to Investigate Memory in
Ageing (OPTIMA), wherein people with early
dementia and age matched controls are assessed and
followed up at regular intervals. Clinical, neuro¬
psychological, neuroradiological and ultimately
neuropathological measurements are made. Brains
from a subgroup of control, AD and non-AD demen¬
tia subjects were selected for APP mRNA studies. The
groups were matched for demographic and con¬
founding variables. The AD and non-AD dementia
groups were matched for degree of dementia (MMSE
score), but there were a wide range of clinical and
pathological severities within the AD group (Table 2).
Initial results of hippocampal APP mRNA expression
in the OPTIMA cases are presented in Figure 2. No
significant differences in APP695 or APPins mRNAs
were seen in the established AD cases compared to
normal controls or cases of non-AD dementia. We
found no differences in the ratio of the two APP iso-
forms between the groups or in relation to age (data
not shown). These negative findings, in a well charac¬
terized and relatively large series, suggest that major
changes in APP mRNA expression do not occur in the
hippocampus in AD. Moreover, no relationship was
seen between the abundance of APP mRNAs and the
severity of AD as assessed using the indices listed in
Table 2 (data not shown), suggesting that aberrant
hippocampal APP expression is not prominent at any
stage of the AD process.
Indeed, more generally, the main conclusion of the
APP mRNA literature must be that no unequivocal,
specific abnormality in AD has been demonstrated.
This negative conclusion seems to apply to familial AD
too (Harrison et al., 1991a, but see Querfurth et al., 1995)
and is supported by the failure to find AD-associated
alterations in APP transcriptional regulation (Lukiw
et al., 1994). It is in keeping with the view that the crit¬
ical abnormalities in APP metabolism occur either
upstream in the gene itself, in familial AD cases due
to a mutation in the gene, or downstream in the pro¬
teolytic processing of APP in other forms of AD
(Checler, 1995). Even where positive APP mRNA
findings have been described in AD (such as decreased
APP695 mRNA), their interpretation and pathogenic
significance is often unclear. For example, some
Table 2. Demographic details of cases used for study of hippocampal APP mRNAs
Normal controls Alzheimer's disease" Non-Alzheimer dementias'"
(n = 7) (n = 10) (n = 6)
Sex (M:F) 3:4 6:4 3:3
Age (y) 79(8) 76(9) 80 (8)
CSF pHc 6.69 (0.41) 6.66 (0.37) 6.85 (0.29)
PMI (h) 40 (17) 36 (13) 23 (13)
Freezer storage (y) 1.9 (1.1) 2.6 (1.6) 3.6 (1.3)
MMSE (0-30) 27 (3) 8 (11) (n = 9) 9(5)
Braak stage (0-6) 1.0 (0.9) (n = 5) 4.7 (1.2) (n = 8) 2.4 (0.5)
Neuritic plaquesd 0 {n = 2) 0.81 (1.40) (n = 4) 0 (n = 4)
NFTsd 0 (n = 2) 3.3 (3.5) (n = 4) 0 (n = 4)
Values are mean (SD). PMI = post mortem interval. MMSE = last recorded mini-mental state score (tested within 6 months of death).
"Definite (n = 9) or probable (n = 1) AD by CERAD criteria.
bDiagnoses: Parkinson's disease, Binswanger's disease, multi-infarct dementia with Parkinson's disease, normal pressure hydrocephalus,
corticobasal degeneration, Huntington's disease.
'Agonal state marker (Harrison et al., 1995).
dMean density in hippocampus (Nagy et al., 1996).
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j Controls (n = 7)
1 AD (n = 10)
! Non-AD dementias (n = 6)
Figure 2. APP mRNAs in hippocampal subfields in Alzheimer's disease and non-Alzheimer
dementias compared to controls using ISHH and film autoradiography. See Harrison et al.









studies have neglected possible differences in overall
gene expression levels (Harrison et al., 1991b). Others
have not taken into account possible changes in
cellular composition of the tissue or have not consid¬
ered whether a change identified in AD also occurs in
other degenerative disorders. Such factors must all be
determined before a given change in APP mRNA can
be concluded to be gene-, isoform-, cell- or AD-
specific. These conceptual issues are in addition to the
methodological confounders of agonal state. Equally,
however, these uncertainties mean that a significant
but currently unrecognized alteration in APP mRNA
expression in AD may exist. For example, several
studies report that APP770 mRNA, although rare in
brain, is increased in AD, probably occurring in glia,
meninges and/or other non-neuronal cells (Tanaka
et al., 1989; Golde et al., 1990; Jacobsen et al., 1991;
Premkumar & Kalaria, 1996).
Overall, therefore, studies of APP expression in AD
should continue, but will benefit from greater atten¬
tion being paid to the factors discussed here.
Interpretation of the data will be enhanced by
clarification of two other issues: by establishing more
clearly the quantitative relationship between each
mRNA and the APP isoform which it encodes, and by
determining if p-amyloid arises proportionally from
all APPs. These data are needed to identify whether
the abundance of an APP mRNA predicts that of the
encoded protein (an assumption implicit in most gene
expression studies) and, if so, whether any particular
APP transcript is of special relevance as an amyloido-
genic precursor.
Other candidate gene mRNAs in Alzheimer's
disease
Following the discovery that the apoE and presenilin
(PS) genes contribute to AD, the expression of their
transcripts has begun to be investigated.
Distribution of apolipoprotein E mRNA
ApoE mRNA is expressed in astrocytes but not in
neurons (Diedrich et al., 1991), an important consider¬
ation when developing models to explain the mecha¬
nism by which apoE is involved in AD. It indicates that
neuronal apoE immunoreactivity (Han et al., 1994) is
due to uptake, rather than synthesis, of apoE by neu¬
rons. In the same paper, Diedrich et al. (1991) reported
elevated apoE mRNA in AD. Although this is unsur¬
prising given the gliosis which occurs in the disease,
apoE mRNA is increased by a greater degree than is
glial fibrillary acidic protein mRNA (Yamada et al.,
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1995), suggesting that the enhanced apoE expression
in AD is not entirely due to gliosis. No association has
been found either between apoE genotype and the
abundance of apoE mRNA (Yamada et al., 1995), APP
or tau mRNAs (Oyama et al., 1995) in the cortex. These
negative observations imply that the influence of apoE
variants on AD, including their effect upon its neuro¬
pathology and neurochemistry, are not exerted via
altered apoE, APP or tau expression.
Distribution ofpresenilin mRNAs
Initial data on the human expression of PS1 and PS2
show that they are synthesized in the brain and in some
peripheral tissues (Rogaev et al., 1995; Suzuki et al.,
1995; Kovacs et al., 1996; Levy-Lahad et al., 1996). ISHH
and immunocytochemical data indicate that, within
the brain, PS1 is predominantly neuronal (Suzuki
et al., 1995; Elder et al., 1996; Kovacs et al., 1996), but
abundant PS1 (and PS2) mRNA is seen in corpus
callosum on northern blots (Rogaev et al., 1995), sug¬
gesting that some glial populations also express them
at high levels. The possibility that aberrant PS expres¬
sion contributes to the roles of these genes in AD will
presumably be investigated in the near future. It is to
be hoped that these studies avoid the pitfalls of the
equivalent studies of APP mRNAs discussed above.
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